



(51) International Patent Classification:
C07D 487/00 (2006.01)

(21) International Application Number:
PCT/US2012/064239

(22) International Filing Date:
8 November 2012 (08.11.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/557,326 8 November 2011 (08.11.2011) US

(71) Applicant (for all designated States except US): **INTEL-
LIKINE, LLC** [US/US]; 10931 North Torrey Pines Road,
Suite 103, La Jolla, CA 92037 (US).

(72) Inventors; and

(71) Applicants (for US only): **LIU, Yi** [US/US]; 4841 Bar-
lows Landing Cove, San Diego, CA 92130 (US). **WANG,
Shunyou** [CN/US]; 4172 Corte De La Siena, San Diego,
CA 92130 (US). **JANES, Matthew, R.** [US/US]; 859
America Way, Del Mar, CA 92014 (US). **LAN, Lucy**
[US/US]; 727 Atwood Place, San Marcos, CA 92069 (US).
REN, Pingda [CN/US]; 5534 Havenridge Way, San
Diego, CA 92130 (US). **ROMMEL, Christian** [DE/US];
528 Westbourne Street, La Jolla, CA 92037 (US).

(74) Agents: **ORBAI, Lucian** et al.; Wilson Sonsini Goodrich
& Rosati, 650 Page Mill Road, Palo Alto, CA 94304-1050
(US).


(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: TREATMENT REGIMENS USING MULTIPLE PHARMACEUTICAL AGENTS



(57) Abstract: The present invention provides for methods and pharmaceutical compositions for treating disorders using treatment regimens involving multiple agents. In one aspect, a method of treatment is provided resulting in reduced toxicity and/or synergistic effect by administration according to a described dosing schedule.

TREATMENT REGIMENS USING MULTIPLE PHARMACEUTICAL AGENTS

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of priority U.S. Provisional Patent Application No. 61/557,326 filed November 8, 2011; entitled, "Treatment Regimens Using Multiple Pharmaceutical Agents," which is fully incorporated by reference for all purposes.

BACKGROUND OF THE INVENTION

[0002] Toxicity and prevalence of side effects are important considerations in structuring courses of treatment for many diseases. For example, treatments which require the use of therapeutic agents which result in severe adverse events may become ineffective due to insufficient patient compliance or because an effective therapeutic dose cannot be administered to the patient. Such situations may occur not only with courses of treatment where the cause is the side effect profile of single therapeutic agents, but also in treatment regimens where two or more therapeutic agents are used. For example, even if two therapeutic agents, when used alone, show an acceptable level of adverse effects, a combination treatment regimen using the two agents may prove too toxic or inconvenient for the patient and an effective dose of one or both of the agents may not be administered.

[0003] One exemplary disorder in which treatment is often limited by adverse effects is renal cell carcinoma, which is a kidney cancer that originates in the lining of the proximal convoluted tubule. Renal cell carcinoma represents a majority of adult kidney cancer cases, and is extremely lethal. In recent years, targeted cancer therapies such as sunitinib, temsirolimus, bevacizumab, interferon-alpha, and sorafenib have been used to treat renal cell carcinoma cases. Although such approaches have been successful, many patients suffer from severe side effects as a result of administration of anti-neoplastic drugs such as sorafenib. As a result, a significant number of cases do not result in a clinically satisfactory outcome either because the tumors are not reduced or because the side effects require that sorafenib dosing be limited or discontinued. Similar considerations are expected to apply when multiple therapeutic agents are used.

SUMMARY OF THE INVENTION

[0004] In one aspect, the invention provides a method of treating a disorder in a subject according to a regimen comprising administering to the subject a first agent, and a second agent which is an mTor inhibitor, wherein the first and second agent are administered according to a dosing schedule such that the first agent and the second agent are not administered within 12 hours of each other; and wherein administering the first and second agent in accordance with the dosing schedule results in a synergistic effect as evidenced by either a) a reduced toxicity level of the first or second agent, as compared to an alternative regimen in which the first and second agent are administered simultaneously or b) enhanced efficacy of the first or second agent, as compared to an alternative regimen in which the first and second agent are administered simultaneously; and wherein the toxicity level is measured by a change in

bodyweight of the subject, a decrease in skin toxicity grade of the subject, a decrease in fatigue of the subject, a decrease in rashes or desquamation of the subject, a decrease in hand-foot skin reactions of the subject, a decrease in alopecia of the subject, a decrease in diarrhea of the subject, a decrease in anorexia of the subject, a decrease in nausea of the subject or a decrease in abdominal pain of the subject. For instance, during the treatment regimen the subject is capable of maintaining bodyweight at a level of $\pm 20\%$ of the starting weight. Alternatively, the toxicity level is measured by a decrease in the skin toxicity grade of the subject. For example, the treatment regimen results in a decrease in the skin toxicity grade of at least 1 grade.

[0005] Each of the first and/or second agent may be administered for one, two, three, four, five, six, seven or eight consecutive days. In some embodiments, the first or second agent is administered for two, three, four, five, six, seven or eight consecutive days.

[0006] The invention also provides a method of treating a disorder in a subject according to a regimen comprising administering to the subject a first agent and a second agent which is an mTor inhibitor, wherein the first and second agent are administered according to a dosing schedule comprising at least one cycle that provides for one, two, three, four, five, six, seven or eight consecutive day(s) of administration of the first agent, followed by at least one day of administration of the second agent, and wherein the regimen yields a synergistic effect in treating said neoplastic condition.

[0007] For instance, the regimen comprises at least one cycle providing for two, three, four or five consecutive days of administration of the first agent, followed by two, three, four or five consecutive days of administration of the second agent. In other cases, the regimen comprises at least two cycles providing for administration of the first agent for at least one day and administration of the second agent for at least one day.

[0008] In some embodiments, the disorder to be treated is a proliferative disorder. Proliferative disorders include neoplastic conditions. For instance, the neoplastic condition is selected from the group consisting of NSCLC, head and neck squamous cell carcinoma, pancreatic cancer, breast cancer, ovarian cancer, sarcoma, renal cell carcinoma, prostate cancer, neuroendocrine cancer, and endometrial cancer. In one embodiment, the neoplastic condition is renal cell carcinoma.

[0009] In some embodiments, the first agent is an anti-diabetic agent and the disorder to be treated is diabetes. In other embodiments, the first agent is an anti-inflammatory agent and the disorder to be treated is inflammation.

[0010] The first agent may be an anti-neoplastic agent. In some embodiments, the anti-neoplastic agent is a receptor tyrosine kinase inhibitor, including an anti-neoplastic agent which is a VEGFR or PDGFR inhibitor. For example, the anti-neoplastic agent is an antiproliferative antibody. In some embodiments, the anti-neoplastic agent is axitinib, cediranib, pazopanib, regorafenib, semaxanib, sorafenib, sunitinib, toceranib, or vandetanib.

[0011] The second agent may be an mTorC1 and mTorC2 inhibitor. For instance, the second agent inhibits both mTORC1 and mTORC2 with an IC₅₀ value of about 100 nM or less as ascertained in an *in*


vitro kinase assay. Alternatively, the second agent inhibits both mTORC1 and mTORC2 with an IC₅₀ value of about 10 nM or less as ascertained in an *in vitro* kinase assay.

[0012] In some embodiments, the first or second agent are administered parenterally, orally, intraperitoneally, intravenously, intraarterially, transdermally, intramuscularly, liposomally, via local delivery by catheter or stent, subcutaneously, intraadiposally, or intrathecally. For example, both first and second agents are administered orally.

[0013] In some embodiments, the mTor inhibitor in the methods and compositions of the invention inhibits mTORC1 selectively. For example, the mTor inhibitor inhibits mTORC1 with an IC₅₀ value of about 1000 nM or less, 500 nM or less, 100 nM or less, 50 nM or less, 10 nM or less, as ascertained in an *in vitro* kinase assay. In some embodiments, the mTor inhibitor is rapamycin or an analogue or derivative of rapamycin. In other embodiments, the mTor inhibitor is sirolimus (rapamycin), deforolimus (AP23573, MK-8669), everolimus (RAD-001), temsirolimus (CCI-779), zotarolimus (ABT-578), or biolimus A9 (umirolimus).

[0014] In some embodiments of the methods and compositions of the invention, the mTOR inhibitor binds to and directly inhibits both mTORC1 and mTORC2. For example, the mTOR inhibitor inhibits both mTORC1 and mTORC2 with an IC₅₀ value of about 500 nM or less, 400 nM or less, 300 nM or less, 200 nM or less, 100 nM or less, 50 nM or less, 10 nM or less, or 1nM or less, as ascertained in an *in vitro* kinase assay. In another embodiment, the mTOR inhibitor inhibits both mTORC1 and mTORC2 with an IC₅₀ value of about 10 nM or less as ascertained in an *in vitro* kinase assay, and the mTOR inhibitor is substantially inactive against one or more type I PI3-kinases selected from the group consisting of PI3-kinase α , PI3-kinase β , PI3-kinase γ , and PI3-kinase δ . Alternatively, the mTOR inhibitor inhibits both mTORC1 and mTORC2 with an IC₅₀ value of about 100 nM or less as ascertained in an *in vitro* kinase assay, and the IC₅₀ value is at least 2, 5 or 10 times less than its IC₅₀ value against all other type I PI3-kinases selected from the group consisting of PI3-kinase α , PI3-kinase β , PI3-kinase γ , and PI3-kinase δ . In other embodiments, the mTor inhibitor inhibits mTORC1 or mTORC2 with an IC₅₀ value of about 500 nM or less, 400 nM or less, 300 nM or less, 200 nM or less, 100 nM or less, 50 nM or less, 10 nM or less, or 1nM or less, as ascertained in an *in vitro* kinase assay, and the mTor inhibitor is also active against one or more type I PI3-kinase selected from the group consisting of PI3-kinase α , PI3-kinase β , PI3-kinase γ , and PI3-kinase δ . For example, the mTor inhibitor inhibits mTORC1 and mTORC2 with an IC₅₀ value of about 100 nM or less, 50 nM or less, 10 nM or less, or 1nM or less, and the mTor inhibitor also inhibits one or more type I PI3-kinase selected from the group consisting of PI3-kinase α , PI3-kinase β , PI3-kinase γ , and PI3-kinase δ with an IC₅₀ value of about 100 nM or less, 50 nM or less, 10 nM or less, or 1nM or less as ascertained in an *in vitro* kinase assay.

[0015] In some embodiments, the mTor inhibitor is a compound of Formula I:



Formula I

or a pharmaceutically acceptable salt thereof, wherein:

X_1 is N or C- E^1 , X_2 is N or C, X_3 is N or C, X_4 is C- R^9 or N, X_5 is N or C- E^1 , X_6 is C or N, and X_7 is C or N; and wherein no more than two nitrogen ring atoms are adjacent;

R_1 is H, -L- C_{1-10} alkyl, -L- C_{3-8} cycloalkyl, -L- C_{1-10} alkyl- C_{3-8} cycloalkyl, -L-aryl, -L-heteroaryl, -L- C_{1-10} alkylaryl, -L- C_{1-10} alkylhetaryl, -L- C_{1-10} alkylheterocycl, -L- C_{2-10} alkenyl, -L- C_{2-10} alkynyl, -L- C_{2-10} alkenyl- C_{3-8} cycloalkyl, -L- C_{2-10} alkynyl- C_{3-8} cycloalkyl, -L-heteroalkyl, -L-heteroalkylaryl, -L-heteroalkylheteroaryl, -L-heteroalkyl-heterocycl, -L-heteroalkyl- C_{3-8} cycloalkyl, -L-aralkyl, -L-heteroaralkyl, or -L-heterocycl, each of which is unsubstituted or is substituted by one or more independent R^3 ;

L is absent, -(C=O)-, -C(=O)O-, -C(=O)N(R^{31})-, -S-, -S(O)-, -S(O)₂-, -S(O)₂N(R^{31})-, or -N(R^{31})-;

E^1 and E^2 are independently -(W^1)_j- R^4 ;

M_1 is a 5, 6, 7, 8, 9, or-10 membered ring system, wherein the ring system is monocyclic or bicyclic, substituted with R_5 and additionally optionally substituted with one or more -(W^2)_k- R^2 ;

each k is 0 or 1;

j in E^1 or j in E^2 , is independently 0 or 1;

W^1 is -O-, -NR⁷-, -S(O)_{0.2}-, -C(O)-, -C(O)N(R^7)-, -N(R^7)C(O)-, -N(R^7)S(O)-, -N(R^7)S(O)₂-, -C(O)O-, -CH(R^7)N(C(O)OR⁸)-, -CH(R^7)N(C(O)R⁸)-, -CH(R^7)N(SO₂R⁸)-, -CH(R^7)N(R⁸)-, -CH(R^7)C(O)N(R⁸)-, -CH(R^7)N(R⁸)C(O)-, -CH(R^7)N(R⁸)S(O)-, or -CH(R^7)N(R⁸)S(O)₂-;

W^2 is -O-, -NR⁷-, -S(O)_{0.2}-, -C(O)-, -C(O)N(R^7)-, -N(R^7)C(O)-, -N(R^7)C(O)N(R⁸)-, -N(R^7)S(O)-, -N(R^7)S(O)₂-, -C(O)O-, -CH(R^7)N(C(O)OR⁸)-, -CH(R^7)N(C(O)R⁸)-, -CH(R^7)N(SO₂R⁸)-, -CH(R^7)N(R⁸)-, -CH(R^7)C(O)N(R⁸)-, -CH(R^7)N(R⁸)C(O)-, -CH(R^7)N(R⁸)S(O)-, or -CH(R^7)N(R⁸)S(O)₂-;

R^2 is hydrogen, halogen, -OH, - R^{31} , -CF₃, -OCF₃, -OR³¹, -NR³¹R³², -NR³⁴R³⁵, -C(O)R³¹, -CO₂R³¹, -C(=O)NR³¹R³², -C(=O)NR³⁴R³⁵, -NO₂, -CN, -S(O)_{0.2}R³¹, -SO₂NR³¹R³², -SO₂NR³⁴R³⁵, -NR³¹C(=O)R³², -NR³¹C(=O)OR³², -NR³¹C(=O)NR³²R³³, -NR³¹S(O)_{0.2}R³², -C(=S)OR³¹, -C(=O)SR³¹, -NR³¹C(=NR³²)NR³³R³², -NR³¹C(=NR³²)OR³³, -NR³¹C(=NR³²)SR³³, -OC(=O)OR³³, -OC(=O)NR³¹R³², -OC(=O)SR³¹, -SC(=O)OR³¹, -P(O)OR³¹OR³², -SC(=O)NR³¹R³², aryl (e.g. bicyclic aryl, unsubstituted aryl, or substituted monocyclic aryl), hetaryl, C_{1-10} alkyl, C_{3-8} cycloalkyl, C_{1-10} alkyl- C_{3-8} cycloalkyl, C_{3-8} cycloalkyl- C_{1-10} alkyl, C_{3-8} cycloalkyl- C_{2-10} alkenyl, C_{3-8} cycloalkyl- C_{2-10} alkynyl, C_{1-10} alkyl- C_{2-10} alkenyl, C_{1-10} alkyl- C_{2-10} alkynyl, C_{1-10} alkylaryl (e.g. C_{2-10} alkyl-monocyclic aryl, C_{1-10} alkyl-substituted monocyclic aryl, or C_{1-10} alkylbicycloaryl), C_{1-10} alkylhetaryl, C_{1-10} alkylheterocycl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{2-10}

₁₀alkenyl-C₁₋₁₀alkyl, C₂₋₁₀alkynyl-C₁₋₁₀alkyl, C₂₋₁₀alkenylaryl, C₂₋₁₀alkenylhetaryl, C₂₋₁₀alkenylheteroalkyl, C₂₋₁₀alkenylheterocyclyl, C₂₋₁₀alkenyl-C₃₋₈cycloalkyl, C₂₋₁₀alkynylaryl, C₂₋₁₀alkynylhetaryl, C₂₋₁₀alkynylheteroalkyl, C₂₋₁₀alkynylheterocyclyl, C₂₋₁₀alkynyl-C₃₋₈cycloalkenyl, C₁₋₁₀alkoxy C₁₋₁₀alkyl, C₁₋₁₀alkoxy-C₂₋₁₀alkenyl, C₁₋₁₀alkoxy-C₂₋₁₀alkynyl, heterocyclyl, heteroalkyl, heterocyclyl-C₁₋₁₀alkyl, heterocyclyl-C₂₋₁₀alkenyl, heterocyclyl-C₂₋₁₀alkynyl, aryl-C₁₋₁₀alkyl (e.g. monocyclic aryl-C₂₋₁₀alkyl, substituted monocyclic aryl-C₁₋₁₀alkyl, or bicycloaryl-C₁₋₁₀alkyl), aryl-C₂₋₁₀alkenyl, aryl-C₂₋₁₀alkynyl, aryl-heterocyclyl, hetaryl-C₁₋₁₀alkyl, hetaryl-C₂₋₁₀alkenyl, hetaryl-C₂₋₁₀alkynyl, hetaryl-C₃₋₈cycloalkyl, hetaryl-heteroalkyl, or hetaryl-heterocyclyl, wherein each of said bicyclic aryl or heteroaryl moiety is unsubstituted, or wherein each of bicyclic aryl, heteroaryl moiety or monocyclic aryl moiety is substituted with one or more independent alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, halo, -OH, -R³¹, -CF₃, -OCF₃, -OR³¹, -NR³¹R³², -NR³⁴R³⁵, -C(O)R³¹, -CO₂R³¹, -C(=O)NR³¹R³², -C(=O)NR³⁴R³⁵, -NO₂, -CN, -S(O)₀₋₂R³¹, -SO₂NR³¹R³², -SO₂NR³⁴R³⁵, -NR³¹C(=O)R³², -NR³¹C(=O)OR³², -NR³¹C(=O)NR³²R³³, -NR³¹S(O)₀₋₂R³², -C(=S)OR³¹, -C(=O)SR³¹, -NR³¹C(=NR³²)NR³³R³², -NR³¹C(=NR³²)OR³³, -NR³¹C(=NR³²)SR³³, -OC(=O)OR³³, -OC(=O)NR³¹R³², -OC(=O)SR³¹, -SC(=O)OR³¹, -P(O)OR³¹OR³², or -SC(=O)NR³¹R³², and wherein each of said alkyl, cycloalkyl, heterocyclyl, or heteroalkyl moiety is unsubstituted or is substituted with one or more alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, halo, -OH, -R³¹, -CF₃, -OCF₃, -OR³¹, -O-aryl, -NR³¹R³², -NR³⁴R³⁵, -C(O)R³¹, -CO₂R³¹, -C(=O)NR³⁴R³⁵, or -C(=O)NR³¹R³²;

R³ and R⁴ are independently hydrogen, halogen, -OH, -R³¹, -CF₃, -OCF₃, -OR³¹, -NR³¹R³², -NR³⁴R³⁵, -C(O)R³¹, -CO₂R³¹, -C(=O)NR³¹R³², -C(=O)NR³⁴R³⁵, -NO₂, -CN, -S(O)₀₋₂R³¹, -SO₂NR³¹R³², -SO₂NR³⁴R³⁵, -NR³¹C(=O)R³², -NR³¹C(=O)OR³², -NR³¹C(=O)NR³²R³³, -NR³¹S(O)₀₋₂R³², -C(=S)OR³¹, -C(=O)SR³¹, -NR³¹C(=NR³²)NR³³R³², -NR³¹C(=NR³²)OR³³, -NR³¹C(=NR³²)SR³³, -OC(=O)OR³³, -OC(=O)NR³¹R³², -OC(=O)SR³¹, -SC(=O)OR³¹, -P(O)OR³¹OR³², -SC(=O)NR³¹R³², aryl, hetaryl, C₁₋₄alkyl, C₁₋₁₀alkyl, C₃₋₈cycloalkyl, C₁₋₁₀alkyl-C₃₋₈cycloalkyl, C₃₋₈cycloalkyl-C₁₋₁₀alkyl, C₃₋₈cycloalkyl-C₂₋₁₀alkenyl, C₃₋₈cycloalkyl-C₂₋₁₀alkynyl, C₁₋₁₀alkyl-C₂₋₁₀alkenyl, C₁₋₁₀alkyl-C₂₋₁₀alkynyl, C₁₋₁₀alkylaryl, C₁₋₁₀alkylhetaryl, C₁₋₁₀alkylheterocyclyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₂₋₁₀alkenyl-C₁₋₁₀alkyl, C₂₋₁₀alkynyl-C₁₋₁₀alkyl, C₂₋₁₀alkenylaryl, C₂₋₁₀alkenylhetaryl, C₂₋₁₀alkenylheteroalkyl, C₂₋₁₀alkenylheterocyclyl, C₂₋₁₀alkenyl-C₃₋₈cycloalkyl, C₂₋₁₀alkynyl-C₃₋₈cycloalkyl, C₂₋₁₀alkynylaryl, C₂₋₁₀alkynylhetaryl, C₂₋₁₀alkynylheteroalkyl, C₂₋₁₀alkynylheterocyclyl, C₁₋₁₀alkoxy C₁₋₁₀alkyl, C₁₋₁₀alkoxy-C₂₋₁₀alkenyl, C₁₋₁₀alkoxy-C₂₋₁₀alkynyl, heterocyclyl, heterocyclyl-C₁₋₁₀alkyl, heterocyclyl-C₂₋₁₀alkenyl, heterocyclyl-C₂₋₁₀alkynyl, aryl-C₁₋₁₀alkyl, aryl-C₂₋₁₀alkenyl, aryl-C₂₋₁₀alkynyl, aryl-heterocyclyl, hetaryl-C₁₋₁₀alkyl, hetaryl-C₂₋₁₀alkenyl, hetaryl-C₂₋₁₀alkynyl, hetaryl-C₃₋₈cycloalkyl, heteroalkyl, hetaryl-heteroalkyl, or hetaryl-heterocyclyl, wherein each of said aryl or heteroaryl moiety is unsubstituted or is substituted with one or more independent halo, -OH, -R³¹, -CF₃, -OCF₃, -OR³¹, -NR³¹R³², -NR³⁴R³⁵, -C(O)R³¹, -CO₂R³¹, -C(=O)NR³¹R³², -C(=O)NR³⁴R³⁵, -NO₂, -CN, -S(O)₀₋₂R³¹, -SO₂NR³¹R³², -SO₂NR³⁴R³⁵, -NR³¹C(=O)R³², -NR³¹C(=O)OR³², -NR³¹C(=O)NR³²R³³, -NR³¹S(O)₀₋₂R³², -C(=S)OR³¹, -C(=O)SR³¹, -NR³¹C(=NR³²)NR³³R³², -NR³¹C(=NR³²)OR³³, -NR³¹C(=NR³²)SR³³, -

OC(=O)OR³³, -OC(=O)NR³¹R³², -OC(=O)SR³¹, -SC(=O)OR³¹, -P(O)OR³¹OR³², or -SC(=O)NR³¹R³², and wherein each of said alkyl, cycloalkyl, heterocyclyl, or heteroalkyl moiety is unsubstituted or is substituted with one or more halo, -OH, -R³¹, -CF₃, -OCF₃, -OR³¹, -O-aryl, -NR³¹R³², -NR³⁴R³⁵, -C(O)R³¹, -CO₂R³¹, -C(=O)NR³⁴R³⁵, or -C(=O)NR³¹R³²;

R⁵ is hydrogen, halogen, -OH, -R³¹, -CF₃, -OCF₃, -OR³¹, -NR³¹R³², -NR³⁴R³⁵, -C(O)R³¹, -CO₂R³¹, -C(=O)NR³¹R³², -C(=O)NR³⁴R³⁵, -NO₂, -CN, -S(O)₀₋₂R³¹, -SO₂NR³¹R³², -SO₂NR³⁴R³⁵, -NR³¹C(=O)R³², -NR³¹C(=O)OR³², -NR³¹C(=O)NR³²R³³, -NR³¹S(O)₀₋₂R³², -C(=S)OR³¹, -C(=O)SR³¹, -NR³¹C(=NR³²)NR³³R³², -NR³¹C(=NR³²)OR³³, -NR³¹C(=NR³²)SR³³, -OC(=O)OR³³, -OC(=O)NR³¹R³², -OC(=O)SR³¹, -SC(=O)OR³¹, -P(O)OR³¹OR³², or -SC(=O)NR³¹R³²;

each of R³¹, R³², and R³³ is independently H or C₁₋₁₀alkyl, wherein the C₁₋₁₀alkyl is unsubstituted or is substituted with one or more aryl, heteroalkyl, heterocyclyl, or hetaryl group, wherein each of said aryl, heteroalkyl, heterocyclyl, or hetaryl group is unsubstituted or is substituted with one or more halo, -OH, -C₁₋₁₀alkyl, -CF₃, -O-aryl, -OCF₃, -OC₁₋₁₀alkyl, -NH₂, -N(C₁₋₁₀alkyl)(C₁₋₁₀alkyl), -NH(C₁₋₁₀alkyl), -NH(aryl), -NR³⁴R³⁵, -C(O)(C₁₋₁₀alkyl), -C(O)(C₁₋₁₀alkyl-aryl), -C(O)(aryl), -CO₂-C₁₋₁₀alkyl, -CO₂-C₁₋₁₀alkylaryl, -CO₂-aryl, -C(=O)N(C₁₋₁₀alkyl)(C₁₋₁₀alkyl), -C(=O)NH(C₁₋₁₀alkyl), -C(=O)NR³⁴R³⁵, -C(=O)NH₂, -OCF₃, -O(C₁₋₁₀alkyl), -O-aryl, -N(aryl)(C₁₋₁₀alkyl), -NO₂, -CN, -S(O)₀₋₂C₁₋₁₀alkyl, -S(O)₀₋₂C₁₋₁₀alkylaryl, -S(O)₀₋₂aryl, -SO₂N(aryl), -SO₂N(C₁₋₁₀alkyl)(C₁₋₁₀alkyl), -SO₂NH(C₁₋₁₀alkyl) or -SO₂NR³⁴R³⁵;

R³⁴ and R³⁵ in -NR³⁴R³⁵, -C(=O)NR³⁴R³⁵, or -SO₂NR³⁴R³⁵, are taken together with the nitrogen atom to which they are attached to form a 3-10 membered saturated or unsaturated ring; wherein said ring is independently unsubstituted or is substituted by one or more -NR³¹R³², hydroxyl, halogen, oxo, aryl, hetaryl, C₁₋₆alkyl, or O-aryl, and wherein said 3-10 membered saturated or unsaturated ring independently contains 0, 1, or 2 more heteroatoms in addition to the nitrogen atom;


each of R⁷ and R⁸ is independently hydrogen, C₁₋₁₀alkyl, C₂₋₁₀alkenyl, aryl, heteroaryl, heterocyclyl or C₃₋₁₀cycloalkyl, each of which except for hydrogen is unsubstituted or is substituted by one or more independent R⁶;

R⁶ is halo, -OR³¹, -SH, -NH₂, -NR³⁴R³⁵, -NR³¹R³², -CO₂R³¹, -CO₂aryl, -C(=O)NR³¹R³², C(=O)NR³⁴R³⁵, -NO₂, -CN, -S(O)₀₋₂C₁₋₁₀alkyl, -S(O)₀₋₂aryl, -SO₂NR³⁴R³⁵, -SO₂NR³¹R³², C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl; aryl-C₁₋₁₀alkyl, aryl-C₂₋₁₀alkenyl, aryl-C₂₋₁₀alkynyl, hetaryl-C₁₋₁₀alkyl, hetaryl-C₂₋₁₀alkenyl, hetaryl-C₂₋₁₀alkynyl, wherein each of said alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heterocyclyl, or hetaryl group is unsubstituted or is substituted with one or more independent halo, cyano, nitro, -OC₁₋₁₀alkyl, C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, haloC₁₋₁₀alkyl, haloC₂₋₁₀alkenyl, haloC₂₋₁₀alkynyl, -COOH, -C(=O)NR³¹R³², -C(=O)NR³⁴R³⁵, -SO₂NR³⁴R³⁵, -SO₂NR³¹R³², -NR³¹R³², or -NR³⁴R³⁵; and

R⁹ is H, halo, -OR³¹, -SH, -NH₂, -NR³⁴R³⁵, -NR³¹R³², -CO₂R³¹, -CO₂aryl, -C(=O)NR³¹R³², C(=O)NR³⁴R³⁵, -NO₂, -CN, -S(O)₀₋₂C₁₋₁₀alkyl, -S(O)₀₋₂aryl, -SO₂NR³⁴R³⁵, -SO₂NR³¹R³², C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl; aryl-C₁₋₁₀alkyl, aryl-C₂₋₁₀alkenyl, aryl-C₂₋₁₀alkynyl, hetaryl-C₁₋₁₀alkyl, hetaryl-C₂₋₁₀alkenyl, hetaryl-C₂₋₁₀alkynyl, wherein each of said alkyl, alkenyl, alkynyl, aryl, heteroalkyl,

heterocyclyl, or hetaryl group is unsubstituted or is substituted with one or more independent halo, cyano, nitro, $-\text{OC}_{1-10}\text{alkyl}$, $\text{C}_{1-10}\text{alkyl}$, $\text{C}_{2-10}\text{alkenyl}$, $\text{C}_{2-10}\text{alkynyl}$, $\text{haloC}_{1-10}\text{alkyl}$, $\text{haloC}_{2-10}\text{alkenyl}$, $\text{haloC}_{2-10}\text{alkynyl}$, $-\text{COOH}$, $-\text{C}(=\text{O})\text{NR}^{31}\text{R}^{32}$, $-\text{C}(=\text{O})\text{NR}^{34}\text{R}^{35}$, $-\text{SO}_2\text{NR}^{34}\text{R}^{35}$, $-\text{SO}_2\text{NR}^{31}\text{R}^{32}$, $-\text{NR}^{31}\text{R}^{32}$, or $-\text{NR}^{34}\text{R}^{35}$.

[0016] The invention further provides a method of treating a disorder in a subject according to a regimen comprising administering to the subject a first agent which is an antiangiogenic agent and a second agent which is a compound of Formula:



or a pharmaceutically acceptable salt thereof, wherein:

X₁ is N or C-E¹ and X₂ is N; or X₁ is NH or CH-E¹ and X₂ is C;

R₁ is hydrogen, -L-C₁₋₁₀alkyl, -L-C₃₋₈cycloalkyl, -L-C₁₋₁₀alkyl-C₃₋₈cycloalkyl, -L-aryl, -L-heteroaryl, -L-C₁₋₁₀alkylaryl, -L-C₁₋₁₀alkylheteroaryl, -L-C₁₋₁₀alkylheterocyclyl, -L-C₂₋₁₀alkenyl, -L-C₂₋₁₀alkynyl, -L-C₂₋₁₀alkenyl-C₃₋₈cycloalkyl, -L-C₂₋₁₀alkynyl-C₃₋₈cycloalkyl, -L-heteroalkyl, -L-heteroalkylaryl, -L-heteroalkylheteroaryl, -L-heteroalkyl-heterocyclyl, -L-heteroalkyl-C₃₋₈cycloalkyl, -L-aralkyl, -L-heteroaralkyl, or -L-heterocyclyl, each of which is unsubstituted or substituted by one or more independent R³ substituents;

L is absent, C=O, -C(=O)O-, -C(=O)N(R³¹)-, -S-, -S(O)-, -S(O)₂-, -S(O)₂N(R³¹)-, or -N(R³¹)-;

k is 0 or 1;

E^1 and E^2 are independently $-(W^1)_i - R^4$;

j in E^1 or j in E^2 , is independently 0 or 1;

W¹ is $-\text{O}-$, $-\text{NR}^7-$, $-\text{S}(\text{O})_{0.2}-$, $-\text{C}(\text{O})-$, $-\text{C}(\text{O})\text{N}(\text{R}^7)-$, $-\text{N}(\text{R}^7)\text{C}(\text{O})-$, $-\text{N}(\text{R}^7)\text{S}(\text{O})-$, $-\text{N}(\text{R}^7)\text{S}(\text{O})_2-$, $-\text{C}(\text{O})\text{O}-$, $-\text{CH}(\text{R}^7)\text{N}(\text{C}(\text{O})\text{OR}^8)-$, $-\text{CH}(\text{R}^7)\text{N}(\text{C}(\text{O})\text{R}^8)-$, $-\text{CH}(\text{R}^7)\text{N}(\text{SO}_2\text{R}^8)-$, $-\text{CH}(\text{R}^7)\text{N}(\text{R}^8)-$, $-\text{CH}(\text{R}^7)\text{C}(\text{O})\text{N}(\text{R}^8)-$, $-\text{CH}(\text{R}^7)\text{N}(\text{R}^8)\text{C}(\text{O})-$, $-\text{CH}(\text{R}^7)\text{N}(\text{R}^8)\text{S}(\text{O})-$, or $-\text{CH}(\text{R}^7)\text{N}(\text{R}^8)\text{S}(\text{O})_2-$;

W² is $-\text{O}-$, $-\text{NR}^7-$, $-\text{S}(\text{O})_{0-2}-$, $-\text{C}(\text{O})-$, $-\text{C}(\text{O})\text{N}(\text{R}^7)-$, $-\text{N}(\text{R}^7)\text{C}(\text{O})-$, $-\text{N}(\text{R}^7)\text{C}(\text{O})\text{N}(\text{R}^8)-$, $-\text{N}(\text{R}^7)\text{S}(\text{O})-$, $-\text{N}(\text{R}^7)\text{S}(\text{O})_2-$, $-\text{C}(\text{O})\text{O}-$, $-\text{CH}(\text{R}^7)\text{N}(\text{C}(\text{O})\text{OR}^8)-$, $-\text{CH}(\text{R}^7)\text{N}(\text{C}(\text{O})\text{R}^8)-$, $-\text{CH}(\text{R}^7)\text{N}(\text{SO}_2\text{R}^8)-$, $-\text{CH}(\text{R}^7)\text{N}(\text{R}^8)-$, $-\text{CH}(\text{R}^7)\text{C}(\text{O})\text{N}(\text{R}^8)-$, $-\text{CH}(\text{R}^7)\text{N}(\text{R}^8)\text{C}(\text{O})-$, $-\text{CH}(\text{R}^7)\text{N}(\text{R}^8)\text{S}(\text{O})-$, or $-\text{CH}(\text{R}^7)\text{N}(\text{R}^8)\text{S}(\text{O})_2-$;

R^3 and R^4 are independently hydrogen, halogen, $-OH$, $-R^{31}$, $-CF_3$, $-OCF_3$, $-OR^{31}$, $-NR^{31}R^{32}$, $-NR^{34}R^{35}$, $-C(O)R^{31}$, $-CO_2R^{31}$, $-C(=O)NR^{31}R^{32}$, $-C(=O)NR^{34}R^{35}$, $-NO_2$, $-CN$, $-S(O)_{0-2}R^{31}$, $-SO_2NR^{31}R^{32}$, $-SO_2NR^{34}R^{35}$, $-NR^{31}C(=O)R^{32}$, $-NR^{31}C(=O)OR^{32}$, $-NR^{31}C(=O)NR^{32}R^{33}$, $-NR^{31}S(O)_{0-2}R^{32}$, $-C(=S)OR^{31}$, $-C(=O)SR^{31}$, $-NR^{31}C(=NR^{32})NR^{33}R^{32}$, $-NR^{31}C(=NR^{32})OR^{33}$, $-NR^{31}C(=NR^{32})SR^{33}$, $-OC(=O)OR^{33}$, $-$

OC(=O)NR³¹R³², -OC(=O)SR³¹, -SC(=O)OR³¹, -P(O)OR³¹OR³², -SC(=O)NR³¹R³², aryl, heteroaryl, C₁₋₁₀alkyl, C₃₋₈cycloalkyl, C₁₋₁₀alkyl-C₃₋₈cycloalkyl, C₃₋₈cycloalkyl-C₁₋₁₀alkyl, C₃₋₈cycloalkyl-C₂₋₁₀alkenyl, C₃₋₈cycloalkyl-C₂₋₁₀alkynyl, C₁₋₁₀alkyl-C₂₋₁₀alkenyl, C₁₋₁₀alkyl-C₂₋₁₀alkynyl, C₁₋₁₀alkylaryl, C₁₋₁₀alkylheteroaryl, C₁₋₁₀alkylheterocyclyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₂₋₁₀alkenyl-C₁₋₁₀alkyl, C₂₋₁₀alkynyl-C₁₋₁₀alkyl, C₂₋₁₀alkenylaryl, C₂₋₁₀alkenylheteroaryl, C₂₋₁₀alkenylheteroalkyl, C₂₋₁₀alkenylheterocyclyl, C₂₋₁₀alkenyl-C₃₋₈cycloalkyl, C₂₋₁₀alkynyl-C₃₋₈cycloalkyl, C₂₋₁₀alkynylaryl, C₂₋₁₀alkynylheteroaryl, C₂₋₁₀alkynylheteroalkyl, C₂₋₁₀alkynylheterocyclyl, C₂₋₁₀alkynyl-C₃₋₈cycloalkenyl, C₁₋₁₀alkoxy C₁₋₁₀alkyl, C₁₋₁₀alkoxy-C₂₋₁₀alkenyl, C₁₋₁₀alkoxy-C₂₋₁₀alkynyl, heterocyclyl, heterocyclyl-C₁₋₁₀alkyl, heterocyclyl-C₂₋₁₀alkenyl, heterocyclyl-C₂₋₁₀alkynyl, aryl-C₁₋₁₀alkyl, aryl-C₂₋₁₀alkenyl, aryl-C₂₋₁₀alkynyl, aryl-heterocyclyl, heteroaryl-C₁₋₁₀alkyl, heteroaryl-C₂₋₁₀alkenyl, heteroaryl-C₂₋₁₀alkynyl, heteroaryl-C₃₋₈cycloalkyl, heteroalkyl, heteroaryl-heteroalkyl, or heteroaryl-heterocyclyl, wherein each of said aryl or heteroaryl moiety is unsubstituted or is substituted with one or more independent halo, -OH, -R³¹, -CF₃, -OCF₃, -OR³¹, -NR³¹R³², -NR³⁴R³⁵, -C(O)R³¹, -CO₂R³¹, -C(=O)NR³¹R³², -C(=O)NR³⁴R³⁵, -NO₂, -CN, -S(O)₀₋₂R³¹, -SO₂NR³¹R³², -SO₂NR³⁴R³⁵, -NR³¹C(=O)R³², -NR³¹C(=O)OR³², -NR³¹C(=O)NR³²R³³, -NR³¹S(O)₀₋₂R³², -C(=S)OR³¹, -C(=O)SR³¹, -NR³¹C(=NR³²)NR³³R³², -NR³¹C(=NR³²)OR³³, -NR³¹C(=NR³²)SR³³, -OC(=O)OR³³, -OC(=O)NR³¹R³², -OC(=O)SR³¹, -SC(=O)OR³¹, -P(O)OR³¹OR³², or -SC(=O)NR³¹R³², and wherein each of said alkyl, cycloalkyl, heterocyclyl, or heteroalkyl moiety is unsubstituted or substituted with one or more halo, -OH, -R³¹, -CF₃, -OCF₃, -OR³¹, -O-aryl, -NR³¹R³², -NR³⁴R³⁵, -C(O)R³¹, -CO₂R³¹, -C(=O)NR³⁴R³⁵, or -C(=O)NR³¹R³²;

R² is hydrogen, halogen, -OH, -R³¹, -CF₃, -OCF₃, -OR³¹, -NR³¹R³², -NR³⁴R³⁵, -C(O)R³¹, -CO₂R³¹, -C(=O)NR³¹R³², -C(=O)NR³⁴R³⁵, -NO₂, -CN, -S(O)₀₋₂R³¹, -SO₂NR³¹R³², -SO₂NR³⁴R³⁵, -NR³¹C(=O)R³², -NR³¹C(=O)OR³², -NR³¹C(=O)NR³²R³³, -NR³¹S(O)₀₋₂R³², -C(=S)OR³¹, -C(=O)SR³¹, -NR³¹C(=NR³²)NR³³R³², -NR³¹C(=NR³²)OR³³, -NR³¹C(=NR³²)SR³³, -OC(=O)OR³³, -OC(=O)NR³¹R³², -OC(=O)SR³¹, -SC(=O)OR³¹, -P(O)OR³¹OR³², -SC(=O)NR³¹R³², bicyclic aryl, substituted monocyclic aryl, heteroaryl, C₁₋₁₀alkyl, C₃₋₈cycloalkyl, C₁₋₁₀alkyl-C₃₋₈cycloalkyl, C₃₋₈cycloalkyl-C₁₋₁₀alkyl, C₃₋₈cycloalkyl-C₂₋₁₀alkenyl, C₃₋₈cycloalkyl-C₂₋₁₀alkynyl, C₂₋₁₀alkyl-monocyclic aryl, monocyclic aryl-C₂₋₁₀alkyl, C₁₋₁₀alkylbicycloaryl, bicycloaryl-C₁₋₁₀alkyl, substituted C₁₋₁₀alkylaryl, substituted aryl-C₁₋₁₀alkyl, C₁₋₁₀alkylheteroaryl, C₁₋₁₀alkylheterocyclyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₂₋₁₀alkenylaryl, C₂₋₁₀alkenylheteroaryl, C₂₋₁₀alkenylheteroalkyl, C₂₋₁₀alkenylheterocyclyl, C₂₋₁₀alkynylaryl, C₂₋₁₀alkynylheteroaryl, C₂₋₁₀alkynylheteroalkyl, C₂₋₁₀alkynylheterocyclyl, C₂₋₁₀alkenyl-C₃₋₈cycloalkyl, C₂₋₁₀alkynyl-C₃₋₈cycloalkenyl, C₁₋₁₀alkoxy C₁₋₁₀alkyl, C₁₋₁₀alkoxyC₂₋₁₀alkenyl, C₁₋₁₀alkoxyC₂₋₁₀alkynyl, heterocyclyl, heterocyclyl C₁₋₁₀alkyl, heterocyclylC₂₋₁₀alkenyl, heterocyclyl-C₂₋₁₀alkynyl, aryl-C₂₋₁₀alkenyl, aryl-C₂₋₁₀alkynyl, aryl-heterocyclyl, heteroaryl-C₁₋₁₀alkyl, heteroaryl-C₂₋₁₀alkenyl, heteroaryl-C₂₋₁₀alkynyl, heteroaryl-C₃₋₈cycloalkyl, heteroaryl-heteroalkyl, or heteroaryl-heterocyclyl, wherein each of said bicyclic aryl, monocyclic aryl, or heteroaryl moiety is unsubstituted or is substituted with one or more independent halo, -OH, -R³¹, -CF₃, -OCF₃, -OR³¹, -NR³¹R³², -NR³⁴R³⁵, -C(O)R³¹, -CO₂R³¹, -C(=O)NR³¹R³², -C(=O)NR³⁴R³⁵, -NO₂, -CN, -S(O)₀₋₂R³¹, -SO₂NR³¹R³², -SO₂NR³⁴R³⁵, -NR³¹C(=O)R³², -NR³¹C(=O)OR³², -NR³¹C(=O)NR³²R³³, -NR³¹S(O)₀₋₂R³², -C(=S)OR³¹, -C(=O)SR³¹, -

$\text{NR}^{31}\text{C}(=\text{NR}^{32})\text{NR}^{33}\text{R}^{32}$, $-\text{NR}^{31}\text{C}(=\text{NR}^{32})\text{OR}^{33}$, $-\text{NR}^{31}\text{C}(=\text{NR}^{32})\text{SR}^{33}$, $-\text{OC}(=\text{O})\text{OR}^{33}$, $-\text{OC}(=\text{O})\text{NR}^{31}\text{R}^{32}$, $-\text{OC}(=\text{O})\text{SR}^{31}$, $-\text{SC}(=\text{O})\text{OR}^{31}$, $-\text{P}(\text{O})\text{OR}^{31}\text{OR}^{32}$, or $-\text{SC}(=\text{O})\text{NR}^{31}\text{R}^{32}$, and wherein each of said alkyl, cycloalkyl, heterocyclyl, or heteroalkyl moiety is unsubstituted or is substituted with one or more halo, $-\text{OH}$, $-\text{R}^{31}$, $-\text{CF}_3$, $-\text{OCF}_3$, $-\text{OR}^{31}$, $-\text{O-aryl}$, $-\text{NR}^{31}\text{R}^{32}$, $-\text{NR}^{34}\text{R}^{35}$, $-\text{C}(\text{O})\text{R}^{31}$, $-\text{CO}_2\text{R}^{31}$, $-\text{C}(=\text{O})\text{NR}^{34}\text{R}^{35}$, or $-\text{C}(=\text{O})\text{NR}^{31}\text{R}^{32}$;

each of R^{31} , R^{32} , and R^{33} is independently H or C_{1-10} alkyl, wherein the C_{1-10} alkyl is unsubstituted or is substituted with one or more aryl, heteroalkyl, heterocyclyl, or heteroaryl substituent, wherein each of said aryl, heteroalkyl, heterocyclyl, or heteroaryl substituent is unsubstituted or is substituted with one or more halo, $-\text{OH}$, $-\text{C}_{1-10}$ alkyl, $-\text{CF}_3$, $-\text{O-aryl}$, $-\text{OCF}_3$, $-\text{OC}_{1-10}$ alkyl, $-\text{NH}_2$, $-\text{N}(\text{C}_{1-10}\text{alkyl})(\text{C}_{1-10}\text{alkyl})$, $-\text{NH}(\text{C}_{1-10}\text{alkyl})$, $-\text{NH}(\text{aryl})$, $-\text{NR}^{34}\text{R}^{35}$, $-\text{C}(\text{O})(\text{C}_{1-10}\text{alkyl})$, $-\text{C}(\text{O})(\text{C}_{1-10}\text{alkyl-aryl})$, $-\text{C}(\text{O})(\text{aryl})$, $-\text{CO}_2\text{-C}_{1-10}\text{alkyl}$, $-\text{CO}_2\text{-C}_{1-10}\text{alkylaryl}$, $-\text{CO}_2\text{-aryl}$, $-\text{C}(=\text{O})\text{N}(\text{C}_{1-10}\text{alkyl})(\text{C}_{1-10}\text{alkyl})$, $-\text{C}(=\text{O})\text{NH}(\text{C}_{1-10}\text{alkyl})$, $-\text{C}(=\text{O})\text{NR}^{34}\text{R}^{35}$, $-\text{C}(=\text{O})\text{NH}_2$, $-\text{OCF}_3$, $-\text{O}(\text{C}_{1-10}\text{alkyl})$, $-\text{O-aryl}$, $-\text{N}(\text{aryl})(\text{C}_{1-10}\text{alkyl})$, $-\text{NO}_2$, $-\text{CN}$, $-\text{S}(\text{O})_{0-2}\text{C}_{1-10}\text{alkyl}$, $-\text{S}(\text{O})_{0-2}\text{C}_{1-10}\text{alkylaryl}$, $-\text{S}(\text{O})_{0-2}\text{aryl}$, $-\text{SO}_2\text{N}(\text{aryl})$, $-\text{SO}_2\text{N}(\text{C}_{1-10}\text{alkyl})(\text{C}_{1-10}\text{alkyl})$, $-\text{SO}_2\text{NH}(\text{C}_{1-10}\text{alkyl})$ or $-\text{SO}_2\text{NR}^{34}\text{R}^{35}$;


R^{34} and R^{35} in $-\text{NR}^{34}\text{R}^{35}$, $-\text{C}(=\text{O})\text{NR}^{34}\text{R}^{35}$, or $-\text{SO}_2\text{NR}^{34}\text{R}^{35}$, are taken together with the nitrogen atom to which they are attached to form a 3-10 membered saturated or unsaturated ring; wherein said ring is independently unsubstituted or is substituted by one or more $-\text{NR}^{31}\text{R}^{32}$, hydroxyl, halogen, oxo, aryl, heteroaryl, C_{1-6} alkyl, or O-aryl , and wherein said 3-10 membered saturated or unsaturated ring independently contains 0, 1, or 2 more heteroatoms in addition to the nitrogen atom;

each of R^7 and R^8 is independently hydrogen, C_{1-10} alkyl, C_{2-10} alkenyl, aryl, heteroaryl, heterocyclyl or C_{3-10} cycloalkyl, each of which except for hydrogen is unsubstituted or is substituted by one or more independent R^6 substituents; and

R^6 is halo, $-\text{OR}^{31}$, $-\text{SH}$, NH_2 , $-\text{NR}^{34}\text{R}^{35}$, $-\text{NR}^{31}\text{R}^{32}$, $-\text{CO}_2\text{R}^{31}$, $-\text{CO}_2\text{aryl}$, $-\text{C}(=\text{O})\text{NR}^{31}\text{R}^{32}$, $\text{C}(=\text{O})\text{NR}^{34}\text{R}^{35}$, $-\text{NO}_2$, $-\text{CN}$, $-\text{S}(\text{O})_{0-2}\text{C}_{1-10}\text{alkyl}$, $-\text{S}(\text{O})_{0-2}\text{aryl}$, $-\text{SO}_2\text{NR}^{34}\text{R}^{35}$, $-\text{SO}_2\text{NR}^{31}\text{R}^{32}$, C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, aryl- C_{1-10} alkyl, aryl- C_{2-10} alkenyl, aryl- C_{2-10} alkynyl, heteroaryl- C_{1-10} alkyl, heteroaryl- C_{2-10} alkenyl, or heteroaryl- C_{2-10} alkynyl, each of which is unsubstituted or is substituted with one or more independent halo, cyano, nitro, $-\text{OC}_{1-10}\text{alkyl}$, $\text{C}_{1-10}\text{alkyl}$, $\text{C}_{2-10}\text{alkenyl}$, $\text{C}_{2-10}\text{alkynyl}$, halo $\text{C}_{1-10}\text{alkyl}$, halo $\text{C}_{2-10}\text{alkenyl}$, halo $\text{C}_{2-10}\text{alkynyl}$, $-\text{COOH}$, $-\text{C}(=\text{O})\text{NR}^{31}\text{R}^{32}$, $-\text{C}(=\text{O})\text{NR}^{34}\text{R}^{35}$, $-\text{SO}_2\text{NR}^{34}\text{R}^{35}$, $-\text{SO}_2\text{NR}^{31}\text{R}^{32}$, $-\text{NR}^{31}\text{R}^{32}$, or $-\text{NR}^{34}\text{R}^{35}$;

wherein the first and second agent are administered according to a dosing schedule such that the first agent and the second agent are administered in an alternating manner; and wherein administering the first and second agent in accordance with the dosing schedule results in a synergistic effect as evidenced by a reduced toxicity level or enhanced efficacy of the first and second agent, as compared to an alternative regimen in which the first and second agent are administered simultaneously.

[0017] In some embodiments, the second agent has the Formula:



wherein:

X_1 is N or C-E¹ and X_2 is N;

R_1 is $-L-C_{1-10}$ alkyl, $-L-C_{3-8}$ cycloalkyl, $-L-C_{1-10}$ alkylheterocyclyl, or $-L$ -heterocyclyl, each of which is unsubstituted or substituted by one or more independent R^3 substituents; and

R^3 is hydrogen, $-OH$, $-OR^{31}$, $-NR^{31}R^{32}$, $-C(O)R^{31}$, $-C(=O)NR^{31}R^{32}$, $-C(=O)NR^{34}R^{35}$, aryl, heteroaryl, C_{1-10} alkyl, C_{3-8} cycloalkyl, or heterocyclyl, wherein each of said aryl or heteroaryl moiety is unsubstituted or is substituted with one or more independent alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, halo, $-OH$, $-R^{31}$, $-CF_3$, $-OCF_3$, $-OR^{31}$, $-NR^{31}R^{32}$, $-NR^{34}R^{35}$, $-C(O)R^{31}$, $-CO_2R^{31}$, $-C(=O)NR^{31}R^{32}$, $-C(=O)NR^{34}R^{35}$, $-NO_2$, $-CN$, $-S(O)_{0-2}R^{31}$, $-SO_2NR^{31}R^{32}$, $-SO_2NR^{34}R^{35}$, $-NR^{31}C(=O)R^{32}$, $-NR^{31}C(=O)OR^{32}$, $-NR^{31}C(=O)NR^{32}R^{33}$, $-NR^{31}S(O)_{0-2}R^{32}$, $-C(=S)OR^{31}$, $-C(=O)SR^{31}$, $-NR^{31}C(=NR^{32})NR^{33}R^{32}$, $-NR^{31}C(=NR^{32})OR^{33}$, $-NR^{31}C(=NR^{32})SR^{33}$, $-OC(=O)OR^{33}$, $-OC(=O)NR^{31}R^{32}$, $-OC(=O)SR^{31}$, $-SC(=O)OR^{31}$, $-P(O)OR^{31}OR^{32}$, or $-SC(=O)NR^{31}R^{32}$, and wherein each of said alkyl, cycloalkyl, or heterocyclyl moiety is unsubstituted or is substituted with one or more alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, halo, $-OH$, $-R^{31}$, $-CF_3$, $-OCF_3$, $-OR^{31}$, $-O$ -aryl, $-NR^{31}R^{32}$, $-NR^{34}R^{35}$, $-C(O)R^{31}$, $-CO_2R^{31}$, $-C(=O)NR^{34}R^{35}$, or $-C(=O)NR^{31}R^{32}$.

[0018] In some embodiments, X_1 and X_2 are N. In other embodiments, R_1 is isopropyl.

[0019] In some embodiments, the first agent is sorafenib. In some embodiments, a cycle of a dosing schedule comprises administering the first agent consecutively for at least two days, followed by administering the second agent for at least two days. For example, the cycle comprises administering the first agent for four days, followed by administering the second agent for three days.

INCORPORATION BY REFERENCE

[0020] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

BRIEF DESCRIPTION OF THE DRAWINGS

[0021] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference

to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:

[0022] **Figure 1A** shows a treatment regimen comprising simultaneous administration of an anti-neoplastic agent and an mTor inhibitor in a 786-0 renal cell carcinoma model.

[0023] **Figure 1B** shows a treatment regimen comprising simultaneous administration of an anti-neoplastic agent and an mTor inhibitor in an A498 renal cell carcinoma model.

[0024] **Figure 1C** shows a treatment regimen comprising a dosing schedule of the invention of an anti-neoplastic agent and an mTor inhibitor in a 786-0 renal cell carcinoma model.

[0025] **Figure 1D** shows a treatment regimen comprising a dosing schedule of the invention of an anti-neoplastic agent and an mTor inhibitor in an A498 renal cell carcinoma model.

[0026] **Figures 2A and 2B** show immunohistochemistry analysis of CD34 and HIF-2a expression in a treatment regimen of the invention.

[0027] **Figure 3A** shows a Western blot analysis of signaling pathways in tumors treated according to a regimen of the invention.

[0028] **Figure 3B** shows an immunohistochemistry analysis of cell proliferation in tumors treated according to a regimen of the invention.

[0029] **Figure 3C** shows an immunohistochemistry analysis of apoptosis in tumors treated according to a regimen of the invention.

[0030] **Figures 4A-4E** show the effect of a treatment regimen of the invention on hypoxia in tumor cells.

DETAILED DESCRIPTION OF THE INVENTION

[0031] Several aspects of the invention are described below with reference to example applications for illustration. It should be understood that numerous specific details, relationships, and methods are set forth to provide a full understanding of the invention. One having ordinary skill in the relevant art, however, will readily recognize that the invention can be practiced without one or more of the specific details or with other methods. Unless stated otherwise, the present invention is not limited by the illustrated ordering of acts or events, as some acts may occur in different orders and/or concurrently with other acts or events. Furthermore, not all illustrated acts or events are required to implement a methodology in accordance with the present invention.

[0032] The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. As used herein, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. Furthermore, to the extent that the terms “including”, “includes”, “having”, “has”, “with”, or variants thereof are used in either the detailed description and/or the claims, such terms are intended to be inclusive in a manner similar to the term “comprising”.

[0033] The term “about” or “approximately” means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, *i.e.*, the limitations of the measurement system. For example, “about” can mean

within 1 or more than 1 standard deviation, per the practice in the art. Alternatively, “about” can mean a range of up to 20%, up to 10%, up to 5%, or up to 1% of a given value. Alternatively, particularly with respect to biological systems or processes, the term can mean within an order of magnitude, preferably within 5-fold, and more preferably within 2-fold, of a value. Where particular values are described in the application and claims, unless otherwise stated the term “about” meaning within an acceptable error range for the particular value should be assumed.

[0034] “Treatment”, “treating”, “palliating” and “ameliorating”, as used herein, are used interchangeably. These terms refer to an approach for obtaining beneficial or desired results including but not limited to therapeutic benefit and/or a prophylactic benefit. By therapeutic benefit is meant eradication or amelioration of the underlying disorder being treated. Also, a therapeutic benefit is achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the patient, notwithstanding that the patient may still be afflicted with the underlying disorder. For prophylactic benefit, the compositions may be administered to a patient at risk of developing a particular disease, or to a patient reporting one or more of the physiological symptoms of a disease, even though a diagnosis of this disease may not have been made.

[0035] As used herein, the term “neoplastic condition” refers to the presence of cells possessing abnormal growth characteristics, such as uncontrolled proliferation, immortality, metastatic potential, rapid growth and proliferation rate, perturbed oncogenic signaling, and certain characteristic morphological features. This includes but is not limited to the growth of: (1) benign or malignant cells (e.g., tumor cells) that correlates with overexpression of a tyrosine or serine/threonine kinase; (2) benign or malignant cells (e.g., tumor cells) that correlates with abnormally high level of tyrosine or serine/threonine kinase activity. Exemplary tyrosine kinases implicated in a neoplastic condition include but are not limited to receptor tyrosine kinases such as epidermal growth factor receptors (EGF receptor), platelet derived growth factor (PDGF) receptors, and cytosolic tyrosine kinases such as *src* and *abl* kinase. Non-limiting serine/threonine kinases implicated in neoplastic condition include but are not limited to *raf* and *mek*.

[0036] The term “effective amount” or “therapeutically effective amount” refers to that amount of an inhibitor described herein that is sufficient to effect the intended application including but not limited to disease treatment, as defined below. The therapeutically effective amount may vary depending upon the intended application (*in vitro* or *in vivo*), or the subject and disease condition being treated, e.g., the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art. The term also applies to a dose that will induce a particular response in target cells, e.g., reduction of proliferation or downregulation of activity of a target protein. The specific dose will vary depending on the particular compounds chosen, the dosing regimen to be followed, whether it is administered in combination with other compounds, timing of administration, the tissue to which it is administered, and the physical delivery system in which it is carried.

[0037] A “sub-therapeutic amount” of an agent or therapy is an amount less than the effective amount for that agent or therapy, but when combined with an effective or sub-therapeutic amount of another agent or therapy can produce a result desired by the physician, due to, for example, synergy in the resulting efficacious effects, or reduced side effects.

[0038] A “synergistically effective” therapeutic amount or “synergistically effective” amount of an agent or therapy is an amount which, when combined with an effective or sub-therapeutic amount of another agent or therapy, produces a greater effect than when either of the two agents are used alone. In some embodiments, a synergistically effective therapeutic amount of an agent or therapy produces a greater effect when used in combination than the additive effects of each of the two agents or therapies when used alone. The term “greater effect” encompasses not only a reduction in symptoms of the disorder to be treated, but also an improved side effect profile, improved tolerability, improved patient compliance, improved efficacy, or any other improved clinical outcome.

[0039] As used herein, “agent” or “biologically active agent” refers to a biological, pharmaceutical, or chemical compound or other moiety. Non-limiting examples include simple or complex organic or inorganic molecule, a peptide, a protein, an oligonucleotide, an antibody, an antibody derivative, antibody fragment, a vitamin derivative, a carbohydrate, a toxin, or a chemotherapeutic compound. Various compounds can be synthesized, for example, small molecules and oligomers (e.g., oligopeptides and oligonucleotides), and synthetic organic compounds based on various core structures. In addition, various natural sources can provide compounds for screening, such as plant or animal extracts, and the like. A skilled artisan can readily recognize that there is no limit as to the structural nature of the agents of the present invention.

[0040] The term “agonist” as used herein refers to a compound having the ability to initiate or enhance a biological function of a target protein, whether by inhibiting the activity or expression of the target protein. Accordingly, the term “agonist” is defined in the context of the biological role of the target polypeptide. While preferred agonists herein specifically interact with (e.g., bind to) the target, compounds that initiate or enhance a biological activity of the target polypeptide by interacting with other members of the signal transduction pathway of which the target polypeptide is a member are also specifically included within this definition.

[0041] The terms “antagonist” and “inhibitor” are used interchangeably, and they refer to a compound having the ability to inhibit a biological function of a target protein, whether by inhibiting the activity or expression of the target protein. Accordingly, the terms “antagonist” and “inhibitors” are defined in the context of the biological role of the target protein. While preferred antagonists herein specifically interact with (e.g., bind to) the target, compounds that inhibit a biological activity of the target protein by interacting with other members of the signal transduction pathway of which the target protein is a member are also specifically included within this definition. A preferred biological activity inhibited by an antagonist is associated with the development, growth, or spread of a tumor, or an undesired immune response as manifested in autoimmune disease.

[0042] The phrase “mTOR inhibitor that binds to and directly inhibits both mTORC1 and mTORC2 kinases” refers to an mTOR inhibitor that interacts with and reduces the kinase activity of both mTORC1 and mTORC2 complexes.

[0043] An “anti-neoplastic”, “anti-cancer agent”, “anti-tumor agent” or “chemotherapeutic agent” refers to any agent useful in the treatment of a neoplastic condition. One class of anti-cancer agents comprises chemotherapeutic agents. “Chemotherapy” means the administration of one or more chemotherapeutic drugs and/or other agents to a cancer patient by various methods, including intravenous, oral, intramuscular, intraperitoneal, intravesical, subcutaneous, transdermal, buccal, or inhalation or in the form of a suppository.

[0044] As used herein, the term “antiangiogenic” refers to the ability to inhibit or impair the formation of blood vessels, including but not limited to inhibiting endothelial cell proliferation, endothelial cell migration, and capillary tube formation.

[0045] The term “cell proliferation” refers to a phenomenon by which the cell number has changed as a result of division. This term also encompasses cell growth by which the cell morphology has changed (e.g., increased in size) consistent with a proliferative signal.

[0046] The terms “co-administration,” “administered in combination with,” and their grammatical equivalents, encompass administration of two or more agents to an animal so that both agents and/or their metabolites are present in the animal at the same time. Co-administration includes simultaneous administration in separate compositions, administration at different times in separate compositions, or administration in a composition in which both agents are present. Co-administered agents may be in the same formulation. Co-administered agents may also be in different formulations.

[0047] A “therapeutic effect,” as used herein, encompasses a therapeutic benefit and/or a prophylactic benefit as described above. A prophylactic effect includes delaying or eliminating the appearance of a disease or condition, delaying or eliminating the onset of symptoms of a disease or condition, slowing, halting, or reversing the progression of a disease or condition, or any combination thereof.

[0048] The term “pharmaceutically acceptable salt” refers to salts derived from a variety of organic and inorganic counter ions well known in the art. Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids. Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like. Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases. Inorganic bases from which salts can be derived include, for example, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like. Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like, specifically such as isopropylamine, trimethylamine,

diethylamine, triethylamine, tripropylamine, and ethanolamine. In some embodiments, the pharmaceutically acceptable base addition salt is chosen from ammonium, potassium, sodium, calcium, and magnesium salts.

[0049] “Pharmaceutically acceptable carrier” or “pharmaceutically acceptable excipient” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions of the invention is contemplated. Supplementary active ingredients can also be incorporated into the compositions.

[0050] “Signal transduction” is a process during which stimulatory or inhibitory signals are transmitted into and within a cell to elicit an intracellular response. A modulator of a signal transduction pathway refers to a compound that modulates the activity of one or more cellular proteins mapped to the same specific signal transduction pathway. A modulator may augment (agonist) or suppress (antagonist) the activity of a signaling molecule.

[0051] The term “selective inhibition” or “selectively inhibit” as applied to a biologically active agent refers to the agent’s ability to selectively reduce the target signaling activity as compared to off-target signaling activity, via direct or indirect interaction with the target.

[0052] “Subject” refers to an animal, such as a mammal, for example a human. The methods described herein can be useful in both human therapeutics, pre-clinical, and veterinary applications. In some embodiments, the subject is a mammal, and in some embodiments, the subject is human.

[0053] The term “*in vivo*” refers to an event that takes place in a subject’s body.

[0054] The term “*in vitro*” refers to an event that takes place outside of a subject’s body. For example, an *in vitro* assay encompasses any assay run outside of a subject assay. *In vitro* assays encompass cell-based assays in which cells alive or dead are employed. *In vitro* assays also encompass a cell-free assay in which no intact cells are employed.

[0055] Unless otherwise stated, the connections of compound name moieties are at the rightmost recited moiety. That is, the substituent name starts with a terminal moiety, continues with any linking moieties, and ends with the linking moiety. For example, heteroarylthio C₁₋₄ alkyl has a heteroaryl group connected through a thio sulfur to a C₁₋₄ alkyl radical that connects to the chemical species bearing the substituent. This condition does not apply where a formula such as, for example “-L-C₁₋₁₀ alkyl – C₃₋₈cycloalkyl” is represented. In such case, the terminal group is a C₃₋₈cycloalkyl group attached to a linking C₁₋₁₀ alkyl moiety which is attached to an element L, which is itself connected to the chemical species bearing the substituent.

[0056] “Alkyl” refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to ten carbon atoms (e.g., C₁-C₁₀ alkyl). Whenever it appears herein, a numerical range such as “1 to 10” refers to each integer in the given range; e.g., “1 to 10 carbon atoms” means that the alkyl group may consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 10 carbon atoms, although the present definition also covers the

occurrence of the term “alkyl” where no numerical range is designated. In some embodiments, it is a C₁-C₄ alkyl group. Typical alkyl groups include, but are in no way limited to, methyl, ethyl, propyl, isopropyl, n-butyl, iso-butyl, sec-butyl, isobutyl, tertiary butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, nonyl, decyl, and the like. The alkyl is attached to the rest of the molecule by a single bond, for example, methyl (Me), ethyl (Et), *n*-propyl, 1-methylethyl (*iso*-propyl), *n*-butyl, *n*-pentyl, 1,1-dimethylethyl (*t*-butyl), 3-methylhexyl, 2-methylhexyl, and the like. Unless stated otherwise specifically in the specification, an alkyl group is optionally substituted by one or more of substituents which independently are: alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilyl, -OR^a, -SR^a, -OC(O)-R^a, -N(R^a)₂, -C(O)R^a, -C(O)OR^a, -OC(O)N(R^a)₂, -C(O)N(R^a)₂, -N(R^a)C(O)OR^a, -N(R^a)C(O)R^a, -N(R^a)C(O)N(R^a)₂, -N(R^a)C(NR^a)N(R^a)₂, -N(R^a)S(O)_tR^a (where t is 1 or 2), -S(O)_tOR^a (where t is 1 or 2), -S(O)_tN(R^a)₂ (where t is 1 or 2), or PO₃(R^a)₂ where each R^a is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroarylalkyl.

[0057] The term “halo” or “halogen” refers to fluoro, chloro, bromo, or iodo.

[0058] The term “haloalkyl” refers to an alkyl group substituted with one or more halo groups, for example chloromethyl, 2-bromoethyl, 3-iodopropyl, trifluoromethyl, perfluoropropyl, 8-chlorononyl, and the like.

[0059] “Acyl” refers to the groups (alkyl)-C(O)-, (aryl)-C(O)-, (heteroaryl)-C(O)-, (heteroalkyl)-C(O)-, and (heterocycloalkyl)-C(O)-, wherein the group is attached to the parent structure through the carbonyl functionality. In some embodiments, it is a C₁-C₁₀ acyl radical which refers to the total number of chain or ring atoms of the alkyl, aryl, heteroaryl or heterocycloalkyl portion of the acyloxy group plus the carbonyl carbon of acyl, i.e. three other ring or chain atoms plus carbonyl. If the R radical is heteroaryl or heterocycloalkyl, the hetero ring or chain atoms contribute to the total number of chain or ring atoms. Unless stated otherwise specifically in the specification, the “R” of an acyloxy group is optionally substituted by one or more substituents which independently are: alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilyl, -OR^a, SR^a, -OC(O)-R^a, -N(R^a)₂, -C(O)R^a, -C(O)OR^a, -OC(O)N(R^a)₂, -C(O)N(R^a)₂, -N(R^a)C(O)OR^a, -N(R^a)C(O)R^a, -N(R^a)C(O)N(R^a)₂, -N(R^a)C(NR^a)N(R^a)₂, -N(R^a)S(O)_tR^a (where t is 1 or 2), -S(O)_tOR^a (where t is 1 or 2), -S(O)_tN(R^a)₂ (where t is 1 or 2), or PO₃(R^a)₂, where each R^a is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroarylalkyl.

[0060] “Cycloalkyl” refers to a monocyclic or polycyclic radical that contains only carbon and hydrogen, and may be saturated, or partially unsaturated. Cycloalkyl groups include groups having from 3 to 10 ring atoms (i.e., C₂-C₁₀ cycloalkyl). Whenever it appears herein, a numerical range such as “3 to 10” refers to each integer in the given range; e.g., “3 to 10 carbon atoms” means that the cycloalkyl group may consist of 3 carbon atoms, etc., up to and including 10 carbon atoms. In some embodiments, it is a C₃-C₈ cycloalkyl radical. In some embodiments, it is a C₃-C₅ cycloalkyl radical. Illustrative examples of

cycloalkyl groups include, but are not limited to the following moieties: cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, norbornyl, and the like. Unless stated otherwise specifically in the specification, a cycloalkyl group is optionally substituted by one or more substituents which independently are: alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilyl, $-OR^a$, $-SR^a$, $-OC(O)-R^a$, $-N(R^a)_2$, $-C(O)R^a$, $-C(O)OR^a$, $-OC(O)N(R^a)_2$, $-C(O)N(R^a)_2$, $-N(R^a)C(O)OR^a$, $-N(R^a)C(O)R^a$, $-N(R^a)C(O)N(R^a)_2$, $N(R^a)C(NR^a)N(R^a)_2$, $-N(R^a)S(O)_tR^a$ (where t is 1 or 2), $-S(O)_tOR^a$ (where t is 1 or 2), $-S(O)_tN(R^a)_2$ (where t is 1 or 2), or $PO_3(R^a)_2$, where each R^a is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroarylalkyl.

[0061] The term “ C_{1-10} alkyl – C_{3-8} cycloalkyl” is used to describe an alkyl group, branched or straight chain and containing 1 to 10 carbon atoms, attached to a linking cycloalkyl group which contains 3 to 8 carbons, such as for example, 2-methyl cyclopropyl, and the like. Either portion of the moiety is unsubstituted or substituted.

[0062] The term “bicycloalkyl” refers to a structure consisting of two cycloalkyl moieties, unsubstituted or substituted, that have two or more atoms in common. If the cycloalkyl moieties have exactly two atoms in common they are said to be “fused”. Examples include, but are not limited to, bicyclo[3.1.0]hexyl, perhydronaphthyl, and the like. If the cycloalkyl moieties have more than two atoms in common they are said to be “bridged”. Examples include, but are not limited to, bicyclo[3.2.1]heptyl (“norbornyl”), bicyclo[2.2.2]octyl, and the like.

[0063] As used herein, the term “heteroatom” or “ring heteroatom” is meant to include oxygen (O), nitrogen (N), sulfur (S), phosphorus (P), and silicon (Si).

[0064] “Heteroalkyl”, “heteroalkenyl” and “heteroalkynyl” include optionally substituted alkyl, alkenyl and alkynyl radicals and which have one or more skeletal chain atoms selected from an atom other than carbon, e.g., oxygen, nitrogen, sulfur, phosphorus or combinations thereof. A numerical range may be given, e.g., C_1 - C_4 heteroalkyl which refers to the chain length in total, which in this example is 4 atoms long. For example, a $-CH_2OCH_2CH_3$ radical is referred to as a “ C_4 ” heteroalkyl, which includes the heteroatom center in the atom chain length description. Connection to the rest of the molecule may be through either a heteroatom or a carbon in the heteroalkyl chain. A heteroalkyl group may be substituted with one or more substituents which independently are: alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano, nitro, oxo, thio, trimethylsilyl, $-OR^a$, $-SR^a$, $-OC(O)-R^a$, $-N(R^a)_2$, $-C(O)R^a$, $-C(O)OR^a$, $-C(O)N(R^a)_2$, $-N(R^a)C(O)OR^a$, $-N(R^a)C(O)R^a$, $-N(R^a)S(O)_tR^a$ (where t is 1 or 2), $-S(O)_tOR^a$ (where t is 1 or 2), $-S(O)_tN(R^a)_2$ (where t is 1 or 2), or $PO_3(R^a)_2$, where each R^a is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroarylalkyl.

[0065] The term “heteroalkylaryl” refers to a heteroalkyl group as defined above which is attached to an aryl group, and may be attached at a terminal point or through a branched portion of the heteroalkyl, for example, an benzyloxymethyl moiety. Either portion of the moiety is unsubstituted or substituted.

[0066] The term “heteroalkylheteroaryl” refers likewise to a heteroalkyl group which is attached to a heteroaryl moiety, for example, an ethoxymethylpyridyl group. Either portion of the moiety is unsubstituted or substituted.

[0067] The term “heteroalkyl-heterocyclyl” refers to a heteroalkyl group as defined above, which is attached to a heterocyclic group, for example, 4(3-aminopropyl)-N-piperazinyl. Either portion of the moiety is unsubstituted or substituted.

[0068] The term “heteroalkyl-C₃₋₈cycloalkyl” refers to a heteroalkyl group as defined above, which is attached to a cyclic alkyl containing 3 to 8 carbons, for example, 1-aminobutyl-4-cyclohexyl. Either portion of the moiety is unsubstituted or substituted.

[0069] The term “heterobicycloalkyl” refers to a bicycloalkyl structure, which is unsubstituted or substituted, in which at least one carbon atom is replaced with a heteroatom independently selected from oxygen, nitrogen, and sulfur.

[0070] The term “heterospiroalkyl” refers to a spiroalkyl structure, which is unsubstituted or substituted, in which at least one carbon atom is replaced with a heteroatom independently selected from oxygen, nitrogen, and sulfur.

[0071] An “alkene” moiety refers to a group consisting of at least two carbon atoms and at least one carbon-carbon double bond, and an “alkyne” moiety refers to a group consisting of at least two carbon atoms and at least one carbon-carbon triple bond. The alkyl moiety, whether saturated or unsaturated, may be branched, straight chain, or cyclic.

[0072] “Alkenyl” refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one double bond, and having from two to ten carbon atoms (i.e., C₂-C₁₀ alkenyl). Whenever it appears herein, a numerical range such as “2 to 10” refers to each integer in the given range; e.g., “2 to 10 carbon atoms” means that the alkenyl group may consist of 2 carbon atoms, 3 carbon atoms, etc., up to and including 10 carbon atoms. In certain embodiments, an alkenyl comprises two to eight carbon atoms. In other embodiments, an alkenyl comprises two to five carbon atoms (e.g., C₂-C₅ alkenyl). The alkenyl is attached to the rest of the molecule by a single bond, for example, ethenyl (*i.e.*, vinyl), prop-1-enyl (*i.e.*, allyl), but-1-enyl, pent-1-enyl, penta-1,4-dienyl, and the like. Unless stated otherwise specifically in the specification, an alkenyl group is optionally substituted by one or more substituents which independently are: alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -OR^a, -SR^a, -OC(O)-R^a, -N(R^a)₂, -C(O)R^a, -C(O)OR^a, -OC(O)N(R^a)₂, -C(O)N(R^a)₂, -N(R^a)C(O)OR^a, -N(R^a)C(O)R^a, -N(R^a)C(O)N(R^a)₂, N(R^a)C(NR^a)N(R^a)₂, -N(R^a)S(O)_tR^a (where t is 1 or 2), -S(O)_tOR^a (where t is 1 or 2), -S(O)_tN(R^a)₂ (where t is 1 or 2), or PO₃(R^a)₂, where each R^a is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroarylalkyl.

[0073] The term “C₂₋₁₀ alkenyl-heteroalkyl” refers to a group having an alkenyl moiety, containing 2 to 10 carbon atoms and is branched or straight chain, which is attached to a linking heteroalkyl group, such as, for example, allyloxy, and the like. Either portion of the moiety is unsubstituted or substituted.

[0074] The term “C₂₋₁₀ alkynyl-heteroalkyl” refers to a group having an alkynyl moiety, which is unsubstituted or substituted, containing 2 to 10 carbon atoms and is branched or straight chain, which is attached to a linking heteroalkyl group, such as, for example, 4-but-1-ynoxy, and the like. Either portion of the moiety is unsubstituted or substituted.

[0075] The term “haloalkenyl” refers to an alkenyl group substituted with one or more halo groups.

[0076] Unless otherwise specified, the term “cycloalkenyl” refers to a cyclic aliphatic 3 to 8 membered ring structure, optionally substituted with alkyl, hydroxy and halo, having 1 or 2 ethylenic bonds such as methylcyclopropenyl, trifluoromethylcyclopropenyl, cyclopentenyl, cyclohexenyl, 1,4-cyclohexadienyl, and the like.

[0077] “Alkynyl” refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one triple bond, having from two to ten carbon atoms (i.e., C₂-C₁₀ alkynyl). Whenever it appears herein, a numerical range such as “2 to 10” refers to each integer in the given range; e.g., “2 to 10 carbon atoms” means that the alkynyl group may consist of 2 carbon atoms, 3 carbon atoms, etc., up to and including 10 carbon atoms. In certain embodiments, an alkynyl comprises two to eight carbon atoms. In other embodiments, an alkynyl has two to five carbon atoms (e.g., C₂-C₅ alkynyl). The alkynyl is attached to the rest of the molecule by a single bond, for example, ethynyl, propynyl, butynyl, pentynyl, hexynyl, and the like. Unless stated otherwise specifically in the specification, an alkynyl group is optionally substituted by one or more substituents which independently are: alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilyl, -OR^a, SR^a, -OC(O)-R^a, -N(R^a)₂, -C(O)R^a, -C(O)OR^a, -OC(O)N(R^a)₂, -C(O)N(R^a)₂, -N(R^a)C(O)OR^a, -N(R^a)C(O)R^a, -N(R^a)C(O)N(R^a)₂, N(R^a)C(NR^a)N(R^a)₂, -N(R^a)S(O)_tR^a (where t is 1 or 2), -S(O)_tOR^a (where t is 1 or 2), -S(O)_tN(R^a)₂ (where t is 1 or 2), or PO₃(R^a)₂, where each R^a is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroarylalkyl.

[0078] The term C₂₋₁₀ alkynyl- C₃₋₈ cycloalkyl refers to a group containing an alkynyl group, containing 2 to 10 carbons and branched or straight chain, which is attached to a linking cycloalkyl group containing 3 to 8 carbons, such as, for example 3-prop-3-ynyl- cyclopent-1-yl, and the like. Either portion of the moiety is unsubstituted or substituted.

[0079] The term “haloalkynyl” refers to an alkynyl group substituted with one or more independent halo groups.

[0080] “Amino” or “amine” refers to a -N(R^a)₂ radical group, where each R^a is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroarylalkyl, unless stated otherwise specifically in the specification. When a -N(R^a)₂ group has two R^a other than hydrogen they can be combined with the nitrogen atom to form a 4-, 5-, 6-, or

7-membered ring. For example, $-N(R^a)_2$ is meant to include, but not be limited to, 1-pyrrolidinyl and 4-morpholinyl. Unless stated otherwise specifically in the specification, an amino group is optionally substituted by one or more substituents which independently are: alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilyl, $-OR^a$, $-SR^a$, $-OC(O)-R^a$, $-N(R^a)_2$, $-C(O)R^a$, $-C(O)OR^a$, $-OC(O)N(R^a)_2$, $-C(O)N(R^a)_2$, $-N(R^a)C(O)OR^a$, $-N(R^a)C(O)R^a$, $-N(R^a)C(O)N(R^a)_2$, $-N(R^a)C(NR^a)N(R^a)_2$, $-N(R^a)S(O)_tR^a$ (where t is 1 or 2), $-S(O)_tOR^a$ (where t is 1 or 2), $-S(O)_tN(R^a)_2$ (where t is 1 or 2), or $PO_3(R^a)_2$, where each R^a is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroarylalkyl and each of these moieties may be optionally substituted as defined herein.

[0081] “Amide” or “amido” refers to a chemical moiety with formula $-C(O)N(R)_2$ or $-NHC(O)R$, where R is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heteroaryl (bonded through a ring carbon) and heteroalicyclic (bonded through a ring carbon), each of which moiety may itself be optionally substituted. In some embodiments it is a C_1 - C_4 amido or amide radical, which includes the amide carbonyl in the total number of carbons in the radical. The R^2 of $-N(R)_2$ of the amide may optionally be taken together with the nitrogen to which it is attached to form a 4-, 5-, 6-, or 7-membered ring. Unless stated otherwise specifically in the specification, an amido group is optionally substituted independently by one or more of the substituents as described herein for alkyl, cycloalkyl, aryl, heteroaryl, or heterocycloalkyl. An amide may be an amino acid or a peptide molecule attached to a compound of Formula (I), thereby forming a prodrug. Any amine, hydroxy, or carboxyl side chain on the compounds described herein can be amidified. The procedures and specific groups to make such amides are known to those of skill in the art and can readily be found in reference sources such as Greene and Wuts, *Protective Groups in Organic Synthesis*, 3rd Ed., John Wiley & Sons, New York, N.Y., 1999, which is incorporated herein by reference in its entirety.

[0082] “Aromatic” or “aryl” refers to an aromatic radical with six to ten ring atoms (e.g., C_6 - C_{10} aromatic or C_6 - C_{10} aryl) which has at least one ring having a conjugated pi electron system which is carbocyclic (e.g., phenyl, fluorenyl, and naphthyl). Bivalent radicals formed from substituted benzene derivatives and having the free valences at ring atoms are named as substituted phenylene radicals. Bivalent radicals derived from univalent polycyclic hydrocarbon radicals whose names end in “-yl” by removal of one hydrogen atom from the carbon atom with the free valence are named by adding “-idene” to the name of the corresponding univalent radical, e.g., a naphthyl group with two points of attachment is termed naphthylidene. Whenever it appears herein, a numerical range such as “6 to 10” refers to each integer in the given range; e.g., “6 to 10 ring atoms” means that the aryl group may consist of 6 ring atoms, 7 ring atoms, etc., up to and including 10 ring atoms. The term includes monocyclic or fused-ring polycyclic (i.e., rings which share adjacent pairs of ring atoms) groups. Unless stated otherwise specifically in the specification, an aryl moiety is optionally substituted by one or more substituents which are independently: alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro,

trimethylsilylanyl, $-OR^a$, $-SR^a$, $-OC(O)-R^a$, $-N(R^a)_2$, $-C(O)R^a$, $-C(O)OR^a$, $-OC(O)N(R^a)_2$, $-C(O)N(R^a)_2$, $-N(R^a)C(O)OR^a$, $-N(R^a)C(O)R^a$, $-N(R^a)C(O)N(R^a)_2$, $N(R^a)C(NR^a)N(R^a)_2$, $-N(R^a)S(O)_tR^a$ (where t is 1 or 2), $-S(O)_tOR^a$ (where t is 1 or 2), $-S(O)_tN(R^a)_2$ (where t is 1 or 2), or $PO_3(R^a)_2$, where each R^a is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroarylalkyl.

[0083] “Heteroaryl” or, alternatively, “heteroaromatic” refers to a 5- to 18-membered aromatic radical (e.g., C_5 - C_{13} heteroaryl) that includes one or more ring heteroatoms selected from nitrogen, oxygen and sulfur, and which may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system. Whenever it appears herein, a numerical range such as “5 to 18” refers to each integer in the given range; e.g., “5 to 18 ring atoms” means that the heteroaryl group may consist of 5 ring atoms, 6 ring atoms, etc., up to and including 18 ring atoms. Bivalent radicals derived from univalent heteroaryl radicals whose names end in “-yl” by removal of one hydrogen atom from the atom with the free valence are named by adding “-idene” to the name of the corresponding univalent radical, e.g., a pyridyl group with two points of attachment is a pyridylidene. An N-containing “heteroaromatic” or “heteroaryl” moiety refers to an aromatic group in which at least one of the skeletal atoms of the ring is a nitrogen atom. The polycyclic heteroaryl group may be fused or non-fused. The heteroatom(s) in the heteroaryl radical is optionally oxidized. One or more nitrogen atoms, if present, are optionally quaternized. The heteroaryl is attached to the rest of the molecule through any atom of the ring(s). Examples of heteroaryls include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzindolyl, 1,3-benzodioxolyl, benzofuranyl, benzooxazolyl, benzo[d]thiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxepinyl, benzo[b][1,4]oxazinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzoxazolyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzofurazanyl, benzothiazolyl, benzothieryl (benzothiophenyl), benzothieno[3,2-d]pyrimidinyl, benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl, cinnolyl, cyclopenta[d]pyrimidinyl, 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl, 5,6-dihydrobenzo[h]quinazolinyl, 5,6-dihydrobenzo[h]cinnolyl, 6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, furazanyl, furanonyl, furo[3,2-c]pyridinyl, 5,6,7,8,9,10-hexahydrocycloocta[d]pyrimidinyl, 5,6,7,8,9,10-hexahydrocycloocta[d]pyridazinyl, 5,6,7,8,9,10-hexahydrocycloocta[d]pyridinyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, indolyl, isoindolyl, isoquinolyl, indolizyl, isoxazolyl, 5,8-methano-5,6,7,8-tetrahydroquinazolinyl, naphthyridinyl, 1,6-naphthyridinonyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl, 5,6,6a,7,8,9,10,10a-octahydrobenzo[h]quinazolinyl, 1-phenyl-1H-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyranyl, pyrrolyl, pyrazolyl, pyrazolo[3,4-d]pyrimidinyl, pyridinyl, pyrido[3,2-d]pyrimidinyl, pyrido[3,4-d]pyrimidinyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, quinazolinyl, quinoxalinyl, quinolyl, isoquinolyl, tetrahydroquinolyl, 5,6,7,8-tetrahydroquinazolinyl, 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinyl, 6,7,8,9-tetrahydro-5H-cyclohepta[4,5]thieno[2,3-d]pyrimidinyl,

5,6,7,8-tetrahydropyrido[4,5-c]pyridazinyl, thiazolyl, thiadiazolyl, thiapyranyl, triazolyl, tetrazolyl, triazinyl, thieno[2,3-d]pyrimidinyl, thieno[3,2-d]pyrimidinyl, thieno[2,3-c]pyridinyl, and thiophenyl (*i.e.* thienyl). Unless stated otherwise specifically in the specification, a heteraryl moiety is optionally substituted by one or more substituents which are independently: alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano, nitro, oxo, thioxo, trimethylsilyl, $-OR^a$, $-SR^a$, $-OC(O)R^a$, $-N(R^a)_2$, $-C(O)R^a$, $-C(O)OR^a$, $-C(O)N(R^a)_2$, $-N(R^a)C(O)OR^a$, $-N(R^a)C(O)R^a$, $-N(R^a)S(O)_tR^a$ (where t is 1 or 2), $-S(O)_tOR^a$ (where t is 1 or 2), $-S(O)_tN(R^a)_2$ (where t is 1 or 2), or $PO_3(R^a)_2$, where each R^a is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroarylalkyl.

[0084] The terms “aryl-alkyl”, “arylalkyl” and “aralkyl” are used to describe a group wherein the alkyl chain can be branched or straight chain forming a linking portion with the terminal aryl, as defined above, of the aryl-alkyl moiety. Examples of aryl-alkyl groups include, but are not limited to, optionally substituted benzyl, phenethyl, phenpropyl and phenbutyl such as 4-chlorobenzyl, 2,4-dibromobenzyl, 2-methylbenzyl, 2-(3-fluorophenyl)ethyl, 2-(4-methylphenyl)ethyl, 2-(4-(trifluoromethyl)phenyl)ethyl, 2-(2-methoxyphenyl)ethyl, 2-(3-nitrophenyl)ethyl, 2-(2,4-dichlorophenyl)ethyl, 2-(3,5-dimethoxyphenyl)ethyl, 3-phenylpropyl, 3-(3-chlorophenyl)propyl, 3-(2-methylphenyl)propyl, 3-(4-methoxyphenyl)propyl, 3-(4-(trifluoromethyl)phenyl)propyl, 3-(2,4-dichlorophenyl)propyl, 4-phenylbutyl, 4-(4-chlorophenyl)butyl, 4-(2-methylphenyl)butyl, 4-(2,4-dichlorophenyl)butyl, 4-(2-methoxyphenyl)butyl, and 10-phenyldecyl. Either portion of the moiety is unsubstituted or substituted.

[0085] The term “ C_{1-10} alkylaryl” as used herein refers to an alkyl group, as defined above, containing 1 to 10 carbon atoms, branched or unbranched, wherein the aryl group replaces one hydrogen on the alkyl group, for example, 3-phenylpropyl. Either portion of the moiety is unsubstituted or substituted.

[0086] The term “ C_{2-10} alkyl monocycloaryl” refers to a group containing a terminal alkyl group, branched or straight chain and containing 2 to 10 atoms attached to a linking aryl group which has only one ring, such as for example, 2-phenyl ethyl. Either portion of the moiety is unsubstituted or substituted.

[0087] The term “ C_{1-10} alkyl bicycloaryl” refers to a group containing a terminal alkyl group, branched or straight chain and containing 2 to 10 atoms attached to a linking aryl group which is bicyclic, such as for example, 2-(1-naphthyl)- ethyl. Either portion of the moiety is unsubstituted or substituted.

[0088] The terms “aryl-cycloalkyl” and “arylcycloalkyl” are used to describe a group wherein the terminal aryl group is attached to a cycloalkyl group, for example phenylcyclopentyl and the like. Either portion of the moiety is unsubstituted or substituted.

[0089] The terms “heteroaryl- C_{3-8} cycloalkyl” and “heteroaryl- C_{3-8} cycloalkyl “ are used to describe a group wherein the terminal heteroaryl group is attached to a cycloalkyl group, which contains 3 to 8 carbons, for example pyrid-2-yl-cyclopentyl and the like. Either portion of the moiety is unsubstituted or substituted.

[0090] The term “heteroaryl- heteroalkyl” refers to a group wherein the terminal heteroaryl group is attached to a linking heteroalkyl group, such as for example, pyrid-2-yl methylenoxy, and the like. Either portion of the moiety is unsubstituted or substituted.

[0091] The terms “aryl-alkenyl”, “arylalkenyl” and “aralkenyl” are used to describe a group wherein the alkenyl chain can be branched or straight chain forming a linking portion of the aralkenyl moiety with the terminal aryl portion, as defined above, for example styryl (2-phenylvinyl), phenpropenyl, and the like. Either portion of the moiety is unsubstituted or substituted.

[0092] The term “aryl-C₂₋₁₀alkenyl” means an arylalkenyl as described above wherein the alkenyl moiety contains 2 to 10 carbon atoms such as for example, styryl (2-phenylvinyl), and the like. Either portion of the moiety is unsubstituted or substituted.

[0093] The term “C₂₋₁₀alkenyl-aryl” is used to describe a group wherein the terminal alkenyl group, which contains 2 to 10 carbon atoms and can be branched or straight chain, is attached to the aryl moiety which forms the linking portion of the alkenyl-aryl moiety, such as for example, 3-propenyl- naphth-1-yl, and the like. Either portion of the moiety is unsubstituted or substituted.

[0094] The terms “aryl-alkynyl”, “arylalkynyl” and “aralkynyl” are used to describe a group wherein the alkynyl chain can be branched or straight chain forming a linking portion of the aryl-alkynyl moiety with the terminal aryl portion, as defined above, for example 3-phenyl-1-propynyl, and the like. Either portion of the moiety is unsubstituted or substituted.

[0095] The term “aryl- C₂₋₁₀alkynyl” means an arylalkynyl as described above wherein the alkynyl moiety contains two to ten carbons, such as, for example 3-phenyl-1-propynyl, and the like . Either portion of the moiety is unsubstituted or substituted.

[0096] The term “C₂₋₁₀alkynyl- aryl” means a group containing an alkynyl moiety attached to an aryl linking group, both as defined above, wherein the alkynyl moiety contains two to ten carbons, such as, for example 3-propynyl-naphth-1-yl. Either portion of the moiety is unsubstituted or substituted.

[0097] The terms “aryl-oxy”, “aryloxy” and “aroxy” are used to describe a terminal aryl group attached to a linking oxygen atom. Typical aryl-oxy groups include phenoxy, 3,4-dichlorophenoxy, and the like. Either portion of the moiety is unsubstituted or substituted.

[0098] The terms “aryl-oxyalkyl”, “aryloxyalkyl” and “aroxyalkyl” are used to describe a group wherein an alkyl group is substituted with a terminal aryl-oxy group, for example pentafluorophenoxymethyl and the like. Either portion of the moiety is unsubstituted or substituted.

[0099] The term “C₁₋₁₀alkoxy-C₁₋₁₀alkyl” refers to a group wherein an alkoxy group, containing 1 to 10 carbon atoms and an oxygen atom within the branching or straight chain, is attached to a linking alkyl group, branched or straight chain which contains 1 to 10 carbon atoms, such as, for example methoxypropyl, and the like. Either portion of the moiety is unsubstituted or substituted.

[00100] The term “C₁₋₁₀alkoxy-C₂₋₁₀alkenyl” refers to a group wherein an alkoxy group, containing 1 to 10 carbon atoms and an oxygen atom within the branching or straight chain, is attached to a linking alkenyl group, branched or straight chain which contains 1 to 10 carbon atoms, such as, for example 3-methoxybut-2-en-1-yl, and the like. Either portion of the moiety is unsubstituted or substituted.

[00101] The term “C₁₋₁₀alkoxy-C₂₋₁₀alkynyl” refers to a group wherein an alkoxy group, containing 1 to 10 carbon atoms and an oxygen atom within the branching or straight chain, is attached to a linking alkynyl group, branched or straight chain which contains 1 to 10 carbon atoms, such as, for example 3-methoxybut-2-in-1-yl, and the like. Either portion of the moiety is unsubstituted or substituted.

[00102] The term “heterocycloalkenyl” refers to a cycloalkenyl structure, which is unsubstituted or substituted in which at least one carbon atom is replaced with a heteroatom selected from oxygen, nitrogen, and sulfur.

[00103] The terms “heteroaryl-oxy”, “heteroaryl-oxy”, “heteroaryloxy”, “heteroaryloxy”, “heteroxy” and “heteroaroxy” are used to describe a terminal heteroaryl group, which is unsubstituted or substituted, attached to a linking oxygen atom. Typical heteroaryl-oxy groups include 4,6-dimethoxypyrimidin-2-yloxy and the like.

[00104] The terms “heteroarylalkyl”, “heteroarylalkyl”, “heteroaryl-alkyl”, “heteroaryl-alkyl”, “heteralkyl” and “heteroaralkyl” are used to describe a group wherein the alkyl chain can be branched or straight chain forming a linking portion of the heteroaralkyl moiety with the terminal heteroaryl portion, as defined above, for example 3-furylmethyl, thenyl, furfuryl, and the like. Either portion of the moiety is unsubstituted or substituted.

[00105] The term “heteroaryl-C₁₋₁₀alkyl” is used to describe a heteroaryl alkyl group as described above where the alkyl group contains 1 to 10 carbon atoms. Either portion of the moiety is unsubstituted or substituted.

[00106] The term “C₁₋₁₀alkyl-heteroaryl” is used to describe a alkyl attached to a heteroaryl group as described above where the alkyl group contains 1 to 10 carbon atoms. Either portion of the moiety is unsubstituted or substituted.

[00107] The terms “heteroarylalkenyl”, “heteroarylalkenyl”, “heteroaryl-alkenyl”, “heteroaryl-alkenyl”, “heteraralkenyl” and “heteroaralkenyl” are used to describe a heteroarylalkenyl group wherein the alkenyl chain can be branched or straight chain forming a linking portion of the heteroaralkenyl moiety with the terminal heteroaryl portion, as defined above, for example 3-(4-pyridyl)-1-propenyl. Either portion of the moiety is unsubstituted or substituted.

[00108] The term “heteroaryl-C₂₋₁₀alkenyl” group is used to describe a group as described above wherein the alkenyl group contains 2 to 10 carbon atoms. Either portion of the moiety is unsubstituted or substituted.

[00109] The term “C₂₋₁₀alkenyl- heteroaryl” is used to describe a group containing an alkenyl group, which is branched or straight chain and contains 2 to 10 carbon atoms, and is attached to a linking heteroaryl group, such as, for example 2-styryl-4-pyridyl, and the like. Either portion of the moiety is unsubstituted or substituted.

[00110] The terms “heteroarylalkynyl”, “heteroarylalkynyl”, “heteroaryl-alkynyl”, “heteroaryl-alkynyl”, “heteralkynyl” and “heteroaralkynyl” are used to describe a group wherein the alkynyl chain can be branched or straight chain forming a linking portion of the heteroaralkynyl moiety with the heteroaryl

portion, as defined above, for example 4-(2-thienyl)-1-butyryl, and the like. Either portion of the moiety is unsubstituted or substituted.

[00111] The term “heteroaryl- C₂₋₁₀alkynyl” is used to describe a heteroarylalkynyl group as described above wherein the alkynyl group contains 2 to 10 carbon atoms. Either portion of the moiety is unsubstituted or substituted.

[00112] The term “C₂₋₁₀alkynyl- heteroaryl” is used to describe a group containing an alkynyl group which contains 2 to 10 carbon atoms and is branched or straight chain, which is attached to a linking heteroaryl group such as, for example, 4(but-1-ynyl) thien-2-yl, and the like. Either portion of the moiety is unsubstituted or substituted.

[00113] The term “heterocyclyl” refers to a four-, five-, six-, or seven-membered ring containing one, two, three or four heteroatoms independently selected from nitrogen, oxygen and sulfur. The four-membered ring has zero double bonds, the five-membered ring has zero to two double bonds, and the six- and seven-membered rings have zero to three double bonds. The term “heterocyclyl” also includes bicyclic groups in which the heterocyclyl ring is fused to another monocyclic heterocyclyl group, or a four- to seven-membered aromatic or nonaromatic carbocyclic ring. The heterocyclyl group can be attached to the parent molecular moiety through any carbon atom or nitrogen atom in the group.

[00114] “Heterocycloalkyl” refers to a stable 3- to 18-membered non-aromatic ring radical that comprises two to twelve carbon atoms and from one to six heteroatoms selected from nitrogen, oxygen and sulfur. Whenever it appears herein, a numerical range such as “3 to 18” refers to each integer in the given range; e.g., “3 to 18 ring atoms” means that the heterocycloalkyl group may consist of 3 ring atoms, 4 ring atoms, etc., up to and including 18 ring atoms. In some embodiments, it is a C₅-C₁₀ heterocycloalkyl. In some embodiments, it is a C₄-C₁₀ heterocycloalkyl. In some embodiments, it is a C₃-C₁₀ heterocycloalkyl. Unless stated otherwise specifically in the specification, the heterocycloalkyl radical is a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems. The heteroatoms in the heterocycloalkyl radical may be optionally oxidized. One or more nitrogen atoms, if present, are optionally quaternized. The heterocycloalkyl radical is partially or fully saturated. The heterocycloalkyl may be attached to the rest of the molecule through any atom of the ring(s). Examples of such heterocycloalkyl radicals include, but are not limited to, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazolyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholyl, thiomorpholyl, 1-oxo-thiomorpholyl, and 1,1-dioxo-thiomorpholyl. Unless stated otherwise specifically in the specification, a heterocycloalkyl moiety is optionally substituted by one or more substituents which independently are: alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano, nitro, oxo, thio, trimethylsilyl, -OR^a, SR^a, -OC(O)-R^a, -N(R^a)₂, -C(O)R^a, -C(O)OR^a, -C(O)N(R^a)₂, -N(R^a)C(O)OR^a, -N(R^a)C(O)R^a, -N(R^a)S(O)_tR^a (where t is 1 or 2), -S(O)_tOR^a (where t is 1 or 2), -S(O)_tN(R^a)₂ (where t is 1 or 2), or PO₃(R^a)₂, where each

R^a is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heteroaryl or heteroarylalkyl.

[00115] “Heterocycloalkyl” also includes bicyclic ring systems wherein one non-aromatic ring, usually with 3 to 7 ring atoms, contains at least 2 carbon atoms in addition to 1-3 heteroatoms independently selected from oxygen, sulfur, and nitrogen, as well as combinations comprising at least one of the foregoing heteroatoms; and the other ring, usually with 3 to 7 ring atoms, optionally contains 1-3 heteroatoms independently selected from oxygen, sulfur, and nitrogen and is not aromatic.

[00116] The terms “heterocyclalkyl”, “heterocycl-alkyl”, “hetcyclalkyl”, and “hetcycl-alkyl” are used to describe a group wherein the alkyl chain can be branched or straight chain forming a linking portion of the heterocyclalkyl moiety with the terminal heterocycl portion, as defined above, for example 3-piperidinylmethyl and the like. The term “heterocycloalkylene” refers to the divalent derivative of heterocycloalkyl.

[00117] The term “C₁₋₁₀alkyl-heterocycl” refers to a group as defined above where the alkyl moiety contains 1 to 10 carbon atoms. Either portion of the moiety is unsubstituted or substituted.

[00118] The term “heterocycl- C₁₋₁₀alkyl” refers to a group containing a terminal heterocyclic group attached to a linking alkyl group which contains 1 to 10 carbons and is branched or straight chain, such as, for example, 4-morpholinyl ethyl, and the like. Either portion of the moiety is unsubstituted or substituted.

[00119] The terms “heterocyclalkenyl”, “heterocycl-alkenyl”, “hetcyclalkenyl” and “hetcycl-alkenyl” are used to describe a group wherein the alkenyl chain can be branched or straight chain forming a linking portion of the heterocyclalkenyl moiety with the terminal heterocycl portion, as defined above, for example 2-morpholinyl-1-propenyl and the like. The term “heterocycloalkenylene” refers to the divalent derivative of heterocyclalkenyl. Either portion of the moiety is unsubstituted or substituted.

[00120] The term “heterocycl- C₂₋₁₀ alkenyl” refers to a group as defined above where the alkenyl group contains 2 to 10 carbon atoms and is branched or straight chain, such as, for example, 4-(N-piperazinyl)-but-2-en-1-yl, and the like. Either portion of the moiety is unsubstituted or substituted.

[00121] The terms “heterocyclalkynyl”, “heterocycl-alkynyl”, “hetcyclalkynyl” and “hetcycl-alkynyl” are used to describe a group wherein the alkynyl chain can be branched or straight chain forming a linking portion of the heterocyclalkynyl moiety with the terminal heterocycl portion, as defined above, for example 2-pyrrolidinyl-1-butynyl and the like. Either portion of the moiety is unsubstituted or substituted.

[00122] The term “heterocycl- C₂₋₁₀ alkynyl” refers to a group as defined above where the alkynyl group contains 2 to 10 carbon atoms and is branched or straight chain, such as, for example, 4-(N-piperazinyl)-but-2-yn-1-yl, and the like.

[00123] The term “aryl- heterocycl” refers to a group containing a terminal aryl group attached to a linking heterocyclic group, such as for example, N4-(4-phenyl)- piperazinyl, and the like. Either portion of the moiety is unsubstituted or substituted.

[00124] The term “heteroaryl- heterocycyl” refers to a group containing a terminal heteroaryl group attached to a linking heterocyclic group, such as for example, N4-(4-pyridyl)- piperaziny, and the like. Either portion of the moiety is unsubstituted or substituted.

[00125] The term “carboxylalkyl” refers to a terminal carboxyl (-COOH) group attached to branched or straight chain alkyl groups as defined above.

[00126] The term “carboxylalkenyl” refers to a terminal carboxyl (-COOH) group attached to branched or straight chain alkenyl groups as defined above.

[00127] The term “carboxylalkynyl” refers to a terminal carboxyl (-COOH) group attached to branched or straight chain alkynyl groups as defined above.

[00128] The term “carboxylcycloalkyl” refers to a terminal carboxyl (-COOH) group attached to a cyclic aliphatic ring structure as defined above.

[00129] The term “carboxylcycloalkenyl” refers to a terminal carboxyl (-COOH) group attached to a cyclic aliphatic ring structure having ethylenic bonds as defined above.

[00130] The terms “cycloalkylalkyl” and “cycloalkyl-alkyl” refer to a terminal cycloalkyl group as defined above attached to an alkyl group, for example cyclopropylmethyl, cyclohexylethyl, and the like. Either portion of the moiety is unsubstituted or substituted.

[00131] The terms “cycloalkylalkenyl” and “cycloalkyl-alkenyl” refer to a terminal cycloalkyl group as defined above attached to an alkenyl group, for example cyclohexylvinyl, cycloheptylallyl, and the like. Either portion of the moiety is unsubstituted or substituted.

[00132] The terms “cycloalkylalkynyl” and “cycloalkyl-alkynyl” refer to a terminal cycloalkyl group as defined above attached to an alkynyl group, for example cyclopropylpropargyl, 4-cyclopentyl-2-butylnyl, and the like. Either portion of the moiety is unsubstituted or substituted.

[00133] The terms “cycloalkenylalkyl” and “cycloalkenyl-alkyl” refer to a terminal cycloalkenyl group as defined above attached to an alkyl group, for example 2-(cyclopenten-1-yl)ethyl and the like. Either portion of the moiety is unsubstituted or substituted.

[00134] The terms “cycloalkenylalkenyl” and “cycloalkenyl-alkenyl” refer to terminal a cycloalkenyl group as defined above attached to an alkenyl group, for example 1-(cyclohexen-3-yl)allyl and the like.

[00135] The terms “cycloalkenylalkynyl” and “cycloalkenyl-alkynyl” refer to terminal a cycloalkenyl group as defined above attached to an alkynyl group, for example 1-(cyclohexen-3-yl)propargyl and the like. Either portion of the moiety is unsubstituted or substituted.

[00136] The term “alkoxy” refers to the group -O-alkyl, including from 1 to 8 carbon atoms of a straight, branched, cyclic configuration and combinations thereof attached to the parent structure through an oxygen. Examples include methoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy, cyclohexyloxy and the like. “Lower alkoxy” refers to alkoxy groups containing one to six carbons. In some embodiments, C₁-C₄ alkyl, is an alkyl group which encompasses both straight and branched chain alkyls of from 1 to 4 carbon atoms.

[00137] The term “haloalkoxy” refers to an alkoxy group substituted with one or more halo groups, for example chloromethoxy, trifluoromethoxy, difluoromethoxy, perfluoroisobutoxy, and the like.

[00138] The term “alkoxyalkoxyalkyl” refers to an alkyl group substituted with an alkoxy moiety which is in turn substituted with a second alkoxy moiety, for example methoxymethoxymethyl, isopropoxymethoxyethyl, and the like. This moiety is substituted with further substituents or not substituted with other substituents.

[00139] The term “alkylthio” includes both branched and straight chain alkyl groups attached to a linking sulfur atom, for example methylthio and the like.

[00140] The term “alkoxyalkyl” refers to an alkyl group substituted with an alkoxy group, for example isopropoxymethyl and the like. Either portion of the moiety is unsubstituted or substituted.

[00141] The term “alkoxyalkenyl” refers to an alkenyl group substituted with an alkoxy group, for example 3-methoxyallyl and the like. Either portion of the moiety is unsubstituted or substituted.

[00142] The term “alkoxyalkynyl” refers to an alkynyl group substituted with an alkoxy group, for example 3-methoxypropargyl and the like. Either portion of the moiety is unsubstituted or substituted.

[00143] The term “C₂₋₁₀alkenylC₃₋₈cycloalkyl” refers to an alkenyl group as defined above substituted with a three to eight membered cycloalkyl group, for example, 4-(cyclopropyl)-2-butenyl and the like. Either portion of the moiety is unsubstituted or substituted.

[00144] The term “C₂₋₁₀alkynylC₃₋₈cycloalkyl” refers to an alkynyl group as defined above substituted with a three to eight membered cycloalkyl group, for example, 4-(cyclopropyl)-2-butynyl and the like. Either portion of the moiety is unsubstituted or substituted.

[00145] The term “heterocyclyl-C₁₋₁₀alkyl” refers to a heterocyclic group as defined above substituted with an alkyl group as defined above having 1 to 10 carbons, for example, 4-(N-methyl)-piperazinyl, and the like. Either portion of the moiety is unsubstituted or substituted.

[00146] The term “heterocyclyl-C₂₋₁₀alkenyl” refers to a heterocyclic group as defined above, substituted with an alkenyl group as defined above, having 2 to 10 carbons, for example, 4-(N-allyl) piperazinyl, and the like. Moieties wherein the heterocyclic group is substituted on a carbon atom with an alkenyl group are also included. Either portion of the moiety is unsubstituted or substituted.

[00147] The term “heterocyclyl-C₂₋₁₀alkynyl” refers to a heterocyclic group as defined above, substituted with an alkynyl group as defined above, having 2 to 10 carbons, for example, 4-(N-propargyl) piperazinyl, and the like. Moieties wherein the heterocyclic group is substituted on a carbon atom with an alkenyl group are also included. Either portion of the moiety is unsubstituted or substituted.

[00148] The term “oxo” refers to an oxygen that is double bonded to a carbon atom. One in the art understands that an “oxo” requires a second bond from the atom to which the oxo is attached. Accordingly, it is understood that oxo cannot be substituted onto an aryl or heteroaryl ring, unless it forms part of the aromatic system as a tautomer.

[00149] The term “oligomer” refers to a low-molecular weight polymer, whose number average molecular weight is typically less than about 5000 g/mol, and whose degree of polymerization (average number of monomer units per chain) is greater than one and typically equal to or less than about 50.

[00150] “Sulfonamidyl” or “sulfonamido” refers to a -S(=O)₂-NR'R' radical, where each R' is selected independently from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heteroaryl (bonded through

a ring carbon) and heteroalicyclic (bonded through a ring carbon). The R' groups in -NR'R' of the -S(=O)₂-NR'R' radical may be taken together with the nitrogen to which it is attached to form a 4-, 5-, 6-, or 7-membered ring. A sulfonamido group is optionally substituted by one or more of the substituents described for alkyl, cycloalkyl, aryl, heteroaryl respectively.

[00151] Compounds described can contain one or more asymmetric centers and may thus give rise to diastereomers and optical isomers. The present invention includes all such possible diastereomers as well as their racemic mixtures, their substantially pure resolved enantiomers, all possible geometric isomers, and pharmaceutically acceptable salts thereof. Compounds may be shown without a definitive stereochemistry at certain positions. The present invention includes all stereoisomers of the disclosed compounds and pharmaceutically acceptable salts thereof. Further, mixtures of stereoisomers as well as isolated specific stereoisomers are also included. During the course of the synthetic procedures used to prepare such compounds, or in using racemization or epimerization procedures known to those skilled in the art, the products of such procedures can be a mixture of stereoisomers.

[00152] The present invention includes all manner of rotamers and conformationally restricted states of an inhibitor of the invention.

[00153] Substituents for alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl monovalent and divalent derivative radicals (including those groups often referred to as alkylene, alkenyl, heteroalkylene, heteroalkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl) can be one or more of a variety of groups selected from, but not limited to: alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, -OR', =O, =NR', =N-OR', -NR'R'', -SR', -halogen, -SiR'R''R''', -OC(O)R', -C(O)R', -CO₂R', -C(O)NR'R'', -OC(O)NR'R'', -NR''C(O)R', -NR'-C(O)NR''R'', -NR''C(O)OR', -NR-C(NR'R'')=NR'', -S(O)R', -S(O)₂R', -S(O)₂NR'R'', -NRSO₂R', -CN and -NO₂ in a number ranging from zero to (2m'+1), where m' is the total number of carbon atoms in such radical. R', R'', R''' and R'''' each preferably independently refer to hydrogen, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl (e.g., aryl substituted with 1-3 halogens), substituted or unsubstituted alkyl, alkoxy or thioalkoxy groups, or arylalkyl groups. When an inhibitor of the invention includes more than one R group, for example, each of the R groups is independently selected as are each R', R'', R''' and R'''' groups when more than one of these groups is present.

[00154] When R' and R'' or R'' and R''' are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 4-, 5-, 6-, or 7-membered ring. For example, -NR'R'' is meant to include, but not be limited to, 1-pyrrolidinyl, 4 piperazinyl, and 4-morpholinyl. From the above discussion of substituents, one of skill in the art will understand that the term "alkyl" is meant to include groups including carbon atoms bound to groups other than hydrogen groups, such as haloalkyl (e.g., -CF₃ and -CH₂CF₃) and acyl (e.g., -C(O)CH₃, -C(O)CF₃, -C(O)CH₂OCH₃, and the like).

[00155] Similar to the substituents described for alkyl radicals above, exemplary substituents for aryl and heteroaryl groups (as well as their divalent derivatives) are varied and are selected from, for example: halogen, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl,

heteroarylalkyl, -OR', -NR'R'', -SR', -halogen, -SiR'R''R''', -OC(O)R', -C(O)R', -CO₂R', -C(O)NR'R'', -OC(O)NR'R'', -NR''C(O)R', -NR'-C(O)NR''R''', -NR'''C(O)OR', -NR-C(NR'R''R''')=NR''''', -NR-C(NR'R'')=NR''', -S(O)R', -S(O)₂R', -S(O)₂NR'R'', -NRSO₂R', -CN and -NO₂, -R', -N₃, -CH(Ph)₂, fluoro(C₁-C₄)alkoxo, and fluoro(C₁-C₄)alkyl, in a number ranging from zero to the total number of open valences on aromatic ring system; and where R', R'', R''' and R'''' are preferably independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl. When an inhibitor of the invention includes more than one R group, for example, each of the R groups is independently selected as are each R', R'', R''' and R'''' groups when more than one of these groups is present.

[00156] As used herein, 0-2 in the context of -S(O)₍₀₋₂₎- are integers of 0, 1, and 2.

[00157] Two of the substituents on adjacent atoms of aryl or heteroaryl ring may optionally form a ring of the formula -T-C(O)-(CRR')_q-U-, wherein T and U are independently -NR-, -O-, -CRR'- or a single bond, and q is an integer of from 0 to 3. Alternatively, two of the substituents on adjacent atoms of aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -A-(CH₂)_r-B-, wherein A and B are independently -CRR'-, -O-, -NR-, -S-, -S(O)-, -S(O)₂-, -S(O)₂NR'- or a single bond, and r is an integer of from 1 to 4. One of the single bonds of the new ring so formed may optionally be replaced with a double bond. Alternatively, two of the substituents on adjacent atoms of aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -(CRR')_s-X'-(C''R''')_d-, where s and d are independently integers of from 0 to 3, and X' is -O-, -NR'-, -S-, -S(O)-, -S(O)₂-, or -S(O)₂NR'-. The substituents R, R', R'' and R''' are preferably independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.

[00158] Unless otherwise stated, structures depicted herein are also meant to include compounds which differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by ¹³C- or ¹⁴C-enriched carbon are within the scope of this invention.

[00159] The compounds of the present invention may also contain unnatural proportions of atomic isotopes at one or more of atoms that constitute such compounds. For example, the compounds may be radiolabeled with radioactive isotopes, such as for example tritium (³H), iodine-125 (¹²⁵I) or carbon-14 (¹⁴C). All isotopic variations of the compounds of the present invention, whether radioactive or not, are encompassed within the scope of the present invention.

Treatment Regimens

[00160] The invention provides, in one aspect, a treatment regimen comprising administering to a subject a first agent and a second agent which is an mTor inhibitor, wherein the first and second agent are administered according to a dosing schedule such that the first agent and the second agent are not

administered within 3, 6, 8, 10 or 12 hours of each other. The first agent can be any first agent described herein, either alone or in combination with one or more other such first agents. The mTOR inhibitor can be any mTOR inhibitor described herein, either alone or in combination with one or more other mTOR inhibitors.

[00161] In some embodiments, the mTOR inhibitor is administered at a point in time that follows the administration of the first agent. However, administration at a later point in time also includes administration of a composition comprising both a first agent and an mTOR inhibitor, wherein the mTOR inhibitor is formulated for delayed release with respect to the first agent, or where the first agent is formulated for delayed release with respect to the mTOR inhibitor. In some embodiments, a composition comprising both a first agent and an mTOR inhibitor releases the majority of the mTOR inhibitor (e.g. at least 60%, 70%, 80%, 85%, 90%, 95%, 99%, or more) as an active compound after the release of the majority of the first agent (e.g. at least 60%, 70%, 80%, 85%, 90%, 95%, 99%, or more) as an active compound. In some embodiments, a first agent is administered before and separately from administration of an mTOR inhibitor. In some embodiments, the mTOR inhibitor is administered at about, or more than about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 30, 36, 42, 48, 72, or more hours after administration of the first agent. In some embodiments, the mTOR inhibitor is administered at about, or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more days after administration of the first agent. In some embodiments, the mTOR inhibitor is administered at about, or more than about 1, 2, 3, 4, 5, 6, or more weeks after administration of the first agent.

[00162] In some embodiments, a first agent and/or an mTOR inhibitor is administered to a subject more than once. In some embodiments, a first agent is administered one or more times (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or more) every 1, 2, 3, 4, 5, 6, 7, or more days (e.g. daily, every other day, every 7 days), where one or more of the administrations of the first agent is followed by one or more administrations (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or more) of an mTOR inhibitor with any desired temporal spacing, such as 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 30, 36, 42, 48, 72, or more hours or otherwise described herein. In some embodiments, a first agent is administered one or more times (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or more) every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more weeks (e.g. administration on 1, 2, 3, 4, 5, 6, and/or 7 days of a week, which may or may not be consecutive days), where one or more of the administrations of the first agent is followed by one or more administrations (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or more) of an mTOR inhibitor with any desired temporal spacing, such as 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 30, 36, 42, 48, 72, or more hours or otherwise described herein. In some embodiments, a given dosing schedule comprising one or more administrations of a first agent and one or more administrations of an mTOR inhibitor, wherein at least one administration of an mTOR inhibitor is subsequent to at least one administration of a first agent, such as described herein, may be repeated on a daily, weekly, biweekly, monthly, bimonthly, annually, semi-annually, or any other period as may be determined by a medical professional. A repeated dosing schedule may be repeated for a fixed period of time determined at the start of the schedule; may be terminated, extended, or

otherwise adjusted based on a measure of therapeutic effect, such as a level of reduction in the presence of detectable disease tissue (e.g. a reduction of at least 50%, 60%, 70%, 80%, 90%, 95%, 99%, or 100%); or may be terminated, extended, or otherwise adjusted for any other reason as determined by a medical professional.

[00163] In some embodiments, a first agent, an mTOR inhibitor, and/or any additional therapeutic compound of the invention is administered in multiple doses. Dosing may be about once, twice, three times, four times, five times, six times, or more than six times per day. Dosing may be about once a month, once every two weeks, once a week, or once every other day. In some embodiments, cycles of administering a first agent followed by one or more administrations of an mTOR inhibitor are repeated for more than about 6, 10, 14, 28 days, two months, six months, or one year. In some cases, repetition of a dosing cycle comprising administration of a first agent followed by one or more administrations of an mTOR inhibitor are continued as long as necessary.

[00164] Administration of the combination treatments of the invention may continue as long as necessary. In some embodiments, a first agent and/or an mTOR inhibitor of the invention are administered for more than 1, 2, 3, 4, 5, 6, 7, 14, or 28 days, wherein an administration of the mTOR inhibitor is subsequent to an administration of the first agent. In some embodiments, a first agent and/or an mTOR inhibitor of the invention is administered for less than 28, 14, 7, 6, 5, 4, 3, 2, or 1 day, wherein an administration of the mTOR inhibitor is subsequent to an administration of the first agent. In some embodiments, a first agent and/or an mTOR inhibitor of the invention is administered chronically on an ongoing basis, e.g., for the treatment of chronic effects, wherein an administration of the mTOR inhibitor is subsequent to an administration of the first agent.

[00165] In some embodiments, the dosing schedule begins with a first cycle comprising administration of the second agent which is an mTOR inhibitor for 1, 2, 3, 4, or 5 days, and administration of the first agent for 1, 2, 3, 4 or 5 days. For example, the first cycle begins with administration of a second agent for three days, followed by administration of the first agent for four days. The cycle may be repeated 2, 3, 4, 5, 6, 7 or more times as needed. Alternatively, the dosing schedule begins with a first cycle comprising administration of the first agent for 1, 2, 3, 4, or 5 days, and continues with administration of the second agent for 1, 2, 3, 4, or 5 days. For example, the first cycle begins with administration of a first agent for four days, followed by administration of the second agent for three days. The cycle may be repeated 2, 3, 4, 5, 6, 7 or more times as needed.

[00166] As used herein, a therapeutically effective amount of a combination of a first agent and an mTOR inhibitor administered in the order disclosed herein refers to a combination of a first agent and an mTOR inhibitor, wherein the combination is sufficient to effect the intended application including but not limited to disease treatment, as defined herein. Encompassed in this subject method is the use of a therapeutically effective amount of a first agent and/or an mTOR inhibitor in combination to effect such treatment. Also contemplated in the subject methods is the use of a sub-therapeutic amount of a first agent and/or an mTOR inhibitor in the combination for treating an intended disease condition. The individual

components of the combination, though present in sub-therapeutic amounts, synergistically yield an efficacious effect and/or reduced a side effect in an intended application.

[00167] The amount of the first agent and the mTOR inhibitor administered in the order disclosed herein may vary depending upon the intended application (*in vitro* or *in vivo*), or the subject and disease condition being treated, e.g., the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art.

First Agents

[00168] The first agent suitable for use in the subject methods can be selected from a variety types of molecules. For example, the first agent can be a biological or chemical compound such as a simple or complex organic or inorganic molecule, peptide, peptide mimetic, protein (e.g. antibody), liposome, or a polynucleotide (e.g. small interfering RNA, microRNA, anti-sense, aptamer, ribozyme, or triple helix). Some exemplary classes of chemical compounds suitable for use in the subject methods are detailed in the sections below.

[00169] In some embodiments, the first agent is an anti-neoplastic agent. Such agents include anti-angiogenesis agents, signal transduction inhibitors, and antiproliferative agents. For example, first agents of the invention may be compounds targeting or decreasing a protein or lipid kinase activity, a protein or lipid phosphatase activity, or anti-angiogenic compounds. Such compounds include, but are not limited to, protein tyrosine kinase and/or serine and/or threonine kinase inhibitors or lipid kinase inhibitors, e.g.,: compounds targeting, decreasing or inhibiting the activity of the platelet-derived growth factor-receptors (PDGFR), such as compounds which target, decrease or inhibit the activity of PDGFR, especially compounds which inhibit the PDGF receptor, e.g., a N-phenyl-2-pyrimidine-amine derivative, e.g., imatinib, SU101, SU6668 and GFB-111, Axitinib, Pazopanib, Sunitinib, Sorafenib, Toseranib); compounds targeting, decreasing or inhibiting the activity of the fibroblast growth factor-receptors (FGFR); compounds targeting, decreasing or inhibiting the activity of the insulin-like growth factor receptor I (IGF-IR), such as compounds which target, decrease or inhibit the activity of IGF-IR, especially compounds which inhibit the kinase activity of IGF-I receptor, such as those compounds disclosed in WO 02/092599 or such as OSI906, or antibodies that target the extracellular domain of IGF-I receptor such as CP-751871, R1507, AVE1642, IMC-A12, AMG479, MK-0646, SCH717454 or its growth factors; compounds targeting, decreasing or inhibiting the activity of the Trk receptor tyrosine kinase family, or ephrin B4 inhibitors; compounds targeting, decreasing or inhibiting the activity of the Axl receptor tyrosine kinase family; compounds targeting, decreasing or inhibiting the activity of the Ret receptor tyrosine kinase; compounds targeting, decreasing or inhibiting the activity of the Kit/SCFR receptor tyrosine kinase, e.g., imatinib; compounds targeting, decreasing or inhibiting the activity of the C-kit receptor tyrosine kinases - (part of the PDGFR family), such as compounds which target, decrease or inhibit the activity of the c-Kit receptor tyrosine kinase family, especially compounds which inhibit the c-Kit receptor, e.g., imatinib; compounds targeting, decreasing or inhibiting the activity of members of the c-Abl family, their gene-fusion products (e.g., BCR-Abl kinase) and mutants, such as compounds which

target decrease or inhibit the activity of c-Abl family members and their gene fusion products, e.g., a N-phenyl-2-pyrimidine-amine derivative, e.g., imatinib or nilotinib (AMN107); PD180970; AG957; NSC 680410; PD173955 from ParkeDavis; or dasatinib (BMS-354825); compounds targeting, decreasing or inhibiting the activity of members of the protein kinase C (PKC) and Raf family of serine/threonine kinases, members of the MEK, SRC, JAK, FAK, PDK1, PKB/Akt, and Ras/MAPK family members, and/or members of the cyclin-dependent kinase family (CDK) and are especially those staurosporine derivatives disclosed in US 5,093,330, e.g., midostaurin; examples of further compounds include e.g., UCN-01, safinolol, BAY 43-9006, Bryostatin 1, Perifosine; Ilmofofosine; RO 318220 and RO 320432; GO 6976; Isis 3521 ; LY333531/LY379196; isochinoline compounds such as those disclosed in WO 00/09495; FTIs; PD184352 or QAN697 (a P13K inhibitor) or AT7519 (CDK inhibitor); compounds targeting, decreasing or inhibiting the activity of protein-tyrosine kinase inhibitors, such as compounds which target, decrease or inhibit the activity of protein-tyrosine kinase inhibitors include imatinib mesylate (GLEEVEC) or tyrphostin. A tyrphostin is preferably a low molecular weight ($M_r < 1500$) compound, or a pharmaceutically acceptable salt thereof, especially a compound selected from the benzylidenemalonitrile class or the S-arylbenzenemalonitrile or bisubstrate quinoline class of compounds, more especially any compound selected from the group consisting of Tyrphostin A23/RG-50810; AG 99; Tyrphostin AG 213; Tyrphostin AG 1748; Tyrphostin AG 490; Tyrphostin B44; Tyrphostin B44 (+) enantiomer; Tyrphostin AG 555; AG 494; Tyrphostin AG 556, AG957 and adaphostin (4-[(2,5-dihydroxyphenyl)methyl]amino}-benzoic acid adamantyl ester; NSC 680410, adaphostin).

[00170] The first agent which are anti-angiogenic agents include receptor tyrosine kinase inhibitors. The receptor tyrosine kinase is, for instance, Her1/EGFR. In such cases, first agents for use in the invention include erlotinib, gefitinib and vandetanib. In some embodiments, the receptor tyrosine kinase inhibitor is an inhibitor of HER2/neu, including but not limited to afatinib, lapatinib and neratinib.

[00171] In some embodiments, the first agent is an inhibitor of a class III receptor tyrosine kinase, including C-kit or PDGFR. For instance, the first agent is axitinib, pazopanib, sunitinib, sorafenib or toceranib. In other embodiments, the first agent is an inhibitor of VEGFR, such as axitinib, cediranib, pazopanib, regorafenib, semaxanib, sorafenib, sunitinib, toceranib, or vandetanib.

[00172] In still other embodiments, the first agent is a non-receptor tyrosine kinase inhibitor. For example, the first agent is a bcr-abl inhibitor (including dasatinib, imatinib, and nilotinib), a Src inhibitor (including bosutinib), a Janus kinase 2 inhibitor (including lestaurtinib), or a EML4-ALK inhibitor (including lestaurtinib).

[00173] Anti-angiogenic agents such as MMP-2 (matrix-metalloproteinase 2) inhibitors, MMP-9 (matrix-metalloproteinase 9) inhibitors, and COX-2 (cyclooxygenase 2) inhibitors, can be used in conjunction with the methods of the present invention and pharmaceutical compositions described herein. Examples of useful COX-2 inhibitors include CELEBREXTM (alecoxib), valdecoxib, and rofecoxib. Examples of useful matrix metalloproteinase inhibitors are described in WO 96/33172 (published October 24, 1996), WO 96/27583 (published March 7, 1996), European Patent Application No. 97304971.1 (filed July 8, 1997), European Patent Application No. 99308617.2 (filed October 29, 1999), WO 98/07697 (published

February 26, 1998), WO 98/03516 (published January 29, 1998), WO 98/34918 (published August 13, 1998), WO 98/34915 (published August 13, 1998), WO 98/33768 (published August 6, 1998), WO 98/30566 (published July 16, 1998), European Patent Publication 606,046 (published July 13, 1994), European Patent Publication 931, 788 (published July 28, 1999), WO 90/05719 (published May 31, 1990), WO 99/52910 (published October 21, 1999), WO 99/52889 (published October 21, 1999), WO 99/29667 (published June 17, 1999), PCT International Application No. PCT/IB98/01113 (filed July 21, 1998), European Patent Application No. 99302232.1 (filed March 25, 1999), Great Britain Patent Application No. 9912961.1 (filed June 3, 1999), United States Provisional Application No. 60/148,464 (filed August 12, 1999), United States Patent 5,863, 949 (issued January 26, 1999), United States Patent 5,861, 510 (issued January 19, 1999), and European Patent Publication 780,386 (published June 25, 1997), all of which are incorporated herein in their entireties by reference. In some embodiments, MMP-2 and MMP-9 inhibitors have little or no activity inhibiting MMP-1, or selectively inhibit MMP-2 and/or MMP-9 relative to the other matrix-metalloproteinases (i. e., MAP-1, MMP-3, MMP-4, MMP-5, MMP-6, MMP- 7, MMP- 8, MMP-10, MMP-11, MMP-12, and MMP-13). Some specific examples of MMP inhibitors useful in the present invention are AG-3340, RO 32-3555, and RS 13-0830.

[00174] In some embodiments, the anti-neoplastic agent is selected from the group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, anti-hormones, angiogenesis inhibitors, immunotherapeutic agents, proapoptotic agents, and anti-androgens. Non-limiting examples are chemotherapeutic agents, cytotoxic agents, and non-peptide small molecules such as Tykerb/Tyverb (lapatinib), Gleevec (Imatinib Mesylate), Velcade (bortezomib), Casodex (bicalutamide), Iressa (gefitinib), and Adriamycin as well as a host of chemotherapeutic agents. Non-limiting examples of chemotherapeutic agents include alkylating agents such as thiotepa and cyclophosphamide (CYTOXANTM); alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, triethylenephosphoramidate, triethylenethiophosphoramidate and trimethylolomelamine; nitrogen mustards such as chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosoureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, ranimustine; oxazaphosphorines; nitrosoureas; triazines; antibiotics such as anthracyclins, actinomycins and bleomycins including aclacinomysins, actinomycin, anthramycin, azaserine, bleomycins, cactinomycin, calicheamicin, carabycin, carminomycin, carzinophilin, CasodexTM, chromomycins, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin, epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; anti-metabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogues such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine;

pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, androgens such as calusterone, dromostanolone propionate, epitio stanol, mepitio stanane, testolactone; anti-adrenals such as aminoglutethimide, mitotane, trilostane; folic acid replenisher such as frolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elfomithine; elliptinium acetate; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidamine; mitoguazone; mitoxantrone; mopidamol; nitracrine; pentostatin; phenamet; pirarubicin; podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK.RTM; razoxane; sizofiran; spirogermanium; tenuazonic acid; triaziquone; 2,2',2''-trichlorotriethylamine; urethan; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C"); cyclophosphamide; thiotepa; taxanes, e.g., paclitaxel (TAXOLTM, Bristol-Myers Squibb Oncology, Princeton, N.J.) and docetaxel (TAXOTERETM, Rhone-Poulenc Rorer, Antony, France); retinoic acid; esperamicins; capecitabine; gemcitabine and pharmaceutically acceptable salts, acids or derivatives of any of the above. Also included as suitable chemotherapeutic cell conditioners are anti-hormonal agents that act to regulate or inhibit hormone action on tumors such as anti-estrogens including for example tamoxifen (NolvadexTM), raloxifene, aromatase inhibiting 4(5)-imidazoles, 4-hydroxytamoxifen, trioxifene, keoxifene, LY 117018, onapristone, and toremifene (Fareston); and anti-androgens such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin; chlorambucil; gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum or platinum analogs and complexes such as cisplatin and carboplatin; anti-microtubule such as diterpenoids, including paclitaxel and docetaxel, or Vinca alkaloids including vinblastine, vincristine, vinflunine, vindesine, and vinorelbine; etoposide (VP-16); ifosfamide; mitomycin C; mitoxantrone; vincristine; vinorelbine; navelbine; novantrone; teniposide; daunomycin; aminopterin; xeloda; ibandronate; topoisomerase I and II inhibitors including camptothecins (e.g., camptothecin-11), topotecan, irinotecan, and epipodophyllotoxins; topoisomerase inhibitor RFS 2000; epothilone A or B; difluoromethylornithine (DMFO); histone deacetylase inhibitors; compounds which induce cell differentiation processes; gonadorelin agonists; methionine aminopeptidase inhibitors; compounds targeting/decreasing a protein or lipid kinase activity; compounds which target, decrease or inhibit the activity of a protein or lipid phosphatase; anti-androgens; bisphosphonates; biological response modifiers; antiproliferative antibodies; heparanase inhibitors; inhibitors of Ras oncogenic isoforms; telomerase inhibitors; proteasome inhibitors; compounds used in the treatment of hematologic malignancies; compounds which target, decrease or inhibit the activity of Flt-3; Hsp90 inhibitors; temozolomide (TEMODAL®); Hsp90 inhibitors such as 17-AAG (17-allylaminogeldanamycin, NSC330507), 17-DMAG (17-dimethylaminoethylamino-17-demethoxy-geldanamycin, NSC707545), IPI-504, CNF1010, CNF2024, CNF1010 from Conforma Therapeutics; temozolomide (TEMODAL®); kinesin spindle protein inhibitors, such as SB715992 or SB743921 from GlaxoSmithKline, or pentamidine/chlorpromazine from CombinatoRx; MEK inhibitors such as ARRY142886 from Array PtoPharma, AZD6244 from AstraZeneca, PD181461 or PD0325901 from Pfizer, leucovorin, EDG binders, antileukemia compounds, ribonucleotide reductase inhibitors, S-adenosylmethionine decarboxylase inhibitors, antiproliferative antibodies or other chemotherapeutic

compounds. Where desired, the compounds or pharmaceutical composition of the present invention can be used in conjunction with commonly prescribed anti-cancer drugs such as Herceptin[®], Avastin[®], Erbitux[®], Rituxan[®], Taxol[®], Arimidex[®], Taxotere[®], and Velcade[®]. Further information on compounds which may be used in conjunction with the compounds of the invention is provided below.

[00175] Proteasome inhibitors include compounds which target, decrease or inhibit the activity of the proteasome. Compounds which target, decrease or inhibit the activity of the proteasome include e.g., Bortezomid (Velcade[™]) and MLN 341. Matrix metalloproteinase inhibitors ("MMP" inhibitors) include, but are not limited to, collagen peptidomimetic and nonpeptidomimetic inhibitors, tetracycline derivatives, e.g., hydroxamate peptidomimetic inhibitor batimastat and its orally bioavailable analogue marimastat (BB-2516), prinomastat (AG3340), metastat (NSC 683551) BMS-279251, BAY 12-9566, TAA211, MMI270B or AAJ996. Compounds used in the treatment of hematologic malignancies include, but are not limited to, FMS-like tyrosine kinase inhibitors e.g., compounds targeting, decreasing or inhibiting the activity of FMS-like tyrosine kinase receptors (Flt-3R); interferon, 1-b-D-arabinofuransylcytosine (ara-c) and bisulfan; and ALK inhibitors e.g., compounds which target, decrease or inhibit anaplastic lymphoma kinase. Compounds which target, decrease or inhibit the activity of FMS-like tyrosine kinase receptors (Flt-3R) are especially compounds, proteins or antibodies which inhibit members of the Flt-3R receptor kinase family, e.g., PKC412, midostaurin, a staurosporine derivative, SU11248 and MLN518.

[00176] Hsp90 inhibitors include compounds such as 17-AAG (17-allylaminogeldanamycin, NSC330507), 17-DMAG (17-dimethylaminoethylamino-17-demethoxy-geldanamycin, NSC707545), IPI-504, CNF1010, CNF2024, CNF1010 from Conforma Therapeutics; temozo- lomide (TEMODAL[®]); kinesin spindle protein inhibitors, such as SB715992 or SB743921 from GlaxoSmithKline, or pentamidine/chlorpromazine from CombinatoRx; MEK inhibitors such as ARRY142886 from Array PionPharma, AZD6244 from AstraZeneca, PD181461 from Pfizer, leucovorin, EDG binders, antileukemia compounds, ribonucleotide reductase inhibitors, S-adenosylmethionine decarboxylase inhibitors, antiproliferative antibodies or other chemotherapeutic compounds.

[00177] Histone deacetylase inhibitors (or "HDAC inhibitors") include compounds which inhibit a histone deacetylase and which possess antiproliferative activity. This includes compounds disclosed in WO 02/22577, especially N-hydroxy-3-[4-[[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]-amino]methyl]phenyl]-2E-2-propenamide, N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl] amino]methyl]phenyl]-2E-2-propenamide and pharmaceutically acceptable salts thereof. It further especially includes Suberoylanilide hydroxamic acid (SAHA).

[00178] Bisphosphonates for use in combination with the compounds of the invention include, but are not limited to, etidronic, clodronic, tiludronic, pamidronic, alendronic, ibandronic, risedronic and zoledronic acid.

[00179] The methods of the invention may also be used with first agents targeting, decreasing or inhibiting the activity of the epidermal growth factor family of receptor tyrosine kinases (EGFR, ErbB2, ErbB3, ErbB4 as homo- or heterodimers) and their mutants, such as compounds which target, decrease or inhibit the activity of the epidermal growth factor receptor family are especially compounds, proteins or

antibodies which inhibit members of the EGF receptor tyrosine kinase family, e.g., EGF receptor, ErbB2, ErbB3 and ErbB4 or bind to EGF or EGF related ligands, and are in particular those compounds, proteins or monoclonal antibodies generically and specifically disclosed in WO 97/02266, e.g., the compound of ex. 39, or in EP 0 564 409, WO 99/03854, EP 0520722, EP 0 566 226, EP 0 787 722, EP 0 837 063, US 5,747,498, WO 98/10767, WO 97/30034, WO 97/49688, WO 97/38983 and, especially, WO 96/30347 (e.g., compound known as CP 358774), WO 96/33980 (e.g., compound ZD 1839) and WO 95/03283 (e.g., compound ZM105180); e.g., trastuzumab (Herceptin™), cetuximab (Erbix™), Iressa, Tarceva, OSI-774, CI-1033, EKB-569, GW-2016, E1.1, E2.4, E2.5, E6.2, E6.4, E2.1.1, E6.3 or E7.6.3, and 7H-pyrrolo-[2,3-d]pyrimidine derivatives which are disclosed in WO 03/013541; and compounds targeting, decreasing or inhibiting the activity of the c-Met receptor, such as compounds which target, decrease or inhibit the activity of c-Met, especially compounds which inhibit the kinase activity of c-Met receptor, or antibodies that target the extracellular domain of c-Met or bind to HGF. Further anti-angiogenic compounds include compounds having another mechanism for their activity, e.g., unrelated to protein or lipid kinase inhibition e.g., thalidomide (THALOMID) and TNP-470.

[00180] Non-receptor kinase angiogenesis inhibitors may also be useful in conjunction with the compounds of the present invention. Angiogenesis in general is linked to erbB2/EGFR signaling since inhibitors of erbB2 and EGFR have been shown to inhibit angiogenesis, primarily VEGF expression. Accordingly, non-receptor tyrosine kinase inhibitors may be used in combination with the compounds of the present invention. For example, anti-VEGF antibodies, which do not recognize VEGFR (the receptor tyrosine kinase), but bind to the ligand; small molecule inhibitors of integrin (α v β 3) that will inhibit angiogenesis; endostatin and angiostatin (non-RTK) may also prove useful in combination with the disclosed compounds. (See Bruns C J et al (2000), Cancer Res., 60: 2926-2935; Schreiber A B, Winkler M E, and Derynck R. (1986), Science, 232: 1250-1253; Yen L et al. (2000), Oncogene 19: 3460-3469).

[00181] First agents which target, decrease or inhibit the activity of a protein or lipid phosphatase include e.g., inhibitors of phosphatase 1, phosphatase 2A, or CDC25, e.g., okadaic acid or a derivative thereof. Compounds which induce cell differentiation processes are e.g., retinoic acid, α - γ - or δ -tocopherol or α - γ - or δ -tocotrienol. Cyclooxygenase inhibitors include, but are not limited to, e.g., Cox-2 inhibitors, 5-alkyl substituted 2-arylaminophenylacetic acid and derivatives, such as celecoxib (CELEBREX), rofecoxib (VIOXX), etoricoxib, valdecoxib or a 5-alkyl-2-arylaminophenylacetic acid, e.g., 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenyl acetic acid, and lumiracoxib.

[00182] First agents which are heparanase inhibitors include compounds which target, decrease or inhibit heparin sulfate degradation, including, but not limited to, PI-88. Biological response modifiers include lymphokines and interferons, e.g., interferon γ . Inhibitors of Ras oncogenic isoforms include H-Ras, K-Ras, N-Ras, and other compounds which target, decrease or inhibit the oncogenic activity of Ras. Farnesyl transferase inhibitors include, but are not limited to, e.g., L-744832, DK8G557 and R115777 (Zarnestra).

[00183] First agents which are telomerase inhibitors include compounds which target, decrease or inhibit the activity of telomerase. Compounds which target, decrease or inhibit the activity of telomerase are especially compounds which inhibit the telomerase receptor, e.g., telomestatin. Methionine

aminopeptidase inhibitors are, for example, compounds which target, decrease or inhibit the activity of methionine aminopeptidase. Compounds which target, decrease or inhibit the activity of methionine aminopeptidase are e.g., bengamide or a derivative thereof.

[00184] First agents which are antiproliferative antibodies include, but are not limited to, trastuzumab (Herceptin™), Trastuzumab-DM1, erbitux, bevacizumab (Avastin™), rituximab (Rituxan®), PRO64553 (anti-CD40) and 2C4 Antibody. By antibodies is meant e.g., intact monoclonal antibodies, polyclonal antibodies, multispecific antibodies formed from at least 2 intact antibodies, and antibodies fragments so long as they exhibit the desired biological activity.

[00185] First agents which are antileukemic compound for use in combination with compounds of the invention include, for example, Ara-C, a pyrimidine analog, which is the 2'-alpha-hydroxy ribose (arabinoside) derivative of deoxycytidine. Also included is the purine analog of hypoxanthine, 6-mercaptopurine (6-MP) and fludarabine phosphate. Compounds which target, decrease or inhibit activity of histone deacetylase (HDAC) inhibitors such as sodium butyrate and suberoylanilide hydroxamic acid (SAHA) inhibit the activity of the enzymes known as histone deacetylases. Specific HDAC inhibitors include MS275, SAHA, FK228 (formerly FR901228), Trichostatin A and compounds disclosed in US 6,552,065, in particular, Λ -hydroxy-3-[4-[[[2-(2-methyl-1 H-indol-3-yl)-ethyl]- amino]methyl]phenyl]-2E-2-propenamide, or a pharmaceutically acceptable salt thereof and Λ -hydroxy-3-[4-[(2-hydroxyethyl){2-(1/-indol-3-yl)ethyl]-amino]methyl]phenyl]-2E-2-propenamide, or a pharmaceutically acceptable salt thereof, e.g., the lactate salt.

[00186] First agents which are somatostatin receptor antagonists include compounds which target, treat or inhibit the somatostatin receptor such as octreotide, and SOM230 (pasireotide). Tumor cell damaging approaches include approaches such as ionizing radiation, e.g., ionizing radiation that occurs as either electromagnetic rays (such as X-rays and gamma rays) or particles (such as alpha and beta particles). Ionizing radiation is provided in, but not limited to, radiation therapy and is known in the art. See Hellman, Principles of Radiation Therapy, Cancer, in Principles and Practice of Oncology, Devita et al., Eds., 4th Edition, Vol. 1, pp. 248-275 (1993). EDG binders includes immunosuppressants that modulate lymphocyte recirculation, such as FTY720.

[00187] First agents which are ribonucleotide reductase inhibitors include pyrimidine or purine nucleoside analogs including, but not limited to, fludarabine and/or cytosine arabinoside (ara-C), 6-thioguanine, 5-fluorouracil, cladribine, 6-mercaptopurine (especially in combination with ara-C against ALL) and/or pentostatin. Ribonucleotide reductase inhibitors are e.g., hydroxyurea or 2-hydroxy-1 -/-isoindole-1,3-dione derivatives, such as PL-1, PL-2, PL-3, PL-4, PL-5, PL-6, PL-7 or PL-8 mentioned in Nandy et al., Acta Oncologica, Vol. 33, No. 8, pp. 953-961 (1994).

[00188] First agents which are S-adenosylmethionine decarboxylase inhibitors include, but are not limited to the compounds disclosed in US 5,461,076.

[00189] Also included as first agents are in particular those compounds, proteins or monoclonal antibodies of VEGF disclosed in WO 98/35958, e.g., 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine or a pharmaceutically acceptable salt thereof, e.g., the succinate, or in WO 00/09495, WO 00/27820, WO

00/59509, WO 98/11223, WO 00/27819 and EP 0 769 947; those as described by Prewett et al, Cancer Res, Vol. 59, pp. 5209-5218 (1999); Yuan et al., Proc Natl Acad Sci U S A, Vol. 93, pp. 14765-14770 (1996); Zhu et al., Cancer Res, Vol. 58, pp. 3209- 3214 (1998); and Mordenti et al., Toxicol Pathol, Vol. 27, No. 1, pp. 14-21 (1999); in WO 00/37502 and WO 94/10202; ANGIOSTATIN, described by O'Reilly et al., Cell, Vol. 79, pp. 315-328 (1994); ENDOSTATIN, described by O'Reilly et al., Cell, Vol. 88, pp. 277-285 (1997); anthranilic acid amides; ZD4190; ZD6474; SU5416; SU6668; bevacizumab; or anti-VEGF antibodies or anti-VEGF receptor antibodies, e.g., rhuMAB and RHUFab, VEGF aptamer e.g., Macugon; FLT-4 inhibitors, FLT-3 inhibitors, VEGFR-2 IgG1 antibody, Angiozyme (RPI 4610) and Bevacizumab (Avastin™).

[00190] Other compounds that can regulate apoptosis (e.g., BCL-2 inhibitors) can be used as first agents.

[00191] First agents which are platinum coordination complexes include non-phase specific anti-cancer agents, which interact with DNA. The platinum complexes enter tumor cells, undergo, aquation and form intra- and interstrand crosslinks with DNA causing adverse biological effects to the tumor. Examples of platinum coordination complexes include, but are not limited to, cisplatin and carboplatin. Cisplatin, cis-diamminedichloroplatinum, is commercially available as PLATINOL® as an injectable solution. Cisplatin is primarily indicated in the treatment of metastatic testicular and ovarian cancer and advanced bladder cancer. The primary dose limiting side effects of cisplatin are nephrotoxicity, which may be controlled by hydration and diuresis, and ototoxicity. Carboplatin, platinum, diammine [1,1-cyclobutane-dicarboxylate(2-)-O,O'], is commercially available as PARAPLATIN® as an injectable solution. Carboplatin is primarily indicated in the first and second line treatment of advanced ovarian carcinoma. Bone marrow suppression is the dose limiting toxicity of carboplatin.

[00192] First agents which are alkylating agents include non-phase anti-cancer specific agents and strong electrophiles. Typically, alkylating agents form covalent linkages, by alkylation, to DNA through nucleophilic moieties of the DNA molecule such as phosphate, amino, sulfhydryl, hydroxyl, carboxyl, and imidazole groups. Such alkylation disrupts nucleic acid function leading to cell death. Examples of alkylating agents include, but are not limited to, nitrogen mustards such as cyclophosphamide, melphalan, and chlorambucil; alkyl sulfonates such as busulfan; nitrosoureas such as carmustine; and triazenes such as dacarbazine. Cyclophosphamide, 2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate, is commercially available as an injectable solution or tablets as CYTOXAN®. Cyclophosphamide is indicated as a single agent or in combination with other chemotherapeutic agents, in the treatment of malignant lymphomas, multiple myeloma, and leukemias. Alopecia, nausea, vomiting and leukopenia are the most common dose limiting side effects of cyclophosphamide. Melphalan, 4-[bis(2-chloroethyl)amino]-L-phenylalanine, is commercially available as an injectable solution or tablets as ALKERAN®. Melphalan is indicated for the palliative treatment of multiple myeloma and non-resectable epithelial carcinoma of the ovary. Bone marrow suppression is the most common dose limiting side effect of melphalan. Chlorambucil, 4-[bis(2-chloroethyl)amino]benzenebutanoic acid, is commercially available as LEUKERAN® tablets. Chlorambucil is indicated for the palliative treatment of chronic lymphatic leukemia, and malignant lymphomas such as lymphosarcoma, giant follicular

lymphoma, and Hodgkin's disease. Bone marrow suppression is the most common dose limiting side effect of chlorambucil. Busulfan, 1,4-butanediol dimethanesulfonate, is commercially available as MYLERAN® TABLETS. Busulfan is indicated for the palliative treatment of chronic myelogenous leukemia. Bone marrow suppression is the most common dose limiting side effects of busulfan. Carmustine, 1,3-[bis(2-chloroethyl)-1-nitrosourea, is commercially available as single vials of lyophilized material as BiCNU®. Carmustine is indicated for the palliative treatment as a single agent or in combination with other agents for brain tumors, multiple myeloma, Hodgkin's disease, and non-Hodgkin's lymphomas. Delayed myelosuppression is the most common dose limiting side effects of carmustine. Dacarbazine, 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide, is commercially available as single vials of material as DTIC-Dome®. Dacarbazine is indicated for the treatment of metastatic malignant melanoma and in combination with other agents for the second line treatment of Hodgkin's Disease. Nausea, vomiting, and anorexia are the most common dose limiting side effects of dacarbazine.

[00193] First agents which are antibiotic anti-neoplastics include non-phase specific agents, which bind or intercalate with DNA. Typically, such action results in stable DNA complexes or strand breakage, which disrupts ordinary function of the nucleic acids leading to cell death. Examples of antibiotic anti-neoplastic agents include, but are not limited to, actinomycins such as dactinomycin, anthracyclins such as daunorubicin and doxorubicin; and bleomycins. Dactinomycin, also known as Actinomycin D, is commercially available in injectable form as COSMEGEN®. Dactinomycin is indicated for the treatment of Wilm's tumor and rhabdomyosarcoma. Nausea, vomiting, and anorexia are the most common dose limiting side effects of dactinomycin. Daunorubicin, (8S-cis-)-8-acetyl-10-[(3-amino-2,3,6-trideoxy- α -L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12 naphthacenedione hydrochloride, is commercially available as a liposomal injectable form as DAUNOXOME® or as an injectable as CERUBIDINE®. Daunorubicin is indicated for remission induction in the treatment of acute nonlymphocytic leukemia and advanced HIV associated Kaposi's sarcoma. Myelosuppression is the most common dose limiting side effect of daunorubicin. Doxorubicin, (8S,10S)-10-[(3-amino-2,3,6-trideoxy- α -L-lyxo-hexopyranosyl)oxy]-8- glycoloyl, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12 naphthacenedione hydrochloride, is commercially available as an injectable form as RUBEX® or ADRIAMYCIN RDF®. Doxorubicin is primarily indicated for the treatment of acute lymphoblastic leukemia and acute myeloblastic leukemia, but is also a useful component in the treatment of some solid tumors and lymphomas. Myelosuppression is the most common dose limiting side effect of doxorubicin. Bleomycin, a mixture of cytotoxic glycopeptide antibiotics isolated from a strain of *Streptomyces verticillus*, is commercially available as BLENOXANE®. Bleomycin is indicated as a palliative treatment, as a single agent or in combination with other agents, of squamous cell carcinoma, lymphomas, and testicular carcinomas. Pulmonary and cutaneous toxicities are the most common dose limiting side effects of bleomycin.

[00194] First agents which are hormones and hormonal analogues are useful compounds for treating cancers in which there is a relationship between the hormone(s) and growth and/or lack of growth of the cancer. Examples of hormones and hormonal analogues useful in cancer treatment include, but are not

limited to, adrenocorticosteroids such as prednisone and prednisolone which are useful in the treatment of malignant lymphoma and acute leukemia in children; aminoglutethimide and other aromatase inhibitors such as aminoglutethimide, roglethimide, pyridoglutethimide, trilostane, testolactone, ketokonazole, vorozole, fadrozole, anastrozole, letrozole, formestane, atamestane and exemestane useful in the treatment of adrenocortical carcinoma and hormone dependent breast carcinoma containing estrogen receptors; progestrins such as megestrol acetate useful in the treatment of hormone dependent breast cancer and endometrial carcinoma; estrogens, androgens, and anti-androgens such as flutamide, nilutamide, bicalutamide, cyproterone acetate and 5α -reductases such as finasteride and dutasteride, useful in the treatment of prostatic carcinoma and benign prostatic hypertrophy; anti-estrogens such as fulvestrant, tamoxifen, toremifene, raloxifene, droloxifene, idoxifene, as well as selective estrogen receptor modulators (SERMS) such those described in U.S. Pat. Nos. 5,681,835, 5,877,219, and 6,207,716, useful in the treatment of hormone dependent breast carcinoma and other susceptible cancers; and gonadotropin-releasing hormone (GnRH) and analogues thereof which stimulate the release of leutinizing hormone (LH) and/or follicle stimulating hormone (FSH) for the treatment prostatic carcinoma, for instance, LHRH agonists and antagonists such as abarelix, goserelin, goserelin acetate and luprolide. SH2/SH3 domain blockers are agents that disrupt SH2 or SH3 domain binding in a variety of enzymes or adaptor proteins including, PI3-K p85 subunit, Src family kinases, adaptor molecules (Shc, Crk, Nck, Grb2) and Ras-GAP. SH2/SH3 domains as targets for anti-cancer drugs are discussed in Smithgall, T. E. (1995), *Journal of Pharmacological and Toxicological Methods*. 34(3) 125-32. Inhibitors of Serine/Threonine Kinases including MAP kinase cascade blockers which include blockers of Raf kinases (rafk), Mitogen or Extracellular Regulated Kinase (MEKs), and Extracellular Regulated Kinases (ERKs); and Protein kinase C family member blockers including blockers of PKCs (alpha, beta, gamma, epsilon, mu, lambda, iota, zeta). Ikb kinase family (IKKa, IKKb), PKB family kinases, akt kinase family members, and TGF beta receptor kinases. Such Serine/Threonine kinases and inhibitors thereof are described in Yamamoto, T., Taya, S., Kaibuchi, K., (1999), *Journal of Biochemistry*. 126 (5) 799-803; Brodt, P., Samani, A., and Navab, R. (2000), *Biochemical Pharmacology*, 60. 1101-1107; Massague, J., Weis-Garcia, F. (1996) *Cancer Surveys*. 27:41-64; Philip, P. A., and Harris, A. L. (1995), *Cancer Treatment and Research*. 78: 3-27, Lackey, K. et al *Bioorganic and Medicinal Chemistry Letters*, (10), 2000, 223-226; U.S. Pat. No. 6,268,391; and Martinez-Iacaci, L., et al, *Int. J. Cancer* (2000), 88(1), 44-52.

[00195] Also of interest for use with the methods of the invention are Myo-inositol signaling inhibitors such as phospholipase C blockers and Myoinositol analogues. Such signal inhibitors are described in Powis, G., and Kozikowski A., (1994) *New Molecular Targets for Cancer Chemotherapy* ed., Paul Workman and David Kerr, CRC press 1994, London.

[00196] Another group of inhibitors useful as first agents are signal transduction pathway inhibitors such as inhibitors of Ras Oncogene. Such inhibitors include inhibitors of farnesyltransferase, geranyl-geranyl transferase, and CAAX proteases as well as anti-sense oligonucleotides, ribozymes and immunotherapy. Such inhibitors have been shown to block ras activation in cells containing wild type mutant ras, thereby acting as antiproliferation agents. Ras oncogene inhibition is discussed in Scharovsky, O. G., Rozados, V.

R., Gervasoni, S. I. Matar, P. (2000), Journal of Biomedical Science. 7(4) 292-8; Ashby, M. N. (1998), Current Opinion in Lipidology. 9 (2) 99-102; and BioChim. Biophys. Acta, (1989) 1423(3):19-30.

[00197] For treatment of autoimmune diseases, the subject methods of treatment can be practiced with commonly prescribed drugs including but not limited to Enbrel[®], Remicade[®], Humira[®], Avonex[®], and Rebif[®]. For treatment of respiratory diseases, the subject methods of treatment can be practiced with commonly prescribed drugs including but not limited to Xolair[®], Advair[®], Singulair[®], and Spiriva[®].

mTOR Inhibitor Compounds

[00198] An mTOR inhibitor for use in the present invention can be any mTOR inhibitor that is known in the art, and can include any chemical entity that, upon administration to a patient, results in inhibition of mTOR in the patient. An mTOR inhibitor can inhibit mTOR by any biochemical mechanism, including competition at the ATP binding site, competition elsewhere at the catalytic site of mTOR kinase, non-competitive inhibition, irreversible inhibition (e.g. covalent protein modification), or modulation of the interactions of other protein subunits or binding proteins with mTOR kinase in a way that results in inhibition of mTOR kinase activity (e.g. modulation of the interaction of mTOR with FKBP12, GβL, (mLST8), RAPTOR (mKOG1), or RICTOR (mAVO3)). Specific examples of mTOR inhibitors include: rapamycin; other rapamycin macrolides, or rapamycin analogues, derivatives or prodrugs; RAD001 (also known as Everolimus, RAD001 is an alkylated rapamycin (40-O-(2-hydroxyethyl)-rapamycin), disclosed in U.S. Pat. No. 5,665,772; Novartis); CCI-779 (also known as Temsirolimus, CCI-779 is an ester of rapamycin (42-ester with 3-hydroxy-2-hydroxymethyl-2-methylpropionic acid), disclosed in U.S. Pat. No. 5,362,718; Wyeth); AP23573 or AP23841 (Ariad Pharmaceuticals); ABT-578 (40-epi-(tetrazolyl)-rapamycin; Abbott Laboratories); KU-0059475 (Kudus Pharmaceuticals); and TAFA-93 (a rapamycin prodrug; Isotechnika). Examples of rapamycin analogs and derivatives known in the art include those compounds described in U.S. Pat. Nos. 6,329,386; 6,200,985; 6,117,863; 6,015,815; 6,015,809; 6,004,973; 5,985,890; 5,955,457; 5,922,730; 5,912,253; 5,780,462; 5,665,772; 5,637,590; 5,567,709; 5,563,145; 5,559,122; 5,559,120; 5,559,119; 5,559,112; 5,550,133; 5,541,192; 5,541,191; 5,532,355; 5,530,121; 5,530,007; 5,525,610; 5,521,194; 5,519,031; 5,516,780; 5,508,399; 5,508,290; 5,508,286; 5,508,285; 5,504,291; 5,504,204; 5,491,231; 5,489,680; 5,489,595; 5,488,054; 5,486,524; 5,486,523; 5,486,522; 5,484,791; 5,484,790; 5,480,989; 5,480,988; 5,463,048; 5,446,048; 5,434,260; 5,411,967; 5,391,730; 5,389,639; 5,385,910; 5,385,909; 5,385,908; 5,378,836; 5,378,696; 5,373,014; 5,362,718; 5,358,944; 5,346,893; 5,344,833; 5,302,584; 5,262,424; 5,262,423; 5,260,300; 5,260,299; 5,233,036; 5,221,740; 5,221,670; 5,202,332; 5,194,447; 5,177,203; 5,169,851; 5,164,399; 5,162,333; 5,151,413; 5,138,051; 5,130,307; 5,120,842; 5,120,727; 5,120,726; 5,120,725; 5,118,678; 5,118,677; 5,100,883; 5,023,264; 5,023,263; and 5,023,262; all of which are incorporated herein by reference. Rapamycin derivatives are also disclosed for example in WO 94/09010, WO 95/16691, WO 96/41807, or WO 99/15530, which are incorporated herein by reference. Such analogs and derivatives include 32-deoxorapamycin, 16-pent-2-ynyloxy-32-deoxorapamycin, 16-pent-2-ynyloxy-32 (S or R)-dihydro-rapamycin, 16-pent-2-ynyloxy-32 (S or R)-dihydro-40-O-(2-hydroxyethyl)-rapamycin, 40-O-(2-

hydroxyethyl)-rapamycin, 32-deoxorapamycin and 16-pent-2-ynyloxy-32(S)-dihydro-rapamycin. Rapamycin derivatives may also include the so-called rapalogs, e.g. as disclosed in WO 98/02441 and WO 01/14387 (e.g. AP23573, AP23464, AP23675 or AP23841). Further examples of a rapamycin derivative are those disclosed under the name biolimus-7 or biolimus-9 (BIOLIMUS A9™) (Biosensors International, Singapore). Any of the above rapamycin analogs or derivatives may be readily prepared by procedures as described in the above references.

[00199] Additional examples of mTOR inhibitors useful in the invention described herein include those disclosed and claimed in US7700594 and in US7651687, a series of compounds that inhibit mTOR by binding to and directly inhibiting both mTORC1 and mTORC2 kinases. Similar results can be obtained with any compound that inhibits mTOR by binding to and directly inhibiting both mTORC1 and mTORC2 kinases, such as those whose structures are disclosed herein. Additional such compounds can readily be identified by determining their ability to inhibit both mTORC1 and mTORC2 kinase activities using immunoprecipitation-kinase assays with antibodies specific to either the raptor or rictor proteins of the mTORC1 and mTORC2 complexes (for an example of such assays, see Jacinto, E. et al. (2004) *Nature Cell Biol.* 6(11): 1122-1128). Also useful in the invention described herein are mTOR inhibitors that are dual PI3K/mTOR kinase inhibitors, such as for example the compound PI-103 as described in Fan, Q-W et al (2006) *Cancer Cell* 9:341-349 and Knight, Z. A. et al. (2006) *Cell* 125:733-747.

[00200] In some embodiments, the capacity of an mTOR inhibitor to inhibit mTOR is expressed in terms of an IC₅₀ value. As used herein, the term "IC₅₀" refers to the half maximal inhibitory concentration of an inhibitor in inhibiting biological or biochemical function. This quantitative measure indicates how much of a particular inhibitor is needed to inhibit a given biological process (or component of a process, i.e. an enzyme, cell, cell receptor or microorganism) by half. In other words, it is the half maximal (50%) inhibitory concentration (IC) of a substance (50% IC, or IC₅₀). EC₅₀ refers to the plasma concentration required for obtaining 50% of a maximum effect *in vivo*.

[00201] Determination of IC₅₀ can be made by determining and constructing a dose-response curve and examining the effect of different concentrations of an inhibitor on reversing agonist activity. *In vitro* assays that are useful in making these determinations are referred to as "in vitro kinase assays."

[00202] In some embodiments, an *in vitro* kinase assay includes the use of labeled ATP as phosphodonor, and following the kinase reaction the substrate peptide is captured on an appropriate filter. Unreacted labeled ATP and metabolites are resolved from the radioactive peptide substrate by various techniques, such as involving trichloroacetic acid precipitation and extensive washing. Addition of several positively charged residues allows capture on phosphocellulose paper followed by washing. Radioactivity incorporated into the substrate peptide is detected by scintillation counting. This assay is relatively simple, reasonably sensitive, and the peptide substrate can be adjusted both in terms of sequence and concentration to meet the assay requirements. Other exemplary kinase assays are detailed in U.S. Pat. No. 5,759,787 and US Application Ser. No. 12/728,926, both of which are incorporated herein by reference.

[00203] The mTOR inhibitor utilized in the subject methods is typically highly selective for the target molecule. In one aspect, the mTOR inhibitor binds to and directly inhibits both mTORC1 and mTORC2.

Such ability can be ascertained using any method known in the art or described herein. For example, inhibition of mTorC1 and/or mTorC2 activity can be determined by a reduction in signal transduction of the PI3K/Akt/mTor pathway. A wide variety of readouts can be utilized to establish a reduction of the output of such signaling pathway. Some non-limiting exemplary readouts include (1) a decrease in phosphorylation of Akt at residues, including but not limited to S473 and T308; (2) a decrease in activation of Akt as evidenced by a reduction of phosphorylation of Akt substrates including but not limited to FoxO1/O3a T24/32, GSK3 α/β S21/9, and TSC2 T1462; (3) a decrease in phosphorylation of signaling molecules downstream of mTor, including but not limited to ribosomal S6 S240/244, 70S6K T389, and 4EBP1 T37/46; (4) inhibition of proliferation of cells including but not limited to normal or neoplastic cells, mouse embryonic fibroblasts, leukemic blast cells, cancer stem cells, and cells that mediate autoimmune reactions; (5) induction of apoptosis of cells or cell cycle arrest (e.g. accumulation of cells in G1 phase); (6) reduction of cell chemotaxis; and (7) an increase in binding of 4EBP1 to eIF4E.

[00204] mTOR exists in two types of complexes, mTorC1 containing the raptor subunit and mTorC2 containing rictor. As known in the art, "rictor" refers to a cell growth regulatory protein having human gene locus 5p13.1. These complexes are regulated differently and have a different spectrum of substrates. For instance, mTorC1 phosphorylates S6 kinase (S6K) and 4EBP1, promoting increased translation and ribosome biogenesis to facilitate cell growth and cell cycle progression. S6K also acts in a feedback pathway to attenuate PI3K/Akt activation. Thus, inhibition of mTorC1 (e.g. by a biologically active agent as discussed herein) results in activation of 4EBP1, resulting in inhibition of (e.g. a decrease in) RNA translation.

[00205] mTorC2 is generally insensitive to rapamycin and selective inhibitors and is thought to modulate growth factor signaling by phosphorylating the C-terminal hydrophobic motif of some AGC kinases such as Akt. In many cellular contexts, mTorC2 is required for phosphorylation of the S473 site of Akt. Thus, mTorC1 activity is partly controlled by Akt whereas Akt itself is partly controlled by mTorC2.

[00206] Growth factor stimulation of PI3K causes activation of Akt by phosphorylation at the two key sites, S473 and T308. It has been reported that full activation of Akt requires phosphorylation of both S473 and T308. Active Akt promotes cell survival and proliferation in many ways including suppressing apoptosis, promoting glucose uptake, and modifying cellular metabolism. Of the two phosphorylation sites on Akt, activation loop phosphorylation at T308, mediated by PDK1, is believed to be indispensable for kinase activity, while hydrophobic motif phosphorylation at S473 enhances Akt kinase activity.

[00207] Inhibition of Akt phosphorylation can be determined using any methods known in the art or described herein. Representative assays include but are not limited to immunoblotting and immunoprecipitation with antibodies such as anti-phosphotyrosine antibodies that recognize the specific phosphorylated proteins. Cell-based ELISA kit quantifies the amount of activated (phosphorylated at S473) Akt relative to total Akt protein is also available (SuperArray Biosciences).

[00208] Selective mTor inhibition may also be determined by expression levels of the mTor genes, its downstream signaling genes (for example by RT-PCR), or expression levels of the proteins (for example

by immunocytochemistry, immunohistochemistry, Western blots) as compared to other PI3-kinases or protein kinases.

[00209] Cell-based assays for establishing selective inhibition of mTorC1 and/or mTorC2 can take a variety of formats. This generally will depend on the biological activity and/or the signal transduction readout that is under investigation. For example, the ability of the agent to inhibit mTorC1 and/or mTorC2 to phosphorylate downstream substrate(s) can be determined by various types of kinase assays known in the art. Representative assays include but are not limited to immunoblotting and immunoprecipitation with antibodies such as anti-phosphotyrosine, anti-phosphoserine or anti-phosphothreonine antibodies that recognize phosphorylated proteins. Alternatively, antibodies that specifically recognize a particular phosphorylated form of a kinase substrate (e.g. anti-phospho AKT S473 or anti-phospho AKT T308) can be used. In addition, kinase activity can be detected by high throughput chemiluminescent assays such as AlphaScreen™ (available from Perkin Elmer) and eTag™ assay (Chan-Hui, et al. (2003) *Clinical Immunology* 111: 162-174). In another aspect, single cell assays such as flow cytometry as described in the phosflow experiment can be used to measure phosphorylation of multiple downstream mTOR substrates in mixed cell populations.

[00210] One advantage of the immunoblotting and phosflow methods is that the phosphorylation of multiple kinase substrates can be measured simultaneously. This provides the advantage that efficacy and selectivity can be measured at the same time. For example, cells may be contacted with an mTOR inhibitor at various concentrations and the phosphorylation levels of substrates of both mTOR and other kinases can be measured. In one aspect, a large number of kinase substrates are assayed in what is termed a “comprehensive kinase survey.” Selective mTOR inhibitors are expected to inhibit phosphorylation of mTOR substrates without inhibiting phosphorylation of the substrates of other kinases. Alternatively, selective mTOR inhibitors may inhibit phosphorylation of substrates of other kinases through anticipated or unanticipated mechanisms such as feedback loops or redundancy.

[00211] Effect of inhibition of mTorC1 and/or mTorC2 can be established by cell colony formation assay or other forms of cell proliferation assay. A wide range of cell proliferation assays are available in the art, and many of which are available as kits. Non-limiting examples of cell proliferation assays include testing for tritiated thymidine uptake assays, BrdU (5'-bromo-2'-deoxyuridine) uptake (kit marketed by Calibrochem), MTS uptake (kit marketed by Promega), MTT uptake (kit marketed by Cayman Chemical), CyQUANT® dye uptake (marketed by Invitrogen).

[00212] Apoptosis and cell cycle arrest analysis can be performed with any methods exemplified herein as well other methods known in the art. Many different methods have been devised to detect apoptosis. Exemplary assays include but are not limited to the TUNEL (TdT-mediated dUTP Nick-End Labeling) analysis, ISEL (in situ end labeling), and DNA laddering analysis for the detection of fragmentation of DNA in populations of cells or in individual cells, Annexin-V analysis that measures alterations in plasma membranes, detection of apoptosis related proteins such p53 and Fas.

[00213] A cell-based assay typically proceeds with exposing the target cells (e.g., in a culture medium) to a test compound which is a potential mTorC1 and/or mTorC2 selective inhibitor, and then assaying for

readout under investigation. Depending on the nature of the candidate mTor inhibitors, they can directly be added to the cells or in conjunction with carriers. For instance, when the agent is nucleic acid, it can be added to the cell culture by methods well known in the art, which include without limitation calcium phosphate precipitation, microinjection or electroporation. Alternatively, the nucleic acid can be incorporated into an expression or insertion vector for incorporation into the cells. Vectors that contain both a promoter and a cloning site into which a polynucleotide can be operatively linked are well known in the art. Such vectors are capable of transcribing RNA *in vitro* or *in vivo*, and are commercially available from sources such as Stratagene (La Jolla, CA) and Promega Biotech (Madison, WI). In order to optimize expression and/or *in vitro* transcription, it may be necessary to remove, add or alter 5' and/or 3' untranslated portions of the clones to eliminate extra, potential inappropriate alternative translation initiation codons or other sequences that may interfere with or reduce expression, either at the level of transcription or translation. Alternatively, consensus ribosome binding sites can be inserted immediately 5' of the start codon to enhance expression. Examples of vectors are viruses, such as baculovirus and retrovirus, bacteriophage, adenovirus, adeno-associated virus, cosmid, plasmid, fungal vectors and other recombination vehicles typically used in the art which have been described for expression in a variety of eukaryotic and prokaryotic hosts, and may be used for gene therapy as well as for simple protein expression. Among these are several non-viral vectors, including DNA/liposome complexes, and targeted viral protein DNA complexes. To enhance delivery to a cell, the nucleic acid or proteins of this invention can be conjugated to antibodies or binding fragments thereof which bind cell surface antigens. Liposomes that also comprise a targeting antibody or fragment thereof can be used in the methods of this invention. Other biologically acceptable carriers can be utilized, including those described in, for example, REMINGTON'S PHARMACEUTICAL SCIENCES, 19th Ed. (2000), in conjunction with the subject compounds. Additional methods for cell-based assays for determining effects of agents on cell-cycle progression are described in US7612189, incorporated herein by reference.

[00214] In practicing the subject methods, any cells that express PI3-kinase α , mTorC1, mTorC2 and/or Akt can be target cells. Non-limiting examples of specific cell types whose proliferation can be inhibited include fibroblast, cells of skeletal tissue (bone and cartilage), cells of epithelial tissues (e.g. liver, lung, breast, skin, bladder and kidney), cardiac and smooth muscle cells, neural cells (glia and neurones), endocrine cells (adrenal, pituitary, pancreatic islet cells), melanocytes, and many different types of haemopoietic cells (e.g., cells of B-cell or T-cell lineage, and their corresponding stem cells, lymphoblasts). Also of interest are cells exhibiting a neoplastic propensity or phenotype. Of particular interest is the type of cells that differentially expresses (over-expresses or under-expresses) a disease-causing gene. The types of diseases involving abnormal functioning of genes include but are not limited to autoimmune diseases, cancer, obesity, hypertension, diabetes, neuronal and/or muscular degenerative diseases, cardiac diseases, endocrine disorders, and any combinations thereof.

[00215] In some embodiments, the mTOR inhibitor inhibits both mTORC1 and mTORC2 with an IC50 value of about 1 nM, 2 nM, 5 nM, 7 nM, 10 nM, 20 nM, 30 nM, 40 nM, 50 nM, 60 nM, 70 nM, 80 nM, 90 nM, 100 nM, 120 nM, 140 nM, 150 nM, 160 nM, 170 nM, 180 nM, 190 nM, 200 nM, 225 nM, 250 nM,

275 nM, 300 nM, 325 nM, 350 nM, 375 nM, 400 nM, 425 nM, 450 nM, 475 nM, 500 nM, 550 nM, 600 nM, 650 nM, 700 nM, 750 nM, 800 nM, 850 nM, 900 nM, 950 nM, 1 μ M, 1.2 μ M, 1.3 μ M, 1.4 μ M, 1.5 μ M, 1.6 μ M, 1.7 μ M, 1.8 μ M, 1.9 μ M, 2 μ M, 5 μ M, 10 μ M, 15 μ M, 20 μ M, 25 μ M, 30 μ M, 40 μ M, 50 μ M, 60 μ M, 70 μ M, 80 μ M, 90 μ M, 100 μ M, 200 μ M, 300 μ M, 400 μ M, or 500 μ M or less as ascertained in an *in vitro* kinase assay, and said IC₅₀ value is at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, or 1000 times less than its IC₅₀ value against all other type I PI3-kinases selected from the group consisting of PI3-kinase α , PI3-kinase β , PI3-kinase γ , and PI3-kinase δ . For example, the mTOR inhibitor inhibits both mTORC1 and mTORC2 with an IC₅₀ value of about 200, 100, 75, 50, 25, 10, 5, 1 or 0.5 nM or less as ascertained in an *in vitro* kinase assay. In one instance, the mTOR inhibitor inhibits both mTORC1 and mTORC2 with an IC₅₀ value of about 100nM or less as ascertained in an *in vitro* kinase assay. As another example, the mTOR inhibitor inhibits both mTORC1 and mTORC2 with an IC₅₀ value of about 10 nM or less as ascertained in an *in vitro* kinase assay.

[00216] In some embodiments, the present invention provides the use of an mTOR inhibitor, wherein the mTOR inhibitor directly binds to and inhibits both mTORC1 and mTORC2 with an IC₅₀ value of about or less than a predetermined value, as ascertained in an *in vitro* kinase assay. In some embodiments, the mTOR inhibitor inhibits both mTORC1 and mTORC2 with an IC₅₀ value of about 1 nM or less, 2 nM or less, 5 nM or less, 7 nM or less, 10 nM or less, 20 nM or less, 30 nM or less, 40 nM or less, 50 nM or less, 60 nM or less, 70 nM or less, 80 nM or less, 90 nM or less, 100 nM or less, 120 nM or less, 140 nM or less, 150 nM or less, 160 nM or less, 170 nM or less, 180 nM or less, 190 nM or less, 200 nM or less, 225 nM or less, 250 nM or less, 275 nM or less, 300 nM or less, 325 nM or less, 350 nM or less, 375 nM or less, 400 nM or less, 425 nM or less, 450 nM or less, 475 nM or less, 500 nM or less, 550 nM or less, 600 nM or less, 650 nM or less, 700 nM or less, 750 nM or less, 800 nM or less, 850 nM or less, 900 nM or less, 950 nM or less, 1 μ M or less, 1.2 μ M or less, 1.3 μ M or less, 1.4 μ M or less, 1.5 μ M or less, 1.6 μ M or less, 1.7 μ M or less, 1.8 μ M or less, 1.9 μ M or less, 2 μ M or less, 5 μ M or less, 10 μ M or less, 15 μ M or less, 20 μ M or less, 25 μ M or less, 30 μ M or less, 40 μ M or less, 50 μ M or less, 60 μ M or less, 70 μ M or less, 80 μ M or less, 90 μ M or less, 100 μ M or less, 200 μ M or less, 300 μ M or less, 400 μ M or less, or 500 μ M or less.

[00217] In some embodiments, the mTOR inhibitor inhibits both mTORC1 and mTORC2 with an IC₅₀ value of about 1 nM or less, 2 nM or less, 5 nM or less, 7 nM or less, 10 nM or less, 20 nM or less, 30 nM or less, 40 nM or less, 50 nM or less, 60 nM or less, 70 nM or less, 80 nM or less, 90 nM or less, 100 nM or less, 120 nM or less, 140 nM or less, 150 nM or less, 160 nM or less, 170 nM or less, 180 nM or less, 190 nM or less, 200 nM or less, 225 nM or less, 250 nM or less, 275 nM or less, 300 nM or less, 325 nM or less, 350 nM or less, 375 nM or less, 400 nM or less, 425 nM or less, 450 nM or less, 475 nM or less, 500 nM or less, 550 nM or less, 600 nM or less, 650 nM or less, 700 nM or less, 750 nM or less, 800 nM or less, 850 nM or less, 900 nM or less, 950 nM or less, 1 μ M or less, 1.2 μ M or less, 1.3 μ M or less, 1.4 μ M or less, 1.5 μ M or less, 1.6 μ M or less, 1.7 μ M or less, 1.8 μ M or less, 1.9 μ M or less, 2 μ M or less, 5 μ M or less, 10 μ M or less, 15 μ M or less, 20 μ M or less, 25 μ M or less, 30 μ M or less, 40 μ M or less, 50 μ M or less, 60 μ M or less, 70 μ M or less, 80 μ M or less, 90 μ M or less, 100 μ M or less, 200 μ M or less,

300 μ M or less, 400 μ M or less, or 500 μ M or less, and the mTOR inhibitor is substantially inactive against one or more types I PI3-kinases selected from the group consisting of PI3-kinase α , PI3-kinase β , PI3-kinase γ , and PI3-kinase δ . In some embodiments, the mTOR inhibitor inhibits both mTORC1 and mTORC2 with an IC₅₀ value of about 10 nM or less as ascertained in an *in vitro* kinase assay, and the mTOR inhibitor is substantially inactive against one or more types I PI3-kinases selected from the group consisting of PI3-kinase α , PI3-kinase β , PI3-kinase γ , and PI3-kinase δ .

[00218] As used herein, the terms “substantially inactive” refers to an inhibitor that inhibits the activity of its target by less than approximately 1%, 5%, 10%, 15% or 20% of its maximal activity in the absence of the inhibitor, as determined by an *in vitro* enzymatic assay (e.g. *in vitro* kinase assay).

[00219] In other embodiments, the mTOR inhibitor inhibits both mTORC1 and mTORC2 with an IC₅₀ value of about 1000, 500, 100, 75, 50, 25, 10, 5, 1, or 0.5 nM or less as ascertained in an *in vitro* kinase assay, and said IC₅₀ value is at least 2, 5, 10, 15, 20, 50, 100 or 100 times less than its IC₅₀ value against all other type I PI3-kinases selected from the group consisting of PI3-kinase α , PI3-kinase β , PI3-kinase γ , and PI3-kinase δ . For example, the mTOR inhibitor inhibits both mTORC1 and mTORC2 with an IC₅₀ value of about 100 nM or less as ascertained in an *in vitro* kinase assay, and said IC₅₀ value is at least 5 times less than its IC₅₀ value against all other type I PI3-kinases selected from the group consisting of PI3-kinase α , PI3-kinase β , PI3-kinase γ , and PI3-kinase δ .

[00220] In some embodiments, the mTOR inhibitor inhibits both mTORC1 and mTORC2 with an IC₅₀ value of about 100 nM or less as ascertained in an *in vitro* kinase assay, and said IC₅₀ value is at least 5 times less than its IC₅₀ value against all other type I PI3-kinases selected from the group consisting of PI3-kinase α , PI3-kinase β , PI3-kinase γ , and PI3-kinase δ .

[00221] In some embodiments, the mTOR inhibitor utilized in the subject methods inhibits one of mTORC1 and mTORC2 selectively with an IC₅₀ value of about 1000, 500, 100, 75, 50, 25, 10, 5, 1, or 0.5 nM or less as ascertained in an *in vitro* kinase. For example, an mTOR inhibitor utilized in the subject methods inhibits mTORC1 selectively with an IC₅₀ value of about 1000, 500, 100, 75, 50, 25, 10, 5, 1, or 0.5 nM or less as ascertained in an *in vitro* kinase assay. For example, rapamycin and rapamycin derivatives or analogues have been shown to primarily inhibit mTORC1 and not mTORC2. Suitable mTORC1 inhibitor compounds include, for example, sirolimus (rapamycin), deforolimus (AP23573, MK-8669), everolimus (RAD-001), temsirolimus (CCI-779), zotarolimus (ABT-578), and biolimus A9 (umiroliimus).


[00222] mTOR inhibitors suitable for use in the subject methods can be selected from a variety types of molecules. For example, an inhibitor can be biological or chemical compound such as a simple or complex organic or inorganic molecule, peptide, peptide mimetic, protein (e.g. antibody), liposome, or a polynucleotide (e.g. small interfering RNA, microRNA, anti-sense, aptamer, ribozyme, or triple helix). Some exemplary classes of chemical compounds suitable for use in the subject methods are detailed in the sections below.

[00223] The advantages of selective inhibition of a cellular target as a way of treating a disease condition mediated by such target are manifold. Because healthy cells depend on the signaling pathways that are

activated in cancers for survival, inhibition of these pathways during cancer treatment can cause harmful side effects. In order for a method of treating cancer to be successful without causing excessive damage to healthy cells, a very high degree of specificity in targeting the aberrant signaling component or components is desirable. Moreover, cancer cells may depend on overactive signaling for their survival (known as the oncogene addiction hypothesis). In this way, cancer cells are frequently observed to adapt to drug inhibition of an aberrant signaling component by selecting for mutations in the same pathway that overcome the effect of the drug. Therefore, cancer therapies may be more successful in overcoming the problem of drug resistance if they target a signaling pathway as a whole, or target more than one component within a signaling pathway.

[00224] One major downstream effector of mTOR signaling is the Akt serine/threonine kinase. Akt possesses a protein domain known as a PH domain, or Pleckstrin Homology domain, which binds to phosphoinositides with high affinity. In the case of the PH domain of Akt, it binds either PIP3 (phosphatidylinositol (3,4,5)-trisphosphate, PtdIns(3,4,5)P3) or PIP2 (phosphatidylinositol (3,4)-bisphosphate, PtdIns(3,4)P2). PI3K phosphorylates PIP2 in response to signals from chemical messengers, such as ligand binding to G protein-coupled receptors or receptor tyrosine kinases. Phosphorylation by PI3K converts PIP2 to PIP3, recruiting Akt to the cell membrane where it is phosphorylated at serine 473 (S473) by mTORC2. Phosphorylation of Akt at another site, threonine 308 (T308), is not directly dependent on mTORC2, but requires PI3K activity. Therefore, PI3K activity towards Akt can be isolated from mTOR activity by examining Akt threonine 308 phosphorylation status in cells lacking mTORC2 activity.

[00225] In one aspect, the invention provides a compound which is an inhibitor of mTor of the Formula I:



Formula I

or a pharmaceutically acceptable salt thereof, wherein:

X₁ is N or C-E¹, X₂ is N or C, X₃ is N or C, X₄ is C-R⁹ or N, X₅ is N or C-E¹, X₆ is C or N, and X₇ is C or N; and wherein no more than two nitrogen ring atoms are adjacent;

R₁ is H, -L-C₁₋₁₀alkyl, -L-C₃₋₈cycloalkyl, -L-C₁₋₁₀alkyl-C₃₋₈cycloalkyl, -L-aryl, -L-heteroaryl, -L-C₁₋₁₀alkylaryl, -L-C₁₋₁₀alkylhetaryl, -L-C₁₋₁₀alkylheterocyl, -L-C₂₋₁₀alkenyl, -L-C₂₋₁₀alkynyl, -L-C₂₋₁₀alkenyl-C₃₋₈cycloalkyl, -L-C₂₋₁₀alkynyl-C₃₋₈cycloalkyl, -L-heteroalkyl, -L-heteroalkylaryl, -L-heteroalkylheteroaryl, -L-heteroalkyl-heterocyl, -L-heteroalkyl-C₃₋₈cycloalkyl, -L-aralkyl, -L-heteroaralkyl, or -L-heterocycyl, each of which is unsubstituted or is substituted by one or more independent R³;

L is absent, -(C=O)-, -C(=O)O-, -C(=O)N(R³¹)-, -S-, -S(O)-, -S(O)₂-, -S(O)₂N(R³¹)-, or -N(R³¹)-;

E¹ and E² are independently -(W¹)_j-R⁴;

M₁ is a 5, 6, 7, 8, 9, or-10 membered ring system, wherein the ring system is monocyclic or bicyclic, substituted with R₅ and additionally optionally substituted with one or more $-(W^2)_k-R^2$;

each k is 0 or 1;

j in E¹ or j in E², is independently 0 or 1;

W¹ is $-O-$, $-NR^7-$, $-S(O)_{0-2}-$, $-C(O)-$, $-C(O)N(R^7)-$, $-N(R^7)C(O)-$, $-N(R^7)S(O)-$, $-N(R^7)S(O)_2-$, $-C(O)O-$, $-CH(R^7)N(C(O)OR^8)-$, $-CH(R^7)N(C(O)R^8)-$, $-CH(R^7)N(SO_2R^8)-$, $-CH(R^7)N(R^8)-$, $-CH(R^7)C(O)N(R^8)-$, $-CH(R^7)N(R^8)C(O)-$, $-CH(R^7)N(R^8)S(O)-$, or $-CH(R^7)N(R^8)S(O)_2-$;

W² is $-O-$, $-NR^7-$, $-S(O)_{0-2}-$, $-C(O)-$, $-C(O)N(R^7)-$, $-N(R^7)C(O)-$, $-N(R^7)C(O)N(R^8)-$, $-N(R^7)S(O)-$, $-N(R^7)S(O)_2-$, $-C(O)O-$, $-CH(R^7)N(C(O)OR^8)-$, $-CH(R^7)N(C(O)R^8)-$, $-CH(R^7)N(SO_2R^8)-$, $-CH(R^7)N(R^8)-$, $-CH(R^7)C(O)N(R^8)-$, $-CH(R^7)N(R^8)C(O)-$, $-CH(R^7)N(R^8)S(O)-$, or $-CH(R^7)N(R^8)S(O)_2-$;

R² is hydrogen, halogen, $-OH$, $-R^{31}$, $-CF_3$, $-OCF_3$, $-OR^{31}$, $-NR^{31}R^{32}$, $-NR^{34}R^{35}$, $-C(O)R^{31}$, $-CO_2R^{31}$, $-C(=O)NR^{31}R^{32}$, $-C(=O)NR^{34}R^{35}$, $-NO_2$, $-CN$, $-S(O)_{0-2}R^{31}$, $-SO_2NR^{31}R^{32}$, $-SO_2NR^{34}R^{35}$, $-NR^{31}C(=O)R^{32}$, $-NR^{31}C(=O)OR^{32}$, $-NR^{31}C(=O)NR^{32}R^{33}$, $-NR^{31}S(O)_{0-2}R^{32}$, $-C(=S)OR^{31}$, $-C(=O)SR^{31}$, $-NR^{31}C(=NR^{32})NR^{33}R^{32}$, $-NR^{31}C(=NR^{32})OR^{33}$, $-NR^{31}C(=NR^{32})SR^{33}$, $-OC(=O)OR^{33}$, $-OC(=O)NR^{31}R^{32}$, $-OC(=O)SR^{31}$, $-SC(=O)OR^{31}$, $-P(O)OR^{31}OR^{32}$, $-SC(=O)NR^{31}R^{32}$, aryl (e.g. bicyclic aryl, unsubstituted aryl, or substituted monocyclic aryl), hetaryl, C₁₋₁₀alkyl, C₃₋₈cycloalkyl, C₁₋₁₀alkyl-C₃₋₈cycloalkyl, C₃₋₈cycloalkyl-C₁₋₁₀alkyl, C₃₋₈cycloalkyl-C₂₋₁₀alkenyl, C₃₋₈cycloalkyl-C₂₋₁₀alkynyl, C₁₋₁₀alkyl-C₂₋₁₀alkenyl, C₁₋₁₀alkyl-C₂₋₁₀alkynyl, C₁₋₁₀alkylaryl (e.g. C₂₋₁₀alkyl-monocyclic aryl, C₁₋₁₀alkyl-substituted monocyclic aryl, or C₁₋₁₀alkylbicycloaryl), C₁₋₁₀alkylhetaryl, C₁₋₁₀alkylheterocyclyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₂₋₁₀alkenyl-C₁₋₁₀alkyl, C₂₋₁₀alkynyl-C₁₋₁₀alkyl, C₂₋₁₀alkenylaryl, C₂₋₁₀alkenylhetaryl, C₂₋₁₀alkenylheteroalkyl, C₂₋₁₀alkenylheterocyclyl, C₂₋₁₀alkenyl-C₃₋₈cycloalkyl, C₂₋₁₀alkynylaryl, C₂₋₁₀alkynylhetaryl, C₂₋₁₀alkynylheteroalkyl, C₂₋₁₀alkynylheterocyclyl, C₂₋₁₀alkynyl-C₃₋₈cycloalkenyl, C₁₋₁₀alkoxy C₁₋₁₀alkyl, C₁₋₁₀alkoxy-C₂₋₁₀alkenyl, C₁₋₁₀alkoxy-C₂₋₁₀alkynyl, heterocyclyl, heteroalkyl, heterocyclyl-C₁₋₁₀alkyl, heterocyclyl-C₂₋₁₀alkenyl, heterocyclyl-C₂₋₁₀alkynyl, aryl-C₁₋₁₀alkyl (e.g. monocyclic aryl-C₂₋₁₀alkyl, substituted monocyclic aryl-C₁₋₁₀alkyl, or bicycloaryl-C₁₋₁₀alkyl), aryl-C₂₋₁₀alkenyl, aryl-C₂₋₁₀alkynyl, aryl-heterocyclyl, hetaryl-C₁₋₁₀alkyl, hetaryl-C₂₋₁₀alkenyl, hetaryl-C₂₋₁₀alkynyl, hetaryl-C₃₋₈cycloalkyl, hetaryl-heteroalkyl, or hetaryl-heterocyclyl, wherein each of said bicyclic aryl or heteroaryl moiety is unsubstituted, or wherein each of bicyclic aryl, heteroaryl moiety or monocyclic aryl moiety is substituted with one or more independent alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl,

heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, halo, $-OH$, $-R^{31}$, $-CF_3$, $-OCF_3$, $-OR^{31}$, $-NR^{31}R^{32}$, $-NR^{34}R^{35}$, $-C(O)R^{31}$, $-CO_2R^{31}$, $-C(=O)NR^{31}R^{32}$, $-C(=O)NR^{34}R^{35}$, $-NO_2$, $-CN$, $-S(O)_{0-2}R^{31}$, $-SO_2NR^{31}R^{32}$, $-SO_2NR^{34}R^{35}$, $-NR^{31}C(=O)R^{32}$, $-NR^{31}C(=O)OR^{32}$, $-NR^{31}C(=O)NR^{32}R^{33}$, $-NR^{31}S(O)_{0-2}R^{32}$, $-C(=S)OR^{31}$, $-C(=O)SR^{31}$, $-NR^{31}C(=NR^{32})NR^{33}R^{32}$, $-NR^{31}C(=NR^{32})OR^{33}$, $-NR^{31}C(=NR^{32})SR^{33}$, $-OC(=O)OR^{33}$, $-OC(=O)NR^{31}R^{32}$, $-OC(=O)SR^{31}$, $-SC(=O)OR^{31}$, $-P(O)OR^{31}OR^{32}$, or $-SC(=O)NR^{31}R^{32}$, and wherein each of said alkyl, cycloalkyl, heterocyclyl, or heteroalkyl moiety is unsubstituted or is substituted with one or more alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl,

arylalkyl, heteroaryl, heteroarylalkyl, halo, -OH, -R³¹, -CF₃, -OCF₃, -OR³¹, -O-aryl, -NR³¹R³², -NR³⁴R³⁵, -C(O)R³¹, -CO₂R³¹, -C(=O)NR³⁴R³⁵, or -C(=O)NR³¹R³²;

R³ and R⁴ are independently hydrogen, halogen, -OH, -R³¹, -CF₃, -OCF₃, -OR³¹, -NR³¹R³², -NR³⁴R³⁵, -C(O)R³¹, -CO₂R³¹, -C(=O)NR³¹R³², -C(=O)NR³⁴R³⁵, -NO₂, -CN, -S(O)₀₋₂R³¹, -SO₂NR³¹R³², -SO₂NR³⁴R³⁵, -NR³¹C(=O)R³², -NR³¹C(=O)OR³², -NR³¹C(=O)NR³²R³³, -NR³¹S(O)₀₋₂R³², -C(=S)OR³¹, -C(=O)SR³¹, -NR³¹C(=NR³²)NR³³R³², -NR³¹C(=NR³²)OR³³, -NR³¹C(=NR³²)SR³³, -OC(=O)OR³³, -OC(=O)NR³¹R³², -OC(=O)SR³¹, -SC(=O)OR³¹, -P(O)OR³¹OR³², -SC(=O)NR³¹R³², aryl, hetaryl, C₁₋₁₀alkyl, C₁₋₁₀alkenyl, C₃₋₈cycloalkyl, C₁₋₁₀alkyl-C₃₋₈cycloalkyl, C₃₋₈cycloalkyl-C₁₋₁₀alkyl, C₃₋₈cycloalkyl-C₂₋₁₀alkenyl, C₃₋₈cycloalkyl-C₂₋₁₀alkynyl, C₁₋₁₀alkyl-C₂₋₁₀alkenyl, C₁₋₁₀alkyl-C₂₋₁₀alkynyl, C₁₋₁₀alkylaryl, C₁₋₁₀alkylhetaryl, C₁₋₁₀alkylheterocyclyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₂₋₁₀alkenyl-C₁₋₁₀alkyl, C₂₋₁₀alkynyl-C₁₋₁₀alkyl, C₂₋₁₀alkenylaryl, C₂₋₁₀alkenylhetaryl, C₂₋₁₀alkenylheteroalkyl, C₂₋₁₀alkenylheterocyclyl, C₂₋₁₀alkenyl-C₃₋₈cycloalkyl, C₂₋₁₀alkynyl-C₃₋₈cycloalkyl, C₂₋₁₀alkynylaryl, C₂₋₁₀alkynylhetaryl, C₂₋₁₀alkynylheteroalkyl, C₂₋₁₀alkynylheterocyclyl, C₂₋₁₀alkynyl-C₃₋₈cycloalkenyl, C₁₋₁₀alkoxy C₁₋₁₀alkyl, C₁₋₁₀alkoxy-C₂₋₁₀alkenyl, C₁₋₁₀alkoxy-C₂₋₁₀alkynyl, heterocyclyl, heterocyclyl-C₁₋₁₀alkyl, heterocyclyl-C₂₋₁₀alkenyl, heterocyclyl-C₂₋₁₀alkynyl, aryl-C₁₋₁₀alkyl, aryl-C₂₋₁₀alkenyl, aryl-C₂₋₁₀alkynyl, aryl-heterocyclyl, hetaryl-C₁₋₁₀alkyl, hetaryl-C₂₋₁₀alkenyl, hetaryl-C₂₋₁₀alkynyl, hetaryl-C₃₋₈cycloalkyl, heteroalkyl, hetaryl-heteroalkyl, or hetaryl-heterocyclyl, wherein each of said aryl or heteroaryl moiety is unsubstituted or is substituted with one or more independent halo, -OH, -R³¹, -CF₃, -OCF₃, -OR³¹, -NR³¹R³², -NR³⁴R³⁵, -C(O)R³¹, -CO₂R³¹, -C(=O)NR³¹R³², -C(=O)NR³⁴R³⁵, -NO₂, -CN, -S(O)₀₋₂R³¹, -SO₂NR³¹R³², -SO₂NR³⁴R³⁵, -NR³¹C(=O)R³², -NR³¹C(=O)OR³², -NR³¹C(=O)NR³²R³³, -NR³¹S(O)₀₋₂R³², -C(=S)OR³¹, -C(=O)SR³¹, -NR³¹C(=NR³²)NR³³R³², -NR³¹C(=NR³²)OR³³, -NR³¹C(=NR³²)SR³³, -OC(=O)OR³³, -OC(=O)NR³¹R³², -OC(=O)SR³¹, -SC(=O)OR³¹, -P(O)OR³¹OR³², or -SC(=O)NR³¹R³², and wherein each of said alkyl, cycloalkyl, heterocyclyl, or heteroalkyl moiety is unsubstituted or is substituted with one or more halo, -OH, -R³¹, -CF₃, -OCF₃, -OR³¹, -O-aryl, -NR³¹R³², -NR³⁴R³⁵, -C(O)R³¹, -CO₂R³¹, -C(=O)NR³⁴R³⁵, or -C(=O)NR³¹R³²;

R⁵ is hydrogen, halogen, -OH, -R³¹, -CF₃, -OCF₃, -OR³¹, -NR³¹R³², -NR³⁴R³⁵, -C(O)R³¹, -CO₂R³¹, -C(=O)NR³¹R³², -C(=O)NR³⁴R³⁵, -NO₂, -CN, -S(O)₀₋₂R³¹, -SO₂NR³¹R³², -SO₂NR³⁴R³⁵, -NR³¹C(=O)R³², -NR³¹C(=O)OR³², -NR³¹C(=O)NR³²R³³, -NR³¹S(O)₀₋₂R³², -C(=S)OR³¹, -C(=O)SR³¹, -NR³¹C(=NR³²)NR³³R³², -NR³¹C(=NR³²)OR³³, -NR³¹C(=NR³²)SR³³, -OC(=O)OR³³, -OC(=O)NR³¹R³², -OC(=O)SR³¹, -SC(=O)OR³¹, -P(O)OR³¹OR³², or -SC(=O)NR³¹R³²;

each of R³¹, R³², and R³³ is independently H or C₁₋₁₀alkyl, wherein the C₁₋₁₀alkyl is unsubstituted or is substituted with one or more aryl, heteroalkyl, heterocyclyl, or hetaryl group, wherein each of said aryl, heteroalkyl, heterocyclyl, or hetaryl group is unsubstituted or is substituted with one or more halo, -OH, -C₁₋₁₀alkyl, -CF₃, -O-aryl, -OCF₃, -OC₁₋₁₀alkyl, -NH₂, -N(C₁₋₁₀alkyl)(C₁₋₁₀alkyl), -NH(C₁₋₁₀alkyl), -NH(aryl), -NR³⁴R³⁵, -C(O)(C₁₋₁₀alkyl), -C(O)(C₁₋₁₀alkyl-aryl), -C(O)(aryl), -CO₂-C₁₋₁₀alkyl, -CO₂-C₁₋₁₀alkylaryl, -CO₂-aryl, -C(=O)N(C₁₋₁₀alkyl)(C₁₋₁₀alkyl), -C(=O)NH(C₁₋₁₀alkyl), -C(=O)NR³⁴R³⁵, -C(=O)NH₂, -OCF₃, -O(C₁₋₁₀alkyl), -O-aryl, -N(aryl)(C₁₋₁₀alkyl), -NO₂, -CN, -S(O)₀₋₂C₁₋₁₀alkyl, -

$S(O)_{0-2}$ C_{1-10} alkylaryl, $-S(O)_{0-2}$ aryl, $-SO_2N(aryl)$, $-SO_2N(C_{1-10}alkyl)(C_{1-10}alkyl)$, $-SO_2NH(C_{1-10}alkyl)$ or $-SO_2NR^{34}R^{35}$;

R^{34} and R^{35} in $-NR^{34}R^{35}$, $-C(=O)NR^{34}R^{35}$, or $-SO_2NR^{34}R^{35}$, are taken together with the nitrogen atom to which they are attached to form a 3-10 membered saturated or unsaturated ring; wherein said ring is independently unsubstituted or is substituted by one or more $-NR^{31}R^{32}$, hydroxyl, halogen, oxo, aryl, hetaryl, $C_{1-6}alkyl$, or O-aryl, and wherein said 3-10 membered saturated or unsaturated ring independently contains 0, 1, or 2 more heteroatoms in addition to the nitrogen atom;

each of R^7 and R^8 is independently hydrogen, $C_{1-10}alkyl$, $C_{2-10}alkenyl$, aryl, heteroaryl, heterocyclyl or $C_{3-10}cycloalkyl$, each of which except for hydrogen is unsubstituted or is substituted by one or more independent R^6 ;


R^6 is halo, $-OR^{31}$, $-SH$, $-NH_2$, $-NR^{34}R^{35}$, $-NR^{31}R^{32}$, $-CO_2R^{31}$, $-CO_2aryl$, $-C(=O)NR^{31}R^{32}$, $C(=O)NR^{34}R^{35}$, $-NO_2$, $-CN$, $-S(O)_{0-2}C_{1-10}alkyl$, $-S(O)_{0-2}aryl$, $-SO_2NR^{34}R^{35}$, $-SO_2NR^{31}R^{32}$, $C_{1-10}alkyl$, $C_{2-10}alkenyl$, $C_{2-10}alkynyl$; aryl- $C_{1-10}alkyl$, aryl- $C_{2-10}alkenyl$, aryl- $C_{2-10}alkynyl$, hetaryl- $C_{1-10}alkyl$, hetaryl- $C_{2-10}alkenyl$, hetaryl- $C_{2-10}alkynyl$, wherein each of said alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heterocyclyl, or hetaryl group is unsubstituted or is substituted with one or more independent halo, cyano, nitro, $-OC_{1-10}alkyl$, $C_{1-10}alkyl$, $C_{2-10}alkenyl$, $C_{2-10}alkynyl$, halo- $C_{1-10}alkyl$, halo- $C_{2-10}alkenyl$, halo- $C_{2-10}alkynyl$, $-COOH$, $-C(=O)NR^{31}R^{32}$, $-C(=O)NR^{34}R^{35}$, $-SO_2NR^{34}R^{35}$, $-SO_2NR^{31}R^{32}$, $-NR^{31}R^{32}$, or $-NR^{34}R^{35}$; and R^9 is H, halo, $-OR^{31}$, $-SH$, $-NH_2$, $-NR^{34}R^{35}$, $-NR^{31}R^{32}$, $-CO_2R^{31}$, $-CO_2aryl$, $-C(=O)NR^{31}R^{32}$, $C(=O)NR^{34}R^{35}$, $-NO_2$, $-CN$, $-S(O)_{0-2}C_{1-10}alkyl$, $-S(O)_{0-2}aryl$, $-SO_2NR^{34}R^{35}$, $-SO_2NR^{31}R^{32}$, $C_{1-10}alkyl$, $C_{2-10}alkenyl$, $C_{2-10}alkynyl$; aryl- $C_{1-10}alkyl$, aryl- $C_{2-10}alkenyl$, aryl- $C_{2-10}alkynyl$, hetaryl- $C_{1-10}alkyl$, hetaryl- $C_{2-10}alkenyl$, hetaryl- $C_{2-10}alkynyl$, wherein each of said alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heterocyclyl, or hetaryl group is unsubstituted or is substituted with one or more independent halo, cyano, nitro, $-OC_{1-10}alkyl$, $C_{1-10}alkyl$, $C_{2-10}alkenyl$, $C_{2-10}alkynyl$, halo- $C_{1-10}alkyl$, halo- $C_{2-10}alkenyl$, halo- $C_{2-10}alkynyl$, $-COOH$, $-C(=O)NR^{31}R^{32}$, $-C(=O)NR^{34}R^{35}$, $-SO_2NR^{34}R^{35}$, $-SO_2NR^{31}R^{32}$, $-NR^{31}R^{32}$, or $-NR^{34}R^{35}$.

[00226] M_1 is a 5, 6, 7, 8, 9, or 10 membered ring system, wherein the ring system is monocyclic or bicyclic. The monocyclic M_1 ring is unsubstituted or substituted with one or more R^5 substituents (including 0, 1, 2, 3, 4, or 5 R^5 substituents). In some embodiments, the monocyclic M_1 ring is aromatic (including phenyl) or heteroaromatic (including but not limited to pyridinyl, pyrrolyl, imidazolyl, thiazolyl, or pyrimidinyl). The monocyclic M_1 ring may be a 5 or 6 membered ring (including but not limited to pyridinyl, pyrrolyl, imidazolyl, thiazolyl, or pyrimidinyl). In some embodiments, M_2 is a five membered heteroaromatic group with one heteroatom, wherein the heteroatom is N, S, or O. In another embodiment, M_2 is a five membered heteroaromatic group with two heteroatoms, wherein the heteroatoms are nitrogen and oxygen or nitrogen and sulfur.


[00227] The bicyclic M_1 ring is unsubstituted or substituted with one or more R^5 substituents (including 0, 1, 2, 3, 4, 5, 6 or 7 R^5 substituents). Bicyclic M_1 ring is a 7, 8, 9, or 10 membered aromatic or heteroaromatic. Examples of an aromatic bicyclic M_1 ring include naphthyl. In other embodiments the

bicyclic M₁ ring is heteroaromatic and includes but is not limited to benzothiazolyl, quinolinyl, quinazolinyl, benzoxazolyl, and benzoimidazolyl.

[00228] The invention also provides compounds wherein M₁ is a moiety having a structure of Formula M1-A or Formula M1-B:




Formula M1-A




Formula M1-B

wherein W_1 , W_2 , and W_7 are independently N or C-R⁵; W_4 and W_{10} are independently N-R⁵, O, or S; W_6 and W_8 are independently N or C-R⁵; W_5 and W_9 are independently N or C-R²; and W_3 is C or N, provided no more than two N and/or N-R⁵ are adjacent and no two O or S are adjacent.


[00229] In some embodiments of the invention, the M₁ moiety of Formula M1-A is a moiety of Formula M1-A1, Formula M1-A2, Formula M1-A3, or Formula M1-A4:




Formula M1-A1



Formula M1-A2






Formula M1-A3



Formula M1-A4


wherein W_4 is N-R⁵, O, or S; W_6 is N or C-R⁵ and W_5 is N or C-R².

[00230] Some nonlimiting examples of the M₁ moiety of Formula M1-A include:




wherein R^5 is $-(W^1)_k - R^{53}$ or R^{55} ; each k is independently 0 or 1, n is 0, 1, 2, or 3, and $-(W^1)_k - R^{53}$ and R^{55} are as defined above.


[00231] In other embodiments of the invention, the M₁ moiety of Formula M1-B is a moiety of Formula M1-B1, Formula M1-B2, Formula M1-B3, or Formula M1-B4:




Formula M1-B1



Formula M1-B2




Formula M1-B3



Formula M1-B4


wherein W_{10} is N-R⁵, O, or S, W_8 is N or C-R⁵, and W_5 is N or C-R².

[00232] Some nonlimiting examples of the M_1 moiety of Formula M1-B include:




wherein R^5 is $-(W^1)_k-R^{53}$ or R^{55} ; k is 0 or 1, n is 0, 1, 2, or 3, and $-(W^1)_k-R^{53}$ and R^{55} are as defined above.

[00233] The invention also provides compounds wherein M_1 is a moiety having a structure of Formula M1-C or Formula M1-D:




Formula M1-C




Formula M1-D

wherein W_{12} , W_{13} , W_{14} , and W_{15} are independently N or $C-R^5$; W_{11} and W_{18} are independently N- R^5 , O, or S; W_{16} and W_{17} are independently N or $C-R^5$; provided no more than two N are adjacent.

[00234] In other embodiments of the invention, the M_1 moiety of Formula M1-C or Formula M1-D is a moiety of Formula M1-C1 or Formula M1-D1:




Formula M1-D1



Formula M1-C1


wherein W_{11} and W_{18} are N- R^5 , O, or S; and W_{16} and W_{17} are N or $C-R^5$.

[00235] Some nonlimiting examples of the M_1 moiety of Formula M1-C and Formula M1-D include:



wherein R^5 is $-(W^1)_k-R^{53}$ or R^{55} ; k is 0 or 1, and $-(W^1)_k-R^{53}$ and R^{55} are as defined above.


[00236] The invention also provides compounds wherein M_1 is a moiety having a structure of Formula M1-E:




Formula M1-E

wherein X_{11} , X_{12} , X_{13} , X_{14} , X_{15} , X_{16} , and X_{17} are independently N, or C- R^5 ; provided that no more than two N are adjacent.


[00237] In some embodiments of the invention, the M_1 moiety having a structure of Formula M1-E, is a moiety having a structure of Formula M1-E1, M1-E2, M1-E3, M1-E4, M1-E5, M1-E6, M1-E7, or M1-E8:




Formula M1-E1




Formula M1-E2




Formula M1-E3




Formula M1-E4




Formula M1-E5



Formula M1-E6




Formula M1-E7




Formula M1-E8

[00238] In some embodiments of the invention, the M_1 moiety having a structure of Formula M1-E, is a moiety having a structure:



[00239] Some nonlimiting examples of the M_1 moiety of Formula M1-E include :



and

wherein R^5 is $-(W^1)_k-R^{53}$ or R^{55} ; k is 0 or 1, n is 0, 1, 2, or 3, and $-(W^1)_k-R^{53}$ or R^{55} are as defined above. In some embodiments, k is 0, and R^5 is R^{53} .

[00240] In some embodiments, R^{53} is hydrogen, unsubstituted or substituted C_1 - C_{10} alkyl (which includes but is not limited to $-CH_3$, $-CH_2CH_3$, *n*-propyl, isopropyl, *n*-butyl, *tert*-butyl, *sec*-butyl, pentyl, hexyl, and heptyl), or unsubstituted or substituted C_3 - C_8 cycloalkyl (which includes but is not limited to cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl). In other embodiments, R^{53} is monocyclic or bicyclic aryl, wherein the R^{53} aryl is unsubstituted or substituted. Some examples of aryl include but are not limited to phenyl, naphthyl or fluorenyl. In some other embodiments, R^{53} is unsubstituted or substituted heteroaryl, including but not limited to monocyclic and bicyclic heteroaryl. Monocyclic heteroaryl R^{53} includes but is not limited to pyrrolyl, thienyl, furyl, pyridinyl, pyranal, imidazolyl, thiazolyl, pyrazolyl, and oxazolyl. Bicyclic heteroaryl R^{53} includes but is not limited to benzothiophenyl, benzofuryl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, quinazolinyl, azaindolyl, pyrazolopyrimidinyl, and purinyl. Additionally, R^{53} may be alkylcycloalkyl (including but not limited to cyclopropylethyl, cyclopentylethyl, and cyclobutylpropyl), -alkylaryl (including but not limited to benzyl, phenylethyl, and phenyl-naphthyl), -alkylheteraryl (including but not limited to pyridinylmethyl, pyrrolylethyl, and imidazolylpropyl), or -alkylheterocyclyl (non-limiting examples are morpholinylmethyl, 1-piperazinylmethyl, and azetidylpropyl). For each of alkylcycloalkyl, alkylaryl, alkylheteraryl, or -alkylheterocyclyl, the moiety is connected to M_1 through the alkyl portion of the moiety. In other embodiments, R^{53} is unsubstituted or substituted C_2 - C_{10} alkenyl (including but not limited to alkenyl such as, for example, vinyl, allyl, 1-methyl propen-1-yl, butenyl, or pentenyl) or unsubstituted or substituted alkynyl (including but not limited to unsubstituted or substituted C_2 - C_{10} alkynyl such as acetylenyl, propargyl, butynyl, or pentynyl).

[00241] Further embodiments provide R^{53} wherein R^{53} is alkenylaryl, alkenylheteroaryl, alkenylheteroalkyl, or alkenylheterocyclyl, wherein each of alkenyl, aryl, heteroaryl, heteroalkyl, and heterocyclyl is as described herein and wherein the alkenylaryl, alkenylheteraryl, alkenylheteroalkyl, or alkenylheterocyclyl moiety is attached to M_1 through the alkenyl. Some nonlimiting examples include styryl, 3-pyridinylallyl, 2-methoxyethoxyvinyl, and 3-morpholinylallyl. In other embodiments, R^{53} is -alkynylaryl, -alkynylheteraryl, -alkynylheteroalkyl, -alkynylheterocyclyl, -alkynylcycloalkyl, or -alkynyl C_{3-8} cycloalkenyl, wherein each of alkynyl, aryl, heteroaryl, heteroalkyl, and heterocyclyl is as described herein and wherein the alkynylaryl, alkynylheteraryl, alkynylheteroalkyl, or alkynylheterocyclyl moiety is attached to M_1 through the alkynyl. Alternatively, R^{53} is -alkoxyalkyl, -alkoxyalkenyl, or -alkoxyalkynyl, wherein each of alkoxy, alkyl, alkenyl, and alkynyl is as described herein and wherein the -alkoxyalkyl, -alkoxyalkenyl, or -alkoxyalkynyl moiety is attached to M_1 through the alkoxy. In yet other embodiments, R^{53} is -heterocyclylalkyl, -heterocyclylalkenyl, or -heterocyclylalkynyl, wherein the heterocyclyl, alkyl, alkenyl, or alkynyl is as described herein and wherein the -heterocyclylalkyl, -heterocyclylalkenyl, or -heterocyclylalkynyl is attached to M_1 through the heterocyclyl portion of the moiety. Further, R^{53} may be aryl-alkenyl, aryl-alkynyl, or aryl-heterocyclyl, wherein the aryl, alkenyl, alkynyl, or heterocyclyl is as described herein and wherein the aryl-alkenyl, aryl-alkynyl, or aryl-heterocyclyl moiety is attached to M_1 through the aryl portion of the moiety. In some other embodiments, R^{53} is heteroaryl-alkyl, heteroaryl-alkenyl, heteroaryl-alkynyl, heteroaryl-cycloalkyl, heteroaryl-

heteroalkyl, or heteroaryl – heterocyclyl, wherein each of heteroaryl, alkyl, alkenyl, alkynyl, cycloalkyl, heteroalkyl, and heterocyclyl is as described herein and wherein the heteroaryl – alkyl, heteroaryl – alkenyl, heteroaryl – alkynyl, heteroaryl – cycloalkyl, heteroaryl – heteroalkyl, or heteroaryl – heterocyclyl moiety is attached to M_1 through the heteroaryl portion of the moiety.


[00242] For each of the aryl or heteroaryl moieties forming part or all of R^{53} , the aryl or heteroaryl is unsubstituted or is substituted with one or more independent halo, $-OH$, $-R^{31}$, $-CF_3$, $-OCF_3$, $-OR^{31}$, $-NR^{31}R^{32}$, $-NR^{34}R^{35}$, $-C(O)R^{31}$, $-CO_2R^{31}$, $-C(=O)NR^{31}R^{32}$, $-C(=O)NNR^{34}R^{35}$, $-NO_2$, $-CN$, $-S(O)_{0-2}R^{31}$, $-SO_2NR^{31}R^{32}$, $-SO_2NR^{34}R^{35}$, $-NR^{31}C(=O)R^{32}$, $-NR^{31}C(=O)OR^{32}$, $-NR^{31}C(=O)NR^{32}R^{33}$, $-NR^{31}S(O)_{0-2}R^{32}$, $-C(=S)OR^{31}$, $-C(=O)SR^{31}$, $-NR^{31}C(=NR^{32})NR^{33}R^{32}$, $-NR^{31}C(=NR^{32})OR^{33}$, $-NR^{31}C(=NR^{32})SR^{33}$, $-OC(=O)OR^{33}$, $-OC(=O)NR^{31}R^{32}$, $-OC(=O)SR^{31}$, $-SC(=O)OR^{31}$, $-P(O)OR^{31}OR^{32}$, or $-SC(=O)NR^{31}R^{32}$ substituents. Additionally, each of the alkyl, cycloalkyl, heterocyclyl, or heteroalkyl moieties forming part of all of R^{53} is unsubstituted or substituted with one or more halo, $-OH$, $-R^{31}$, $-CF_3$, $-OCF_3$, $-OR^{31}$, $-O$ -aryl, $-NR^{31}R^{32}$, $-NR^{34}R^{35}$, $-C(O)R^{31}$, $-CO_2R^{31}$, $-C(=O)NNR^{34}R^{35}$, or $-C(=O)NR^{31}R^{32}$ substituents.

[00243] In other embodiments, R^5 is $-W^1-R^{53}$. In some embodiments, R^5 is $-OR^{53}$, including but not limited to Oalkyl (including but not limited to methoxy or ethoxy), $-O$ aryl (including but not limited to phenoxy), $-O$ -heteroaryl (including but not limited to pyridinoxy) and $-O$ -heterocycloxy (including but not limited to 4-N-piperidinoxy). In some embodiments R^5 is $-NR^6R^{53}$ including but not limited to aniliny, diethylamino, and 4-N-piperidinylamino. In yet other embodiments R^5 is $-S(O)_{0-2}R^{53}$, including but not limited to phenylsulfonyl and pyridinylsulfonyl. The invention also provides compounds wherein R^5 is $-C(O)$ (including but not limited to acetyl, benzoyl, and pyridinoyl) or $-C(O)OR^{53}$ (including but not limited to carboxyethyl, and carboxybenzyl). In other embodiments, R^5 is $-C(O)N(R^6)R^{53}$ (including but not limited to $C(O)NH$ (cyclopropyl) and $C(O)N(Me)$ (phenyl)) or $-CH(R^6)N(R^7)R^{53}$ (including but not limited to $-CH_2-NH$ -pyrrolidinyl, CH_2-NH cyclopropyl, and CH_2 -aniliny). Alternatively, R^5 is $-N(R^6)C(O)R^{53}$ (including but not limited to $-NHC(O)$ phenyl, $-NHC(O)$ cyclopentyl, and to $-NHC(O)$ piperidinyl) or $-N(R^6)S(O)_2R^{53}$ (including but not limited to $-NHS(O)_2$ phenyl, $-NHS(O)_2$ piperazinyl, and $-NHS(O)_2$ methyl. Additionally, R^5 is $-N(R^6)S(O)R^{53}$, $-CH(R^6)N(C(O)OR^7)R^{53}$, $-CH(R^7)N(C(O)R^7)R^{53}$, $-CH(R^6)N(SO_2R^7)R^{53}$, $-CH(R^6)N(R^7)R^{53}$, $-CH(R^6)C(O)N(R^7)R^{53}$, $-CH(R^6)N(R^7)C(O)R^{53}$, $-CH(R^6)N(R^7)S(O)R^{53}$, or $-CH(R^6)N(R^7)S(O)_2R^{53}$.

[00244] Alternatively, R^5 is R^{55} . R^{55} is halo, $-OH$, $-NO_2$, $-CF_3$, $-OCF_3$, or $-CN$. In some other embodiments, R^{55} is $-R^{31}$, $-OR^{31}$ (including but not limited to methoxy, ethoxy, and butoxy) $-C(O)R^{31}$ (non-limiting examples include acetyl, propionyl, and pentanoyl), or $-CO_2R^{31}$ (including but not limited to carboxymethyl, carboxyethyl and carboxypropyl). In further embodiments, R^{55} is $-NR^{31}R^{32}$, $-C(=O)NR^{31}R^{32}$, $-SO_2NR^{31}R^{32}$, or $-S(O)_{0-2}R^{31}$. In other embodiments, R^{55} is $-NR^{34}R^{35}$ or $-SO_2NR^{34}R^{35}$, wherein $R^{34}R^{35}$ are taken together with the nitrogen to which $R^{34}R^{35}$ are attached to form a cyclic moiety. The cyclic moiety so formed may be unsubstituted or substituted, wherein the substituents are selected from the group consisting of alkyl, $-C(O)$ alkyl, $-S(O)_2$ alkyl, and $-S(O)_2$ aryl. Examples include but are not limited to morpholinyl, piperazinyl, or $-SO_2$ -(4-N-methyl-piperazin-1-yl). Additionally, R^{55} is $-NR^{31}C(=O)R^{32}$, $-NR^{31}C(=O)OR^{32}$, $-NR^{31}C(=O)NR^{32}R^{33}$, $-NR^{31}S(O)_{0-2}R^{32}$, $-C(=S)OR^{31}$, $-C(=O)SR^{31}$, $-$

$\text{NR}^{31}\text{C}(=\text{NR}^{32})\text{NR}^{33}\text{R}^{32}$, $-\text{NR}^{31}\text{C}(=\text{NR}^{32})\text{OR}^{33}$, $-\text{NR}^{31}\text{C}(=\text{NR}^{32})\text{SR}^{33}$, $-\text{OC}(=\text{O})\text{OR}^{33}$, $-\text{OC}(=\text{O})\text{NR}^{31}\text{R}^{32}$, $-\text{C}(=\text{O})\text{NNR}^{34}\text{R}^{35}$, $-\text{OC}(=\text{O})\text{SR}^{31}$, $-\text{SC}(=\text{O})\text{OR}^{31}$, $-\text{P}(\text{O})\text{OR}^{31}\text{OR}^{32}$, or $-\text{SC}(=\text{O})\text{NR}^{31}\text{R}^{32}$; . In yet another embodiment, R^{55} is -O-aryl, including but not limited to phenoxy, and naphthyloxy.

[00245] The invention further provides a compound which is an mTor inhibitor, wherein the compound has the Formula I-A:



Formula I-A


[00246] or a pharmaceutically acceptable salt thereof, wherein:

[00247] X_1 is N or C- E^1 , X_2 is N, X_3 is C, and X_4 is C- R^9 or N; or X_1 is N or C- E^1 , X_2 is C, X_3 is N, and X_4 is C- R^9 or N;

[00248] R_1 is -H, -L- C_{1-10} alkyl, -L- C_{3-8} cycloalkyl, -L- C_{1-10} alkyl- C_{3-8} cycloalkyl, -L-aryl, -L-heteroaryl, -L- C_{1-10} alkylaryl, -L- C_{1-10} alkylheteroaryl, -L- C_{1-10} alkylheterocyclyl, -L- C_{2-10} alkenyl, -L- C_{2-10} alkynyl, -L- C_{2-10} alkenyl- C_{3-8} cycloalkyl, -L- C_{2-10} alkynyl- C_{3-8} cycloalkyl, -L-heteroalkyl, -L-heteroalkylaryl, -L-heteroalkylheteroaryl, -L-heteroalkyl-heterocyclyl, -L-heteroalkyl- C_{3-8} cycloalkyl, -L-aralkyl, -L-heteroaralkyl, or -L-heterocyclyl, each of which is unsubstituted or is substituted by one or more independent R^3 ;

[00249] L is absent, $-(\text{C}=\text{O})-$, $-\text{C}(=\text{O})\text{O}-$, $-\text{C}(=\text{O})\text{N}(\text{R}^{31})-$, $-\text{S}-$, $-\text{S}(\text{O})-$, $-\text{S}(\text{O})_2-$, $-\text{S}(\text{O})_2\text{N}(\text{R}^{31})-$, or $-\text{N}(\text{R}^{31})-$;

[00250] M_1 is a moiety having the structure of Formula M1-F1 or M1-F2:



Formula M1-F1

Formula M1-F2

[00251] k is 0 or 1;

[00252] E^1 and E^2 are independently $-(\text{W}^1)_j-\text{R}^4$;

[00253] j, in each instance (i.e., in E^1 or j in E^2), is independently 0 or 1

[00254] W^1 is $-\text{O}-$, $-\text{NR}^7-$, $-\text{S}(\text{O})_{0.2}-$, $-\text{C}(\text{O})-$, $-\text{C}(\text{O})\text{N}(\text{R}^7)-$, $-\text{N}(\text{R}^7)\text{C}(\text{O})-$, $-\text{N}(\text{R}^7)\text{S}(\text{O})-$, $-\text{N}(\text{R}^7)\text{S}(\text{O})_2-$, $-\text{C}(\text{O})\text{O}-$, $-\text{CH}(\text{R}^7)\text{N}(\text{C}(\text{O})\text{OR}^8)-$, $-\text{CH}(\text{R}^7)\text{N}(\text{C}(\text{O})\text{R}^8)-$, $-\text{CH}(\text{R}^7)\text{N}(\text{SO}_2\text{R}^8)-$, $-\text{CH}(\text{R}^7)\text{N}(\text{R}^8)-$, $-\text{CH}(\text{R}^7)\text{C}(\text{O})\text{N}(\text{R}^8)-$, $-\text{CH}(\text{R}^7)\text{N}(\text{R}^8)\text{C}(\text{O})-$, $-\text{CH}(\text{R}^7)\text{N}(\text{R}^8)\text{S}(\text{O})-$, or $-\text{CH}(\text{R}^7)\text{N}(\text{R}^8)\text{S}(\text{O})_2-$;

[00255] W^2 is $-O-$, $-NR^7-$, $-S(O)_{0-2}-$, $-C(O)-$, $-C(O)N(R^7)-$, $-N(R^7)C(O)-$, $-N(R^7)C(O)N(R^8)-$, $-N(R^7)S(O)-$, $-N(R^7)S(O)_2-$, $-C(O)O-$, $-CH(R^7)N(C(O)OR^8)-$, $-CH(R^7)N(C(O)R^8)-$, $-CH(R^7)N(SO_2R^8)-$, $-CH(R^7)N(R^8)-$, $-CH(R^7)C(O)N(R^8)-$, $-CH(R^7)N(R^8)C(O)-$, $-CH(R^7)N(R^8)S(O)-$, or $-CH(R^7)N(R^8)S(O)_2-$;

[00256] R^2 is hydrogen, halogen, $-OH$, $-R^{31}$, $-CF_3$, $-OCF_3$, $-OR^{31}$, $-NR^{31}R^{32}$, $-NR^{34}R^{35}$, $-C(O)R^{31}$, $-CO_2R^{31}$, $-C(=O)NR^{31}R^{32}$, $-C(=O)NR^{34}R^{35}$, $-NO_2$, $-CN$, $-S(O)_{0-2}R^{31}$, $-SO_2NR^{31}R^{32}$, $-SO_2NR^{34}R^{35}$, $-NR^{31}C(=O)R^{32}$, $-NR^{31}C(=O)OR^{32}$, $-NR^{31}C(=O)NR^{32}R^{33}$, $-NR^{31}S(O)_{0-2}R^{32}$, $-C(=S)OR^{31}$, $-C(=O)SR^{31}$, $-NR^{31}C(=NR^{32})NR^{33}R^{32}$, $-NR^{31}C(=NR^{32})OR^{33}$, $-NR^{31}C(=NR^{32})SR^{33}$, $-OC(=O)OR^{33}$, $-OC(=O)NR^{31}R^{32}$, $-OC(=O)SR^{31}$, $-SC(=O)OR^{31}$, $-P(O)OR^{31}OR^{32}$, $-SC(=O)NR^{31}R^{32}$, aryl (e.g. bicyclic aryl, unsubstituted aryl, or substituted monocyclic aryl), heteroaryl, C_{1-10} alkyl, C_{3-8} cycloalkyl, C_{1-10} alkyl- C_{3-8} cycloalkyl, C_{3-8} cycloalkyl- C_{1-10} alkyl, C_{3-8} cycloalkyl- C_{2-10} alkenyl, C_{3-8} cycloalkyl- C_{2-10} alkynyl, C_{1-10} alkyl- C_{2-10} alkenyl, C_{1-10} alkyl- C_{2-10} alkynyl, C_{1-10} alkylaryl (e.g. C_{2-10} alkyl-monocyclic aryl, C_{1-10} alkyl-substituted monocyclic aryl, or C_{1-10} alkylbicycloaryl), C_{1-10} alkylheteroaryl, C_{1-10} alkylheterocyclyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{2-10} alkenyl- C_{1-10} alkyl, C_{2-10} alkynyl- C_{1-10} alkyl, C_{2-10} alkenylaryl, C_{2-10} alkenylheteroaryl, C_{2-10} alkenylheteroalkyl, C_{2-10} alkenylheterocyclyl, C_{2-10} alkenyl- C_{3-8} cycloalkyl, C_{2-10} alkynylaryl, C_{2-10} alkynylheteroaryl, C_{2-10} alkynylheteroalkyl, C_{2-10} alkynylheterocyclyl, C_{2-10} alkynyl- C_{3-8} cycloalkenyl, C_{1-10} alkoxy C_{1-10} alkyl, C_{1-10} alkoxy- C_{2-10} alkenyl, C_{1-10} alkoxy- C_{2-10} alkynyl, heterocyclyl, heteroalkyl, heterocyclyl- C_{1-10} alkyl, heterocyclyl- C_{2-10} alkenyl, heterocyclyl- C_{2-10} alkynyl, aryl- C_{1-10} alkyl (e.g. monocyclic aryl- C_{2-10} alkyl, substituted monocyclic aryl- C_{1-10} alkyl, or bicycloaryl- C_{1-10} alkyl), aryl- C_{2-10} alkenyl, aryl- C_{2-10} alkynyl, aryl-heterocyclyl, heteroaryl- C_{1-10} alkyl, heteroaryl- C_{2-10} alkenyl, heteroaryl- C_{2-10} alkynyl, heteroaryl- C_{3-8} cycloalkyl, heteroaryl-heteroalkyl, or heteroaryl-heterocyclyl, wherein each of said bicyclic aryl or heteroaryl moiety is unsubstituted, or wherein each of bicyclic aryl, heteroaryl moiety or monocyclic aryl moiety is substituted with one or more independent alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, halo, $-OH$, $-R^{31}$, $-CF_3$, $-OCF_3$, $-OR^{31}$, $-NR^{31}R^{32}$, $-NR^{34}R^{35}$, $-C(O)R^{31}$, $-CO_2R^{31}$, $-C(=O)NR^{31}R^{32}$, $-C(=O)NR^{34}R^{35}$, $-NO_2$, $-CN$, $-S(O)_{0-2}R^{31}$, $-SO_2NR^{31}R^{32}$, $-SO_2NR^{34}R^{35}$, $-NR^{31}C(=O)R^{32}$, $-NR^{31}C(=O)OR^{32}$, $-NR^{31}C(=O)NR^{32}R^{33}$, $-NR^{31}S(O)_{0-2}R^{32}$, $-C(=S)OR^{31}$, $-C(=O)SR^{31}$, $-NR^{31}C(=NR^{32})NR^{33}R^{32}$, $-NR^{31}C(=NR^{32})OR^{33}$, $-NR^{31}C(=NR^{32})SR^{33}$, $-OC(=O)OR^{33}$, $-OC(=O)NR^{31}R^{32}$, $-OC(=O)SR^{31}$, $-SC(=O)OR^{31}$, $-P(O)OR^{31}OR^{32}$, or $-SC(=O)NR^{31}R^{32}$, and wherein each of said alkyl, cycloalkyl, heterocyclyl, or heteroalkyl moiety is unsubstituted or is substituted with one or more alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, halo, $-OH$, $-R^{31}$, $-CF_3$, $-OCF_3$, $-OR^{31}$, $-O$ -aryl, $-NR^{31}R^{32}$, $-NR^{34}R^{35}$, $-C(O)R^{31}$, $-CO_2R^{31}$, $-C(=O)NR^{34}R^{35}$, or $-C(=O)NR^{31}R^{32}$;

[00257] R^3 and R^4 are independently hydrogen, halogen, $-OH$, $-R^{31}$, $-CF_3$, $-OCF_3$, $-OR^{31}$, $-NR^{31}R^{32}$, $-NR^{34}R^{35}$, $-C(O)R^{31}$, $-CO_2R^{31}$, $-C(=O)NR^{31}R^{32}$, $-C(=O)NR^{34}R^{35}$, $-NO_2$, $-CN$, $-S(O)_{0-2}R^{31}$, $-SO_2NR^{31}R^{32}$, $-SO_2NR^{34}R^{35}$, $-NR^{31}C(=O)R^{32}$, $-NR^{31}C(=O)OR^{32}$, $-NR^{31}C(=O)NR^{32}R^{33}$, $-NR^{31}S(O)_{0-2}R^{32}$, $-C(=S)OR^{31}$, $-C(=O)SR^{31}$, $-NR^{31}C(=NR^{32})NR^{33}R^{32}$, $-NR^{31}C(=NR^{32})OR^{33}$, $-NR^{31}C(=NR^{32})SR^{33}$, $-OC(=O)OR^{33}$, $-OC(=O)NR^{31}R^{32}$, $-OC(=O)SR^{31}$, $-SC(=O)OR^{31}$, $-P(O)OR^{31}OR^{32}$, $-SC(=O)NR^{31}R^{32}$, aryl, heteroaryl, C_{1-4} alkyl, C_{1-10} alkyl, C_{3-8} cycloalkyl, C_{1-10} alkyl- C_{3-8} cycloalkyl, C_{3-8} cycloalkyl- C_{1-10} alkyl, C_{3-8} cycloalkyl- C_{2-10}

$_{10}$ alkenyl, C_{3-8} cycloalkyl- C_{2-10} alkynyl, C_{1-10} alkyl- C_{2-10} alkenyl, C_{1-10} alkyl- C_{2-10} alkynyl, C_{1-10} alkylaryl, C_{1-10} alkylheteroaryl, C_{1-10} alkylheterocyclyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{2-10} alkenyl- C_{1-10} alkyl, C_{2-10} alkynyl- C_{1-10} alkyl, C_{2-10} alkenylaryl, C_{2-10} alkenylheteroaryl, C_{2-10} alkenylheteroalkyl, C_{2-10} alkenylheterocyclyl, C_{2-10} alkenyl- C_{3-8} cycloalkyl, C_{2-10} alkynyl- C_{3-8} cycloalkyl, C_{2-10} alkynylaryl, C_{2-10} alkynylheteroaryl, C_{2-10} alkynylheteroalkyl, C_{2-10} alkynylheterocyclyl, C_{2-10} alkynyl- C_{3-8} cycloalkenyl, C_{1-10} alkoxy C_{1-10} alkyl, C_{1-10} alkoxy- C_{2-10} alkenyl, C_{1-10} alkoxy- C_{2-10} alkynyl, heterocyclyl, heterocyclyl- C_{1-10} alkyl, heterocyclyl- C_{2-10} alkenyl, heterocyclyl- C_{2-10} alkynyl, aryl- C_{1-10} alkyl, aryl- C_{2-10} alkenyl, aryl- C_{2-10} alkynyl, aryl-heterocyclyl, heteroaryl- C_{1-10} alkyl, heteroaryl- C_{2-10} alkenyl, heteroaryl- C_{2-10} alkynyl, heteroaryl- C_{3-8} cycloalkyl, heteroalkyl, heteroaryl-heteroalkyl, or heteroaryl-heterocyclyl, wherein each of said aryl or heteroaryl moiety is unsubstituted or is substituted with one or more independent halo, $-OH$, $-R^{31}$, $-CF_3$, $-OCF_3$, $-OR^{31}$, $-NR^{31}R^{32}$, $-NR^{34}R^{35}$, $-C(O)R^{31}$, $-CO_2R^{31}$, $-C(=O)NR^{31}R^{32}$, $-C(=O)NR^{34}R^{35}$, $-NO_2$, $-CN$, $-S(O)_{0-2}R^{31}$, $-SO_2NR^{31}R^{32}$, $-SO_2NR^{34}R^{35}$, $-NR^{31}C(=O)R^{32}$, $-NR^{31}C(=O)OR^{32}$, $-NR^{31}C(=O)NR^{32}R^{33}$, $-NR^{31}S(O)_{0-2}R^{32}$, $-C(=S)OR^{31}$, $-C(=O)SR^{31}$, $-NR^{31}C(=NR^{32})NR^{33}R^{32}$, $-NR^{31}C(=NR^{32})OR^{33}$, $-NR^{31}C(=NR^{32})SR^{33}$, $-OC(=O)OR^{33}$, $-OC(=O)NR^{31}R^{32}$, $-OC(=O)SR^{31}$, $-SC(=O)OR^{31}$, $-P(O)OR^{31}OR^{32}$, or $-SC(=O)NR^{31}R^{32}$, and wherein each of said alkyl, cycloalkyl, heterocyclyl, or heteroalkyl moiety is unsubstituted or is substituted with one or more halo, $-OH$, $-R^{31}$, $-CF_3$, $-OCF_3$, $-OR^{31}$, $-O$ -aryl, $-NR^{31}R^{32}$, $-NR^{34}R^{35}$, $-C(O)R^{31}$, $-CO_2R^{31}$, $-C(=O)NR^{34}R^{35}$, or $-C(=O)NR^{31}R^{32}$;

[00258] R^5 is hydrogen, halogen, $-OH$, $-R^{31}$, $-CF_3$, $-OCF_3$, $-OR^{31}$, $-NR^{31}R^{32}$, $-NR^{34}R^{35}$, $-C(O)R^{31}$, $-CO_2R^{31}$, $-C(=O)NR^{31}R^{32}$, $-C(=O)NR^{34}R^{35}$, $-NO_2$, $-CN$, $-S(O)_{0-2}R^{31}$, $-SO_2NR^{31}R^{32}$, $-SO_2NR^{34}R^{35}$, $-NR^{31}C(=O)R^{32}$, $-NR^{31}C(=O)OR^{32}$, $-NR^{31}C(=O)NR^{32}R^{33}$, $-NR^{31}S(O)_{0-2}R^{32}$, $-C(=S)OR^{31}$, $-C(=O)SR^{31}$, $-NR^{31}C(=NR^{32})NR^{33}R^{32}$, $-NR^{31}C(=NR^{32})OR^{33}$, $-NR^{31}C(=NR^{32})SR^{33}$, $-OC(=O)OR^{33}$, $-OC(=O)NR^{31}R^{32}$, $-OC(=O)SR^{31}$, $-SC(=O)OR^{31}$, $-P(O)OR^{31}OR^{32}$, or $-SC(=O)NR^{31}R^{32}$;

[00259] R^{31} , R^{32} , and R^{33} , in each instance, are independently H or C_{1-10} alkyl, wherein the C_{1-10} alkyl is unsubstituted or is substituted with one or more aryl, heteroalkyl, heterocyclyl, or heteroaryl group, wherein each of said aryl, heteroalkyl, heterocyclyl, or heteroaryl group is unsubstituted or is substituted with one or more halo, $-OH$, $-C_{1-10}$ alkyl, $-CF_3$, $-O$ -aryl, $-OCF_3$, $-OC_{1-10}$ alkyl, $-NH_2$, $-N(C_{1-10}alkyl)(C_{1-10}alkyl)$, $-NH(C_{1-10}alkyl)$, $-NH(aryl)$, $-NR^{34}R^{35}$, $-C(O)(C_{1-10}alkyl)$, $-C(O)(C_{1-10}alkyl-aryl)$, $-C(O)(aryl)$, $-CO_2-C_{1-10}alkyl$, $-CO_2-C_{1-10}alkylaryl$, $-CO_2-aryl$, $-C(=O)N(C_{1-10}alkyl)(C_{1-10}alkyl)$, $-C(=O)NH(C_{1-10}alkyl)$, $-C(=O)NR^{34}R^{35}$, $-C(=O)NH_2$, $-OCF_3$, $-O(C_{1-10}alkyl)$, $-O$ -aryl, $-N(aryl)(C_{1-10}alkyl)$, $-NO_2$, $-CN$, $-S(O)_{0-2}C_{1-10}alkyl$, $-S(O)_{0-2}C_{1-10}alkylaryl$, $-S(O)_{0-2}aryl$, $-SO_2N(aryl)$, $-SO_2N(C_{1-10}alkyl)(C_{1-10}alkyl)$, $-SO_2NH(C_{1-10}alkyl)$ or $-SO_2NR^{34}R^{35}$;

[00260] R^{34} and R^{35} in $-NR^{34}R^{35}$, $-C(=O)NR^{34}R^{35}$, or $-SO_2NR^{34}R^{35}$, are taken together with the nitrogen atom to which they are attached to form a 3-10 membered saturated or unsaturated ring; wherein said ring is independently unsubstituted or is substituted by one or more $-NR^{31}R^{32}$, hydroxyl, halogen, oxo, aryl, heteroaryl, C_{1-6} alkyl, or O -aryl, and wherein said 3-10 membered saturated or unsaturated ring independently contains 0, 1, or 2 more heteroatoms in addition to the nitrogen atom;


[00261] R^7 and R^8 are each independently hydrogen, C_{1-10} alkyl, C_{2-10} alkenyl, aryl, heteroaryl, heterocyclyl or C_{3-10} cycloalkyl, each of which except for hydrogen is unsubstituted or is substituted by one or more independent R^6 ;

[00262] R^6 is halo, $-OR^{31}$, $-SH$, $-NH_2$, $-NR^{34}R^{35}$, $-NR^{31}R^{32}$, $-CO_2R^{31}$, $-CO_2$ aryl, $-C(=O)NR^{31}R^{32}$, $C(=O)NR^{34}R^{35}$, $-NO_2$, $-CN$, $-S(O)_{0-2}C_{1-10}$ alkyl, $-S(O)_{0-2}$ aryl, $-SO_2NR^{34}R^{35}$, $-SO_2NR^{31}R^{32}$, C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl; aryl- C_{1-10} alkyl, aryl- C_{2-10} alkenyl, aryl- C_{2-10} alkynyl, heteroaryl- C_{1-10} alkyl, heteroaryl- C_{2-10} alkenyl, heteroaryl- C_{2-10} alkynyl, wherein each of said alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heterocyclyl, or heteroaryl group is unsubstituted or is substituted with one or more independent halo, cyano, nitro, $-OC_{1-10}$ alkyl, C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, halo- C_{1-10} alkyl, halo- C_{2-10} alkenyl, halo- C_{2-10} alkynyl, $-COOH$, $-C(=O)NR^{31}R^{32}$, $-C(=O)NR^{34}R^{35}$, $-SO_2NR^{34}R^{35}$, $-SO_2NR^{31}R^{32}$, $-NR^{31}R^{32}$, or $-NR^{34}R^{35}$; and

[00263] R^9 is H, halo, $-OR^{31}$, $-SH$, $-NH_2$, $-NR^{34}R^{35}$, $-NR^{31}R^{32}$, $-CO_2R^{31}$, $-CO_2$ aryl, $-C(=O)NR^{31}R^{32}$, $C(=O)NR^{34}R^{35}$, $-NO_2$, $-CN$, $-S(O)_{0-2}C_{1-10}$ alkyl, $-S(O)_{0-2}$ aryl, $-SO_2NR^{34}R^{35}$, $-SO_2NR^{31}R^{32}$, C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl; aryl- C_{1-10} alkyl, aryl- C_{2-10} alkenyl, aryl- C_{2-10} alkynyl, heteroaryl- C_{1-10} alkyl, heteroaryl- C_{2-10} alkenyl, heteroaryl- C_{2-10} alkynyl, wherein each of said alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heterocyclyl, or heteroaryl group is unsubstituted or is substituted with one or more independent halo, cyano, nitro, $-OC_{1-10}$ alkyl, C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, halo- C_{1-10} alkyl, halo- C_{2-10} alkenyl, halo- C_{2-10} alkynyl, $-COOH$, $-C(=O)NR^{31}R^{32}$, $-C(=O)NR^{34}R^{35}$, $-SO_2NR^{34}R^{35}$, $-SO_2NR^{31}R^{32}$, $-NR^{31}R^{32}$, or $-NR^{34}R^{35}$.

[00264] In some embodiments, X_4 is $C-R^9$.


[00265] The invention also provides an inhibitor as defined above, wherein the compound is of Formula I:




Formula I-B

or a pharmaceutically acceptable salt thereof, and wherein the substituents are as defined above.

[00266] In various embodiments the compound of Formula I-B or its pharmaceutically acceptable salt thereof, is a compound having the structure of Formula I-B1 or Formula I-B2:



Formula I-B1



Formula I-B2

or a pharmaceutically acceptable salt thereof.

[00267] In various embodiments of Formula I-B1, X_1 is N and X_2 is N. In other embodiments, X_1 is C-E¹ and X_2 is N. In yet other embodiments, X_1 is NH and X_2 is C. In further embodiments, X_1 is CH-E¹ and X_2 is C.

[00268] In various embodiments of Formula I-B2, X_1 is N and X_2 is C. In further embodiments, X_1 is C-E¹ and X_2 is C.

[00269] In various embodiments, X_1 is C-(W¹)_j-R⁴, where j is 0.

[00270] In another embodiment, X_1 is CH. In yet another embodiment, X_1 is C-halogen, where halogen is Cl, F, Br, or I.

[00271] In various embodiments of X_1 , it is C-(W¹)_j-R⁴. In various embodiments of X_1 , j is 1, and W¹ is -O-. In various embodiments of X_1 , j is 1, and W¹ is -NR⁷-. In various embodiments of X_1 , j is 1, and W¹ is -NH-. In various embodiments of X_1 , j is 1, and W¹ is -S(O)_{0.2}-. In various embodiments of X_1 , j is 1, and W¹ is -C(O)-. In various embodiments of X_1 , j is 1, and W¹ is -C(O)N(R⁷)-. In various embodiments of X_1 , j is 1, and W¹ is -N(R⁷)C(O)-. In various embodiments of X_1 , j is 1, and W¹ is -N(R⁷)S(O)-. In various embodiments of X_1 , j is 1, and W¹ is -N(R⁷)S(O)₂-. In various embodiments of X_1 , j is 1, and W¹ is -C(O)O-. In various embodiments of X_1 , j is 1, and W¹ is -CH(R⁷)N(C(O)OR⁸)-. In various embodiments of X_1 , j is 1, and W¹ is -CH(R⁷)N(C(O)R⁸)-. In various embodiments of X_1 , j is 1, and W¹ is -CH(R⁷)N(SO₂R⁸)-. In various embodiments of X_1 , j is 1, and W¹ is -CH(R⁷)N(R⁸)-. In various embodiments of X_1 , j is 1, and W¹ is -CH(R⁷)C(O)N(R⁸)-. In various embodiments of X_1 , j is 1, and W¹ is -CH(R⁷)N(R⁸)C(O)-. In various embodiments of X_1 , j is 1, and W¹ is -CH(R⁷)N(R⁸)S(O)-. In various embodiments of X_1 , j is 1, and W¹ is -CH(R⁷)N(R⁸)S(O)₂-.

[00272] In another embodiment, X_1 is CH₂. In yet another embodiment, X_1 is CH-halogen, where halogen is Cl, F, Br, or I.

[00273] In another embodiment, X_1 is N.

[00274] In various embodiments, X_2 is N. In other embodiments, X_2 is C.


[00275] In various embodiments, E² is -(W¹)_j-R⁴, where j is 0.

[00276] In another embodiment, E² is CH. In yet another embodiment, E² is C-halogen, where halogen is Cl, F, Br, or I.


[00277] In various embodiments of E², it is -(W¹)_j-R⁴. In various embodiments of E², j is 1, and W¹ is -O-. In various embodiments of E², j is 1, and W¹ is -NR⁷-. In various embodiments of E², j is 1, and W¹ is -NH-. In various embodiments of E², j is 1, and W¹ is -S(O)_{0.2}-. In various embodiments of E², j is 1, and W¹ is -C(O)-. In various embodiments of E², j is 1, and W¹ is -C(O)N(R⁷)-. In various embodiments of E², j is 1, and W¹ is -N(R⁷)C(O)-. In various embodiments of E², j is 1, and W¹ is -N(R⁷)S(O)-. In various embodiments of E², j is 1, and W¹ is -N(R⁷)S(O)₂-. In various embodiments of E², j is 1, and W¹ is -C(O)O-. In various embodiments of E², j is 1, and W¹ is -CH(R⁷)N(C(O)OR⁸)-. In various embodiments of E², j is 1, and W¹ is -CH(R⁷)N(C(O)R⁸)-. In various embodiments of E², j is 1, and W¹ is -CH(R⁷)N(SO₂R⁸)-. In various embodiments of E², j is 1, and W¹ is -CH(R⁷)N(R⁸)-. In various embodiments of E², j is 1, and W¹ is -CH(R⁷)C(O)N(R⁸)-. In various embodiments of E², j is 1, and W¹ is -CH(R⁷)N(R⁸)S(O)-. In various embodiments of E², j is 1, and W¹ is -CH(R⁷)N(R⁸)S(O)₂-.

and W^1 is $-\text{CH}(\text{R}^7)\text{N}(\text{R}^8)\text{C}(\text{O})-$. In various embodiments of E^2 , j is 1, and W^1 is $-\text{CH}(\text{R}^7)\text{N}(\text{R}^8)\text{S}(\text{O})-$. In various embodiments of E^2 , j is 1, and W^1 is $-\text{CH}(\text{R}^7)\text{N}(\text{R}^8)\text{S}(\text{O})_2-$.


[00278] In various embodiments when M_1 is a moiety of Formula M1-F1, M_1 is benzoxazolyl substituted with $-(W^2)_k\text{R}_2$. In some embodiments, M_1 is a benzoxazolyl substituted at the 2-position with $-(W^2)_j\text{R}^2$. In some embodiments, M_1 is either a 5- benzoxazolyl or a 6- benzoxazolyl moiety, optionally substituted at the 2-position with $-(W^2)_j\text{R}^2$. Exemplary Formula M1-F1 M_1 moieties include but are not limited to the following:



[00279] In various embodiments when M_1 is a moiety of Formula M1-F2, Formula M1-F2 is an aza-substituted benzoxazolyl moiety having a structure of one of the following formulae:




[00280] Exemplary Formula M1-F2 M₁ moieties include but are not limited to the following:



[00281] In various embodiments of M₁, k is 0. In other embodiments of M₁, k is 1, and W² is selected from one of the following: -O-, -NR⁷-, -S(O)_{0.2}-, -C(O)-, -C(O)N(R⁷)-, -N(R⁷)C(O)-, or -N(R⁷)C(O)N(R⁸)-. In yet another embodiment of M₁, k is 1, and W² is -N(R⁷)S(O)-, -N(R⁷)S(O)₂-, -C(O)O-, -CH(R⁷)N(C(O)OR⁸)-, -CH(R⁷)N(C(O)R⁸)-, or -CH(R⁷)N(SO₂R⁸)-. In a further embodiment of M₁, k is 1, and W² is -CH(R⁷)N(R⁸)-, -CH(R⁷)C(O)N(R⁸)-, -CH(R⁷)N(R⁸)C(O)-, or -CH(R⁷)N(R⁸)S(O)-. In yet another embodiment of M₁, k is 1, and W² is -CH(R⁷)N(R⁸)S(O)₂-.

[00282] The invention provides an inhibitor of mTor which is a compound of Formula I-C or Formula I-D:



Formula I-C

Formula I-D

or a pharmaceutically acceptable salt thereof, wherein X_1 is N or C-E¹, X_2 is N, and X_3 is C; or X_1 is N or C-E¹, X_2 is C, and X_3 is N;

[00283] R_1 is -H, -L-C₁₋₁₀alkyl, -L-C₃₋₈cycloalkyl, -L-C₁₋₁₀alkyl-C₃₋₈cycloalkyl, -L-aryl, -L-heteroaryl, -L-C₁₋₁₀alkylaryl, -L-C₁₋₁₀alkylheteroaryl, -L-C₁₋₁₀alkylheterocyclyl, -L-C₂₋₁₀alkenyl, -L-C₂₋₁₀alkynyl, -L-C₂₋₁₀alkenyl-C₃₋₈cycloalkyl, -L-C₂₋₁₀alkynyl-C₃₋₈cycloalkyl, -L-heteroalkyl, -L-heteroalkylaryl, -L-heteroalkylheteroaryl, -L-heteroalkyl-heterocyclyl, -L-heteroalkyl-C₃₋₈cycloalkyl, -L-aralkyl, -L-heteroaralkyl, or -L-heterocyclyl, each of which is unsubstituted or is substituted by one or more independent R^3 ;

[00284] L is absent, -(C=O)-, -C(=O)O-, -C(=O)N(R³¹)-, -S-, -S(O)-, -S(O)₂-, -S(O)₂N(R³¹)-, or -N(R³¹)-;

[00285] E¹ and E² are independently -(W¹)_j-R⁴;

[00286] j in E¹ or j in E², is independently 0 or 1;

[00287] W¹ is -O-, -NR⁷-, -S(O)_{0.2}-, -C(O)-, -C(O)N(R⁷)-, -N(R⁷)C(O)-, -N(R⁷)S(O)-, -N(R⁷)S(O)₂-, -C(O)O-, -CH(R⁷)N(C(O)OR⁸)-, -CH(R⁷)N(C(O)R⁸)-, -CH(R⁷)N(SO₂R⁸)-, -CH(R⁷)N(R⁸)-, -CH(R⁷)C(O)N(R⁸)-, -CH(R⁷)N(R⁸)C(O)-, -CH(R⁷)N(R⁸)S(O)-, or -CH(R⁷)N(R⁸)S(O)₂-;

[00288] W² is -O-, -NR⁷-, -S(O)_{0.2}-, -C(O)-, -C(O)N(R⁷)-, -N(R⁷)C(O)-, -N(R⁷)C(O)N(R⁸)-, -N(R⁷)S(O)-, -N(R⁷)S(O)₂-, -C(O)O-, -CH(R⁷)N(C(O)OR⁸)-, -CH(R⁷)N(C(O)R⁸)-, -CH(R⁷)N(SO₂R⁸)-, -CH(R⁷)N(R⁸)-, -CH(R⁷)C(O)N(R⁸)-, -CH(R⁷)N(R⁸)C(O)-, -CH(R⁷)N(R⁸)S(O)-, or -CH(R⁷)N(R⁸)S(O)₂-;

[00289] k is 0 or 1;

[00290] R² is hydrogen, halogen, -OH, -R³¹, -CF₃, -OCF₃, -OR³¹, -NR³¹R³², -NR³⁴R³⁵, -C(O)R³¹, -CO₂R³¹, -C(=O)NR³¹R³², -C(=O)NR³⁴R³⁵, -NO₂, -CN, -S(O)_{0.2}R³¹, -SO₂NR³¹R³², -SO₂NR³⁴R³⁵, -NR³¹C(=O)R³², -NR³¹C(=O)OR³², -NR³¹C(=O)NR³²R³³, -NR³¹S(O)_{0.2}R³², -C(=S)OR³¹, -C(=O)SR³¹, -NR³¹C(=NR³²)NR³³R³², -NR³¹C(=NR³²)OR³³, -NR³¹C(=NR³²)SR³³, -OC(=O)OR³³, -OC(=O)NR³¹R³², -OC(=O)SR³¹, -SC(=O)OR³¹, -P(O)OR³¹OR³², -SC(=O)NR³¹R³², aryl (e.g. bicyclic aryl, unsubstituted aryl, or substituted monocyclic aryl), heteroaryl, C₁₋₁₀alkyl, C₃₋₈cycloalkyl, C₁₋₁₀alkyl-C₃₋₈cycloalkyl, C₃₋

₈cycloalkyl -C₁₋₁₀alkyl, C₃₋₈cycloalkyl -C₂₋₁₀alkenyl, C₃₋₈cycloalkyl- C₂₋₁₀alkynyl, C₁₋₁₀alkyl- C₂₋₁₀alkenyl, C₁₋₁₀alkyl- C₂₋₁₀alkynyl, C₁₋₁₀alkylaryl (e.g. C₂₋₁₀alkyl-monocyclic aryl, C₁₋₁₀alkyl-substituted monocyclic aryl, or C₁₋₁₀alkylbicycloaryl), C₁₋₁₀alkylheteroaryl, C₁₋₁₀alkylheterocyclyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₂₋₁₀alkenyl -C₁₋₁₀alkyl, C₂₋₁₀alkynyl -C₁₋₁₀alkyl, C₂₋₁₀alkenylaryl, C₂₋₁₀alkenylheteroaryl, C₂₋₁₀alkenylheteroalkyl, C₂₋₁₀alkenylheterocyclyl, C₂₋₁₀alkenyl-C₃₋₈cycloalkyl, C₂₋₁₀alkynylaryl, C₂₋₁₀alkynylheteroaryl, C₂₋₁₀alkynylheteroalkyl, C₂₋₁₀alkynylheterocyclyl, C₂₋₁₀alkynyl-C₃₋₈cycloalkenyl, C₁₋₁₀alkoxy C₁₋₁₀alkyl, C₁₋₁₀alkoxy-C₂₋₁₀alkenyl, C₁₋₁₀alkoxy-C₂₋₁₀alkynyl, heterocyclyl -C₁₋₁₀alkyl, heterocyclyl-C₂₋₁₀alkenyl, heterocyclyl-C₂₋₁₀alkynyl, aryl- C₁₋₁₀alkyl (e.g. monocyclic aryl-C₂₋₁₀alkyl, substituted monocyclic aryl- C₁₋₁₀alkyl, or bicycloaryl-C₁₋₁₀alkyl), aryl-C₂₋₁₀alkenyl, aryl-C₂₋₁₀alkynyl, aryl-heterocyclyl, heteroaryl-C₁₋₁₀alkyl, heteroaryl-C₂₋₁₀alkenyl, heteroaryl-C₂₋₁₀alkynyl, heteroaryl-C₃₋₈cycloalkyl, heteroaryl-heteroalkyl, or heteroaryl-heterocyclyl, wherein each of said bicyclic aryl or heteroaryl moiety is unsubstituted, or wherein each of bicyclic aryl, heteroaryl moiety or monocyclic aryl moiety is substituted with one or more independent alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, halo, -OH, -R³¹, -CF₃, -OCF₃, -OR³¹, -NR³¹R³², -NR³⁴R³⁵, -C(O)R³¹, -CO₂R³¹, -C(=O)NR³¹R³², -C(=O)NR³⁴R³⁵, -NO₂, -CN, -S(O)₀₋₂R³¹, -SO₂NR³¹R³², -SO₂NR³⁴R³⁵, -NR³¹C(=O)R³², -NR³¹C(=O)OR³², -NR³¹C(=O)NR³²R³³, -NR³¹S(O)₀₋₂R³², -C(=S)OR³¹, -C(=O)SR³¹, -NR³¹C(=NR³²)NR³³R³², -NR³¹C(=NR³²)OR³³, -NR³¹C(=NR³²)SR³³, -OC(=O)OR³³, -OC(=O)NR³¹R³², -OC(=O)SR³¹, -SC(=O)OR³¹, -P(O)OR³¹OR³², or -SC(=O)NR³¹R³² s, and wherein each of said alkyl, cycloalkyl, heterocyclyl, or heteroalkyl moiety is unsubstituted or is substituted with one or more alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, halo, -OH, -R³¹, -CF₃, -OCF₃, -OR³¹, -O-aryl, -NR³¹R³², -NR³⁴R³⁵, -C(O)R³¹, -CO₂R³¹, -C(=O)NR³⁴R³⁵, or -C(=O)NR³¹R³²;

[00291] R³ and R⁴ are independently hydrogen, halogen, -OH, -R³¹, -CF₃, -OCF₃, -OR³¹, -NR³¹R³², -NR³⁴R³⁵, -C(O)R³¹, -CO₂R³¹, -C(=O)NR³¹R³², -C(=O)NR³⁴R³⁵, -NO₂, -CN, -S(O)₀₋₂R³¹, -SO₂NR³¹R³², -SO₂NR³⁴R³⁵, -NR³¹C(=O)R³², -NR³¹C(=O)OR³², -NR³¹C(=O)NR³²R³³, -NR³¹S(O)₀₋₂R³², -C(=S)OR³¹, -C(=O)SR³¹, -NR³¹C(=NR³²)NR³³R³², -NR³¹C(=NR³²)OR³³, -NR³¹C(=NR³²)SR³³, -OC(=O)OR³³, -OC(=O)NR³¹R³², -OC(=O)SR³¹, -SC(=O)OR³¹, -P(O)OR³¹OR³², -SC(=O)NR³¹R³², aryl, heteroaryl, C₁₋₁₀alkyl, C₃₋₈cycloalkyl, C₁₋₁₀alkyl-C₃₋₈cycloalkyl, C₃₋₈cycloalkyl -C₁₋₁₀alkyl, C₃₋₈cycloalkyl -C₂₋₁₀alkenyl, C₃₋₈cycloalkyl- C₂₋₁₀alkynyl, C₁₋₁₀alkyl- C₂₋₁₀alkenyl, C₁₋₁₀alkyl- C₂₋₁₀alkynyl, C₁₋₁₀alkylaryl, C₁₋₁₀alkylheteroaryl, C₁₋₁₀alkylheterocyclyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₂₋₁₀alkenyl -C₁₋₁₀alkyl, C₂₋₁₀alkynyl -C₁₋₁₀alkyl, C₂₋₁₀alkenylaryl, C₂₋₁₀alkenylheteroaryl, C₂₋₁₀alkenylheteroalkyl, C₂₋₁₀alkenylheterocyclyl, C₂₋₁₀alkenyl-C₃₋₈cycloalkyl, C₂₋₁₀alkynylaryl, C₂₋₁₀alkynylheteroaryl, C₂₋₁₀alkynylheteroalkyl, C₂₋₁₀alkynylheterocyclyl, C₂₋₁₀alkynyl-C₃₋₈cycloalkenyl, C₁₋₁₀alkoxy C₁₋₁₀alkyl, C₁₋₁₀alkoxy-C₂₋₁₀alkenyl, C₁₋₁₀alkoxy-C₂₋₁₀alkynyl, heterocyclyl -C₁₋₁₀alkyl, heterocyclyl-C₂₋₁₀alkenyl, heterocyclyl-C₂₋₁₀alkynyl, aryl-C₁₋₁₀alkyl, aryl-C₂₋₁₀alkenyl, aryl-C₂₋₁₀alkynyl, aryl-heterocyclyl, heteroaryl-C₁₋₁₀alkyl, heteroaryl-C₂₋₁₀alkenyl, heteroaryl-C₂₋₁₀alkynyl, heteroaryl-C₃₋₈cycloalkyl, heteroaryl-heteroalkyl, or heteroaryl-heterocyclyl, wherein each of said aryl or heteroaryl moiety is unsubstituted or is substituted with one or more independent alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl,

heteroaryl, heteroarylalkyl, halo, $-\text{OH}$, $-\text{R}^{31}$, $-\text{CF}_3$, $-\text{OCF}_3$, $-\text{OR}^{31}$, $-\text{NR}^{31}\text{R}^{32}$, $-\text{NR}^{34}\text{R}^{35}$, $-\text{C}(\text{O})\text{R}^{31}$, $-\text{CO}_2\text{R}^{31}$, $-\text{C}(\text{=O})\text{NR}^{31}\text{R}^{32}$, $-\text{C}(\text{=O})\text{NR}^{34}\text{R}^{35}$, $-\text{NO}_2$, $-\text{CN}$, $-\text{S}(\text{O})_{0-2}\text{R}^{31}$, $-\text{SO}_2\text{NR}^{31}\text{R}^{32}$, $-\text{SO}_2\text{NR}^{34}\text{R}^{35}$, $-\text{NR}^{31}\text{C}(\text{=O})\text{R}^{32}$, $-\text{NR}^{31}\text{C}(\text{=O})\text{OR}^{32}$, $-\text{NR}^{31}\text{C}(\text{=O})\text{NR}^{32}\text{R}^{33}$, $-\text{NR}^{31}\text{S}(\text{O})_{0-2}\text{R}^{32}$, $-\text{C}(\text{=S})\text{OR}^{31}$, $-\text{C}(\text{=O})\text{SR}^{31}$, $-\text{NR}^{31}\text{C}(\text{=NR}^{32})\text{NR}^{33}\text{R}^{32}$, $-\text{NR}^{31}\text{C}(\text{=NR}^{32})\text{OR}^{33}$, $-\text{NR}^{31}\text{C}(\text{=NR}^{32})\text{SR}^{33}$, $-\text{OC}(\text{=O})\text{OR}^{33}$, $-\text{OC}(\text{=O})\text{NR}^{31}\text{R}^{32}$, $-\text{OC}(\text{=O})\text{SR}^{31}$, $-\text{SC}(\text{=O})\text{OR}^{31}$, $-\text{P}(\text{O})\text{OR}^{31}\text{OR}^{32}$, or $-\text{SC}(\text{=O})\text{NR}^{31}\text{R}^{32}$, and wherein each of said alkyl, cycloalkyl, heterocyclyl, or heteroalkyl moiety is unsubstituted or is substituted with one or more alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, halo, $-\text{OH}$, $-\text{R}^{31}$, $-\text{CF}_3$, $-\text{OCF}_3$, $-\text{OR}^{31}$, $-\text{O-aryl}$, $-\text{NR}^{31}\text{R}^{32}$, $-\text{NR}^{34}\text{R}^{35}$, $-\text{C}(\text{O})\text{R}^{31}$, $-\text{CO}_2\text{R}^{31}$, $-\text{C}(\text{=O})\text{NR}^{34}\text{R}^{35}$, or $-\text{C}(\text{=O})\text{NR}^{31}\text{R}^{32}$;


[00292] R^5 is hydrogen, halogen, $-\text{OH}$, $-\text{R}^{31}$, $-\text{CF}_3$, $-\text{OCF}_3$, $-\text{OR}^{31}$, $-\text{NR}^{31}\text{R}^{32}$, $-\text{NR}^{34}\text{R}^{35}$, $-\text{C}(\text{O})\text{R}^{31}$, $-\text{CO}_2\text{R}^{31}$, $-\text{C}(\text{=O})\text{NR}^{31}\text{R}^{32}$, $-\text{C}(\text{=O})\text{NR}^{34}\text{R}^{35}$, $-\text{NO}_2$, $-\text{CN}$, $-\text{S}(\text{O})_{0-2}\text{R}^{31}$, $-\text{SO}_2\text{NR}^{31}\text{R}^{32}$, $-\text{SO}_2\text{NR}^{34}\text{R}^{35}$, $-\text{NR}^{31}\text{C}(\text{=O})\text{R}^{32}$, $-\text{NR}^{31}\text{C}(\text{=O})\text{OR}^{32}$, $-\text{NR}^{31}\text{C}(\text{=O})\text{NR}^{32}\text{R}^{33}$, $-\text{NR}^{31}\text{S}(\text{O})_{0-2}\text{R}^{32}$, $-\text{C}(\text{=S})\text{OR}^{31}$, $-\text{C}(\text{=O})\text{SR}^{31}$, $-\text{NR}^{31}\text{C}(\text{=NR}^{32})\text{NR}^{33}\text{R}^{32}$, $-\text{NR}^{31}\text{C}(\text{=NR}^{32})\text{OR}^{33}$, $-\text{NR}^{31}\text{C}(\text{=NR}^{32})\text{SR}^{33}$, $-\text{OC}(\text{=O})\text{OR}^{33}$, $-\text{OC}(\text{=O})\text{NR}^{31}\text{R}^{32}$, $-\text{OC}(\text{=O})\text{SR}^{31}$, $-\text{SC}(\text{=O})\text{OR}^{31}$, $-\text{P}(\text{O})\text{OR}^{31}\text{OR}^{32}$, or $-\text{SC}(\text{=O})\text{NR}^{31}\text{R}^{32}$;

[00293] R^{31} , R^{32} , and R^{33} , in each instance, are independently H or C_{1-10} alkyl, wherein the C_{1-10} alkyl is unsubstituted or is substituted with one or more aryl, heteroalkyl, heterocyclyl, or heteroaryl group, wherein each of said aryl, heteroalkyl, heterocyclyl, or heteroaryl group is unsubstituted or is substituted with one or more halo, $-\text{OH}$, $-\text{C}_{1-10}$ alkyl, $-\text{CF}_3$, $-\text{O-aryl}$, $-\text{OCF}_3$, $-\text{OC}_{1-10}$ alkyl, $-\text{NH}_2$, $-\text{N}(\text{C}_{1-10}\text{alkyl})(\text{C}_{1-10}\text{alkyl})$, $-\text{NH}(\text{C}_{1-10}\text{alkyl})$, $-\text{NH}(\text{aryl})$, $-\text{NR}^{34}\text{R}^{35}$, $-\text{C}(\text{O})(\text{C}_{1-10}\text{alkyl})$, $-\text{C}(\text{O})(\text{C}_{1-10}\text{alkyl-aryl})$, $-\text{C}(\text{O})(\text{aryl})$, $-\text{CO}_2\text{-C}_{1-10}\text{alkyl}$, $-\text{CO}_2\text{-C}_{1-10}\text{alkylaryl}$, $-\text{CO}_2\text{-aryl}$, $-\text{C}(\text{=O})\text{N}(\text{C}_{1-10}\text{alkyl})(\text{C}_{1-10}\text{alkyl})$, $-\text{C}(\text{=O})\text{NH}(\text{C}_{1-10}\text{alkyl})$, $-\text{C}(\text{=O})\text{NR}^{34}\text{R}^{35}$, $-\text{C}(\text{=O})\text{NH}_2$, $-\text{OCF}_3$, $-\text{O}(\text{C}_{1-10}\text{alkyl})$, $-\text{O-aryl}$, $-\text{N}(\text{aryl})(\text{C}_{1-10}\text{alkyl})$, $-\text{NO}_2$, $-\text{CN}$, $-\text{S}(\text{O})_{0-2}\text{C}_{1-10}\text{alkyl}$, $-\text{S}(\text{O})_{0-2}\text{C}_{1-10}\text{alkylaryl}$, $-\text{S}(\text{O})_{0-2}\text{aryl}$, $-\text{SO}_2\text{N}(\text{aryl})$, $-\text{SO}_2\text{N}(\text{C}_{1-10}\text{alkyl})(\text{C}_{1-10}\text{alkyl})$, $-\text{SO}_2\text{NH}(\text{C}_{1-10}\text{alkyl})$ or $-\text{SO}_2\text{NR}^{34}\text{R}^{35}$;

[00294] R^{34} and R^{35} in $-\text{NR}^{34}\text{R}^{35}$, $-\text{C}(\text{=O})\text{NR}^{34}\text{R}^{35}$, or $-\text{SO}_2\text{NR}^{34}\text{R}^{35}$, are taken together with the nitrogen atom to which they are attached to form a 3-10 membered saturated or unsaturated ring; wherein said ring is independently unsubstituted or is substituted by one or more $-\text{NR}^{31}\text{R}^{32}$, hydroxyl, halogen, oxo, aryl, heteroaryl, C_{1-6} alkyl, or O-aryl , and wherein said 3-10 membered saturated or unsaturated ring independently contains 0, 1, or 2 more heteroatoms in addition to the nitrogen atom; and

[00295] R^7 and R^8 are each independently hydrogen, C_{1-10} alkyl, C_{2-10} alkenyl, aryl, heteroaryl, heterocyclyl or C_{3-10} cycloalkyl, each of which except for hydrogen is unsubstituted or is substituted by one or more independent R^6 ; and R^6 is halo, $-\text{OR}^{31}$, $-\text{SH}$, NH_2 , $-\text{NR}^{34}\text{R}^{35}$, $-\text{NR}^{31}\text{R}^{32}$, $-\text{CO}_2\text{R}^{31}$, $-\text{CO}_2\text{aryl}$, $-\text{C}(\text{=O})\text{NR}^{31}\text{R}^{32}$, $-\text{C}(\text{=O})\text{NR}^{34}\text{R}^{35}$, $-\text{NO}_2$, $-\text{CN}$, $-\text{S}(\text{O})_{0-2}\text{C}_{1-10}\text{alkyl}$, $-\text{S}(\text{O})_{0-2}\text{aryl}$, $-\text{SO}_2\text{NR}^{34}\text{R}^{35}$, $-\text{SO}_2\text{NR}^{31}\text{R}^{32}$, C_{1-10} alkyl, C_{2-10} alkenyl, or C_{2-10} alkynyl; or R^6 is aryl- C_{1-10} alkyl, aryl- C_{2-10} alkenyl, aryl- C_{2-10} alkynyl, heteroaryl- C_{1-10} alkyl, heteroaryl- C_{2-10} alkenyl, heteroaryl- C_{2-10} alkynyl, each of which is unsubstituted or is substituted with one or more independent halo, cyano, nitro, $-\text{OC}_{1-10}\text{alkyl}$, C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, halo- C_{1-10} alkyl, halo- C_{2-10} alkenyl, halo- C_{2-10} alkynyl, $-\text{COOH}$, $-\text{C}(\text{=O})\text{NR}^{31}\text{R}^{32}$, $-\text{C}(\text{=O})\text{NR}^{34}\text{R}^{35}$, $-\text{SO}_2\text{NR}^{34}\text{R}^{35}$, $-\text{SO}_2\text{NR}^{31}\text{R}^{32}$, $-\text{NR}^{31}\text{R}^{32}$, or $-\text{NR}^{34}\text{R}^{35}$.

[00296] In various embodiments of the compound of Formula I-C, the compound has a structure of Formula I-C1 or Formula I-C2:



Formula I-C1


Formula I-C2

or a pharmaceutically acceptable salt thereof.

[00297] In some embodiments of Formula I-C1, X₁ is N and X₂ is N. In other embodiments, X₁ is C-E¹ and X₂ is N. In yet other embodiments, X₁ is NH and X₂ is C. In further embodiments, X₁ is CH-E¹ and X₂ is C.

[00298] In several embodiments of Formula I-C2, X₁ is N and X₂ is C. In yet other embodiments, X₁ is NH and X₂ is C. In further embodiments, X₁ is CH-E¹ and X₂ is C.

[00299] In various embodiments of the compound of Formula I-D, the compound has a structure of Formula I-D1 or Formula I-D2:



Formula I-D1

Formula I-D2

or a pharmaceutically acceptable salt thereof.

[00300] In some embodiments of Formula I-D1, X₁ is N and X₂ is N. In other embodiments, X₁ is C-E¹ and X₂ is N. In yet other embodiments, X₁ is NH and X₂ is C. In further embodiments, X₁ is CH-E¹ and X₂ is C.

[00301] In several embodiments of Formula I-D2, X₁ is N and X₂ is C. In further embodiments, X₁ is C-E¹ and X₂ is C.

[00302] In various embodiments, X₁ is C-(W¹)_j-R⁴, where j is 0.

[00303] In another embodiment, X₁ is CH. In yet another embodiment, X₁ is C-halogen, where halogen is Cl, F, Br, or I.

[00304] In various embodiments of X₁, it is C-(W¹)_j-R⁴. In various embodiments of X₁, j is 1, and W¹ is -O-. In various embodiments of X₁, j is 1, and W¹ is -NR⁷-. In various embodiments of X₁, j is 1, and W¹ is -NH-. In various embodiments of X₁, j is 1, and W¹ is -S(O)₀₋₂-. In various embodiments of X₁, j

is 1, and W^1 is $—C(O)—$. In various embodiments of X_1 , j is 1, and W^1 is $—C(O)N(R^7)—$. In various embodiments of X_1 , j is 1, and W^1 is $—N(R^7)C(O)—$. In various embodiments of X_1 , j is 1, and W^1 is $—N(R^7)S(O)—$. In various embodiments of X_1 , j is 1, and W^1 is $—N(R^7)S(O)_2—$. In various embodiments of X_1 , j is 1, and W^1 is $—C(O)O—$. In various embodiments of X_1 , j is 1, and W^1 is $CH(R^7)N(C(O)OR^8)—$. In various embodiments of X_1 , j is 1, and W^1 is $—CH(R^7)N(C(O)R^8)—$. In various embodiments of X_1 , j is 1, and W^1 is $—CH(R^7)N(SO_2R^8)—$. In various embodiments of X_1 , j is 1, and W^1 is $—CH(R^7)N(R^8)—$. In various embodiments of X_1 , j is 1, and W^1 is $—CH(R^7)C(O)N(R^8)—$. In various embodiments of X_1 , j is 1, and W^1 is $—CH(R^7)N(R^8)C(O)—$. In various embodiments of X_1 , j is 1, and W^1 is $—CH(R^7)N(R^8)S(O)—$. In various embodiments of X_1 , j is 1, and W^1 is $—CH(R^7)N(R^8)S(O)_2—$.

[00305] In various embodiments, X_1 is $CH-(W^1)_j-R^4$, where j is 0.

[00306] In another embodiment, X_1 is CH_2 . In yet another embodiment, X_1 is CH -halogen, where halogen is Cl , F , Br , or I .

[00307] In various embodiments of X_1 , it is $CH-(W^1)_j-R^4$. In various embodiments of X_1 , j is 1, and W^1 is $—O—$. In various embodiments of X_1 , j is 1, and W^1 is $—NR^7—$. In various embodiments of X_1 , j is 1, and W^1 is $—NH—$. In various embodiments of X_1 , j is 1, and W^1 is $—S(O)_{0-2}—$. In various embodiments of X_1 , j is 1, and W^1 is $—C(O)—$. In various embodiments of X_1 , j is 1, and W^1 is $—C(O)N(R^7)—$. In various embodiments of X_1 , j is 1, and W^1 is $—N(R^7)C(O)—$. In various embodiments of X_1 , j is 1, and W^1 is $—N(R^7)S(O)—$. In various embodiments of X_1 , j is 1, and W^1 is $—N(R^7)S(O)_2—$. In various embodiments of X_1 , j is 1, and W^1 is $—C(O)O—$. In various embodiments of X_1 , j is 1, and W^1 is $CH(R^7)N(C(O)OR^8)—$. In various embodiments of X_1 , j is 1, and W^1 is $—CH(R^7)N(C(O)R^8)—$. In various embodiments of X_1 , j is 1, and W^1 is $—CH(R^7)N(SO_2R^8)—$. In various embodiments of X_1 , j is 1, and W^1 is $—CH(R^7)N(R^8)—$. In various embodiments of X_1 , j is 1, and W^1 is $—CH(R^7)C(O)N(R^8)—$. In various embodiments of X_1 , j is 1, and W^1 is $—CH(R^7)N(R^8)C(O)—$. In various embodiments of X_1 , j is 1, and W^1 is $—CH(R^7)N(R^8)S(O)—$. In various embodiments of X_1 , j is 1, and W^1 is $—CH(R^7)N(R^8)S(O)_2—$.

[00308] In another embodiment, X_1 is N .

[00309] In various embodiments, X_2 is N . In other embodiments, X_2 is C .

[00310] In various embodiments, E^2 is $-(W^1)_j-R^4$, where j is 0.


[00311] In another embodiment, E^2 is CH . In yet another embodiment, E^2 is C -halogen, where halogen is Cl , F , Br , or I .

[00312] In various embodiments of E^2 , it is $-(W^1)_j-R^4$. In various embodiments of E^2 , j is 1, and W^1 is $—O—$. In various embodiments of E^2 , j is 1, and W^1 is $—NR^7—$. In various embodiments of E^2 , j is 1, and W^1 is $—NH—$. In various embodiments of E^2 , j is 1, and W^1 is $—S(O)_{0-2}—$. In various embodiments of E^2 , j is 1, and W^1 is $—C(O)—$. In various embodiments of E^2 , j is 1, and W^1 is $—C(O)N(R^7)—$. In various embodiments of E^2 , j is 1, and W^1 is $—N(R^7)C(O)—$. In various embodiments of E^2 , j is 1, and W^1 is $—N(R^7)S(O)—$. In various embodiments of E^2 , j is 1, and W^1 is $—N(R^7)S(O)_2—$. In various embodiments of E^2 , j is 1, and W^1 is $—C(O)O—$. In various embodiments of E^2 , j is 1, and W^1 is $CH(R^7)N(C(O)OR^8)—$. In various embodiments of E^2 , j is 1, and W^1 is $—CH(R^7)N(C(O)R^8)—$. In various embodiments of E^2 , j is 1, and W^1 is $—CH(R^7)N(SO_2R^8)—$. In various embodiments of E^2 , j is 1, and W^1 is $—CH(R^7)N(R^8)—$. In

various embodiments of E^2 , j is 1, and W^1 is $-\text{CH}(\text{R}^7)\text{C}(\text{O})\text{N}(\text{R}^8)-$. In various embodiments of E^2 , j is 1, and W^1 is $-\text{CH}(\text{R}^7)\text{N}(\text{R}^8)\text{C}(\text{O})-$. In various embodiments of E^2 , j is 1, and W^1 is $-\text{CH}(\text{R}^7)\text{N}(\text{R}^8)\text{S}(\text{O})-$. In various embodiments of E^2 , j is 1, and W^1 is $-\text{CH}(\text{R}^7)\text{N}(\text{R}^8)\text{S}(\text{O})_2-$.

[00313] In various embodiments, k is 0. In other embodiments, k is 1 and W^2 is $-\text{O}-$. In another embodiment, k is 1 and W^2 is $-\text{NR}^7-$. In yet another embodiment of, k is 1, and W^2 is $-\text{S}(\text{O})_{0-2}-$. In another embodiment of, k is 1 and W^2 is $-\text{C}(\text{O})-$. In a further embodiment, k is 1 and W^2 is $-\text{C}(\text{O})\text{N}(\text{R}^7)-$. In another embodiment, k is 1, and W^2 is $-\text{N}(\text{R}^7)\text{C}(\text{O})-$. In another embodiment, k is 1 and W^2 is $-\text{N}(\text{R}^7)\text{C}(\text{O})\text{N}(\text{R}^8)-$. In yet another embodiment, k is 1 and W^2 is $-\text{N}(\text{R}^7)\text{S}(\text{O})-$. In still yet another embodiment, k is 1 and W^2 is $-\text{N}(\text{R}^7)\text{S}(\text{O})_2-$. In a further embodiment, k is 1 and W^2 is $-\text{C}(\text{O})\text{O}-$. In another embodiment, k is 1 and W^2 is $-\text{CH}(\text{R}^7)\text{N}(\text{C}(\text{O})\text{OR}^8)-$. In another embodiment, k is 1 and W^2 is $-\text{CH}(\text{R}^7)\text{N}(\text{C}(\text{O})\text{R}^8)-$. In another embodiment, k is 1 and W^2 is $-\text{CH}(\text{R}^7)\text{N}(\text{SO}_2\text{R}^8)-$. In a further embodiment, k is 1 and W^2 is $-\text{CH}(\text{R}^7)\text{N}(\text{R}^8)-$. In another embodiment, k is 1 and W^2 is $-\text{CH}(\text{R}^7)\text{C}(\text{O})\text{N}(\text{R}^8)-$. In yet another embodiment, k is 1 and W^2 is $-\text{CH}(\text{R}^7)\text{N}(\text{R}^8)\text{C}(\text{O})-$. In another embodiment, k is 1 and W^2 is $-\text{CH}(\text{R}^7)\text{N}(\text{R}^8)\text{S}(\text{O})-$. In yet another embodiment, k is 1 and W^2 is $-\text{CH}(\text{R}^7)\text{N}(\text{R}^8)\text{S}(\text{O})_2-$.

[00314] The invention also provides a compound which is an mTor inhibitor of Formula I-E:




Formula I-E

[00315] or a pharmaceutically acceptable salt thereof, wherein: X_1 is N or $\text{C}-\text{E}^1$, X_2 is N, and X_3 is C; or X_1 is N or $\text{C}-\text{E}^1$, X_2 is C, and X_3 is N;

[00316] R_1 is $-\text{H}$, $-\text{L}-\text{C}_{1-10}\text{alkyl}$, $-\text{L}-\text{C}_{3-8}\text{cycloalkyl}$, $-\text{L}-\text{C}_{1-10}\text{alkyl}-\text{C}_{3-8}\text{cycloalkyl}$, $-\text{L}-\text{aryl}$, $-\text{L}-\text{heteroaryl}$, $-\text{L}-\text{C}_{1-10}\text{alkylaryl}$, $-\text{L}-\text{C}_{1-10}\text{alkylheteroaryl}$, $-\text{L}-\text{C}_{1-10}\text{alkylheterocyclyl}$, $-\text{L}-\text{C}_{2-10}\text{alkenyl}$, $-\text{L}-\text{C}_{2-10}\text{alkynyl}$, $-\text{L}-\text{C}_{2-10}\text{alkenyl}-\text{C}_{3-8}\text{cycloalkyl}$, $-\text{L}-\text{C}_{2-10}\text{alkynyl}-\text{C}_{3-8}\text{cycloalkyl}$, $-\text{L}-\text{heteroalkyl}$, $-\text{L}-\text{heteroalkylaryl}$, $-\text{L}-\text{heteroalkylheteroaryl}$, $-\text{L}-\text{heteroalkylheterocyclyl}$, $-\text{L}-\text{heteroalkyl}-\text{C}_{3-8}\text{cycloalkyl}$, $-\text{L}-\text{aralkyl}$, $-\text{L}-\text{heteroaralkyl}$, or $-\text{L}-\text{heterocyclyl}$, each of which is unsubstituted or is substituted by one or more independent R^3 ;

[00317] L is absent, $-(\text{C}=\text{O})-$, $-(\text{C}=\text{O})\text{O}-$, $-(\text{C}=\text{O})\text{N}(\text{R}^{31})-$, $-\text{S}-$, $-\text{S}(\text{O})-$, $-\text{S}(\text{O})_2-$, $-\text{S}(\text{O})_2\text{N}(\text{R}^{31})-$, or $-\text{N}(\text{R}^{31})-$;

[00318] M_1 is a moiety having the structure of Formula M1-F1 or Formula M1-F2:



Formula M1-F1

Formula M1-F2

[00319] k is 0 or 1;

[00320] E^1 and E^2 are independently $-(W^1)_j-R^4$;

[00321] j in E^1 or j in E^2 , is independently 0 or 1;

[00322] W^1 is $-O-$, $-NR^7-$, $-S(O)_{0.2}-$, $-C(O)-$, $-C(O)N(R^7)-$, $-N(R^7)C(O)-$, $-N(R^7)S(O)-$, $-N(R^7)S(O)_2-$, $-C(O)O-$, $-CH(R^7)N(C(O)OR^8)-$, $-CH(R^7)N(C(O)R^8)-$, $-CH(R^7)N(SO_2R^8)-$, $-CH(R^7)N(R^8)-$, $-CH(R^7)C(O)N(R^8)-$, $-CH(R^7)N(R^8)C(O)-$, $-CH(R^7)N(R^8)S(O)-$, or $-CH(R^7)N(R^8)S(O)_2-$;

[00323] W^2 is $-O-$, $-NR^7-$, $-S(O)_{0.2}-$, $-C(O)-$, $-C(O)N(R^7)-$, $-N(R^7)C(O)-$, $-N(R^7)C(O)N(R^8)-$, $-N(R^7)S(O)-$, $-N(R^7)S(O)_2-$, $-C(O)O-$, $-CH(R^7)N(C(O)OR^8)-$, $-CH(R^7)N(C(O)R^8)-$, $-CH(R^7)N(SO_2R^8)-$, $-CH(R^7)N(R^8)-$, $-CH(R^7)C(O)N(R^8)-$, $-CH(R^7)N(R^8)C(O)-$, $-CH(R^7)N(R^8)S(O)-$, or $-CH(R^7)N(R^8)S(O)_2-$;

[00324] R^2 is hydrogen, halogen, $-OH$, $-R^{31}$, $-CF_3$, $-OCF_3$, $-OR^{31}$, $-NR^{31}R^{32}$, $-NR^{34}R^{35}$, $-C(O)R^{31}$, $-CO_2R^{31}$, $-C(=O)NR^{31}R^{32}$, $-C(=O)NR^{34}R^{35}$, $-NO_2$, $-CN$, $-S(O)_{0.2}R^{31}$, $-SO_2NR^{31}R^{32}$, $-SO_2NR^{34}R^{35}$, $-NR^{31}C(=O)R^{32}$, $-NR^{31}C(=O)OR^{32}$, $-NR^{31}C(=O)NR^{32}R^{33}$, $-NR^{31}S(O)_{0.2}R^{32}$, $-C(=S)OR^{31}$, $-C(=O)SR^{31}$, $-NR^{31}C(=NR^{32})NR^{33}R^{32}$, $-NR^{31}C(=NR^{32})OR^{33}$, $-NR^{31}C(=NR^{32})SR^{33}$, $-OC(=O)OR^{33}$, $-OC(=O)NR^{31}R^{32}$, $-OC(=O)SR^{31}$, $-SC(=O)OR^{31}$, $-P(O)OR^{31}OR^{32}$, $-SC(=O)NR^{31}R^{32}$, aryl (e.g. bicyclic aryl, unsubstituted aryl, or substituted monocyclic aryl), heteroaryl, C_{1-10} alkyl, C_{3-8} cycloalkyl, C_{1-10} alkyl- C_{3-8} cycloalkyl, C_{3-8} cycloalkyl- C_{1-10} alkyl, C_{3-8} cycloalkyl- C_{2-10} alkenyl, C_{3-8} cycloalkyl- C_{2-10} alkynyl, C_{1-10} alkyl- C_{2-10} alkenyl, C_{1-10} alkyl- C_{2-10} alkynyl, C_{1-10} alkylaryl (e.g. C_{2-10} alkyl-monocyclic aryl, C_{1-10} alkyl-substituted monocyclic aryl, or C_{1-10} alkylbicycloaryl), C_{1-10} alkylheteroaryl, C_{1-10} alkylheterocyclyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{2-10} alkenyl- C_{1-10} alkyl, C_{2-10} alkynyl- C_{1-10} alkyl, C_{2-10} alkenylaryl, C_{2-10} alkenylheteroaryl, C_{2-10} alkenylheteroalkyl, C_{2-10} alkenylheterocyclyl, C_{2-10} alkenyl- C_{3-8} cycloalkyl, C_{2-10} alkynylaryl, C_{2-10} alkynylheteroaryl, C_{2-10} alkynylheteroalkyl, C_{2-10} alkynylheterocyclyl, C_{2-10} alkynyl- C_{3-8} cycloalkenyl, C_{1-10} alkoxy C_{1-10} alkyl, C_{1-10} alkoxy- C_{2-10} alkenyl, C_{1-10} alkoxy- C_{2-10} alkynyl, heterocyclyl- C_{1-10} alkyl, heterocyclyl- C_{2-10} alkenyl, heterocyclyl- C_{2-10} alkynyl, aryl- C_{1-10} alkyl (e.g. monocyclic aryl- C_{2-10} alkyl, substituted monocyclic aryl- C_{1-10} alkyl, or bicycloaryl- C_{1-10} alkyl), aryl- C_{2-10} alkenyl, aryl- C_{2-10} alkynyl, aryl-heterocyclyl, heteroaryl- C_{1-10} alkyl, heteroaryl- C_{2-10} alkenyl, heteroaryl- C_{2-10} alkynyl, heteroaryl- C_{3-8} cycloalkyl, heteroaryl-heteroalkyl, or heteroaryl-heterocyclyl, wherein each of said bicyclic aryl or heteroaryl moiety is unsubstituted, or wherein each of bicyclic aryl, heteroaryl moiety or monocyclic aryl moiety is substituted with one or more independent alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, halo, $-OH$, $-R^{31}$, $-CF_3$, $-OCF_3$, $-OR^{31}$, $-$

$\text{NR}^{31}\text{R}^{32}$, $-\text{NR}^{34}\text{R}^{35}$, $-\text{C}(\text{O})\text{R}^{31}$, $-\text{CO}_2\text{R}^{31}$, $-\text{C}(=\text{O})\text{NR}^{31}\text{R}^{32}$, $-\text{C}(=\text{O})\text{NR}^{34}\text{R}^{35}$, $-\text{NO}_2$, $-\text{CN}$, $-\text{S}(\text{O})_{0-2}\text{R}^{31}$, $-\text{SO}_2\text{NR}^{31}\text{R}^{32}$, $-\text{SO}_2\text{NR}^{34}\text{R}^{35}$, $-\text{NR}^{31}\text{C}(=\text{O})\text{R}^{32}$, $-\text{NR}^{31}\text{C}(=\text{O})\text{OR}^{32}$, $-\text{NR}^{31}\text{C}(=\text{O})\text{NR}^{32}\text{R}^{33}$, $-\text{NR}^{31}\text{S}(\text{O})_{0-2}\text{R}^{32}$, $-\text{C}(=\text{S})\text{OR}^{31}$, $-\text{C}(=\text{O})\text{SR}^{31}$, $-\text{NR}^{31}\text{C}(=\text{NR}^{32})\text{NR}^{33}\text{R}^{32}$, $-\text{NR}^{31}\text{C}(=\text{NR}^{32})\text{OR}^{33}$, $-\text{NR}^{31}\text{C}(=\text{NR}^{32})\text{SR}^{33}$, $-\text{OC}(=\text{O})\text{OR}^{33}$, $-\text{OC}(=\text{O})\text{NR}^{31}\text{R}^{32}$, $-\text{OC}(=\text{O})\text{SR}^{31}$, $-\text{SC}(=\text{O})\text{OR}^{31}$, $-\text{P}(\text{O})\text{OR}^{31}\text{OR}^{32}$, or $-\text{SC}(=\text{O})\text{NR}^{31}\text{R}^{32}$, and wherein each of said alkyl, cycloalkyl, heterocyclyl, or heteroalkyl moiety is unsubstituted or is substituted with one or more alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, halo, $-\text{OH}$, $-\text{R}^{31}$, $-\text{CF}_3$, $-\text{OCF}_3$, $-\text{OR}^{31}$, $-\text{O-aryl}$, $-\text{NR}^{31}\text{R}^{32}$, $-\text{NR}^{34}\text{R}^{35}$, $-\text{C}(\text{O})\text{R}^{31}$, $-\text{CO}_2\text{R}^{31}$, $-\text{C}(=\text{O})\text{NR}^{34}\text{R}^{35}$, or $-\text{C}(=\text{O})\text{NR}^{31}\text{R}^{32}$;

¹⁰⁰³²⁵¹ R³ and R⁴ are independently hydrogen, halogen, -OH, -R³¹, -CF₃, -OCF₃, -OR³¹, -NR³¹R³², -NR³⁴R³⁵, -C(O)R³¹, -CO₂R³¹, -C(=O)NR³¹R³², -C(=O)NR³⁴R³⁵, -NO₂, -CN, -S(O)₀₋₂R³¹, -SO₂NR³¹R³², -SO₂NR³⁴R³⁵, -NR³¹C(=O)R³², -NR³¹C(=O)OR³², -NR³¹C(=O)NR³²R³³, -NR³¹S(O)₀₋₂R³², -C(=S)OR³¹, -C(=O)SR³¹, -NR³¹C(=NR³²)NR³³R³², -NR³¹C(=NR³²)OR³³, -NR³¹C(=NR³²)SR³³, -OC(=O)OR³³, -OC(=O)NR³¹R³², -OC(=O)SR³¹, -SC(=O)OR³¹, -P(O)OR³¹OR³², -SC(=O)NR³¹R³², aryl, heteroaryl, C₁₋₁₀alkyl, C₁₋₁₀cycloalkyl, C₃₋₈cycloalkyl, C₁₋₁₀alkyl-C₃₋₈cycloalkyl, C₃₋₈cycloalkyl-C₁₋₁₀alkyl, C₃₋₈cycloalkyl-C₂₋₁₀alkenyl, C₃₋₈cycloalkyl-C₂₋₁₀alkynyl, C₁₋₁₀alkyl-C₂₋₁₀alkenyl, C₁₋₁₀alkyl-C₂₋₁₀alkynyl, C₁₋₁₀alkylaryl, C₁₋₁₀alkylheteroaryl, C₁₋₁₀alkylheterocyclyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₂₋₁₀alkenyl-C₁₋₁₀alkyl, C₂₋₁₀alkynyl-C₁₋₁₀alkyl, C₂₋₁₀alkenylaryl, C₂₋₁₀alkenylheteroaryl, C₂₋₁₀alkenylheterocyclyl, C₂₋₁₀alkenyl-C₃₋₈cycloalkyl, C₂₋₁₀alkynyl-C₃₋₈cycloalkyl, C₂₋₁₀alkynylaryl, C₂₋₁₀alkynylheteroaryl, C₂₋₁₀alkynylheteroalkyl, C₂₋₁₀alkynylheterocyclyl, C₂₋₁₀alkynyl-C₃₋₈cycloalkyl, C₂₋₁₀alkynyl-C₂₋₁₀alkenyl, C₁₋₁₀alkoxy-C₁₋₁₀alkyl, C₁₋₁₀alkoxy-C₂₋₁₀alkenyl, C₁₋₁₀alkoxy-C₂₋₁₀alkynyl, heterocyclyl, heterocyclyl-C₁₋₁₀alkyl, heterocyclyl-C₂₋₁₀alkenyl, heterocyclyl-C₂₋₁₀alkynyl, aryl-C₁₋₁₀alkyl, aryl-C₂₋₁₀alkenyl, aryl-C₂₋₁₀alkynyl, aryl-heterocyclyl, heteroaryl-C₁₋₁₀alkyl, heteroaryl-C₂₋₁₀alkenyl, heteroaryl-C₂₋₁₀alkynyl, heteroaryl-C₃₋₈cycloalkyl, heteroalkyl, heteroaryl-heteroalkyl, or heteroaryl-heterocyclyl, wherein each of said aryl or heteroaryl moiety is unsubstituted or is substituted with one or more independent halo, -OH, -R³¹, -CF₃, -OCF₃, -OR³¹, -NR³¹R³², -NR³⁴R³⁵, -C(O)R³¹, -CO₂R³¹, -C(=O)NR³¹R³², -C(=O)NR³⁴R³⁵, -NO₂, -CN, -S(O)₀₋₂R³¹, -SO₂NR³¹R³², -SO₂NR³⁴R³⁵, -NR³¹C(=O)R³², -NR³¹C(=O)OR³², -NR³¹C(=O)NR³²R³³, -NR³¹S(O)₀₋₂R³², -C(=S)OR³¹, -C(=O)SR³¹, -NR³¹C(=NR³²)NR³³R³², -NR³¹C(=NR³²)OR³³, -NR³¹C(=NR³²)SR³³, -OC(=O)OR³³, -OC(=O)NR³¹R³², -OC(=O)SR³¹, -SC(=O)OR³¹, -P(O)OR³¹OR³², or -SC(=O)NR³¹R³², and wherein each of said alkyl, cycloalkyl, heterocyclyl, or heteroalkyl moiety is unsubstituted or is substituted with one or more halo, -OH, -R³¹, -CF₃, -OCF₃, -OR³¹, -O-aryl, -NR³¹R³², -NR³⁴R³⁵, -C(O)R³¹, -CO₂R³¹, -C(=O)NR³⁴R³⁵, or -C(=O)NR³¹R³²;

[00326] R⁵ is hydrogen, halogen, -OH, -R³¹, -CF₃, -OCF₃, -OR³¹, -NR³¹R³², -NR³⁴R³⁵, -C(O)R³¹, -CO₂R³¹, -C(=O)NR³¹R³², -C(=O)NR³⁴R³⁵, -NO₂, -CN, -S(O)₀₋₂R³¹, -SO₂NR³¹R³², -SO₂NR³⁴R³⁵, -NR³¹C(=O)R³², -NR³¹C(=O)OR³², -NR³¹C(=O)NR³²R³³, -NR³¹S(O)₀₋₂R³², -C(=S)OR³¹, -C(=O)SR³¹, -NR³¹C(=NR³²)NR³³R³², -NR³¹C(=NR³²)OR³³, -NR³¹C(=NR³²)SR³³, -OC(=O)OR³³, -OC(=O)NR³¹R³², -OC(=O)SR³¹, -SC(=O)OR³¹, -P(O)OR³¹OR³², or -SC(=O)NR³¹R³²;

[00327] R³¹, R³², and R³³, in each instance, are independently H or C₁₋₁₀alkyl, wherein the C₁₋₁₀alkyl is unsubstituted or is substituted with one or more aryl, heteroalkyl, heterocyclyl, or heteroaryl group

wherein each of said aryl, heteroalkyl, heterocyclyl, or heteroaryl group is unsubstituted or is substituted with one or more halo, $-\text{OH}$, $-\text{C}_{1-10}\text{alkyl}$, $-\text{CF}_3$, $-\text{O-aryl}$, $-\text{OCF}_3$, $-\text{OC}_{1-10}\text{alkyl}$, $-\text{NH}_2$, $-\text{N}(\text{C}_{1-10}\text{alkyl})(\text{C}_{1-10}\text{alkyl})$, $-\text{NH}(\text{C}_{1-10}\text{alkyl})$, $-\text{NH}(\text{aryl})$, $-\text{NR}^{34}\text{R}^{35}$, $-\text{C}(\text{O})(\text{C}_{1-10}\text{alkyl})$, $-\text{C}(\text{O})(\text{C}_{1-10}\text{alkyl-aryl})$, $-\text{C}(\text{O})(\text{aryl})$, $-\text{CO}_2\text{-C}_{1-10}\text{alkyl}$, $-\text{CO}_2\text{-C}_{1-10}\text{alkylaryl}$, $-\text{CO}_2\text{-aryl}$, $-\text{C}(=\text{O})\text{N}(\text{C}_{1-10}\text{alkyl})(\text{C}_{1-10}\text{alkyl})$, $-\text{C}(=\text{O})\text{NH}(\text{C}_{1-10}\text{alkyl})$, $-\text{C}(=\text{O})\text{NR}^{34}\text{R}^{35}$, $-\text{C}(=\text{O})\text{NH}_2$, $-\text{OCF}_3$, $-\text{O}(\text{C}_{1-10}\text{alkyl})$, $-\text{O-aryl}$, $-\text{N}(\text{aryl})(\text{C}_{1-10}\text{alkyl})$, $-\text{NO}_2$, $-\text{CN}$, $-\text{S}(\text{O})_{0-2}\text{C}_{1-10}\text{alkyl}$, $-\text{S}(\text{O})_{0-2}\text{C}_{1-10}\text{alkylaryl}$, $-\text{S}(\text{O})_{0-2}\text{aryl}$, $-\text{SO}_2\text{N}(\text{aryl})$, $-\text{SO}_2\text{N}(\text{C}_{1-10}\text{alkyl})(\text{C}_{1-10}\text{alkyl})$, $-\text{SO}_2\text{NH}(\text{C}_{1-10}\text{alkyl})$ or $-\text{SO}_2\text{NR}^{34}\text{R}^{35}$;


[00328] R^{34} and R^{35} in $-\text{NR}^{34}\text{R}^{35}$, $-\text{C}(=\text{O})\text{NR}^{34}\text{R}^{35}$, or $-\text{SO}_2\text{NR}^{34}\text{R}^{35}$, are taken together with the nitrogen atom to which they are attached to form a 3-10 membered saturated or unsaturated ring; wherein said ring is independently unsubstituted or is substituted by one or more $-\text{NR}^{31}\text{R}^{32}$, hydroxyl, halogen, oxo, aryl, heteroaryl, $\text{C}_{1-6}\text{alkyl}$, or O-aryl , and wherein said 3-10 membered saturated or unsaturated ring independently contains 0, 1, or 2 more heteroatoms in addition to the nitrogen atom;

[00329] R^7 and R^8 are each independently hydrogen, $\text{C}_{1-10}\text{alkyl}$, $\text{C}_{2-10}\text{alkenyl}$, aryl, heteroaryl, heterocyclyl or $\text{C}_{3-10}\text{cycloalkyl}$, each of which except for hydrogen is unsubstituted or is substituted by one or more independent R^6 ;


[00330] R^6 is halo, $-\text{OR}^{31}$, $-\text{SH}$, $-\text{NH}_2$, $-\text{NR}^{34}\text{R}^{35}$, $-\text{NR}^{31}\text{R}^{32}$, $-\text{CO}_2\text{R}^{31}$, $-\text{CO}_2\text{aryl}$, $-\text{C}(=\text{O})\text{NR}^{31}\text{R}^{32}$, $\text{C}(=\text{O})\text{NR}^{34}\text{R}^{35}$, $-\text{NO}_2$, $-\text{CN}$, $-\text{S}(\text{O})_{0-2}\text{C}_{1-10}\text{alkyl}$, $-\text{S}(\text{O})_{0-2}\text{aryl}$, $-\text{SO}_2\text{NR}^{34}\text{R}^{35}$, $-\text{SO}_2\text{NR}^{31}\text{R}^{32}$, $\text{C}_{1-10}\text{alkyl}$, $\text{C}_{2-10}\text{alkenyl}$, $\text{C}_{2-10}\text{alkynyl}$; aryl- $\text{C}_{1-10}\text{alkyl}$, aryl- $\text{C}_{2-10}\text{alkenyl}$, aryl- $\text{C}_{2-10}\text{alkynyl}$, heteroaryl- $\text{C}_{1-10}\text{alkyl}$, heteroaryl- $\text{C}_{2-10}\text{alkenyl}$, heteroaryl- $\text{C}_{2-10}\text{alkynyl}$, wherein each of said alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heterocyclyl, or heteroaryl group is unsubstituted or is substituted with one or more independent halo, cyano, nitro, $-\text{OC}_{1-10}\text{alkyl}$, $\text{C}_{1-10}\text{alkyl}$, $\text{C}_{2-10}\text{alkenyl}$, $\text{C}_{2-10}\text{alkynyl}$, halo $\text{C}_{1-10}\text{alkyl}$, halo $\text{C}_{2-10}\text{alkenyl}$, halo $\text{C}_{2-10}\text{alkynyl}$, $-\text{COOH}$, $-\text{C}(=\text{O})\text{NR}^{31}\text{R}^{32}$, $-\text{C}(=\text{O})\text{NR}^{34}\text{R}^{35}$, $-\text{SO}_2\text{NR}^{34}\text{R}^{35}$, $-\text{SO}_2\text{NR}^{31}\text{R}^{32}$, $-\text{NR}^{31}\text{R}^{32}$, or $-\text{NR}^{34}\text{R}^{35}$; and

[00331] R^9 is H, halo, $-\text{OR}^{31}$, $-\text{SH}$, $-\text{NH}_2$, $-\text{NR}^{34}\text{R}^{35}$, $-\text{NR}^{31}\text{R}^{32}$, $-\text{CO}_2\text{R}^{31}$, $-\text{CO}_2\text{aryl}$, $-\text{C}(=\text{O})\text{NR}^{31}\text{R}^{32}$, $\text{C}(=\text{O})\text{NR}^{34}\text{R}^{35}$, $-\text{NO}_2$, $-\text{CN}$, $-\text{S}(\text{O})_{0-2}\text{C}_{1-10}\text{alkyl}$, $-\text{S}(\text{O})_{0-2}\text{aryl}$, $-\text{SO}_2\text{NR}^{34}\text{R}^{35}$, $-\text{SO}_2\text{NR}^{31}\text{R}^{32}$, $\text{C}_{1-10}\text{alkyl}$, $\text{C}_{2-10}\text{alkenyl}$, $\text{C}_{2-10}\text{alkynyl}$; aryl- $\text{C}_{1-10}\text{alkyl}$, aryl- $\text{C}_{2-10}\text{alkenyl}$, aryl- $\text{C}_{2-10}\text{alkynyl}$, heteroaryl- $\text{C}_{1-10}\text{alkyl}$, heteroaryl- $\text{C}_{2-10}\text{alkenyl}$, heteroaryl- $\text{C}_{2-10}\text{alkynyl}$, wherein each of said alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heterocyclyl, or heteroaryl group is unsubstituted or is substituted with one or more independent halo, cyano, nitro, $-\text{OC}_{1-10}\text{alkyl}$, $\text{C}_{1-10}\text{alkyl}$, $\text{C}_{2-10}\text{alkenyl}$, $\text{C}_{2-10}\text{alkynyl}$, halo $\text{C}_{1-10}\text{alkyl}$, halo $\text{C}_{2-10}\text{alkenyl}$, halo $\text{C}_{2-10}\text{alkynyl}$, $-\text{COOH}$, $-\text{C}(=\text{O})\text{NR}^{31}\text{R}^{32}$, $-\text{C}(=\text{O})\text{NR}^{34}\text{R}^{35}$, $-\text{SO}_2\text{NR}^{34}\text{R}^{35}$, $-\text{SO}_2\text{NR}^{31}\text{R}^{32}$, $-\text{NR}^{31}\text{R}^{32}$, or $-\text{NR}^{34}\text{R}^{35}$.

[00332] In various embodiments of the compound of Formula I-E, the compound has a structure of Formula I-E1 or Formula I-E2:



Formula I-E1



Formula I-E2

or a pharmaceutically acceptable salt thereof.

[00333] In some embodiments of Formula I-E1, X_1 is N and X_2 is N. In other embodiments, X_1 is C-E¹ and X_2 is N. In yet other embodiments, X_1 is NH and X_2 is C. In further embodiments, X_1 is CH-E¹ and X_2 is C.

[00334] In several embodiments of Formula I-E2, X_1 is N and X_2 is C. In further embodiments, X_1 is C-E¹ and X_2 is C.

[00335] In various embodiments, X_1 is C-(W¹)_j-R⁴, where j is 0.

[00336] In another embodiment, X_1 is CH. In yet another embodiment, X_1 is C-halogen, where halogen is Cl, F, Br, or I.

[00337] In various embodiments of X_1 , it is C-(W¹)_j-R⁴. In various embodiments of X_1 , j is 1, and W¹ is -O-. In various embodiments of X_1 , j is 1, and W¹ is -NR⁷-. In various embodiments of X_1 , j is 1, and W¹ is -NH-. In various embodiments of X_1 , j is 1, and W¹ is -S(O)₀₋₂-. In various embodiments of X_1 , j is 1, and W¹ is -C(O)-. In various embodiments of X_1 , j is 1, and W¹ is -C(O)N(R⁷)-. In various embodiments of X_1 , j is 1, and W¹ is -N(R⁷)C(O)-. In various embodiments of X_1 , j is 1, and W¹ is -N(R⁷)S(O)-. In various embodiments of X_1 , j is 1, and W¹ is -N(R⁷)S(O)₂-. In various embodiments of X_1 , j is 1, and W¹ is -C(O)O-. In various embodiments of X_1 , j is 1, and W¹ is CH(R⁷)N(C(O)OR⁸)-. In various embodiments of X_1 , j is 1, and W¹ is -CH(R⁷)N(C(O)R⁸)-. In various embodiments of X_1 , j is 1, and W¹ is -CH(R⁷)N(SO₂R⁸)-. In various embodiments of X_1 , j is 1, and W¹ is -CH(R⁷)N(R⁸)-. In various embodiments of X_1 , j is 1, and W¹ is -CH(R⁷)C(O)N(R⁸)-. In various embodiments of X_1 , j is 1, and W¹ is -CH(R⁷)N(R⁸)C(O)-. In various embodiments of X_1 , j is 1, and W¹ is -CH(R⁷)N(R⁸)S(O)-. In various embodiments of X_1 , j is 1, and W¹ is -CH(R⁷)N(R⁸)S(O)₂-.

[00338] In another embodiment, X_1 is N.

[00339] In various embodiments, X_2 is N. In other embodiments, X_2 is C.


[00340] In various embodiments, E² is -(W¹)_j-R⁴, where j is 0.

[00341] In another embodiment, E² is CH. In yet another embodiment, E² is C-halogen, where halogen is Cl, F, Br, or I.


[00342] In various embodiments of E², it is -(W¹)_j-R⁴. In various embodiments of E², j is 1, and W¹ is -O-. In various embodiments of E², j is 1, and W¹ is -NR⁷-. In various embodiments of E², j is 1, and W¹ is -NH-. In various embodiments of E², j is 1, and W¹ is -S(O)₀₋₂-. In various embodiments of E², j is 1, and W¹ is -C(O)-. In various embodiments of E², j is 1, and W¹ is -C(O)N(R⁷)-. In various embodiments of E², j is 1, and W¹ is -N(R⁷)C(O)-. In various embodiments of E², j is 1, and W¹ is -

$N(R^7)S(O)-$. In various embodiments of E^2 , j is 1, and W^1 is $-N(R^7)S(O)_2-$. In various embodiments of E^2 , j is 1, and W^1 is $-C(O)O-$. In various embodiments of E^2 , j is 1, and W^1 is $CH(R^7)N(C(O)OR^8)-$. In various embodiments of E^2 , j is 1, and W^1 is $-CH(R^7)N(C(O)R^8)-$. In various embodiments of E^2 , j is 1, and W^1 is $-CH(R^7)N(SO_2R^8)-$. In various embodiments of E^2 , j is 1, and W^1 is $-CH(R^7)N(R^8)-$. In various embodiments of E^2 , j is 1, and W^1 is $-CH(R^7)C(O)N(R^8)-$. In various embodiments of E^2 , j is 1, and W^1 is $-CH(R^7)N(R^8)C(O)-$. In various embodiments of E^2 , j is 1, and W^1 is $-CH(R^7)N(R^8)S(O)-$. In various embodiments of E^2 , j is 1, and W^1 is $-CH(R^7)N(R^8)S(O)_2-$.


[00343] In various embodiments when M_1 is a moiety of Formula I-E1, M_1 is benzoxazolyl substituted with $-(W_2)_k-R_2$. In some embodiments, M_1 is a benzoxazolyl moiety, substituted at the 2-position with $-(W_2)_k-R_2$. In some embodiments, M_1 is either a 5- benzoxazolyl or a 6- benzoxazolyl moiety, optionally substituted with $-(W_2)_k-R_2$. Exemplary Formula I-E1 M_1 moieties include but are not limited to the following:



[00344] In various embodiments when M_1 is a moiety of Formula I-E2, Formula I-E2 is an aza-substituted benzoxazolyl moiety having a structure of one of the following formulae:



[00345] Exemplary Formula I-E2 M_1 moieties include but are not limited to the following:



[00346] In various embodiments of M_1 , k is 0. In other embodiments of M_1 , k is 1 and W^2 is $-O-$. In another embodiment of M_1 , k is 1 and W^2 is $-NR^7-$. In yet another embodiment of M_1 , k is 1 and W^2 is $-S(O)_{0-2}-$. In another embodiment of M_1 , k is 1 and W^2 is $-C(O)-$. In a further embodiment of M_1 , k is 1 and W^2 is $-C(O)N(R^7)-$. In another embodiment of M_1 , k is 1 and W^2 is $-N(R^7)C(O)-$. In another embodiment, k is 1 and W^2 is $-N(R^7)C(O)N(R^8)-$. In yet another embodiment of M_1 , k is 1 and W^2 is $-N(R^7)S(O)-$. In still yet another embodiment of M_1 , k is 1 and W^2 is $-N(R^7)S(O)_2-$. In a further

embodiment of M_1 , k is 1 and W^2 is $-C(O)O-$. In another embodiment of M_1 , k is 1 and W^2 is $-CH(R^7)N(C(O)OR^8)-$. In another embodiment of M_1 , k is 1 and W^2 is $-CH(R^7)N(C(O)R^8)-$. In another embodiment of M_1 , k is 1 and W^2 is $-CH(R^7)N(SO_2R^8)-$. In a further embodiment of M_1 , k is 1 and W^2 is $-CH(R^7)N(R^8)-$. In another embodiment of M_1 , k is 1 and W^2 is $-CH(R^7)C(O)N(R^8)-$. In yet another embodiment of M_1 , k is 1 and W^2 is $-CH(R^7)N(R^8)C(O)-$. In another embodiment of M_1 , k is 1 and W^2 is $-CH(R^7)N(R^8)S(O)-$. In yet another embodiment of M_1 , k is 1 and W^2 is $-CH(R^7)N(R^8)S(O)_2-$.

[00347] Additional embodiments of compounds of Formula I, including I-A, I-B, I-C, I-D, I-E and others are described below.

[00348] In various embodiments of compounds of Formula I, L is absent. In another embodiment, L is $-C(=O)-$. In another embodiment, L is $C(=O)O-$. In a further embodiment, L is $-C(=O)NR^{31}-$. In yet another embodiment, L is $-S-$. In one embodiment, L is $-S(O)-$. In another embodiment, L is $-S(O)_2-$. In yet another embodiment, L is $-S(O)_2NR^{31}-$. In another embodiment, L is $-NR^{31}-$.

[00349] In various embodiments of compounds of Formula I, R_1 is $-L-C_{1-10}alkyl$, which is unsubstituted. In another embodiment, R_1 is $-L-C_{1-10}alkyl$, which is substituted by one or more independent R^3 . In yet another embodiment, R_1 is $-L-$ unsubstituted $C_{1-10}alkyl$, where L is absent. In another embodiment, R_1 is $-L-C_{1-10}alkyl$, which is substituted by one or more independent R^3 , and L is absent.

[00350] In various embodiments of compounds of Formula I, R_1 is $-L-C_{3-8}cycloalkyl$, which is unsubstituted. In another embodiment, R_1 is $L-C_{3-8}cycloalkyl$, which is substituted by one or more independent R^3 . In yet another embodiment, R_1 is $-L-C_{3-8}cycloalkyl$, which is unsubstituted, and L is absent. In a further embodiment, R_1 is $-L-C_{3-8}cycloalkyl$ which is substituted by one or more independent R^3 , and L is absent.

[00351] In various embodiments of compounds of Formula I, R_1 is H .

[00352] In various embodiments of compounds of Formula I, R_1 is $-L-$ aryl, which is unsubstituted. In another embodiment, R_1 is $-L-$ aryl, which is substituted by one or more independent R^3 . In another embodiment, R_1 is $-L-$ aryl which is unsubstituted, and L is absent. In yet another embodiment, R_1 is $-L-$ aryl, which is substituted by one or more independent R^3 , and L is absent.

[00353] In various embodiments of compounds of Formula I, R_1 is $-L-$ heteroaryl, which is unsubstituted. In another embodiment, R_1 is $-L-$ heteroaryl, which is substituted by one or more independent R^3 . In a further embodiment, R_1 is $-L-$ heteroaryl which is unsubstituted and L is absent. In yet another embodiment, R_1 is $-L-$ heteroaryl, which is substituted by one or more independent R^3 , and L is absent.

[00354] In various embodiments of compounds of Formula I, R_1 is $-L-C_{1-10}alkyl-C_{3-8}cycloalkyl$, which is unsubstituted. In another embodiment, R_1 is $-L-C_{1-10}alkyl-C_{3-8}cycloalkyl$, which is substituted by one or more independent R^3 . In a further embodiment, R_1 is $-L-C_{1-10}alkyl-C_{3-8}cycloalkyl$ which is unsubstituted and L is absent. In yet another embodiment, R_1 is $-L-C_{1-10}alkyl-C_{3-8}cycloalkyl$, which is substituted by one or more independent R^3 , and L is absent.

[00355] In various embodiments of compounds of Formula I, R_1 is $-L-C_{1-10}alkylaryl$, which is unsubstituted. In another embodiment, R_1 is $-L-C_{1-10}alkylaryl$, which is substituted by one or more independent R^3 . In a further embodiment, R_1 is $-L-C_{1-10}alkylaryl$ which is unsubstituted and L is absent.

In yet another embodiment, R_1 is -L- C_{1-10} alkylaryl, which is substituted by one or more independent R^3 , where L is absent.

[00356] In various embodiments of compounds of Formula I, R_1 is -L- C_{1-10} alkylheteroaryl, which is unsubstituted. In another embodiment, R_1 is -L- C_{1-10} alkylheteroaryl, which is substituted by one or more independent R^3 . In a further embodiment, R_1 is -L- C_{1-10} alkylheteroaryl which is unsubstituted and L is absent. In yet another embodiment, R_1 is -L- C_{1-10} alkylheteroaryl, which is substituted by one or more independent R^3 , where L is absent.

[00357] In various embodiments of compounds of Formula I, R_1 is -L- C_{1-10} alkylheterocyclyl, which is unsubstituted. In another embodiment, R_1 is -L- C_{1-10} alkylheterocyclyl, which is substituted by one or more independent R^3 . In a further embodiment, R_1 is -L- C_{1-10} alkylheterocyclyl which is unsubstituted and L is absent. In yet another embodiment, R_1 is -L- C_{1-10} alkylheterocyclyl, which is substituted by one or more independent R^3 , where L is absent.

[00358] In various embodiments of compounds of Formula I, R_1 is -L- C_{2-10} alkenyl, which is unsubstituted. In another embodiment, R_1 is -L- C_{2-10} alkenyl which is substituted by one or more independent R^3 . In a further embodiment, R_1 is -L- C_{2-10} alkenyl which is unsubstituted and L is absent. In yet another embodiment, R_1 is -L- C_{2-10} alkenyl, which is substituted by one or more independent R^3 , where L is absent.

[00359] In various embodiments of compounds of Formula I, R_1 is -L- C_{2-10} alkynyl, which is unsubstituted. In another embodiment, R_1 is -L- C_{2-10} alkynyl which is substituted by one or more independent R^3 . In a further embodiment, R_1 is -L- C_{2-10} alkynyl which is unsubstituted and L is absent. In yet another embodiment, R_1 is -L- C_{2-10} alkynyl, which is substituted by one or more independent R^3 , where L is absent.

[00360] In various embodiments of compounds of Formula I, R_1 is -L- C_{2-10} alkenyl- C_{3-8} cycloalkyl, which is unsubstituted. In another embodiment, R_1 is -L- C_{2-10} alkenyl- C_{3-8} cycloalkyl which is substituted by one or more independent R^3 . In a further embodiment, R_1 is -L- C_{2-10} alkenyl- C_{3-8} cycloalkyl which is unsubstituted and L is absent. In yet another embodiment, R_1 is -L- C_{2-10} alkenyl- C_{3-8} cycloalkyl, which is substituted by one or more independent R^3 , where L is absent.

[00361] In various embodiments of compounds of Formula I, R_1 is -L- C_{2-10} alkynyl- C_{3-8} cycloalkyl, which is unsubstituted. In another embodiment, R_1 is -L- C_{2-10} alkynyl- C_{3-8} cycloalkyl which is substituted by one or more independent R^3 . In a further embodiment, R_1 is -L- C_{2-10} alkynyl- C_{3-8} cycloalkyl which is unsubstituted and L is absent. In yet another embodiment, R_1 is -L- C_{2-10} alkynyl- C_{3-8} cycloalkyl, which is substituted by one or more independent R^3 , where L is absent.

[00362] In various embodiments of compounds of Formula I, R_1 is -L- C_{2-10} alkynyl- C_{3-8} cycloalkyl, which is unsubstituted. In another embodiment, R_1 is -L- C_{2-10} alkynyl- C_{3-8} cycloalkyl which is substituted by one or more independent R^3 . In a further embodiment, R_1 is -L- C_{2-10} alkynyl- C_{3-8} cycloalkyl which is unsubstituted and L is absent. In yet another embodiment, R_1 is -L- C_{2-10} alkynyl- C_{3-8} cycloalkyl, which is substituted by one or more independent R^3 , where L is absent.

[00363] In various embodiments of compounds of Formula I, R_1 is -L-heteroalkyl, which is unsubstituted. In another embodiment, R_1 is -L-heteroalkyl which is substituted by one or more independent R^3 . In a

further embodiment, R_1 is -L-heteroalkyl which is unsubstituted and L is absent. In yet another embodiment, R_1 is -L-heteroalkyl, which is substituted by one or more independent R^3 , where L is absent.

[00364] In various embodiments of compounds of Formula I, R_1 is -L-heteroalkylaryl, which is unsubstituted. In another embodiment, R_1 is -L-heteroalkylaryl which is substituted by one or more independent R^3 . In a further embodiment, R_1 is -L-heteroalkylaryl which is unsubstituted and L is absent. In yet another embodiment, R_1 is -L-heteroalkylaryl, which is substituted by one or more independent R^3 , where L is absent.

[00365] In various embodiments of compounds of Formula I, R_1 is -L-heteroalkylheteroaryl, which is unsubstituted. In another embodiment, R_1 is -L-heteroalkylheteroaryl, which is substituted by one or more independent R^3 . In a further embodiment, R_1 is -L-heteroalkylheteroaryl which is unsubstituted and L is absent. In yet another embodiment, R_1 is -L-heteroalkylheteroaryl, which is substituted by one or more independent R^3 , where L is absent.

[00366] In various embodiments of compounds of Formula I, R_1 is -L-heteroalkyl-heterocyclyl, which is unsubstituted. In another embodiment, R_1 is -L-heteroalkyl-heterocyclyl, which is substituted by one or more independent R^3 . In a further embodiment, R_1 is -L-heteroalkyl-heterocyclyl which is unsubstituted, and L is absent. In yet another embodiment, R_1 is -L-heteroalkyl-heterocyclyl, which is substituted by one or more independent R^3 , where L is absent.


[00367] In various embodiments of compounds of Formula I, R_1 is -L-heteroalkyl- C_{3-8} cycloalkyl, which is unsubstituted. In another embodiment, R_1 is -L-heteroalkyl- C_{3-8} cycloalkyl, which is substituted by one or more independent R^3 . In a further embodiment, R_1 is -L-heteroalkyl- C_{3-8} cycloalkyl which is unsubstituted and L is absent. In yet another embodiment, R_1 is -L-heteroalkyl- C_{3-8} cycloalkyl, which is substituted by one or more independent R^3 , where L is absent.

[00368] In various embodiments of compounds of Formula I, R_1 is -L-aralkyl, which is unsubstituted. In another embodiment, R_1 is -L-aralkyl, which is substituted by one or more independent R^3 . In a further embodiment, R_1 is -L-aralkyl which is unsubstituted. In yet another embodiment, R_1 is -L-aralkyl, which is substituted by one or more independent R^3 , where L is absent.

[00369] In various embodiments of compounds of Formula I, R_1 is -L-heteroaralkyl, which is unsubstituted. In another embodiment, R_1 is -L-heteroaralkyl, which is substituted by one or more independent R^3 . In a further embodiment, R_1 is -L-heteroaralkyl which is unsubstituted and L is absent. In yet another embodiment, R_1 is -L-heteroaralkyl, which is substituted by one or more independent R^3 , where L is absent.

[00370] In various embodiments of compounds of Formula I, R_1 is -L-heterocyclyl, which is unsubstituted. In another embodiment, R_1 is -L-heterocyclyl, which is substituted by one or more independent R^3 . In a further embodiment, R_1 is -L-heterocyclyl which is unsubstituted and L is absent. In yet another embodiment, R_1 is -L-heterocyclyl, which is substituted by one or more independent R^3 , where L is absent.

[00371] In various embodiments of compounds of Formula I, R_1 is a substituent as shown below:



[00372] In various embodiments of compounds of Formula I, R^2 is hydrogen. In another embodiment, R^2 is halogen. In another embodiment, R^2 is $-OH$. In another embodiment, R^2 is $-R^{31}$. In another embodiment, R^2 is $-CF_3$. In another embodiment, R^2 is $-OCF_3$. In another embodiment, R^2 is $-OR^{31}$. In another embodiment, R^2 is $-NR^{31}R^{32}$. In another embodiment, R^2 is $-NR^{34}R^{35}$. In another embodiment, R^2 is $-C(O)R^{31}$. In another embodiment, R^2 is $-CO_2R^{31}$. In another embodiment, R^2 is $-C(=O)NR^{31}R^{32}$. In another embodiment, R^2 is $-C(=O)NR^{34}R^{35}$. In another embodiment, R^2 is $-NO_2$. In another embodiment, R^2 is $-CN$. In another embodiment, R^2 is $-S(O)_{0-2}R^{31}$. In another embodiment, R^2 is $-SO_2NR^{31}R^{32}$. In another embodiment, R^2 is $-SO_2NR^{34}R^{35}$. In another embodiment, R^2 is $-NR^{31}C(=O)R^{32}$. In another embodiment, R^2 is $-NR^{31}C(=O)OR^{32}$. In another embodiment, R^2 is $-NR^{31}C(=O)NR^{32}R^{33}$. In another embodiment, R^2 is $-NR^{31}S(O)_{0-2}R^{32}$. In another embodiment, R^2 is $-C(=S)OR^{31}$. In another embodiment, R^2 is $-C(=O)SR^{31}$. In another embodiment, R^2 is $-NR^{31}C(=NR^{32})NR^{33}R^{32}$. In another embodiment, R^2 is $-NR^{31}C(=NR^{32})OR^{33}$. In another embodiment, R^2 is $-NR^{31}C(=NR^{32})SR^{33}$. In another embodiment, R^2 is $-OC(=O)OR^{33}$. In another embodiment, R^2 is $-OC(=O)NR^{31}R^{32}$. In another embodiment, R^2 is $-OC(=O)SR^{31}$. In another embodiment, R^2 is $-SC(=O)OR^{31}$. In another embodiment, R^2 is $-P(O)OR^{31}OR^{32}$. In another embodiment, R^2 is $-SC(=O)NR^{31}R^{32}$. In another embodiment, R^2 is monocyclic aryl. In another embodiment, R^2 is bicyclic aryl. In another embodiment, R^2 is substituted monocyclic aryl. In another embodiment, R^2 is heteroaryl. In another embodiment, R^2 is C_{1-4} alkyl. In another embodiment, R^2 is C_{1-10} alkyl. In another embodiment, R^2 is C_{3-8} cycloalkyl. In another embodiment, R^2 is C_{3-8} cycloalkyl- C_{1-10} alkyl. In another embodiment, R^2 is C_{1-10} alkyl- C_{3-8} cycloalkyl. In another embodiment, R^2 is C_{1-10} alkyl-monocyclic aryl. In another embodiment, R^2 is C_{2-10} alkyl-monocyclic aryl. In another embodiment, R^2 is monocyclic aryl- C_{2-10} alkyl. In another embodiment, R^2 is C_{1-10} alkyl-bicyclic aryl. In another embodiment, R^2 is bicyclic aryl- C_{1-10} alkyl. In another embodiment, R^2 is $-C_{1-10}$ alkylheteroaryl. In another embodiment, R^2 is $-C_{1-10}$ alkylheterocyclyl. In another embodiment, R^2 is $-C_{2-10}$ alkenyl. In another embodiment, R^2 is $-C_{2-10}$ alkynyl. In another embodiment, R^2 is C_{2-10} alkenylaryl. In another embodiment, R^2 is C_{2-10} alkenylheteroaryl. In another embodiment, R^2 is C_{2-10} alkenylheteroalkyl. In another embodiment, R^2 is C_{2-10} alkenylheterocyclyl. In another embodiment, R^2 is $-C_{2-10}$ alkynylaryl. In another embodiment, R^2 is $-C_{2-10}$ alkynylheteroaryl. In another embodiment, R^2 is $-C_{2-10}$ alkynylheteroalkyl. In another embodiment, R^2 is $-C_{2-10}$ alkynylheterocyclyl. In another embodiment, R^2 is $-C_{2-10}$ alkynyl C_{3-8} cycloalkyl. In another embodiment, R^2 is $-C_{2-10}$ alkynyl C_{3-8} cycloalkenyl. In another embodiment, R^2 is $-C_{1-10}$ alkoxy- C_{1-10} alkyl. In another embodiment, R^2 is $-C_{1-10}$ alkoxy- C_{2-10} alkenyl. In another embodiment, R^2 is $-C_{1-10}$ alkoxy- C_{2-10} alkynyl. In another embodiment, R^2 is $-heterocyclyl$ C_{1-10} alkyl. In another embodiment, R^2 is $heterocyclyl$ C_{2-10} alkenyl. In another embodiment, R^2 is $heterocyclyl$ C_{2-10} alkynyl. In another embodiment, R^2 is aryl- C_{2-10} alkyl. In another embodiment, R^2 is aryl- C_{1-10} alkyl. In another embodiment, R^2 is aryl- C_{2-10} alkenyl. In another embodiment, R^2 is aryl- C_{2-10} alkynyl. In another embodiment, R^2 is aryl-heterocyclyl. In another embodiment, R^2 is heteroaryl- C_{1-10} alkyl. In another embodiment, R^2 is heteroaryl- C_{2-10} alkenyl. In another embodiment, R^2 is heteroaryl- C_{2-10} alkynyl. . In another embodiment, R^2 is heteroaryl- C_3 .

cycloalkyl. In another embodiment, R² is heteroaryl–heteroalkyl. In another embodiment, R² is heteroaryl–heterocyclyl.

[illegible]

[illegible]

[illegible]

₁₀alkyl, C₃₋₈cycloalkyl, heterocyclyl, heteroalkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, monocyclic aryl-C₂₋₁₀alkyl, heterocyclyl C₁₋₁₀alkyl, or C₃₋₈cycloalkyl-C₁₋₁₀alkyl, it is substituted with one or more independent heterocycloalkyl. In another embodiment, when R² is bicyclic aryl, monocyclic aryl, heteroaryl, C₁₋₁₀alkyl, C₃₋₈cycloalkyl, heterocyclyl, heteroalkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, monocyclic aryl-C₂₋₁₀alkyl, heterocyclyl C₁₋₁₀alkyl, or C₃₋₈cycloalkyl-C₁₋₁₀alkyl, it is substituted with one or more independent aryl. In another embodiment, when R² is bicyclic aryl, monocyclic aryl, heteroaryl, C₁₋₁₀alkyl, C₃₋₈cycloalkyl, heterocyclyl, heteroalkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, monocyclic aryl-C₂₋₁₀alkyl, heterocyclyl C₁₋₁₀alkyl, or C₃₋₈cycloalkyl-C₁₋₁₀alkyl, it is substituted with one or more independent arylalkyl. In another embodiment, when R² is bicyclic aryl, monocyclic aryl, heteroaryl, C₁₋₁₀alkyl, C₃₋₈cycloalkyl, heterocyclyl, heteroalkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, monocyclic aryl-C₂₋₁₀alkyl, heterocyclyl C₁₋₁₀alkyl, or C₃₋₈cycloalkyl-C₁₋₁₀alkyl, it is substituted with one or more independent heteroaryl. In another embodiment, when R² is bicyclic aryl, monocyclic aryl, heteroaryl, C₁₋₁₀alkyl, C₃₋₈cycloalkyl, heterocyclyl, heteroalkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, monocyclic aryl-C₂₋₁₀alkyl, heterocyclyl C₁₋₁₀alkyl, or C₃₋₈cycloalkyl-C₁₋₁₀alkyl, it is substituted with one or more independent heteroarylalkyl.

[00374] In various embodiments of compounds of Formula I, R³ is hydrogen. In another embodiment, R³ is halogen. In another embodiment, R³ is -OH. In another embodiment, R³ is -R³¹. In another embodiment, R³ is -CF₃. In another embodiment, R³ is -OCF₃. In another embodiment, R³ is -OR³¹. In another embodiment, R³ is -NR³¹R³². In another embodiment, R³ is -NR³⁴R³⁵. In another embodiment, R³ is -C(O)R³¹. In another embodiment, R³ is -CO₂R³¹. In another embodiment, R³ is -C(=O)NR³¹R³². In another embodiment, R³ is -C(=O)NR³⁴R³⁵. In another embodiment, R³ is -NO₂. In another embodiment, R³ is -CN. In another embodiment, R³ is -S(O)₀₋₂R³. In another embodiment, R³ is -SO₂NR³¹R³². In another embodiment, R³ is -SO₂NR³⁴R³⁵. In another embodiment, R³ is -NR³¹C(=O)R³². In another embodiment, R³ is -NR³¹C(=O)OR³². In another embodiment, R³ is -NR³¹C(=O)NR³²R³³. In another embodiment, R³ is -NR³¹S(O)₀₋₂R³². In another embodiment, R³ is -C(=S)OR³¹. In another embodiment, R³ is -C(=O)SR³¹. In another embodiment, R³ is -NR³¹C(=NR³²)NR³³R³². In another embodiment, R³ is -NR³¹C(=NR³²)OR³³. In another embodiment, R³ is -NR³¹C(=NR³²)SR³³. In another embodiment, R³ is -OC(=O)OR³³. In another embodiment, R³ is -OC(=O)NR³¹R³². In another embodiment, R³ is -OC(=O)SR³¹. In another embodiment, R³ is -SC(=O)OR³¹. In another embodiment, R³ is -P(O)OR³¹OR³². In another embodiment, R³ is -SC(=O)NR³¹R³². In another embodiment, R³ is aryl. In another embodiment, R² is heteroaryl. In another embodiment, R³ is C₁₋₄alkyl. In another embodiment, R³ is C₁₋₁₀alkyl. In another embodiment, R³ is C₃₋₈cycloalkyl. In another embodiment, R³ is C₃₋₈cycloalkyl-C₁₋₁₀alkyl. In another embodiment, R³ is -C₁₋₁₀alkyl-C₃₋₈cycloalkyl. In another embodiment, R³ is C₂₋₁₀alkyl-monocyclic aryl. In another embodiment, R³ is monocyclic aryl-C₂₋₁₀alkyl. In another embodiment, R³ is C₁₋₁₀alkyl-bicyclicaryl. In another embodiment, R³ is bicyclicaryl-C₁₋₁₀alkyl. In another embodiment, R³ is C₁₋₁₀alkylheteroaryl. In another embodiment, R³ is C₁₋₁₀alkylheterocyclyl. In another embodiment, R³ is C₂₋₁₀alkenyl. In another embodiment, R³ is C₂₋₁₀alkynyl. In another embodiment, R³ is C₂₋₁₀alkenylaryl. In another embodiment, R³ is C₂₋₁₀alkenylheteroaryl. In another embodiment, R³ is C₂₋₁₀alkenylheteroalkyl. In another embodiment, R³ is C₂₋₁₀alkenylheterocyclyl. In

another embodiment, R^3 is $-C_{2-10}alkynylaryl$. In another embodiment, R^3 is $-C_{2-10}alkynylheteroaryl$. In another embodiment, R^3 is $-C_{2-10}alkynylheteroalkyl$. In another embodiment, R^3 is $C_{2-10}alkynylheterocyclyl$. In another embodiment, R^3 is $-C_{2-10}alkynylC_{3-8}cycloalkyl$. In another embodiment, R^3 is $C_{2-10}alkynylC_{3-8}cycloalkenyl$. In another embodiment, R^3 is $-C_{1-10}alkoxy-C_{1-10}alkyl$. In another embodiment, R^3 is $C_{1-10}alkoxy-C_{2-10}alkenyl$. In another embodiment, R^3 is $-C_{1-10}alkoxy-C_{2-10}alkynyl$. In another embodiment, R^3 is heterocyclyl- $C_{1-10}alkyl$. In another embodiment, R^3 is heterocyclyl- $C_{2-10}alkenyl$. In another embodiment, R^3 is heterocyclyl- $C_{2-10}alkynyl$. In another embodiment, R^3 is aryl- $C_{1-10}alkyl$. In another embodiment, R^3 is aryl- $C_{2-10}alkenyl$. In another embodiment, R^3 is aryl- $C_{2-10}alkynyl$. In another embodiment, R^3 is aryl-heterocyclyl. In another embodiment, R^3 is heteroaryl- $C_{1-10}alkyl$. In another embodiment, R^3 is heteroaryl- $C_{2-10}alkenyl$. In another embodiment, R^3 is heteroaryl- $C_{2-10}alkynyl$. In another embodiment, R^3 is heteroaryl- $C_{3-8}cycloalkyl$. In another embodiment, R^3 is heteroaryl-heteroalkyl. In another embodiment, R^3 is heteroaryl-heterocyclyl.

[00375] In various embodiments of compounds of Formula I, when R^3 is aryl, heteroaryl, $C_{1-10}alkyl$, $C_{3-8}cycloalkyl$, $C_{3-8}cycloalkyl-C_{1-10}alkyl$, heterocyclyl, heterocyclyl- $C_{1-10}alkyl$, or heteroalkyl, it is unsubstituted. In another embodiment, when R^3 is aryl, heteroaryl, $C_{1-10}alkyl$, $C_{3-8}cycloalkyl$, $C_{3-8}cycloalkyl-C_{1-10}alkyl$, heterocyclyl, heterocyclyl- $C_{1-10}alkyl$, or heteroalkyl, it is substituted with one or more independent halo. In another embodiment, when R^3 is aryl, heteroaryl, $C_{1-10}alkyl$, $C_{3-8}cycloalkyl$, $C_{3-8}cycloalkyl-C_{1-10}alkyl$, heterocyclyl, heterocyclyl- $C_{1-10}alkyl$, or heteroalkyl, it is substituted with one or more independent $-OH$. In another embodiment, when R^3 is aryl, heteroaryl, $C_{1-10}alkyl$, $C_{3-8}cycloalkyl$, $C_{3-8}cycloalkyl-C_{1-10}alkyl$, heterocyclyl, heterocyclyl- $C_{1-10}alkyl$, or heteroalkyl, it is substituted with one or more independent $-R^{31}$. In another embodiment, when R^3 is aryl, heteroaryl, $C_{1-10}alkyl$, $C_{3-8}cycloalkyl$, $C_{3-8}cycloalkyl-C_{1-10}alkyl$, heterocyclyl, heterocyclyl- $C_{1-10}alkyl$, or heteroalkyl, it is substituted with one or more independent $-CF_3$. In another embodiment, when R^3 is aryl, heteroaryl, $C_{1-10}alkyl$, $C_{3-8}cycloalkyl$, $C_{3-8}cycloalkyl-C_{1-10}alkyl$, heterocyclyl, heterocyclyl- $C_{1-10}alkyl$, or heteroalkyl, it is substituted with one or more independent $-OCF_3$. In another embodiment, when R^3 is aryl, heteroaryl, $C_{1-10}alkyl$, $C_{3-8}cycloalkyl$, $C_{3-8}cycloalkyl-C_{1-10}alkyl$, heterocyclyl, heterocyclyl- $C_{1-10}alkyl$, or heteroalkyl, it is substituted with one or more independent $-OR^{31}$. In another embodiment, when R^3 is aryl, heteroaryl, $C_{1-10}alkyl$, $C_{3-8}cycloalkyl$, $C_{3-8}cycloalkyl-C_{1-10}alkyl$, heterocyclyl, heterocyclyl- $C_{1-10}alkyl$, or heteroalkyl, it is substituted with one or more independent $-NR^{31}R^{32}$. In another embodiment, when R^3 is aryl, heteroaryl, $C_{1-10}alkyl$, $C_{3-8}cycloalkyl$, $C_{3-8}cycloalkyl-C_{1-10}alkyl$, heterocyclyl, heterocyclyl- $C_{1-10}alkyl$, or heteroalkyl, it is substituted with one or more independent $-NR^{34}R^{35}$. In another embodiment, when R^3 is aryl, heteroaryl, $C_{1-10}alkyl$, $C_{3-8}cycloalkyl$, $C_{3-8}cycloalkyl-C_{1-10}alkyl$, heterocyclyl, heterocyclyl- $C_{1-10}alkyl$, or heteroalkyl, it is substituted with one or more independent $-C(O)R^{31}$. In another embodiment, when R^3 is aryl, heteroaryl, $C_{1-10}alkyl$, $C_{3-8}cycloalkyl$, $C_{3-8}cycloalkyl-C_{1-10}alkyl$, heterocyclyl, heterocyclyl- $C_{1-10}alkyl$, or heteroalkyl, it is substituted with one or more independent $-CO_2R^{31}$. In another embodiment, when R^3 is aryl, heteroaryl, $C_{1-10}alkyl$, $C_{3-8}cycloalkyl$, $C_{3-8}cycloalkyl-C_{1-10}alkyl$, heterocyclyl, heterocyclyl- $C_{1-10}alkyl$, or heteroalkyl, it is substituted with one or more independent $-C(=O)NR^{31}R^{32}$. In another embodiment, when R^3 is aryl, heteroaryl, $C_{1-10}alkyl$, cycloalkyl, heterocyclyl, heteroalkyl, $C_{2-10}alkenyl$, $C_{2-10}alkynyl$,

[illegible]

₁₀alkynyl, aryl-C₂₋₁₀alkyl, heterocyclyl C₁₋₁₀alkyl, or C₃₋₈cycloalkyl-C₁₋₁₀alkyl, it is substituted with one or more independent -OC(=O)NR³¹R³². In another embodiment, when R³ is aryl, heteroaryl, C₁₋₁₀alkyl, cycloalkyl, heterocyclyl, heteroalkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, aryl-C₂₋₁₀alkyl, heterocyclyl C₁₋₁₀alkyl, or C₃₋₈cycloalkyl-C₁₋₁₀alkyl, it is substituted with one or more independent -OC(=O)SR³¹. In another embodiment, when R³ is aryl, heteroaryl, C₁₋₁₀alkyl, cycloalkyl, heterocyclyl, heteroalkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, aryl-C₂₋₁₀alkyl, heterocyclyl C₁₋₁₀alkyl, or C₃₋₈cycloalkyl-C₁₋₁₀alkyl, it is substituted with one or more independent -SC(=O)OR³¹. In another embodiment, when R³ is aryl, heteroaryl, C₁₋₁₀alkyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkyl-C₁₋₁₀alkyl, heterocyclyl, heterocyclyl C₁₋₁₀alkyl, or heteroalkyl, it is substituted with one or more independent -P(O)OR³¹OR³². In another embodiment, when R³ is aryl, heteroaryl, C₁₋₁₀alkyl, cycloalkyl, heterocyclyl, heteroalkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, aryl-C₂₋₁₀alkyl, heterocyclyl C₁₋₁₀alkyl, or C₃₋₈cycloalkyl-C₁₋₁₀alkyl, it is substituted with one or more independent -SC(=O)NR³¹R³².

[00376] In various embodiments of compounds of Formula I, R⁴ is hydrogen. In another embodiment, R⁴ is halogen. In another embodiment, R⁴ is -OH. In another embodiment, R⁴ is -R³¹. In another embodiment, R⁴ is -CF₃. In another embodiment, R⁴ is -OCF₃. In another embodiment, R⁴ is -OR³¹. In another embodiment, R⁴ is -NR³¹R³². In another embodiment, R⁴ is -NR³⁴R³⁵. In another embodiment, R⁴ is -C(O)R³¹. In another embodiment, R⁴ is -CO₂R³¹. In another embodiment, R⁴ is -C(=O)NR³¹R³². In another embodiment, R⁴ is -C(=O)NR³⁴R³⁵. In another embodiment, R⁴ is -NO₂. In another embodiment, R⁴ is -CN. In another embodiment, R⁴ is -S(O)₀₋₂R³. In another embodiment, R⁴ is -SO₂NR³¹R³². In another embodiment, R⁴ is -SO₂NR³⁴R³⁵. In another embodiment, R⁴ is -NR³¹C(=O)R³². In another embodiment, R⁴ is -NR³¹C(=O)OR³². In another embodiment, R⁴ is -NR³¹C(=O)NR³²R³³. In another embodiment, R⁴ is -NR³¹S(O)₀₋₂R³². In another embodiment, R⁴ is -C(=S)OR³¹. In another embodiment, R⁴ is -C(=O)SR³¹. In another embodiment, R⁴ is -NR³¹C(=NR³²)NR³³R³². In another embodiment, R⁴ is -NR³¹C(=NR³²)OR³³. In another embodiment, R⁴ is -NR³¹C(=NR³²)SR³³. In another embodiment, R⁴ is -OC(=O)OR³³. In another embodiment, R⁴ is -OC(=O)NR³¹R³². In another embodiment, R⁴ is -OC(=O)SR³¹. In another embodiment, R⁴ is -SC(=O)OR³¹. In another embodiment, R⁴ is -P(O)OR³¹OR³². In another embodiment, R⁴ is -SC(=O)NR³¹R³². In another embodiment, R⁴ is aryl. In another embodiment, R⁴ is heteroaryl. In another embodiment, R⁴ is C₁₋₄alkyl. In another embodiment, R⁴ is C₁₋₁₀alkyl. In another embodiment, R⁴ is C₃₋₈cycloalkyl. In another embodiment, R⁴ is C₁₋₁₀alkyl-C₃₋₈cycloalkyl. In another embodiment, R⁴ is C₁₋₁₀alkylaryl. In another embodiment, R⁴ is C₁₋₁₀alkylheteroaryl. In another embodiment, R⁴ is C₁₋₁₀alkylheterocyclyl. In another embodiment, R⁴ is C₂₋₁₀alkenyl. In another embodiment, R⁴ is C₂₋₁₀alkynyl. In another embodiment, R⁴ is C₂₋₁₀alkynyl-C₃₋₈cycloalkyl. R⁴ is C₂₋₁₀alkenyl-C₃₋₈cycloalkyl. In another embodiment, R⁴ is C₂₋₁₀alkenylaryl. In another embodiment, R⁴ is C₂₋₁₀alkenyl-heteroaryl. In another embodiment, R⁴ is C₂₋₁₀alkenylheteroalkyl. In another embodiment, R⁴ is C₂₋₁₀alkenylheterocyclyl. In another embodiment, R⁴ is -C₂₋₁₀alkynylaryl. In another embodiment, R⁴ is C₂₋₁₀alkynylheteroaryl. In another embodiment, R⁴ is C₂₋₁₀alkynylheteroalkyl. In another embodiment, R⁴ is C₂₋₁₀alkynylheterocyclyl. In another embodiment, R⁴ is C₂₋₁₀alkynylC₃₋₈cycloalkyl. In another embodiment, R⁴ is heterocyclyl C₁₋₁₀alkyl. In another embodiment, R⁴ is

heterocyclyl-C₂₋₁₀alkenyl. In another embodiment, R⁴ is heterocyclyl-C₂₋₁₀alkynyl. In another embodiment, R⁴ is aryl-C₁₋₁₀alkyl. In another embodiment, R⁴ is aryl-C₂₋₁₀alkenyl. In another embodiment, R⁴ is aryl-C₂₋₁₀alkynyl. In another embodiment, R⁴ is aryl-heterocyclyl. In another embodiment, R⁴ is heteroaryl-C₁₋₁₀alkyl. In another embodiment, R⁴ is heteroaryl-C₂₋₁₀alkenyl. In another embodiment, R⁴ is heteroaryl-C₂₋₁₀alkynyl. In another embodiment, R⁴ is C₃₋₈cycloalkyl-C₁₋₁₀alkyl. In another embodiment, R⁴ is C₃₋₈cycloalkyl-C₂₋₁₀alkenyl. In another embodiment, R⁴ is C₃₋₈cycloalkyl-C₂₋₁₀alkynyl.

[illegible]

[illegible]

more independent $-\text{SC}(=\text{O})\text{OR}^{31}$. In another embodiment, when R^4 is aryl, heteroaryl, C_{1-10} alkyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkyl- C_{1-10} alkyl, heterocyclyl, heterocyclyl C_{1-10} alkyl, or heteroalkyl, it is substituted with one or more independent $-\text{P}(\text{O})\text{OR}^{31}\text{OR}^{32}$. In another embodiment, when R^4 is aryl, heteroaryl, C_{1-10} alkyl, cycloalkyl, heterocyclyl, heteroalkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, aryl- C_{2-10} alkyl, heterocyclyl C_{1-10} alkyl, or C_{3-8} cycloalkyl- C_{1-10} alkyl, it is substituted with one or more independent $-\text{SC}(=\text{O})\text{NR}^{31}\text{R}^{32}$.

[00378] In various embodiments of compounds of Formula I, R^5 is hydrogen. In another embodiment, R^5 is halogen. In another embodiment, R^5 is $-\text{OH}$. In another embodiment, R^5 is $-\text{R}^{31}$. In another embodiment, R^5 is $-\text{CF}_3$. In another embodiment, R^5 is $-\text{OCF}_3$. In another embodiment, R^5 is $-\text{OR}^{31}$. In another embodiment, R^5 is $-\text{NR}^{31}\text{R}^{32}$. In another embodiment, R^5 is $-\text{NR}^{34}\text{R}^{35}$. In another embodiment, R^5 is $-\text{C}(\text{O})\text{R}^{31}$. In another embodiment, R^5 is $-\text{CO}_2\text{R}^{31}$. In another embodiment, R^5 is $-\text{C}(=\text{O})\text{NR}^{31}\text{R}^{32}$. In another embodiment, R^5 is $-\text{C}(=\text{O})\text{NR}^{34}\text{R}^{35}$. In another embodiment, R^5 is $-\text{NO}_2$. In another embodiment, R^5 is $-\text{CN}$. In another embodiment, R^5 is $-\text{S}(\text{O})_{0-2}\text{R}^{31}$. In another embodiment, R^5 is $-\text{SO}_2\text{NR}^{31}\text{R}^{32}$. In another embodiment, R^5 is $-\text{SO}_2\text{NR}^{34}\text{R}^{35}$. In another embodiment, R^5 is $-\text{NR}^{31}\text{C}(=\text{O})\text{R}^{32}$. In another embodiment, R^5 is $-\text{NR}^{31}\text{C}(=\text{O})\text{OR}^{32}$. In another embodiment, R^5 is $-\text{NR}^{31}\text{C}(=\text{O})\text{NR}^{32}\text{R}^{33}$. In another embodiment, R^5 is $-\text{NR}^{31}\text{S}(\text{O})_{0-2}\text{R}^{32}$. In another embodiment, R^5 is $-\text{C}(=\text{S})\text{OR}^{31}$. In another embodiment, R^5 is $-\text{C}(=\text{O})\text{SR}^{31}$. In another embodiment, R^5 is $-\text{NR}^{31}\text{C}(=\text{NR}^{32})\text{NR}^{33}\text{R}^{32}$. In another embodiment, R^5 is $-\text{NR}^{31}\text{C}(=\text{NR}^{32})\text{OR}^{33}$. In another embodiment, R^5 is $-\text{NR}^{31}\text{C}(=\text{NR}^{32})\text{SR}^{33}$. In another embodiment, R^5 is $-\text{OC}(=\text{O})\text{OR}^{33}$. In another embodiment, R^5 is $-\text{OC}(=\text{O})\text{NR}^{31}\text{R}^{32}$. In another embodiment, R^5 is $-\text{OC}(=\text{O})\text{SR}^{31}$. In another embodiment, R^5 is $-\text{SC}(=\text{O})\text{OR}^{31}$. In another embodiment, R^5 is $-\text{P}(\text{O})\text{OR}^{31}\text{OR}^{32}$. In another embodiment, R^5 is or $-\text{SC}(=\text{O})\text{NR}^{31}\text{R}^{32}$.

[00379] In various embodiments of compounds of Formula I, R^7 is hydrogen. In another embodiment, R^7 is unsubstituted C_{1-10} alkyl. In another embodiment, R^7 is unsubstituted C_{2-10} alkenyl. In another embodiment, R^7 is unsubstituted aryl. In another embodiment, R^7 is unsubstituted heteroaryl. In another embodiment, R^7 is unsubstituted heterocyclyl. In another embodiment, R^7 is unsubstituted C_{3-10} cycloalkyl. In another embodiment, R^7 is C_{1-10} alkyl substituted by one or more independent R^6 . In another embodiment, R^7 is C_{2-10} alkenyl substituted by one or more independent R^6 . In another embodiment, R^7 is aryl substituted by one or more independent R^6 . In another embodiment, R^7 is heteroaryl substituted by one or more independent R^6 . In another embodiment, R^7 is heterocyclyl substituted by one or more independent R^6 . In another embodiment, R^7 is C_{3-10} cycloalkyl substituted by one or more independent R^6 .

[00380] In various embodiments of compounds of Formula I, R^8 is hydrogen. In another embodiment, R^8 is unsubstituted C_{1-10} alkyl. In another embodiment, R^8 is unsubstituted C_{2-10} alkenyl. In another embodiment, R^8 is unsubstituted aryl. In another embodiment, R^8 is unsubstituted heteroaryl. In another embodiment, R^8 is unsubstituted heterocyclyl. In another embodiment, R^8 is unsubstituted C_{3-10} cycloalkyl. In another embodiment, R^8 is C_{1-10} alkyl substituted by one or more independent R^6 . In another embodiment, R^8 is C_{2-10} alkenyl substituted by one or more independent R^6 . In another embodiment, R^8 is aryl substituted by one or more independent R^6 . In another embodiment, R^8 is heteroaryl substituted by

one or more independent R^6 . In another embodiment, R^8 is heterocyclyl substituted by one or more independent R^6 . In another embodiment, R^8 is C_{3-10} cycloalkyl substituted by one or more independent R^6 .

[00381] In various embodiments of compounds of Formula I, R^6 is halo. In another embodiment, R^6 is OR^{31} . In another embodiment, R^6 is $-SH$. In another embodiment, R^6 is NH_2 . In another embodiment, R^6 is $-NR^{34}R^{35}$. In another embodiment, R^6 is $-NR^{31}R^{32}$. In another embodiment, R^6 is $-CO_2R^{31}$. In another embodiment, R^6 is $-CO_2aryl$. In another embodiment, R^6 is $-C(=O)NR^{31}R^{32}$. In another embodiment, R^6 is $C(=O)NR^{34}R^{35}$. In another embodiment, R^6 is $-NO_2$. In another embodiment, R^6 is $-CN$. In another embodiment, R^6 is $-S(O)_{0-2}C_{1-10}alkyl$. In another embodiment, R^6 is $-S(O)_{0-2}aryl$. In another embodiment, R^6 is $-SO_2NR^{34}R^{35}$. In another embodiment, R^6 is $-SO_2NR^{31}R^{32}$. In another embodiment, R^6 is $C_{1-10}alkyl$. In another embodiment, R^6 is $C_{2-10}alkenyl$. In another embodiment, R^6 is $C_{2-10}alkynyl$. In another embodiment, R^6 is unsubstituted $aryl-C_{1-10}alkyl$. In another embodiment, R^6 is unsubstituted $aryl-C_{2-10}alkenyl$. In another embodiment, R^6 is unsubstituted $aryl-C_{2-10}alkynyl$. In another embodiment, R^6 is unsubstituted heteroaryl- $C_{1-10}alkyl$. In another embodiment, R^6 is unsubstituted heteroaryl- $C_{2-10}alkenyl$. In another embodiment, R^6 is $aryl-C_{1-10}alkyl$, $aryl-C_{2-10}alkenyl$, $aryl-C_{2-10}alkynyl$, heteroaryl- $C_{1-10}alkyl$, or heteroaryl- $C_{2-10}alkenyl$ substituted by one or more independent halo. In another embodiment, R^6 is $aryl-C_{1-10}alkyl$, $aryl-C_{2-10}alkenyl$, $aryl-C_{2-10}alkynyl$, heteroaryl- $C_{1-10}alkyl$, or heteroaryl- $C_{2-10}alkenyl$ substituted by one or more independent cyano. In another embodiment, R^6 is $aryl-C_{1-10}alkyl$, $aryl-C_{2-10}alkenyl$, $aryl-C_{2-10}alkynyl$, heteroaryl- $C_{1-10}alkyl$, or heteroaryl- $C_{2-10}alkenyl$ substituted by one or more independent nitro. In another embodiment, R^6 is $aryl-C_{1-10}alkyl$, $aryl-C_{2-10}alkenyl$, $aryl-C_{2-10}alkynyl$, heteroaryl- $C_{1-10}alkyl$, or heteroaryl- $C_{2-10}alkenyl$ substituted by one or more independent $-OC_{1-10}alkyl$. In another embodiment, R^6 is $aryl-C_{1-10}alkyl$, $aryl-C_{2-10}alkenyl$, $aryl-C_{2-10}alkynyl$, heteroaryl- $C_{1-10}alkyl$, or heteroaryl- $C_{2-10}alkenyl$ substituted by one or more independent $-C_{1-10}alkyl$. In another embodiment, R^6 is $aryl-C_{1-10}alkyl$, $aryl-C_{2-10}alkenyl$, $aryl-C_{2-10}alkynyl$, heteroaryl- $C_{1-10}alkyl$, or heteroaryl- $C_{2-10}alkenyl$ substituted by one or more independent $-C_{2-10}alkenyl$. In another embodiment, R^6 is $aryl-C_{1-10}alkyl$, $aryl-C_{2-10}alkenyl$, $aryl-C_{2-10}alkynyl$, heteroaryl- $C_{1-10}alkyl$, or heteroaryl- $C_{2-10}alkenyl$ substituted by one or more independent $-(halo)C_{1-10}alkyl$. In another embodiment, R^6 is $aryl-C_{1-10}alkyl$, $aryl-C_{2-10}alkenyl$, $aryl-C_{2-10}alkynyl$, heteroaryl- $C_{1-10}alkyl$, or heteroaryl- $C_{2-10}alkenyl$ substituted by one or more independent $-(halo)C_{2-10}alkenyl$. In another embodiment, R^6 is $aryl-C_{1-10}alkyl$, $aryl-C_{2-10}alkenyl$, $aryl-C_{2-10}alkynyl$, heteroaryl- $C_{1-10}alkyl$, or heteroaryl- $C_{2-10}alkenyl$ substituted by one or more independent $-COOH$. In another embodiment, R^6 is $aryl-C_{1-10}alkyl$, $aryl-C_{2-10}alkenyl$, $aryl-C_{2-10}alkynyl$, heteroaryl- $C_{1-10}alkyl$, or heteroaryl- $C_{2-10}alkenyl$ substituted by one or more independent $-C(=O)NR^{31}R^{32}$. In another embodiment, R^6 is $aryl-C_{1-10}alkyl$, $aryl-C_{2-10}alkenyl$, $aryl-C_{2-10}alkynyl$, heteroaryl- $C_{1-10}alkyl$, or heteroaryl- $C_{2-10}alkenyl$ substituted by one or more independent $-C(=O)NR^{34}R^{35}$. In another embodiment, R^6 is $aryl-C_{1-10}alkyl$, $aryl-C_{2-10}alkenyl$, $aryl-C_{2-10}alkynyl$, heteroaryl- $C_{1-10}alkyl$, or heteroaryl- $C_{2-10}alkenyl$ substituted by one or more independent $-SO_2NR^{34}R^{35}$. In another

embodiment, R^6 is aryl- C_{1-10} alkyl, aryl- C_{2-10} alkenyl, aryl- C_{2-10} alkynyl, heteroaryl- C_{1-10} alkyl, or heteroaryl- C_{2-10} alkenyl substituted by one or more independent $-SO_2NR^{31}R^{32}$. In another embodiment, R^6 is aryl- C_{1-10} alkyl, aryl- C_{2-10} alkenyl, aryl- C_{2-10} alkynyl, heteroaryl- C_{1-10} alkyl, or heteroaryl- C_{2-10} alkenyl substituted by one or more independent $-NR^{31}R^{32}$. In another embodiment, R^6 is aryl- C_{1-10} alkyl, aryl- C_{2-10} alkenyl, aryl- C_{2-10} alkynyl, heteroaryl- C_{1-10} alkyl, or heteroaryl- C_{2-10} alkenyl substituted by one or more independent $-NR^{34}R^{35}$.

[00382] In various embodiments of compounds of Formula I, R^9 is H. In another embodiment, R^9 is halo. In another embodiment, R^9 is $-OR^{31}$. In another embodiment, R^9 is $-SH$. In another embodiment, R^9 is NH_2 . In another embodiment, R^9 is $-NR^{34}R^{35}$. In another embodiment, R^9 is $-NR^{31}R^{32}$. In another embodiment, R^9 is $-CO_2R^{31}$. In another embodiment, R^9 is $-CO_2$ aryl. In another embodiment, R^9 is $-C(=O)NR^{31}R^{32}$. In another embodiment, R^9 is $C(=O)NR^{34}R^{35}$. In another embodiment, R^9 is $-NO_2$. In another embodiment, R^9 is $-CN$. In another embodiment, R^9 is $-S(O)_{0-2}C_{1-10}$ alkyl. In another embodiment, R^9 is $-S(O)_{0-2}$ aryl. In another embodiment, R^9 is $-SO_2NR^{34}R^{35}$. In another embodiment, R^9 is $-SO_2NR^{31}R^{32}$. In another embodiment, R^9 is C_{1-10} alkyl. In another embodiment, R^9 is C_{2-10} alkenyl. In another embodiment, R^9 is C_{2-10} alkynyl. In another embodiment, R^9 is unsubstituted aryl- C_{1-10} alkyl. In another embodiment, R^9 is unsubstituted aryl- C_{2-10} alkenyl. In another embodiment, R^9 is unsubstituted aryl- C_{2-10} alkynyl. In another embodiment, R^9 is unsubstituted heteroaryl- C_{1-10} alkyl. In another embodiment, R^9 is unsubstituted heteroaryl- C_{2-10} alkenyl. In another embodiment, R^9 is aryl- C_{1-10} alkyl, aryl- C_{2-10} alkenyl, aryl- C_{2-10} alkynyl, heteroaryl- C_{1-10} alkyl, or heteroaryl- C_{2-10} alkenyl substituted by one or more independent halo. In another embodiment, R^9 is aryl- C_{1-10} alkyl, aryl- C_{2-10} alkenyl, aryl- C_{2-10} alkynyl, heteroaryl- C_{1-10} alkyl, or heteroaryl- C_{2-10} alkenyl substituted by one or more independent cyano. In another embodiment, R^9 is aryl- C_{1-10} alkyl, aryl- C_{2-10} alkenyl, aryl- C_{2-10} alkynyl, heteroaryl- C_{1-10} alkyl, or heteroaryl- C_{2-10} alkenyl substituted by one or more independent nitro. In another embodiment, R^9 is aryl- C_{1-10} alkyl, aryl- C_{2-10} alkenyl, aryl- C_{2-10} alkynyl, heteroaryl- C_{1-10} alkyl, or heteroaryl- C_{2-10} alkenyl substituted by one or more independent $-OC_{1-10}$ alkyl. In another embodiment, R^9 is aryl- C_{1-10} alkyl, aryl- C_{2-10} alkenyl, aryl- C_{2-10} alkynyl, heteroaryl- C_{1-10} alkyl, or heteroaryl- C_{2-10} alkenyl substituted by one or more independent $-C_{1-10}$ alkyl. In another embodiment, R^9 is aryl- C_{1-10} alkyl, aryl- C_{2-10} alkenyl, aryl- C_{2-10} alkynyl, heteroaryl- C_{1-10} alkyl, or heteroaryl- C_{2-10} alkenyl substituted by one or more independent $-C_{2-10}$ alkenyl. In another embodiment, R^9 is aryl- C_{1-10} alkyl, aryl- C_{2-10} alkenyl, aryl- C_{2-10} alkynyl, heteroaryl- C_{1-10} alkyl, or heteroaryl- C_{2-10} alkenyl substituted by one or more independent $-C_{2-10}$ alkynyl. In another embodiment, R^9 is aryl- C_{1-10} alkyl, aryl- C_{2-10} alkenyl, aryl- C_{2-10} alkynyl, heteroaryl- C_{1-10} alkyl, or heteroaryl- C_{2-10} alkenyl substituted by one or more independent $-(halo)C_{1-10}$ alkyl. In another embodiment, R^9 is aryl- C_{1-10} alkyl, aryl- C_{2-10} alkenyl, aryl- C_{2-10} alkynyl, heteroaryl- C_{1-10} alkyl, or heteroaryl- C_{2-10} alkenyl substituted by one or more independent $-(halo)C_{2-10}$ alkenyl. In another embodiment, R^9 is aryl- C_{1-10} alkyl, aryl- C_{2-10} alkenyl, aryl- C_{2-10} alkynyl, heteroaryl- C_{1-10} alkyl, or heteroaryl- C_{2-10} alkenyl substituted by one or more independent $-(halo)C_{2-10}$ alkynyl. In another embodiment, R^9 is aryl- C_{1-10} alkyl, aryl- C_{2-10} alkenyl, aryl- C_{2-10} alkynyl, heteroaryl- C_{1-10} alkyl, or heteroaryl- C_{2-10} alkenyl substituted by one or more independent $-COOH$. In another embodiment, R^9 is aryl- C_{1-10} alkyl, aryl- C_{2-10} alkenyl, aryl- C_{2-10} alkynyl, heteroaryl- C_{1-10} alkyl, or

heteroaryl-C₂₋₁₀alkenyl substituted by one or more independent -C(=O)NR³¹R³². In another embodiment, R⁹ is aryl-C₁₋₁₀alkyl, aryl-C₂₋₁₀alkenyl, aryl-C₂₋₁₀alkynyl, heteroaryl-C₁₋₁₀alkyl, or heteroaryl-C₂₋₁₀alkenyl substituted by one or more independent -C(=O)NR³⁴R³⁵. In another embodiment, R⁹ is aryl-C₁₋₁₀alkyl, aryl-C₂₋₁₀alkenyl, aryl-C₂₋₁₀alkynyl, heteroaryl-C₁₋₁₀alkyl, or heteroaryl-C₂₋₁₀alkenyl substituted by one or more independent -SO₂NR³⁴R³⁵. In another embodiment, R⁹ is aryl-C₁₋₁₀alkyl, aryl-C₂₋₁₀alkenyl, aryl-C₂₋₁₀alkynyl, heteroaryl-C₁₋₁₀alkyl, or heteroaryl-C₂₋₁₀alkenyl substituted by one or more independent -SO₂NR³¹R³². In another embodiment, R⁹ is aryl-C₁₋₁₀alkyl, aryl-C₂₋₁₀alkenyl, aryl-C₂₋₁₀alkynyl, heteroaryl-C₁₋₁₀alkyl, or heteroaryl-C₂₋₁₀alkenyl substituted by one or more independent -NR³¹R³². In another embodiment, R⁹ is aryl-C₁₋₁₀alkyl, aryl-C₂₋₁₀alkenyl, aryl-C₂₋₁₀alkynyl, heteroaryl-C₁₋₁₀alkyl, or heteroaryl-C₂₋₁₀alkenyl substituted by one or more independent -NR³⁴R³⁵.

[00383] In various embodiments of compounds of Formula I, R³¹ is H. In some embodiments, R³¹ is unsubstituted C₁₋₁₀alkyl. In some embodiments, R³¹ is substituted C₁₋₁₀alkyl. In some embodiments, R³¹ is C₁₋₁₀alkyl substituted with one or more aryl. In some embodiments, R³¹ is C₁₋₁₀alkyl substituted with one or more heteroalkyl. In some embodiments, R³¹ is C₁₋₁₀alkyl substituted with one or more heterocyclyl. In some embodiments, R³¹ is C₁₋₁₀alkyl substituted with one or more heteroaryl. In some embodiments, when R³¹ is C₁₋₁₀alkyl substituted with one or more aryl, each of said aryl substituents is unsubstituted or substituted with one or more halo, -OH, -C₁₋₁₀alkyl, -CF₃, -O-aryl, -OCF₃, -OC₁₋₁₀alkyl, -NH₂, -N(C₁₋₁₀alkyl)(C₁₋₁₀alkyl), -NH(C₁₋₁₀alkyl), -NH(aryl), -NR³⁴R³⁵, -C(O)(C₁₋₁₀alkyl), -C(O)(C₁₋₁₀alkyl-aryl), -C(O)(aryl), -CO₂-C₁₋₁₀alkyl, -CO₂-C₁₋₁₀alkylaryl, -CO₂-aryl, -C(=O)N(C₁₋₁₀alkyl)(C₁₋₁₀alkyl), -C(=O)NH(C₁₋₁₀alkyl), -C(=O)NR³⁴R³⁵, -C(=O)NH₂, -OCF₃, -O(C₁₋₁₀alkyl), -O-aryl, -N(aryl)(C₁₋₁₀alkyl), -NO₂, -CN, -S(O)₀₋₂C₁₋₁₀alkyl, -S(O)₀₋₂C₁₋₁₀alkylaryl, -S(O)₀₋₂aryl, -SO₂N(aryl), -SO₂N(C₁₋₁₀alkyl)(C₁₋₁₀alkyl), -SO₂NH(C₁₋₁₀alkyl) or -SO₂NR³⁴R³⁵. In some embodiments, when R³¹ is C₁₋₁₀alkyl substituted with one or more heteroalkyl, each of said heteroalkyl group is unsubstituted or substituted with one or more halo, -OH, -C₁₋₁₀alkyl, -CF₃, -O-aryl, -OCF₃, -OC₁₋₁₀alkyl, -NH₂, -N(C₁₋₁₀alkyl)(C₁₋₁₀alkyl), -NH(C₁₋₁₀alkyl), -NH(aryl), -NR³⁴R³⁵, -C(O)(C₁₋₁₀alkyl), -C(O)(C₁₋₁₀alkyl-aryl), -C(O)(aryl), -CO₂-C₁₋₁₀alkyl, -CO₂-C₁₋₁₀alkylaryl, -CO₂-aryl, -C(=O)N(C₁₋₁₀alkyl)(C₁₋₁₀alkyl), -C(=O)NH(C₁₋₁₀alkyl), -C(=O)NR³⁴R³⁵, -C(=O)NH₂, -OCF₃, -O(C₁₋₁₀alkyl), -O-aryl, -N(aryl)(C₁₋₁₀alkyl), -NO₂, -CN, -S(O)₀₋₂C₁₋₁₀alkyl, -S(O)₀₋₂C₁₋₁₀alkylaryl, -S(O)₀₋₂aryl, -SO₂N(aryl), -SO₂N(C₁₋₁₀alkyl)(C₁₋₁₀alkyl), -SO₂NH(C₁₋₁₀alkyl) or -SO₂NR³⁴R³⁵ substituents. In some embodiments, when R³¹ is C₁₋₁₀alkyl substituted with one or more heterocyclyl, each of said heterocyclyl group is unsubstituted or substituted with one or more halo, -OH, -C₁₋₁₀alkyl, -CF₃, -O-aryl, -OCF₃, -OC₁₋₁₀alkyl, -NH₂, -N(C₁₋₁₀alkyl)(C₁₋₁₀alkyl), -NH(C₁₋₁₀alkyl), -NH(aryl), -NR³⁴R³⁵, -C(O)(C₁₋₁₀alkyl), -C(O)(C₁₋₁₀alkyl-aryl), -C(O)(aryl), -CO₂-C₁₋₁₀alkyl, -CO₂-C₁₋₁₀alkylaryl, -CO₂-aryl, -C(=O)N(C₁₋₁₀alkyl)(C₁₋₁₀alkyl), -C(=O)NH(C₁₋₁₀alkyl), -C(=O)NR³⁴R³⁵, -C(=O)NH₂, -OCF₃, -O(C₁₋₁₀alkyl), -O-aryl, -N(aryl)(C₁₋₁₀alkyl), -NO₂, -CN, -S(O)₀₋₂C₁₋₁₀alkyl, -S(O)₀₋₂C₁₋₁₀alkylaryl, -S(O)₀₋₂aryl, -SO₂N(aryl), -SO₂N(C₁₋₁₀alkyl)(C₁₋₁₀alkyl), -SO₂NH(C₁₋₁₀alkyl) or -SO₂NR³⁴R³⁵. In some embodiments, when R³¹ is C₁₋₁₀alkyl substituted with one or more heteroaryl, each of said heteroaryl group is unsubstituted or substituted with one or more halo, -OH, -C₁₋₁₀alkyl, -CF₃, -O-aryl, -OCF₃, -OC₁₋₁₀alkyl, -NH₂, -N(C₁₋₁₀alkyl)(C₁₋₁₀alkyl), -NH(C₁₋₁₀alkyl), -

NH(aryl), $-NR^{34}R^{35}$, $-C(O)(C_{1-10}alkyl)$, $-C(O)(C_{1-10}alkyl-aryl)$, $-C(O)(aryl)$, $-CO_2-C_{1-10}alkyl$, $-CO_2-C_{1-10}alkylaryl$, $-CO_2-aryl$, $-C(=O)N(C_{1-10}alkyl)(C_{1-10}alkyl)$, $-C(=O)NH(C_{1-10}alkyl)$, $-C(=O)NR^{34}R^{35}$, $-C(=O)NH_2$, $-OCF_3$, $-O(C_{1-10}alkyl)$, $-O-aryl$, $-N(aryl)(C_{1-10}alkyl)$, $-NO_2$, $-CN$, $-S(O)_{0-2}C_{1-10}alkyl$, $-S(O)_{0-2}C_{1-10}alkylaryl$, $-S(O)_{0-2}aryl$, $-SO_2N(aryl)$, $-SO_2N(C_{1-10}alkyl)(C_{1-10}alkyl)$, $-SO_2NH(C_{1-10}alkyl)$ or $-SO_2NR^{34}R^{35}$. In some embodiments, when R^{31} is substituted $C_{1-10}alkyl$, it is substituted by a combination of aryl, heteroalkyl, heterocyclyl, or heteroaryl groups.

[00384] In various embodiments of compounds of Formula I, R^{32} is H. In some embodiments, R^{32} is unsubstituted $C_{1-10}alkyl$. In some embodiments, R^{32} is substituted $C_{1-10}alkyl$. In some embodiments, R^{32} is $C_{1-10}alkyl$ substituted with one or more aryl. In some embodiments, R^{32} is $C_{1-10}alkyl$ substituted with one or more heteroalkyl. In some embodiments, R^{32} is $C_{1-10}alkyl$ substituted with one or more heterocyclyl. In some embodiments, R^{32} is $C_{1-10}alkyl$ substituted with one or more heteroaryl. In some embodiments, when R^{32} is $C_{1-10}alkyl$ substituted with one or more aryl, each of said aryl group is unsubstituted or substituted with one or more halo, $-OH$, $-C_{1-10}alkyl$, $-CF_3$, $-O-aryl$, $-OCF_3$, $-OC_{1-10}alkyl$, $-NH_2$, $-N(C_{1-10}alkyl)(C_{1-10}alkyl)$, $-NH(C_{1-10}alkyl)$, $-NH(aryl)$, $-NR^{34}R^{35}$, $-C(O)(C_{1-10}alkyl)$, $-C(O)(C_{1-10}alkyl-aryl)$, $-C(O)(aryl)$, $-CO_2-C_{1-10}alkyl$, $-CO_2-C_{1-10}alkylaryl$, $-CO_2-aryl$, $-C(=O)N(C_{1-10}alkyl)(C_{1-10}alkyl)$, $-C(=O)NH(C_{1-10}alkyl)$, $-C(=O)NR^{34}R^{35}$, $-C(=O)NH_2$, $-OCF_3$, $-O(C_{1-10}alkyl)$, $-O-aryl$, $-N(aryl)(C_{1-10}alkyl)$, $-NO_2$, $-CN$, $-S(O)_{0-2}C_{1-10}alkyl$, $-S(O)_{0-2}C_{1-10}alkylaryl$, $-S(O)_{0-2}aryl$, $-SO_2N(aryl)$, $-SO_2N(C_{1-10}alkyl)(C_{1-10}alkyl)$, $-SO_2NH(C_{1-10}alkyl)$ or $-SO_2NR^{34}R^{35}$. In some embodiments, when R^{32} is $C_{1-10}alkyl$ substituted with one or more heteroalkyl, each of said heteroalkyl group is unsubstituted or substituted with one or more halo, $-OH$, $-C_{1-10}alkyl$, $-CF_3$, $-O-aryl$, $-OCF_3$, $-OC_{1-10}alkyl$, $-NH_2$, $-N(C_{1-10}alkyl)(C_{1-10}alkyl)$, $-NH(C_{1-10}alkyl)$, $-NH(aryl)$, $-NR^{34}R^{35}$, $-C(O)(C_{1-10}alkyl)$, $-C(O)(C_{1-10}alkyl-aryl)$, $-C(O)(aryl)$, $-CO_2-C_{1-10}alkyl$, $-CO_2-C_{1-10}alkylaryl$, $-CO_2-aryl$, $-C(=O)N(C_{1-10}alkyl)(C_{1-10}alkyl)$, $-C(=O)NH(C_{1-10}alkyl)$, $-C(=O)NR^{34}R^{35}$, $-C(=O)NH_2$, $-OCF_3$, $-O(C_{1-10}alkyl)$, $-O-aryl$, $-N(aryl)(C_{1-10}alkyl)$, $-NO_2$, $-CN$, $-S(O)_{0-2}C_{1-10}alkyl$, $-S(O)_{0-2}C_{1-10}alkylaryl$, $-S(O)_{0-2}aryl$, $-SO_2N(aryl)$, $-SO_2N(C_{1-10}alkyl)(C_{1-10}alkyl)$, $-SO_2NH(C_{1-10}alkyl)$ or $-SO_2NR^{34}R^{35}$. In some embodiments, when R^{32} is $C_{1-10}alkyl$ substituted with one or more heterocyclyl, each of said heterocyclyl group is unsubstituted or substituted with one or more halo, $-OH$, $-C_{1-10}alkyl$, $-CF_3$, $-O-aryl$, $-OCF_3$, $-OC_{1-10}alkyl$, $-NH_2$, $-N(C_{1-10}alkyl)(C_{1-10}alkyl)$, $-NH(C_{1-10}alkyl)$, $-NH(aryl)$, $-NR^{34}R^{35}$, $-C(O)(C_{1-10}alkyl)$, $-C(O)(C_{1-10}alkyl-aryl)$, $-C(O)(aryl)$, $-CO_2-C_{1-10}alkyl$, $-CO_2-C_{1-10}alkylaryl$, $-CO_2-aryl$, $-C(=O)N(C_{1-10}alkyl)(C_{1-10}alkyl)$, $-C(=O)NH(C_{1-10}alkyl)$, $-C(=O)NR^{34}R^{35}$, $-C(=O)NH_2$, $-OCF_3$, $-O(C_{1-10}alkyl)$, $-O-aryl$, $-N(aryl)(C_{1-10}alkyl)$, $-NO_2$, $-CN$, $-S(O)_{0-2}C_{1-10}alkyl$, $-S(O)_{0-2}C_{1-10}alkylaryl$, $-S(O)_{0-2}aryl$, $-SO_2N(aryl)$, $-SO_2N(C_{1-10}alkyl)(C_{1-10}alkyl)$, $-SO_2NH(C_{1-10}alkyl)$ or $-SO_2NR^{34}R^{35}$. In some embodiments, when R^{32} is $C_{1-10}alkyl$ substituted with one or more heteroaryl, each of said heteroaryl group is unsubstituted or substituted with one or more halo, $-OH$, $-C_{1-10}alkyl$, $-CF_3$, $-O-aryl$, $-OCF_3$, $-OC_{1-10}alkyl$, $-NH_2$, $-N(C_{1-10}alkyl)(C_{1-10}alkyl)$, $-NH(C_{1-10}alkyl)$, $-NH(aryl)$, $-NR^{34}R^{35}$, $-C(O)(C_{1-10}alkyl)$, $-C(O)(C_{1-10}alkyl-aryl)$, $-C(O)(aryl)$, $-CO_2-C_{1-10}alkyl$, $-CO_2-C_{1-10}alkylaryl$, $-CO_2-aryl$, $-C(=O)N(C_{1-10}alkyl)(C_{1-10}alkyl)$, $-C(=O)NH(C_{1-10}alkyl)$, $-C(=O)NR^{34}R^{35}$, $-C(=O)NH_2$, $-OCF_3$, $-O(C_{1-10}alkyl)$, $-O-aryl$, $-N(aryl)(C_{1-10}alkyl)$, $-NO_2$, $-CN$, $-S(O)_{0-2}C_{1-10}alkyl$, $-S(O)_{0-2}C_{1-10}alkylaryl$, $-S(O)_{0-2}aryl$, $-SO_2N(aryl)$, $-SO_2N(C_{1-10}alkyl)(C_{1-10}alkyl)$, $-SO_2NH(C_{1-10}alkyl)$ or $-SO_2NR^{34}R^{35}$.


—SO₂NR³⁴R³⁵. In some embodiments, when R³² is substituted C₁₋₁₀alkyl, it is substituted by a combination of aryl, heteroalkyl, heterocyclyl, or heteroaryl groups.

[00385] In various embodiments of compounds of Formula I, R³³ is unsubstituted C₁₋₁₀alkyl. In some embodiments, R³³ is substituted C₁₋₁₀alkyl. In some embodiments, R³³ is C₁₋₁₀alkyl substituted with one or more aryl. In some embodiments, R³³ is C₁₋₁₀alkyl substituted with one or more heteroalkyl. In some embodiments, R³³ is C₁₋₁₀alkyl substituted with one or more heterocyclyl. In some embodiments, R³³ is C₁₋₁₀alkyl substituted with one or more heteroaryl. In some embodiments, when R³³ is C₁₋₁₀alkyl substituted with one or more aryl, each of said aryl group is unsubstituted or substituted with one or more halo, —OH, —C₁₋₁₀alkyl, —CF₃, —O-aryl, —OCF₃, —OC₁₋₁₀alkyl, —NH₂, —N(C₁₋₁₀alkyl)(C₁₋₁₀alkyl), —NH(C₁₋₁₀alkyl), —NH(aryl), —NR³⁴R³⁵, —C(O)(C₁₋₁₀alkyl), —C(O)(C₁₋₁₀alkyl-aryl), —C(O)(aryl), —CO₂-C₁₋₁₀alkyl, —CO₂-C₁₋₁₀alkylaryl, —CO₂-aryl, —C(=O)N(C₁₋₁₀alkyl)(C₁₋₁₀alkyl), —C(=O)NH(C₁₋₁₀alkyl), —C(=O)NR³⁴R³⁵, —C(=O)NH₂, —OCF₃, —O(C₁₋₁₀alkyl), —O-aryl, —N(aryl)(C₁₋₁₀alkyl), —NO₂, —CN, —S(O)₀₋₂C₁₋₁₀alkyl, —S(O)₀₋₂C₁₋₁₀alkylaryl, —S(O)₀₋₂aryl, —SO₂N(aryl), —SO₂N(C₁₋₁₀alkyl)(C₁₋₁₀alkyl), —SO₂NH(C₁₋₁₀alkyl) or —SO₂NR³⁴R³⁵. In some embodiments, when R³³ is C₁₋₁₀alkyl substituted with one or more heteroalkyl, each of said heteroalkyl group is unsubstituted or substituted with one or more halo, —OH, —C₁₋₁₀alkyl, —CF₃, —O-aryl, —OCF₃, —OC₁₋₁₀alkyl, —NH₂, —N(C₁₋₁₀alkyl)(C₁₋₁₀alkyl), —NH(C₁₋₁₀alkyl), —NH(aryl), —NR³⁴R³⁵, —C(O)(C₁₋₁₀alkyl), —C(O)(C₁₋₁₀alkyl-aryl), —C(O)(aryl), —CO₂-C₁₋₁₀alkyl, —CO₂-C₁₋₁₀alkylaryl, —CO₂-aryl, —C(=O)N(C₁₋₁₀alkyl)(C₁₋₁₀alkyl), —C(=O)NH(C₁₋₁₀alkyl), —C(=O)NR³⁴R³⁵, —C(=O)NH₂, —OCF₃, —O(C₁₋₁₀alkyl), —O-aryl, —N(aryl)(C₁₋₁₀alkyl), —NO₂, —CN, —S(O)₀₋₂C₁₋₁₀alkyl, —S(O)₀₋₂C₁₋₁₀alkylaryl, —S(O)₀₋₂aryl, —SO₂N(aryl), —SO₂N(C₁₋₁₀alkyl)(C₁₋₁₀alkyl), —SO₂NH(C₁₋₁₀alkyl) or —SO₂NR³⁴R³⁵. In some embodiments, when R³³ is C₁₋₁₀alkyl substituted with one or more heterocyclyl, each of said heterocyclyl group is unsubstituted or substituted with one or more halo, —OH, —C₁₋₁₀alkyl, —CF₃, —O-aryl, —OCF₃, —OC₁₋₁₀alkyl, —NH₂, —N(C₁₋₁₀alkyl)(C₁₋₁₀alkyl), —NH(C₁₋₁₀alkyl), —NH(aryl), —NR³⁴R³⁵, —C(O)(C₁₋₁₀alkyl), —C(O)(C₁₋₁₀alkyl-aryl), —C(O)(aryl), —CO₂-C₁₋₁₀alkyl, —CO₂-C₁₋₁₀alkylaryl, —CO₂-aryl, —C(=O)N(C₁₋₁₀alkyl)(C₁₋₁₀alkyl), —C(=O)NH(C₁₋₁₀alkyl), —C(=O)NR³⁴R³⁵, —C(=O)NH₂, —OCF₃, —O(C₁₋₁₀alkyl), —O-aryl, —N(aryl)(C₁₋₁₀alkyl), —NO₂, —CN, —S(O)₀₋₂C₁₋₁₀alkyl, —S(O)₀₋₂C₁₋₁₀alkylaryl, —S(O)₀₋₂aryl, —SO₂N(aryl), —SO₂N(C₁₋₁₀alkyl)(C₁₋₁₀alkyl), —SO₂NH(C₁₋₁₀alkyl) or —SO₂NR³⁴R³⁵. In some embodiments, when R³³ is C₁₋₁₀alkyl substituted with one or more heteroaryl, each of said heteroaryl group is unsubstituted or substituted with one or more halo, —OH, —C₁₋₁₀alkyl, —CF₃, —O-aryl, —OCF₃, —OC₁₋₁₀alkyl, —NH₂, —N(C₁₋₁₀alkyl)(C₁₋₁₀alkyl), —NH(C₁₋₁₀alkyl), —NH(aryl), —NR³⁴R³⁵, —C(O)(C₁₋₁₀alkyl), —C(O)(C₁₋₁₀alkyl-aryl), —C(O)(aryl), —CO₂-C₁₋₁₀alkyl, —CO₂-C₁₋₁₀alkylaryl, —CO₂-aryl, —C(=O)N(C₁₋₁₀alkyl)(C₁₋₁₀alkyl), —C(=O)NH(C₁₋₁₀alkyl), —C(=O)NR³⁴R³⁵, —C(=O)NH₂, —OCF₃, —O(C₁₋₁₀alkyl), —O-aryl, —N(aryl)(C₁₋₁₀alkyl), —NO₂, —CN, —S(O)₀₋₂C₁₋₁₀alkyl, —S(O)₀₋₂C₁₋₁₀alkylaryl, —S(O)₀₋₂aryl, —SO₂N(aryl), —SO₂N(C₁₋₁₀alkyl)(C₁₋₁₀alkyl), —SO₂NH(C₁₋₁₀alkyl) or —SO₂NR³⁴R³⁵. In some embodiments, when R³³ is substituted C₁₋₁₀alkyl, it is substituted by a combination of aryl, heteroalkyl, heterocyclyl, or heteroaryl groups.

[00386] In various embodiments of compounds of Formula I, R³⁴ and R³⁵ in —NR³⁴R³⁵, —C(=O)NR³⁴R³⁵, or —SO₂NR³⁴R³⁵, are taken together with the nitrogen atom to which they are attached to form a 3-10


membered saturated or unsaturated ring; wherein said ring is independently unsubstituted or is substituted by one or more —NR³¹R³², hydroxyl, halogen, oxo, aryl, heteroaryl, C₁₋₆alkyl, or O-aryl, and wherein said 3-10 membered saturated or unsaturated ring independently contains 0, 1, or 2 more heteroatoms in addition to the nitrogen.

[00387] In some embodiments, the R³⁴ and R³⁵ in -NR³⁴R³⁵, -C(=O)NR³⁴R³⁵, or -SO₂NR³⁴R³⁵, are taken together with the nitrogen atom to which they are attached to form:




[00388] In another embodiment, X₁ is C—NH₂.

[00389] In various embodiments, X_1 is $C-NH-R^4$, where $-NH-R^4$ is:



[00390] In one embodiment, the invention provides an inhibitor of Formula I-C1 where R⁵ is H. In another embodiment, the invention provides an inhibitor of Formula I-C2 where R⁵ is H.

[00391] In some embodiments, the invention provides an inhibitor of Formula I-C1a:



Formula I-C1a

[00392] or a pharmaceutically acceptable salt thereof wherein:

[00393] E² is -H;

[00394] X₁ and X₂ are N;

[00395] R₁ is -L-C₁₋₁₀alkyl, -L-C₃₋₈cycloalkyl, -L-C₁₋₁₀alkylheterocyclyl, or -L-heterocyclyl, each of which is unsubstituted or is substituted by one or more independent R³;

[00396] L is absent, -(C=O)-, -C(=O)O-, -C(=O)N(R³¹)-, -S-, -S(O)-, -S(O)₂-, -S(O)₂N(R³¹)-, or -N(R³¹)-;

[00397] R³ is hydrogen, -OH, -OR³¹, -NR³¹R³², -C(O)R³¹, -C(=O)NR³¹R³², -C(=O)NR³⁴R³⁵, aryl,

heteroaryl, C₁₋₄alkyl, C₁₋₁₀alkyl, C₃₋₈cycloalkyl, or heterocyclyl, wherein each of said aryl or heteroaryl moiety is unsubstituted or is substituted with one or more independent alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, halo, -OH, -R³¹, -CF₃, -OCF₃, -OR³¹, -NR³¹R³², -NR³⁴R³⁵, -C(O)R³¹, -CO₂R³¹, -C(=O)NR³¹R³², -C(=O)NR³⁴R³⁵, -NO₂, -CN, -S(O)₀₋₂R³¹, -SO₂NR³¹R³², -SO₂NR³⁴R³⁵, -NR³¹C(=O)R³², -NR³¹C(=O)OR³², -NR³¹C(=O)NR³²R³³, -NR³¹S(O)₀₋₂R³², -C(=S)OR³¹, -C(=O)SR³¹, -NR³¹C(=NR³²)NR³³R³², -NR³¹C(=NR³²)OR³³, -NR³¹C(=NR³²)SR³³, -OC(=O)OR³³, -OC(=O)NR³¹R³², -OC(=O)SR³¹, -SC(=O)OR³¹, -P(O)OR³¹OR³², or -SC(=O)NR³¹R³², and wherein each of said alkyl, cycloalkyl, or heterocyclyl moiety is unsubstituted or is substituted with one or more alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, halo, -OH, -R³¹, -CF₃, -OCF₃, -OR³¹, -O-aryl, -NR³¹R³², -NR³⁴R³⁵, -C(O)R³¹, -CO₂R³¹, -C(=O)NR³⁴R³⁵, or -C(=O)NR³¹R³²;

[00398] -(W²)_k- is -NH-, -N(H)C(O)- or -N(H)S(O)₂-;


[00399] R² is hydrogen, halogen, -OR³¹, -NR³¹R³², -NR³⁴R³⁵, -C(O)R³¹, -CO₂R³¹, -C(=O)NR³¹R³², -C(=O)NR³⁴R³⁵, -S(O)₀₋₂R³¹, -SO₂NR³¹R³², -SO₂NR³⁴R³⁵, bicyclic aryl, substituted monocyclic aryl, heteroaryl, C₁₋₁₀alkyl, C₃₋₈cycloalkyl, C₁₋₁₀alkyl-C₃₋₈cycloalkyl, C₃₋₈cycloalkyl-C₁₋₁₀alkyl, C₃₋₈cycloalkyl-C₂₋₁₀alkenyl, C₃₋₈cycloalkyl-C₂₋₁₀alkynyl, C₂₋₁₀alkyl-monocyclic aryl, monocyclic aryl-C₂₋₁₀alkyl, C₁₋₁₀alkylbicycloaryl, bicycloaryl-C₁₋₁₀alkyl, substituted C₁₋₁₀alkylaryl, substituted aryl-C₁₋₁₀alkyl, C₁₋₁₀alkylheteroaryl, C₁₋₁₀alkylheterocyclyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₂₋₁₀alkenylaryl, C₂₋₁₀alkenylheteroaryl, C₂₋₁₀alkenylheteroalkyl, C₂₋₁₀alkenylheterocyclyl, C₂₋₁₀alkynylaryl, C₂₋₁₀alkynylheteroaryl, C₂₋₁₀alkynylheteroalkyl, C₂₋₁₀alkynylheterocyclyl, C₂₋₁₀alkenyl-C₃₋₈cycloalkyl, C₂₋₁₀alkynyl-C₃₋₈cycloalkenyl, C₁₋₁₀alkoxy C₁₋₁₀alkyl, C₁₋₁₀alkoxyC₂₋₁₀alkenyl, C₁₋₁₀alkoxyC₂₋₁₀alkynyl, heterocyclyl, heterocyclyl C₁₋₁₀alkyl, heterocyclylC₂₋₁₀alkenyl, heterocyclyl-C₂₋₁₀alkynyl, aryl-C₂₋₁₀alkenyl, aryl-C₂₋₁₀alkynyl, aryl-heterocyclyl, heteroaryl-C₁₋₁₀alkyl, heteroaryl-C₂₋₁₀alkenyl, heteroaryl-

C₂₋₁₀alkynyl, heteroaryl-C₃₋₈cycloalkyl, heteroaryl-heteroalkyl, or heteroaryl-heterocyclyl, wherein each of said bicyclic aryl or heteroaryl moiety is unsubstituted, or wherein each of bicyclic aryl, heteroaryl moiety or monocyclic aryl moiety is substituted with one or more independent halo, -OH, -R³¹, -CF₃, -OCF₃, -OR³¹, -NR³¹R³², -NR³⁴R³⁵, -C(O)R³¹, -CO₂R³¹, -C(=O)NR³¹R³², -C(=O)NR³⁴R³⁵, -NO₂, -CN, -S(O)₀₋₂R³¹, -SO₂NR³¹R³², -SO₂NR³⁴R³⁵, -NR³¹C(=O)R³², -NR³¹C(=O)OR³², -NR³¹C(=O)NR³²R³³, -NR³¹S(O)₀₋₂R³², -C(=S)OR³¹, -C(=O)SR³¹, -NR³¹C(=NR³²)NR³³R³², -NR³¹C(=NR³²)OR³³, -NR³¹C(=NR³²)SR³³, -OC(=O)OR³³, -OC(=O)NR³¹R³², -OC(=O)SR³¹, -SC(=O)OR³¹, -P(O)OR³¹OR³², or -SC(=O)NR³¹R³², and wherein each of said alkyl, cycloalkyl, heterocyclyl, or heteroalkyl moiety is unsubstituted or is substituted with one or more halo, -OH, -R³¹, -CF₃, -OCF₃, -OR³¹, -O-aryl, -NR³¹R³², -NR³⁴R³⁵, -C(O)R³¹, -CO₂R³¹, -C(=O)NR³⁴R³⁵, or -C(=O)NR³¹R³²;

[00400] R³¹, R³², and R³³, in each instance, are independently H or C₁₋₁₀alkyl, wherein the C₁₋₁₀alkyl is unsubstituted; and

[00401] R³⁴ and R³⁵ in -NR³⁴R³⁵, -C(=O)NR³⁴R³⁵, or -SO₂NR³⁴R³⁵, are taken together with the nitrogen atom to which they are attached to form a 3-10 membered saturated or unsaturated ring; wherein said ring is independently unsubstituted or is substituted by one or more -NR³¹R³², hydroxyl, halogen, oxo, aryl, heteroaryl, C₁₋₆alkyl, or O-aryl, and wherein said 3-10 membered saturated or unsaturated ring independently contains 0, 1, or 2 more heteroatoms in addition to the nitrogen.

[00402] In another aspect, an inhibitor of Formula I-C1 is a compound of Formula I-C1a:



Formula I-C1b

[00403] or a pharmaceutically acceptable salt thereof, wherein: E² is -H; X₁ is CH and X₂ is N;

[00404] R₁ is -L-C₁₋₁₀alkyl, -L-C₃₋₈cycloalkyl, -L-C₁₋₁₀alkylheterocyclyl, or -L-heterocyclyl, each of which is unsubstituted or is substituted by one or more independent R³;

[00405] L is absent, -(C=O)-, -C(=O)O-, -C(=O)N(R³¹)-, -S-, -S(O)-, -S(O)₂-, -S(O)₂N(R³¹)-, or -N(R³¹)-;

[00406] R³ is hydrogen, -OH, -OR³¹, -NR³¹R³², -C(O)R³¹, -C(=O)NR³¹R³², -C(=O)NR³⁴R³⁵, aryl, heteroaryl, C₁₋₄alkyl, C₁₋₁₀alkyl, C₃₋₈cycloalkyl, or heterocyclyl, wherein each of said aryl or heteroaryl moiety is unsubstituted or is substituted with one or more independent alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, halo, -OH, -R³¹, -CF₃, -OCF₃, -OR³¹, -NR³¹R³², -NR³⁴R³⁵, -C(O)R³¹, -CO₂R³¹, -C(=O)NR³¹R³², -C(=O)NR³⁴R³⁵, -NO₂, -CN, -S(O)₀₋₂R³¹, -SO₂NR³¹R³², -SO₂NR³⁴R³⁵, -NR³¹C(=O)R³², -NR³¹C(=O)OR³², -NR³¹C(=O)NR³²R³³, -NR³¹S(O)₀₋₂R³², -C(=S)OR³¹, -C(=O)SR³¹, -NR³¹C(=NR³²)NR³³R³², -NR³¹C(=NR³²)OR³³, -NR³¹C(=NR³²)SR³³, -OC(=O)OR³³, -OC(=O)NR³¹R³², -OC(=O)SR³¹, -SC(=O)OR³¹, -P(O)OR³¹OR³², or -SC(=O)NR³¹R³², and wherein each of said alkyl, cycloalkyl, or heterocyclyl moiety is unsubstituted or is substituted with

one or more alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, halo, $-\text{OH}$, $-\text{R}^{31}$, $-\text{CF}_3$, $-\text{OCF}_3$, $-\text{OR}^{31}$, $-\text{O-aryl}$, $-\text{NR}^{31}\text{R}^{32}$, $-\text{NR}^{34}\text{R}^{35}$, $-\text{C(O)R}^{31}$, $-\text{CO}_2\text{R}^{31}$, $-\text{C(=O)NR}^{34}\text{R}^{35}$, or $-\text{C(=O)NR}^{31}\text{R}^{32}$;


[00407] $-(\text{W}^2)_k-$ is $-\text{NH}-$, $-\text{N(H)C(O)}-$ or $-\text{N(H)S(O)}_2-$;

[00408] R^2 is hydrogen, halogen, $-\text{OR}^{31}$, $-\text{NR}^{31}\text{R}^{32}$, $-\text{NR}^{34}\text{R}^{35}$, $-\text{C(O)R}^{31}$, $-\text{CO}_2\text{R}^{31}$, $-\text{C(=O)NR}^{31}\text{R}^{32}$, $-\text{C(=O)NR}^{34}\text{R}^{35}$, $-\text{S(O)}_{0-2}\text{R}^{31}$, $-\text{SO}_2\text{NR}^{31}\text{R}^{32}$, $-\text{SO}_2\text{NR}^{34}\text{R}^{35}$, bicyclic aryl, substituted monocyclic aryl, heteroaryl, C_{1-10} alkyl, C_{3-8} cycloalkyl, C_{1-10} alkyl- C_{3-8} cycloalkyl, C_{3-8} cycloalkyl- C_{1-10} alkyl, C_{2-10} alkyl-monocyclic aryl, monocyclic aryl- C_{2-10} alkyl, C_{1-10} alkylbicycloaryl, bicycloaryl- C_{1-10} alkyl, substituted C_{1-10} alkylaryl, substituted aryl- C_{1-10} alkyl, C_{1-10} alkylheteroaryl, C_{1-10} alkylheterocyclyl, C_{2-10} alkenyl, C_{2-10} alkynyl, heterocyclyl, heterocyclyl C_{1-10} alkyl, heterocyclyl- C_{2-10} alkenyl, heterocyclyl- C_{2-10} alkynyl, aryl-heterocyclyl, heteroaryl- C_{1-10} alkyl, heteroaryl-heteroalkyl, or heteroaryl-heterocyclyl, wherein each of said bicyclic aryl or heteroaryl moiety is unsubstituted, or wherein each of bicyclic aryl, heteroaryl moiety or monocyclic aryl moiety is substituted with one or more independent halo, $-\text{OH}$, $-\text{R}^{31}$, $-\text{CF}_3$, $-\text{OCF}_3$, $-\text{OR}^{31}$, $-\text{NR}^{31}\text{R}^{32}$, $-\text{NR}^{34}\text{R}^{35}$, $-\text{C(O)R}^{31}$, $-\text{CO}_2\text{R}^{31}$, $-\text{C(=O)NR}^{31}\text{R}^{32}$, $-\text{C(=O)NR}^{34}\text{R}^{35}$, $-\text{NO}_2$, $-\text{CN}$, $-\text{S(O)}_{0-2}\text{R}^{31}$, $-\text{SO}_2\text{NR}^{31}\text{R}^{32}$, $-\text{SO}_2\text{NR}^{34}\text{R}^{35}$, $-\text{NR}^{31}\text{C(=O)R}^{32}$, $-\text{NR}^{31}\text{C(=O)OR}^{32}$, $-\text{NR}^{31}\text{C(=O)NR}^{32}\text{R}^{33}$, $-\text{NR}^{31}\text{S(O)}_{0-2}\text{R}^{32}$, $-\text{C(=S)OR}^{31}$, $-\text{C(=O)SR}^{31}$, $-\text{NR}^{31}\text{C(=NR}^{32})\text{NR}^{33}\text{R}^{32}$, $-\text{NR}^{31}\text{C(=NR}^{32})\text{OR}^{33}$, $-\text{NR}^{31}\text{C(=NR}^{32})\text{SR}^{33}$, $-\text{OC(=O)OR}^{33}$, $-\text{OC(=O)NR}^{31}\text{R}^{32}$, $-\text{OC(=O)SR}^{31}$, $-\text{SC(=O)OR}^{31}$, $-\text{P(O)OR}^{31}\text{OR}^{32}$, or $-\text{SC(=O)NR}^{31}\text{R}^{32}$, and wherein each of said alkyl, cycloalkyl, heterocyclyl, or heteroalkyl moiety is unsubstituted or is substituted with one or more halo, $-\text{OH}$, $-\text{R}^{31}$, $-\text{CF}_3$, $-\text{OCF}_3$, $-\text{OR}^{31}$, $-\text{O-aryl}$, $-\text{NR}^{31}\text{R}^{32}$, $-\text{NR}^{34}\text{R}^{35}$, $-\text{C(O)R}^{31}$, $-\text{CO}_2\text{R}^{31}$, $-\text{C(=O)NR}^{34}\text{R}^{35}$, or $-\text{C(=O)NR}^{31}\text{R}^{32}$;

[00409] R^{31} , R^{32} , and R^{33} , in each instance, are independently H or C_{1-10} alkyl, wherein the C_{1-10} alkyl is unsubstituted; and

[00410] R^{34} and R^{35} in $-\text{NR}^{34}\text{R}^{35}$, $-\text{C(=O)NR}^{34}\text{R}^{35}$, or $-\text{SO}_2\text{NR}^{34}\text{R}^{35}$, are taken together with the nitrogen atom to which they are attached to form a 3-10 membered saturated or unsaturated ring; wherein said ring is independently unsubstituted or is substituted by one or more $-\text{NR}^{31}\text{R}^{32}$, hydroxyl, halogen, oxo, aryl, heteroaryl, C_{1-6} alkyl, or O-aryl, and wherein said 3-10 membered saturated or unsaturated ring independently contains 0, 1, or 2 more heteroatoms in addition to the nitrogen.

[00411] The invention further provides a compound which is an mTor inhibitor, wherein the compound has the Formula I-A:



Formula I-A

[00412] or a pharmaceutically acceptable salt thereof, wherein:

[00413] X_1 is N or C-E¹, X_2 is N, X_3 is C, and X_4 is C-R⁹ or N; or X_1 is N or C-E¹, X_2 is C, X_3 is N, and X_4 is C-R⁹ or N;

[00414] R_1 is -H, -L-C₁₋₁₀alkyl, -L-C₃₋₈cycloalkyl, -L-C₁₋₁₀alkyl-C₃₋₈cycloalkyl, -L-aryl, -L-heteroaryl, -L-C₁₋₁₀alkylaryl, -L-C₁₋₁₀alkylheteroaryl, -L-C₁₋₁₀alkylheterocyclyl, -L-C₂₋₁₀alkenyl, -L-C₂₋₁₀alkynyl, -L-C₂₋₁₀alkenyl-C₃₋₈cycloalkyl, -L-C₂₋₁₀alkynyl-C₃₋₈cycloalkyl, -L-heteroalkyl, -L-heteroalkylaryl, -L-heteroalkylheteroaryl, -L-heteroalkyl-heterocyclyl, -L-heteroalkyl-C₃₋₈cycloalkyl, -L-aralkyl, -L-heteroaralkyl, or -L-heterocyclyl, each of which is unsubstituted or is substituted by one or more independent R³;

[00415] L is absent, -(C=O)-, -C(=O)O-, -C(=O)N(R³¹)-, -S-, -S(O)-, -S(O)₂-, -S(O)₂N(R³¹)-, or -N(R³¹)-;

[00416] M_1 is benzothiazolyl substituted with -(W²)_k-R²;

[00417] k is 0 or 1;

[00418] E¹ and E² are independently -(W¹)_j-R⁴;

[00419] j, in each instance (i.e., in E¹ or j in E²), is independently 0 or 1

[00420] W¹ is -O-, -NR⁷-, -S(O)_{0.2}-, -C(O)-, -C(O)N(R⁷)-, -N(R⁷)C(O)-, -N(R⁷)S(O)-, -N(R⁷)S(O)₂-, -C(O)O-, -CH(R⁷)N(C(O)OR⁸)-, -CH(R⁷)N(C(O)R⁸)-, -CH(R⁷)N(SO₂R⁸)-, -CH(R⁷)N(R⁸)-, -CH(R⁷)C(O)N(R⁸)-, -CH(R⁷)N(R⁸)C(O)-, -CH(R⁷)N(R⁸)S(O)-, or -CH(R⁷)N(R⁸)S(O)₂-;

[00421] W² is -O-, -NR⁷-, -S(O)_{0.2}-, -C(O)-, -C(O)N(R⁷)-, -N(R⁷)C(O)-, -N(R⁷)C(O)N(R⁸)-, -N(R⁷)S(O)-, -N(R⁷)S(O)₂-, -C(O)O-, -CH(R⁷)N(C(O)OR⁸)-, -CH(R⁷)N(C(O)R⁸)-, -CH(R⁷)N(SO₂R⁸)-, -CH(R⁷)N(R⁸)-, -CH(R⁷)C(O)N(R⁸)-, -CH(R⁷)N(R⁸)C(O)-, -CH(R⁷)N(R⁸)S(O)-, or -CH(R⁷)N(R⁸)S(O)₂-;

[00422] R² is hydrogen, halogen, -OH, -R³¹, -CF₃, -OCF₃, -OR³¹, -NR³¹R³², -NR³⁴R³⁵, -C(O)R³¹, -CO₂R³¹, -C(=O)NR³¹R³², -C(=O)NR³⁴R³⁵, -NO₂, -CN, -S(O)_{0.2}R³¹, -SO₂NR³¹R³², -SO₂NR³⁴R³⁵, -NR³¹C(=O)R³², -NR³¹C(=O)OR³², -NR³¹C(=O)NR³²R³³, -NR³¹S(O)_{0.2}R³², -C(=S)OR³¹, -C(=O)SR³¹, -NR³¹C(=NR³²)NR³³R³², -NR³¹C(=NR³²)OR³³, -NR³¹C(=NR³²)SR³³, -OC(=O)OR³³, -OC(=O)NR³¹R³², -OC(=O)SR³¹, -SC(=O)OR³¹, -P(O)OR³¹OR³², -SC(=O)NR³¹R³², aryl (e.g. bicyclic aryl, unsubstituted aryl, or substituted monocyclic aryl), heteroaryl, C₁₋₁₀alkyl, C₃₋₈cycloalkyl, C₁₋₁₀alkyl-C₃₋₈cycloalkyl, C₃₋₈cycloalkyl-C₁₋₁₀alkyl, C₃₋₈cycloalkyl-C₂₋₁₀alkenyl, C₃₋₈cycloalkyl-C₂₋₁₀alkynyl, C₁₋₁₀alkyl-C₂₋₁₀alkenyl, C₁₋₁₀alkyl-C₂₋₁₀alkynyl, C₁₋₁₀alkylaryl (e.g. C₂₋₁₀alkyl-monocyclic aryl, C₁₋₁₀alkyl-substituted monocyclic aryl, or C₁₋₁₀alkylbicycloaryl), C₁₋₁₀alkylheteroaryl, C₁₋₁₀alkylheterocyclyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₂₋₁₀alkenyl-C₁₋₁₀alkyl, C₂₋₁₀alkynyl-C₁₋₁₀alkyl, C₂₋₁₀alkenylaryl, C₂₋₁₀alkenylheteroaryl, C₂₋₁₀alkenylheteroalkyl, C₂₋₁₀alkenylheterocyclyl, C₂₋₁₀alkenyl-C₃₋₈cycloalkyl, C₂₋₁₀alkynylaryl, C₂₋₁₀alkynylheteroaryl, C₂₋₁₀alkynylheteroalkyl, C₂₋₁₀alkynylheterocyclyl, C₂₋₁₀alkynyl-C₃₋₈cycloalkenyl, C₁₋₁₀alkoxy C₁₋₁₀alkyl, C₁₋₁₀alkoxy-C₂₋₁₀alkenyl, C₁₋₁₀alkoxy-C₂₋₁₀alkynyl, heterocyclyl, heteroalkyl, heterocyclyl-C₁₋₁₀alkyl, heterocyclyl-C₂₋₁₀alkenyl, heterocyclyl-C₂₋₁₀alkynyl, aryl-C₁₋₁₀alkyl (e.g. monocyclic aryl-C₂₋₁₀alkyl, substituted monocyclic aryl-C₁₋₁₀alkyl, or bicycloaryl-C₁₋₁₀alkyl), aryl-C₂₋₁₀alkenyl, aryl-C₂₋₁₀alkynyl, aryl-heterocyclyl, heteroaryl-C₁₋₁₀alkyl, heteroaryl-C₂₋₁₀alkenyl, heteroaryl-C₂₋₁₀alkynyl, heteroaryl-C₃₋₈cycloalkyl, heteroaryl-heteroalkyl, or heteroaryl-heterocyclyl, wherein each of said bicyclic aryl or heteroaryl moiety is unsubstituted, or wherein each of bicyclic aryl, heteroaryl

moiety or monocyclic aryl moiety is substituted with one or more independent alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, halo, $-\text{OH}$, $-\text{R}^{31}$, $-\text{CF}_3$, $-\text{OCF}_3$, $-\text{OR}^{31}$, $-\text{NR}^{31}\text{R}^{32}$, $-\text{NR}^{34}\text{R}^{35}$, $-\text{C}(\text{O})\text{R}^{31}$, $-\text{CO}_2\text{R}^{31}$, $-\text{C}(=\text{O})\text{NR}^{31}\text{R}^{32}$, $-\text{C}(=\text{O})\text{NR}^{34}\text{R}^{35}$, $-\text{NO}_2$, $-\text{CN}$, $-\text{S}(\text{O})_{0-2}\text{R}^{31}$, $-\text{SO}_2\text{NR}^{31}\text{R}^{32}$, $-\text{SO}_2\text{NR}^{34}\text{R}^{35}$, $-\text{NR}^{31}\text{C}(=\text{O})\text{R}^{32}$, $-\text{NR}^{31}\text{C}(=\text{O})\text{OR}^{32}$, $-\text{NR}^{31}\text{C}(=\text{O})\text{NR}^{32}\text{R}^{33}$, $-\text{NR}^{31}\text{S}(\text{O})_{0-2}\text{R}^{32}$, $-\text{C}(=\text{S})\text{OR}^{31}$, $-\text{C}(=\text{O})\text{SR}^{31}$, $-\text{NR}^{31}\text{C}(=\text{NR}^{32})\text{NR}^{33}\text{R}^{32}$, $-\text{NR}^{31}\text{C}(=\text{NR}^{32})\text{OR}^{33}$, $-\text{NR}^{31}\text{C}(=\text{NR}^{32})\text{SR}^{33}$, $-\text{OC}(=\text{O})\text{OR}^{33}$, $-\text{OC}(=\text{O})\text{NR}^{31}\text{R}^{32}$, $-\text{OC}(=\text{O})\text{SR}^{31}$, $-\text{SC}(=\text{O})\text{OR}^{31}$, $-\text{P}(\text{O})\text{OR}^{31}\text{OR}^{32}$, or $-\text{SC}(=\text{O})\text{NR}^{31}\text{R}^{32}$, and wherein each of said alkyl, cycloalkyl, heterocyclyl, or heteroalkyl moiety is unsubstituted or is substituted with one or more alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, halo, $-\text{OH}$, $-\text{R}^{31}$, $-\text{CF}_3$, $-\text{OCF}_3$, $-\text{OR}^{31}$, $-\text{O-aryl}$, $-\text{NR}^{31}\text{R}^{32}$, $-\text{NR}^{34}\text{R}^{35}$, $-\text{C}(\text{O})\text{R}^{31}$, $-\text{CO}_2\text{R}^{31}$, $-\text{C}(=\text{O})\text{NR}^{34}\text{R}^{35}$, or $-\text{C}(=\text{O})\text{NR}^{31}\text{R}^{32}$;

[00423] R^3 and R^4 are independently hydrogen, halogen, $-\text{OH}$, $-\text{R}^{31}$, $-\text{CF}_3$, $-\text{OCF}_3$, $-\text{OR}^{31}$, $-\text{NR}^{31}\text{R}^{32}$, $-\text{NR}^{34}\text{R}^{35}$, $-\text{C}(\text{O})\text{R}^{31}$, $-\text{CO}_2\text{R}^{31}$, $-\text{C}(=\text{O})\text{NR}^{31}\text{R}^{32}$, $-\text{C}(=\text{O})\text{NR}^{34}\text{R}^{35}$, $-\text{NO}_2$, $-\text{CN}$, $-\text{S}(\text{O})_{0-2}\text{R}^{31}$, $-\text{SO}_2\text{NR}^{31}\text{R}^{32}$, $-\text{SO}_2\text{NR}^{34}\text{R}^{35}$, $-\text{NR}^{31}\text{C}(=\text{O})\text{R}^{32}$, $-\text{NR}^{31}\text{C}(=\text{O})\text{OR}^{32}$, $-\text{NR}^{31}\text{C}(=\text{O})\text{NR}^{32}\text{R}^{33}$, $-\text{NR}^{31}\text{S}(\text{O})_{0-2}\text{R}^{32}$, $-\text{C}(=\text{S})\text{OR}^{31}$, $-\text{C}(=\text{O})\text{SR}^{31}$, $-\text{NR}^{31}\text{C}(=\text{NR}^{32})\text{NR}^{33}\text{R}^{32}$, $-\text{NR}^{31}\text{C}(=\text{NR}^{32})\text{OR}^{33}$, $-\text{NR}^{31}\text{C}(=\text{NR}^{32})\text{SR}^{33}$, $-\text{OC}(=\text{O})\text{OR}^{33}$, $-\text{OC}(=\text{O})\text{NR}^{31}\text{R}^{32}$, $-\text{OC}(=\text{O})\text{SR}^{31}$, $-\text{SC}(=\text{O})\text{OR}^{31}$, $-\text{P}(\text{O})\text{OR}^{31}\text{OR}^{32}$, $-\text{SC}(=\text{O})\text{NR}^{31}\text{R}^{32}$, aryl, heteroaryl, C_{1-4} alkyl, C_{1-10} alkyl, C_{3-8} cycloalkyl, C_{1-10} alkyl- C_{3-8} cycloalkyl, C_{3-8} cycloalkyl- C_{1-10} alkyl, C_{3-8} cycloalkyl- C_{2-10} alkenyl, C_{3-8} cycloalkyl- C_{2-10} alkynyl, C_{1-10} alkyl- C_{2-10} alkenyl, C_{1-10} alkyl- C_{2-10} alkynyl, C_{1-10} alkylaryl, C_{1-10} alkylheteroaryl, C_{1-10} alkylheterocyclyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{2-10} alkenyl- C_{1-10} alkyl, C_{2-10} alkynyl- C_{1-10} alkyl, C_{2-10} alkenylaryl, C_{2-10} alkenylheteroaryl, C_{2-10} alkenylheteroalkyl, C_{2-10} alkenylheterocyclyl, C_{2-10} alkenyl- C_{3-8} cycloalkyl, C_{2-10} alkynyl- C_{3-8} cycloalkyl, C_{2-10} alkynylaryl, C_{2-10} alkynylheteroaryl, C_{2-10} alkynylheteroalkyl, C_{2-10} alkynylheterocyclyl, C_{2-10} alkynyl- C_{3-8} cycloalkenyl, C_{1-10} alkoxy C_{1-10} alkyl, C_{1-10} alkoxy- C_{2-10} alkenyl, C_{1-10} alkoxy- C_{2-10} alkynyl, heterocyclyl, heterocyclyl- C_{1-10} alkyl, heterocyclyl- C_{2-10} alkenyl, heterocyclyl- C_{2-10} alkynyl, aryl- C_{1-10} alkyl, aryl- C_{2-10} alkenyl, aryl- C_{2-10} alkynyl, aryl-heterocyclyl, heteroaryl- C_{1-10} alkyl, heteroaryl- C_{2-10} alkenyl, heteroaryl- C_{2-10} alkynyl, heteroaryl- C_{3-8} cycloalkyl, heteroalkyl, heteroaryl-heteroalkyl, or heteroaryl-heterocyclyl, wherein each of said aryl or heteroaryl moiety is unsubstituted or is substituted with one or more independent halo, $-\text{OH}$, $-\text{R}^{31}$, $-\text{CF}_3$, $-\text{OCF}_3$, $-\text{OR}^{31}$, $-\text{O-aryl}$, $-\text{NR}^{31}\text{R}^{32}$, $-\text{NR}^{34}\text{R}^{35}$, $-\text{C}(\text{O})\text{R}^{31}$, $-\text{CO}_2\text{R}^{31}$, $-\text{C}(=\text{O})\text{NR}^{34}\text{R}^{35}$, or $-\text{C}(=\text{O})\text{NR}^{31}\text{R}^{32}$;

[00424] R^5 is hydrogen, halogen, $-\text{OH}$, $-\text{R}^{31}$, $-\text{CF}_3$, $-\text{OCF}_3$, $-\text{OR}^{31}$, $-\text{NR}^{31}\text{R}^{32}$, $-\text{NR}^{34}\text{R}^{35}$, $-\text{C}(\text{O})\text{R}^{31}$, $-\text{CO}_2\text{R}^{31}$, $-\text{C}(=\text{O})\text{NR}^{31}\text{R}^{32}$, $-\text{C}(=\text{O})\text{NR}^{34}\text{R}^{35}$, $-\text{NO}_2$, $-\text{CN}$, $-\text{S}(\text{O})_{0-2}\text{R}^{31}$, $-\text{SO}_2\text{NR}^{31}\text{R}^{32}$, $-\text{SO}_2\text{NR}^{34}\text{R}^{35}$, $-\text{NR}^{31}\text{C}(=\text{O})\text{R}^{32}$, $-\text{NR}^{31}\text{C}(=\text{O})\text{OR}^{32}$, $-\text{NR}^{31}\text{C}(=\text{O})\text{NR}^{32}\text{R}^{33}$, $-\text{NR}^{31}\text{S}(\text{O})_{0-2}\text{R}^{32}$, $-\text{C}(=\text{S})\text{OR}^{31}$, $-\text{C}(=\text{O})\text{SR}^{31}$, $-\text{NR}^{31}\text{C}(=\text{NR}^{32})\text{NR}^{33}\text{R}^{32}$, $-\text{NR}^{31}\text{C}(=\text{NR}^{32})\text{OR}^{33}$, $-\text{NR}^{31}\text{C}(=\text{NR}^{32})\text{SR}^{33}$, $-\text{OC}(=\text{O})\text{OR}^{33}$, $-\text{OC}(=\text{O})\text{NR}^{31}\text{R}^{32}$, $-\text{OC}(=\text{O})\text{SR}^{31}$, $-\text{SC}(=\text{O})\text{OR}^{31}$, $-\text{P}(\text{O})\text{OR}^{31}\text{OR}^{32}$, or $-\text{SC}(=\text{O})\text{NR}^{31}\text{R}^{32}$;

[00425] R^{31} , R^{32} , and R^{33} , in each instance, are independently H or C_{1-10} alkyl, wherein the C_{1-10} alkyl is unsubstituted or is substituted with one or more aryl, heteroalkyl, heterocyclyl, or heteroaryl group, wherein each of said aryl, heteroalkyl, heterocyclyl, or heteroaryl group is unsubstituted or is substituted with one or more halo, -OH, - C_{1-10} alkyl, -CF₃, -O-aryl, -OCF₃, -OC₁₋₁₀alkyl, -NH₂, -N(C_{1-10} alkyl)(C_{1-10} alkyl), -NH(C_{1-10} alkyl), -NH(aryl), -NR³⁴R³⁵, -C(O)(C_{1-10} alkyl), -C(O)(C_{1-10} alkyl-aryl), -C(O)(aryl), -CO₂- C_{1-10} alkyl, -CO₂- C_{1-10} alkylaryl, -CO₂-aryl, -C(=O)N(C_{1-10} alkyl)(C_{1-10} alkyl), -C(=O)NH(C_{1-10} alkyl), -C(=O)NR³⁴R³⁵, -C(=O)NH₂, -OCF₃, -O(C_{1-10} alkyl), -O-aryl, -N(aryl)(C_{1-10} alkyl), -NO₂, -CN, -S(O)₀₋₂ C_{1-10} alkyl, -S(O)₀₋₂ C_{1-10} alkylaryl, -S(O)₀₋₂aryl, -SO₂N(aryl), -SO₂N(C_{1-10} alkyl)(C_{1-10} alkyl), -SO₂NH(C_{1-10} alkyl) or -SO₂NR³⁴R³⁵;

[00426] R^{34} and R^{35} in -NR³⁴R³⁵, -C(=O)NR³⁴R³⁵, or -SO₂NR³⁴R³⁵, are taken together with the nitrogen atom to which they are attached to form a 3-10 membered saturated or unsaturated ring; wherein said ring is independently unsubstituted or is substituted by one or more -NR³¹R³², hydroxyl, halogen, oxo, aryl, heteroaryl, C_{1-6} alkyl, or O-aryl, and wherein said 3-10 membered saturated or unsaturated ring independently contains 0, 1, or 2 more heteroatoms in addition to the nitrogen atom;


[00427] R^7 and R^8 are each independently hydrogen, C_{1-10} alkyl, C_{2-10} alkenyl, aryl, heteroaryl, heterocyclyl or C_{3-10} cycloalkyl, each of which except for hydrogen is unsubstituted or is substituted by one or more independent R^6 ;

[00428] R^6 is halo, -OR³¹, -SH, -NH₂, -NR³⁴R³⁵, -NR³¹R³², -CO₂R³¹, -CO₂aryl, -C(=O)NR³¹R³², C(=O)NR³⁴R³⁵, -NO₂, -CN, -S(O)₀₋₂ C_{1-10} alkyl, -S(O)₀₋₂aryl, -SO₂NR³⁴R³⁵, -SO₂NR³¹R³², C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl; aryl- C_{1-10} alkyl, aryl- C_{2-10} alkenyl, aryl- C_{2-10} alkynyl, heteroaryl- C_{1-10} alkyl, heteroaryl- C_{2-10} alkenyl, heteroaryl- C_{2-10} alkynyl, wherein each of said alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heterocyclyl, or heteroaryl group is unsubstituted or is substituted with one or more independent halo, cyano, nitro, -OC₁₋₁₀alkyl, C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, halo C_{1-10} alkyl, halo C_{2-10} alkenyl, halo C_{2-10} alkynyl, -COOH, -C(=O)NR³¹R³², -C(=O)NR³⁴R³⁵, -SO₂NR³⁴R³⁵, -SO₂NR³¹R³², -NR³¹R³², or -NR³⁴R³⁵; and

[00429] R^9 is H, halo, -OR³¹, -SH, -NH₂, -NR³⁴R³⁵, -NR³¹R³², -CO₂R³¹, -CO₂aryl, -C(=O)NR³¹R³², C(=O)NR³⁴R³⁵, -NO₂, -CN, -S(O)₀₋₂ C_{1-10} alkyl, -S(O)₀₋₂aryl, -SO₂NR³⁴R³⁵, -SO₂NR³¹R³², C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl; aryl- C_{1-10} alkyl, aryl- C_{2-10} alkenyl, aryl- C_{2-10} alkynyl, heteroaryl- C_{1-10} alkyl, heteroaryl- C_{2-10} alkenyl, heteroaryl- C_{2-10} alkynyl, wherein each of said alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heterocyclyl, or heteroaryl group is unsubstituted or is substituted with one or more independent halo, cyano, nitro, -OC₁₋₁₀alkyl, C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, halo C_{1-10} alkyl, halo C_{2-10} alkenyl, halo C_{2-10} alkynyl, -COOH, -C(=O)NR³¹R³², -C(=O)NR³⁴R³⁵, -SO₂NR³⁴R³⁵, -SO₂NR³¹R³², -NR³¹R³², or -NR³⁴R³⁵.

[00430] In some embodiments, X_4 is C- R^9 .


[00431] The invention also provides an inhibitor as defined above, wherein the compound is of Formula I-B:




Formula I-B

or a pharmaceutically acceptable salt thereof, and wherein the substituents are as defined above.

[00432] In various embodiments the compound of Formula I-B or its pharmaceutically acceptable salt thereof, is an inhibitor having the structure of Formula I-B1 or Formula I-B2:



Formula I-B1



Formula I-B2

or a pharmaceutically acceptable salt thereof.

[00433] In various embodiments of Formula I-B1, X_1 is N and X_2 is N. In other embodiments, X_1 is C- E^1 and X_2 is N. In yet other embodiments, X_1 is NH and X_2 is C. In further embodiments, X_1 is CH- E^1 and X_2 is C.

[00434] In various embodiments of Formula I-B2, X_1 is N and X_2 is C. In further embodiments, X_1 is C- E^1 and X_2 is C.

[00435] In various embodiments, X_1 is C-(W^1)_j- R^4 , where j is 0.

[00436] In another embodiment, X_1 is CH. In yet another embodiment, X_1 is C-halogen, where halogen is Cl, F, Br, or I.

[00437] In various embodiments of X_1 , it is C-(W^1)_j- R^4 . In various embodiments of X_1 , j is 1, and W^1 is -O-. In various embodiments of X_1 , j is 1, and W^1 is -NR⁷-. In various embodiments of X_1 , j is 1, and W^1 is -NH-. In various embodiments of X_1 , j is 1, and W^1 is -S(O)₀₋₂-. In various embodiments of X_1 , j is 1, and W^1 is -C(O)-. In various embodiments of X_1 , j is 1, and W^1 is -C(O)N(R⁷)-. In various embodiments of X_1 , j is 1, and W^1 is -N(R⁷)C(O)-. In various embodiments of X_1 , j is 1, and W^1 is -N(R⁷)S(O)-. In various embodiments of X_1 , j is 1, and W^1 is -N(R⁷)S(O)₂-. In various embodiments of X_1 , j is 1, and W^1 is -C(O)O-. In various embodiments of X_1 , j is 1, and W^1 is CH(R⁷)N(C(O)OR⁸)-. In various embodiments of X_1 , j is 1, and W^1 is -CH(R⁷)N(C(O)R⁸)-. In various embodiments of X_1 , j is 1, and W^1 is -CH(R⁷)N(SO₂R⁸)-. In various embodiments of X_1 , j is 1, and W^1 is -CH(R⁷)N(R⁸)-. In various embodiments of X_1 , j is 1, and W^1 is -CH(R⁷)C(O)N(R⁸)-. In various embodiments of X_1 , j is 1, and W^1 is -CH(R⁷)N(R⁸)C(O)-. In various embodiments of X_1 , j is 1, and W^1 is -CH(R⁷)N(R⁸)S(O)-. In various embodiments of X_1 , j is 1, and W^1 is -CH(R⁷)N(R⁸)S(O)₂-.

[00438] In another embodiment, X_1 is CH_2 . In yet another embodiment, X_1 is CH-halogen, where halogen is Cl, F, Br, or I.

[00439] In another embodiment, X_1 is N.


[00440] In various embodiments, X_2 is N. In other embodiments, X_2 is C.

[00441] In various embodiments, E^2 is $-(W^1)_j-R^4$, where j is 0.

[00442] In another embodiment, E^2 is CH. In yet another embodiment, E^2 is C-halogen, where halogen is Cl, F, Br, or I.

[00443] In various embodiments of E^2 , it is $-(W^1)_j-R^4$. In various embodiments of E^2 , j is 1, and W^1 is $-O-$. In various embodiments of E^2 , j is 1, and W^1 is $-\text{NR}^7-$. In various embodiments of E^2 , j is 1, and W^1 is $-\text{NH}-$. In various embodiments of E^2 , j is 1, and W^1 is $-\text{S(O)}_{0.2}-$. In various embodiments of E^2 , j is 1, and W^1 is $-\text{C(O)}-$. In various embodiments of E^2 , j is 1, and W^1 is $-\text{C(O)N(R}^7)-$. In various embodiments of E^2 , j is 1, and W^1 is $-\text{N(R}^7)\text{C(O)}-$. In various embodiments of E^2 , j is 1, and W^1 is $-\text{N(R}^7)\text{S(O)}-$. In various embodiments of E^2 , j is 1, and W^1 is $-\text{N(R}^7)\text{S(O)}_2-$. In various embodiments of E^2 , j is 1, and W^1 is $-\text{C(O)O}-$. In various embodiments of E^2 , j is 1, and W^1 is $-\text{CH(R}^7)\text{N(C(O)OR}^8)-$. In various embodiments of E^2 , j is 1, and W^1 is $-\text{CH(R}^7)\text{N(C(O)R}^8)-$. In various embodiments of E^2 , j is 1, and W^1 is $-\text{CH(R}^7)\text{N(SO}_2\text{R}^8)-$. In various embodiments of E^2 , j is 1, and W^1 is $-\text{CH(R}^7)\text{N(R}^8)-$. In various embodiments of E^2 , j is 1, and W^1 is $-\text{CH(R}^7)\text{C(O)N(R}^8)-$. In various embodiments of E^2 , j is 1, and W^1 is $-\text{CH(R}^7)\text{N(R}^8)\text{C(O)}-$. In various embodiments of E^2 , j is 1, and W^1 is $-\text{CH(R}^7)\text{N(R}^8)\text{S(O)}-$. In various embodiments of E^2 , j is 1, and W^1 is $-\text{CH(R}^7)\text{N(R}^8)\text{S(O)}_2-$.


[00444] In various embodiments of Formula I-A, I-B, I-B1 and I-B2, M_1 is :



[00445] In some embodiments of the invention, M_1 is benzothiazolyl substituted with $-(W^2)_k-R^2$. W^2 can be $-O-$, $-\text{S(O)}_{0.2}-$ (including but not limited to $-\text{S}-$, $-\text{S(O)}-$, and $-\text{S(O)}_2-$), $-\text{C(O)}-$, or $-\text{C(O)O}-$. In other embodiments, W^1 is $-\text{NR}^6-$ or $-\text{CH(R}^6)\text{N(R}^7)-$, wherein R^6 and R^7 are each independently hydrogen, unsubstituted or substituted C_1 - C_{10} alkyl (which includes but is not limited to $-\text{CH}_3$, $-\text{CH}_2\text{CH}_3$, *n*-propyl, isopropyl, *n*-butyl, *tert*-butyl, *sec*-butyl, pentyl, hexyl, and heptyl), unsubstituted or substituted C_2 - C_{10} alkenyl (including but not limited to alkenyl such as, for example, vinyl, allyl, 1-methyl propen-1-yl, butenyl, or pentenyl). Additionally when W^2 is $-\text{NR}^6-$ or $-\text{CH(R}^6)\text{N(R}^7)-$, R^6 and R^7 are each independently unsubstituted or substituted aryl (including phenyl and naphthyl). In yet other embodiments, when W^2 is $-\text{NR}^6-$ or $-\text{CH(R}^6)\text{N(R}^7)-$, R^6 and R^7 are each independently heteroaryl, wherein the heteroaryl is unsubstituted or substituted. R^6 and R^7 heteroaryl is monocyclic heteroaryl, and includes but is not limited to imidazolyl, pyrrolyl, oxazolyl, thiazolyl, and pyridinyl. In some other embodiments, when W^2 is $-\text{NR}^6-$ or $-\text{CH(R}^6)\text{N(R}^7)-$, R^6 and R^7 are each independently unsubstituted or


substituted heterocyclyl (which includes but is not limited to pyrrolidinyl, tetrahydrofuranyl, piperidinyl, tetrahydropyranyl, thiazolidinyl, imidazolidinyl, morpholinyl, and piperazinyl) or unsubstituted or substituted C₃₋₈cycloalkyl (including but not limited to cyclopropyl, cyclobutyl, and cyclopentyl). Non limiting exemplary W² include -NH-, -N(cyclopropyl), and -N(4-N-piperidinyl).

[00446] For example, exemplary mTor inhibitors of the invention have the Formulas:



Reaction Schemes – mTor inhibitor compounds

[00448] The mTor inhibitor compounds disclosed herein may be prepared by the routes described below. Materials used herein are either commercially available or prepared by synthetic methods generally known in the art. These schemes are not limited to the compounds listed or by any particular substituents employed for illustrative purposes. Numbering does not necessarily correspond to that of claims or other tables.




[00449] In one embodiment, compounds are synthesized by condensing a functionalized heterocycle A-1 with formamide, to provide a pyrazolopyrimidine A-2. The pyrazolopyrimidine is treated with N-iodosuccinimide, which introduces an iodo substituent in the pyrazole ring as in A-3. The R₁ substituent is introduced by reacting the pyrazolopyrimidine A3 with a compound of Formula R₁-Lg in the presence

of a base such as potassium carbonate to produce a compound of Formula A-4. Other bases that are suitable for use in this step include but are not limited to sodium hydride and potassium t- butoxide. The compound of Formula R₁-Lg has a moiety R₁ as defined for R₁ of a compound of Formula I-A, and wherein -Lg is an appropriate leaving group such as halide (including bromo, iodo, and chloro), tosylate, or other suitable leaving group,


[00450] The substituents corresponding to M₁ are thereafter introduced by reacting aryl or heteroaryl boronic acids with the compound of Formula A-4 to obtain compound A- 5.

Scheme A-1



[00451] Alternatively, Mitsunobu chemistry can be used to obtain alkylated pyrazolopyrimidine A-4, as shown in Scheme A-1. Iodopyrazolopyrimidine A-3 is reacted with a suitable alcohol, in the presence of triphenylphosphine and diisopropylazodicarboxylate (DIAD) to produce pyrazolopyrimidine A-4.


Scheme B




[00452] The compounds of the invention may be synthesized via a reaction scheme represented generally in Scheme B. The synthesis proceeds via coupling a compound of Formula A with a compound of Formula B to yield a compound of Formula C. The coupling step is typically catalyzed by using, e.g., a palladium catalyst, including but not limited to palladium tetrakis (triphenylphosphine). The coupling is generally performed in the presence of a suitable base, a nonlimiting example being sodium carbonate. One example of a suitable solvent for the reaction is aqueous dioxane.

[00453] A compound of Formula A for use in Scheme B has a structure of Formula A, wherein T₁ is triflate or halo (including bromo, chloro, and iodo), and wherein R₁, X₁, X₂, X₃, R₃₁ and R₃₂ are defined as for a compound of Formula I-A. For boronic acids and acid derivatives as depicted in Formula B, M is either M₁ or M₂. M₁ is defined as for a compound of Formula I-A. For example, M₁ can be a 5-benzoxazolyl or a 6-benzoxazolyl moiety, including but not limited to those M₁ moieties disclosed herein. M₂ is a moiety which is synthetically transformed to form M₁, after the M₂ moiety has been coupled to the bicyclic core of the compound of Formula A.


[00454] For a compound of Formula B, G is hydrogen or R_{G1} , wherein R_{G1} is alkyl, alkenyl, or aryl. Alternatively, $B(OG)_2$ is taken together to form a 5- or 6- membered cyclic moiety. In some embodiments, the compound of Formula B is a compound having a structure of Formula E:



Formula E

[00455] wherein G is H or R_{G1} ; R_{G1} is alkyl, alkenyl, or aryl. Alternatively,  forms a 5- or 6- membered cyclic moiety; and R_2 is a R_{G2} moiety, wherein the R_{G2} moiety is H, acyl, or an amino protecting group including but not limited to tert-butyl carbamate (Boc), carbobenzyloxy (Cbz), benzyl (Bz), fluorenylmethoxycarbonyl (Fmoc), p-methoxybenzyl (PMB), and the like.

Scheme C



[00456] In some embodiments, a compound of Formula B is a compound of Formula B', wherein G is R_{G1} , or a compound of Formula B'', wherein G is hydrogen. Scheme C depicts an exemplary scheme for synthesizing a compound of Formula B' or, optionally, Formula B'' for use in Reaction Scheme C. This reaction proceeds via reacting a compound of Formula D with a trialkyl borate or a boronic acid derivative to produce a compound of Formula B'. The reaction is typically run in a solvent such as dioxane or tetrahydrofuran. The trialkyl borate includes but is not limited to triisopropyl borate and the boronic acid derivative includes but is not limited to bis(pinacolato)diboron.


[00457] When the reaction is performed with trialkyl borate, a base such as n-butyllithium is first added to the compound of Formula D to generate an anion, prior to the addition of the borate. When the reaction is performed with a boronic acid derivative such as bis(pinacolato)diboron, a palladium catalyst and a base is used. Typical palladium catalysts include but are not limited to palladium chloride (diphenylphosphino)ferrocene). A suitable base includes but is not limited to potassium acetate.

[00458] A compound of Formula D for use in Scheme C is a compound wherein T_2 is halo or another leaving group, and M is as defined above in Scheme B. The compound of Formula B' may further be converted to a compound of Formula B'' by treatment with an acid such as hydrochloric acid.

[00459] In one embodiment of a compound of Formula B, B', B'', or E, the G groups are hydrogen. In another of a compound of Formula B, B', B'', or E, the G groups are R_{G1} .

[00460] In some embodiments, no further synthetic transformation of M_1 moiety is performed after the coupling reaction when, e.g. M_1 is 2- N-acetyl-benzoxazol-5-yl.

[00461] Some exemplary compounds of Formula B that can be synthesized via Scheme C include but are not limited to compounds of the following formulae:



[00462] In other embodiments of the invention, a compound of Formula E is synthesized from a compound of Formula F, as shown in Scheme C-1:

Scheme C-1




[00463] Scheme C-1 depicts an exemplary scheme for synthesizing a compound of Formula E. This reaction proceeds via reacting a compound of Formula F with a trialkyl borate or a boronic acid derivative to produce a compound of Formula E. The conditions of the reaction are as described above in Scheme C.

[00464] A compound of Formula F for use in Scheme C-1 is a compound wherein T₂ is halo (including Br, Cl, and I) or another leaving group (including but not limited to triflate, tosylate, and mesylate), and the G_p moiety is H, acyl, or an amino protecting group including but not limited to tert-butyl carbamate (Boc), carbobenzyloxy (Cbz), benzyl (Bz), fluorenylmethyloxycarbonyl (Fmoc), p-methoxybenzyl (PMB), and the like.

[00465] The compound of Formula E, wherein G is alkyl, may further be converted to a compound of Formula E, wherein G is hydrogen, by treatment with an acid such as hydrochloric acid


[00466] Where desired, deprotection of a substituent (e.g., removal of Boc protection from an amino substituent) on the benzoxazolyl moiety (i.e. M₁ of Formula C) is performed after coupling the compound of Formula B to the compound of Formula A.

[00467] Some exemplary compounds with such protecting groups, include but are not limited to compounds of the following formulae:



[00468] An exemplary transformation of M₂ to M₁ can be carried out via Scheme D as shown below.

Scheme D



[00469] In Step 1, a compound of Formula 3-1 is reacted with boronic acid 3-2, in the presence of palladium tetrakis (triphenylphosphine) and a suitable base, such as sodium carbonate in an aqueous/organic solvent mixture to produce a compound of Formula 3-3. In Step 2, the compound of Formula 3-3 is reacted with about 2 equivalents of nitric acid in acetic acid as solvent to produce a compound of Formula 3-4. Two alternative transformations may be used to effect the next transformation of Step 3. In the first method, the compound of Formula 3-4 is treated with sodium dithionite and sodium hydroxide in water to produce a compound of Formula 3-5. Alternatively, the compound of Formula 3-4 is reduced


using palladium on carbon in a suitable solvent under a hydrogen atmosphere to yield a compound of Formula 3-5.

[00470] In Step 4, compound 3-5 is reacted with about 1.2 equivalents of cyanogen bromide in a solvent such as methanol/tetrahydrofuran mixture to produce a compound of Formula 3-6. The compound of Formula 3-6 may be further transformed by other substitution or derivatization.

[00471] A compound of Formula 3-1 useful in the method of Scheme D is a compound having a structure of Formula 3-1, wherein wherein T_1 is triflate or halo (including bromo, chloro, and iodo), and wherein R_1 , X_1 , X_2 , X_3 , R_{31} and R_{32} are defined as for a compound of Formula I-A.

[00472] Exemplary compounds having a pyrazolopyrimidine core can be synthesized via Scheme E.

Scheme E




[00473] In Step 1 of Scheme E, compound A-2 in dimethylformamide (DMF), is reacted with an N-halosuccinimide (NT_1S) at about 80°C , to provide compound 4-1, where T_1 is iodo or bromo. In Step 2, compound 4-1 in DMF is reacted with a compound R_1T_x , in the presence of potassium carbonate, to provide compound 4-2. In Step 4, compound 4-2 is coupled with a compound of Formula B using palladium catalysis such as palladium tetrakis (triphenylphosphine), and in the presence of sodium carbonate, to yield a pyrazolopyrimidine compound as shown.


[00474] A compound of Formula R_1T_x suitable for use in Reaction Scheme E is the compound wherein R_1 is cycloalkyl or alkyl and T_x is halo (including bromo, iodo, or chloro) or a leaving group, including but not limited to mesylate or tosylate.

[00475] Reaction Schemes F-M illustrate methods of synthesis of borane reagents useful in preparing intermediates of use in synthesis of the compounds of the invention as described in Reaction Schemes A, B, and E above, to introduce M_1 substituents.


Reaction Scheme F




Reaction Scheme G




Reaction Scheme H




Reaction Scheme I




Reaction Scheme J




Reaction Scheme K




Reaction Scheme L



Reaction Scheme M



Reaction Scheme N




[00476] In an alternative method of synthesis, a compound of Formula N-1 and a compound of N-2 are coupled to produce a compound of Formula C. The coupling step is typically catalyzed by using, e.g., a palladium catalyst, including but not limited to palladium tetrakis (triphenylphosphine). The coupling is generally performed in the presence of a suitable base, a nonlimiting example being sodium carbonate. One example of a suitable solvent for the reaction is aqueous dioxane.

[00477] A compound of Formula N-1 for use in Scheme N has a structure of Formula N-1, wherein G is hydrogen or R_{G1} , wherein R_{G1} is alkyl, alkenyl, or aryl. Alternatively, $B(OG)_2$ of the compound of Formula N-1 is taken together to form a 5- or 6- membered cyclic moiety. R_1 , X_1 , X_2 , X_3 , R_{31} and R_{32} of the compound of Formula N-1 are defined as for a compound of Formula I-A.

[00478] A compound of Formula N-2 for use in Scheme N has a structure of Formula N-2 wherein T_1 is triflate or halo (including bromo, chloro, and iodo). M of the compound of Formula N-2 is either M_1 or M_2 . M_1 is defined as for a compound of Formula I. For example, M_1 can be a 5- benzoxazolyl or a 6- benzoxazolyl moiety, including but not limited to those M_1 moieties disclosed herein. M_2 is a moiety which is synthetically transformed to form M_1 , after the M_2 moiety has been coupled to the bicyclic core of the compound of Formula N-1.

Scheme N-1



[00479] A compound of Formula N-1 may be synthesized as shown in Scheme N-1. A compound of Formula N-1 is reacted with a trialkyl borate or a boronic acid derivative to produce a compound of Formula N-1. The reaction is typically run a solvent such as dioxane or tetrahydrofuran. The trialkyl borate includes but is not limited to triisopropyl borate and the boronic acid derivative includes but is not limited to bis(pinacolato)diboron.

[00480] When the reaction is performed with trialkyl borate, a base such as n-butyllithium is first added to the compound of Formula N-3 to generate an anion, prior to the addition of the borate. When the reaction is performed with a boronic acid derivative such as bis(pinacolato)diboron, a palladium catalyst and a base is used. Typical palladium catalysts include but is not limited to palladium chloride (diphenylphosphino)ferrocene). A suitable base includes but is not limited to potassium acetate.

[00481] A compound of Formula N-3 suitable for use in Scheme N-1 is a compound wherein T_2 is halo or another leaving group such as mesylate, tosylate, or triflate. X_1 , X_2 , X_3 , R_1 , R_{31} , and R_{32} of the compound of Formula N-3 is as defined for a compound of Formula I-A.

[00482] In some embodiments of the invention, a compound of Formula A, B, B', B'', C, C'', D, E, E'', 3-1, 3-2, 3-3, 3-4, 3-5, 3-6, N-1'', N-3'', 3-1'', 3-3'', 3-4'', 3-5'', 3-6'', N-1'', or N-3'' is provided as its salt, including but not limited to hydrochloride, acetate, formate, nitrate, sulfate, and boronate.


[00483] In some embodiments of the invention, a palladium compound, including but not limited to palladium chloride (diphenylphosphino)ferrocene) and palladium tetrakis (triphenylphosphine), is used in the synthesis of a compound of Formula A, B, B', B'', C, C'', D, E, E'', 3-1, 3-2, 3-3, 3-4, 3-5, 3-6, N-1'', N-3'', 3-1'', 3-3'', 3-4'', 3-5'', 3-6'', N-1'', or N-3'' . When a palladium compound is present in the synthesis of a compound of Formula A, B, B', B'', C, C'', D, E, E'', 3-1, 3-2, 3-3, 3-4, 3-5, 3-6, N-1'', N-3'',

3-1'', 3-3'', 3-4'', 3-5'', 3-6'', N-1'', or N-3'' , it is present in an amount ranging from about 0.005 molar equivalents to about 0.5 molar equivalents, from about 0.05 molar equivalents to about 0.20 molar equivalents, from about 0.05 molar equivalents to about 0.25 molar equivalents, from about 0.07 molar equivalents to about 0.15 molar equivalents, or about 0.8 molar equivalents to about 0.1 molar equivalents of the compound of Formula A, B, B', B'', C, D, E, 3-1, 3-2, 3-3, 3-4, 3-5, 3-6, N-1, or N-3. In some embodiments, a palladium compound, including but not limited to palladium chloride (diphenylphosphino)ferrocene) and palladium tetrakis (triphenylphosphine) is present in the synthesis of a compound of Formula A, B, B', B'', C, C'', D, E, E'', 3-1, 3-2, 3-3, 3-4, 3-5, 3-6, N-1'', N-3'', 3-1'', 3-3'', 3-4'', 3-5'', 3-6'', N-1'', or N-3'' in about 0.07, about 0.08, about 0.09, about 0.10, about 0.11, about 0.12, about 0.13, about 0.14, or about 0.15 molar equivalents of a starting material of Formula A, B, B', B'', C, C'', D, E, E'', 3-1, 3-2, 3-3, 3-4, 3-5, 3-6, N-1'', N-3'', 3-1'', 3-3'', 3-4'', 3-5'', 3-6'', N-1'', or N-3'' that is used to synthesize a compound of Formula A, B, B', B'', C, C'', D, E, E'', 3-1, 3-2, 3-3, 3-4, 3-5, 3-6, N-1'', N-3'', 3-1'', 3-3'', 3-4'', 3-5'', 3-6'', N-1'', or N-3'' .


[00484] In some embodiments of the above reaction schemes B, D, E, N or N-1, another embodiment of the compounds of Formula A, C, 3-1, 3-3, 3-4, 3-5, 3-6, A-2, 4-1, 4-2, N-1 and N-3 is as shown in Schemes B'. D'. E', N' or N-1' below. In these alternative syntheses, producing a compound of Formula C, 3-1, 3-3, 3-4, 3-5, 3-6, A-2, 4-1, 4-2, N-1 or N-3, use compounds that comprise an amino moiety having a R_{G2} moiety present during one or more of the synthetic steps, wherein R_{G2} is an amino protecting group including but not limited to tert-butyl carbamate (Boc), carbobenzyloxy (Cbz), benzyl (Bz), fluorenylmethyloxycarbonyl (Fmoc), p-methoxybenzyl (PMB), and the like. These compounds include a compound of Formula A'', C'', 3-1'', 3-3'', 3-4'', 3-5'', 3-6'', A-2'', 4-1'', 4-2'', N-1'' or N-3''.

[00485] The R_{G2} moiety is removed, using suitable methods, at any point desired, whereupon the compound of Formula C, 3-1, 3-3, 3-4, 3-5, 3-6, A-2, 4-1, 4-2, N-1 or N-3 has a R₃₁ hydrogen replacing the R_{G2} moiety on the amino moiety. This transformation is specifically illustrated for the conversion of a compound of Formula C'' to a compound of C (i.e., as in Step 4 of Scheme E') and for the conversion of a compound of Formula 3-6'' to a compound of Formula 3-6 (i.e., as in Step 5 of Scheme D'). This illustration is in no way limiting as to the choice of steps wherein a compound comprising a NR₃₁R_{G2} moiety may be converted to a compound comprising a NR₃₁R₃₂ moiety wherein the R₃₂ moiety is hydrogen.


Scheme B'




Scheme D'



Scheme E'



Scheme N' and N-1''




[00486] Additionally, the invention encompasses methods of synthesis of the compounds of A, B, B', B'', C, E, 3-1, 3-2, 3-3, 3-4, 3-5, 3-6, N-1 or N-3, wherein one or more of M, M₁, or R₁ has a protecting group present during one or more steps of the synthesis. Protecting groups suitable for use for a M, M₁, or R₁

moiety are well known in the art, as well as the methods of incorporation and removal, and the reagents suitable for such transformations.

[00487] Compounds of the invention where X_4 is C-R⁹ may be prepared by methods analogous to the ones described in the Schemes illustrated above.


Reaction Schemes O, P and Q illustrate methods of synthesis of borane reagents useful in preparing intermediates of use in synthesis of the compounds of the invention as described in Reaction Schemes 1 and 2 above, to introduce benzothiazolyl substituents.

Scheme O



A compound of Formula O-1 is treated with, for example, nitric acid to produce a compound of Formula O-2. The compound of Formula O-2 is treated with a reducing agent such as stannous chloride to produce a compound of Formula O-3. The compound of O-3 is treated with sodium nitrate in acid and cupric bromide to produce a compound of Formula O-4. The compound of O-4 is treated a base such as butyl lithium and boron tris-isopropoxide to produce a compound of Formula O-5.


Scheme P



A compound of Formula P-1 is treated with, for example, potassium thiocyanate and bromine in acetic acid to produce a compound of Formula P-2. The compound of Formula P-2 is treated with an acetylating reagent such as acetyl chloride to produce a compound of Formula P-3. The compound of P-3 is reacted


with, for example, bis(pinacolato)diboron (compound P-4) in the presence of a catalyst such as palladium chloride to produce a compound of Formula P-5.

Scheme Q




[00488] The compound of Formula P-2 is reacted with, for example, methyl carbamic acid chloride to produce a compound of Formula Q-1. The compound of Formula Q-1 is reacted with bis(pinacolato)diboron (compound P-4) in the presence of a catalyst such as $\text{Pd}_2(\text{dba})_3$, 2-chlorohexylphosphino-2, 4, 6-triisopropylbiphenyl, a base such as potassium acetate, to produce the compound of Formula Q-2.

[00489] Some illustrative compounds of the invention which are mTor inhibitors are described below. The compounds of the invention are not limited in any way to the compounds illustrated herein.




Subclass 1a


Subclass 1b




Subclass 2a




Subclass 2b




Subclass 3a




Subclass 3b




Subclass 4a




Subclass 4b




Subclass 5a




Subclass 5b




Subclass 6a




Subclass 6b




Subclass 7a




Subclass 7b




Subclass 8a




Subclass 8b




Subclass 9a




Subclass 9b




Subclass 10a




Subclass 10b




Subclass 11a




Subclass 11b




Subclass 12a




Subclass 12b




Subclass 13a




Subclass 13b




Subclass 14a




Subclass 14b




Subclass 15a



Subclass 15b



Subclass 16a



Subclass 16b

[00490] Illustrative compounds of the invention include those of subclass 1a, 1b, 2a, 2b, 3a, 3b, 4a, 4b, 5a, 5b, 6a, 6b, 7a, 7b, 8a, 8b, 9a, 9b, 10a, 10b, 11a, 11b, 12a, 12b, 13a, 13b, 14a, 14b, 15a, 15b, 16a, or 16b, where the substituents R_1 , X_1 , and V are as described below.


[00491] In some embodiments, when R_1 is H and X_1 is CH, V is phenylamino, benzyl, phenyl, NHMe, NH_2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R_1 is H and X_1 is N, V is phenylamino, benzyl, phenyl, NHMe, NH_2 , NHEt,


NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is CH₃ and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is CH₃ and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is Et and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is Et and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is iPr and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is iPr and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO₂Me. In one embodiment, R₁ is iPr, X₁ is N, and V is NH₂. In another embodiment, R₁ is iPr, X₁ is N, and V is NHCOMe. In other embodiments, when R₁ is cyclobutyl and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is cyclobutyl and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is cyclopentyl and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is cyclopentyl and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is phenyl and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is phenyl and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is pyridin-2-yl and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is pyridin-2-yl and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is N-methylaminocyclohex-4-yl and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is N-methylaminocyclohex-4-yl and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is N-methylpiperidin-4-yl and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is N-methylpiperidin-4-yl and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁


is N-methylaminocyclobut-3-yl and X_1 is CH, V is phenylamino, benzyl, phenyl, NHMe, NH_2 , NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or $NHSO_2Me$. In other embodiments, when R_1 is N-methylaminocyclobut-3-yl and X_1 is N, V is phenylamino, benzyl, phenyl, NHMe, NH_2 , NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or $NHSO_2Me$. In other embodiments, when R_1 is *tert*-butyl and X_1 is CH, V is phenylamino, benzyl, phenyl, NHMe, NH_2 , NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or $NHSO_2Me$. In other embodiments, when R_1 is *tert*-butyl and X_1 is N, V is phenylamino, benzyl, phenyl, NHMe, NH_2 , NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or $NHSO_2Me$. In other embodiments, when R_1 is 1-cyano-but-4-yl and X_1 is CH, V is phenylamino, benzyl, phenyl, NHMe, NH_2 , NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or $NHSO_2Me$. In other embodiments, when R_1 is 1-cyano-but-4-yl and X_1 is N, V is phenylamino, benzyl, phenyl, NHMe, NH_2 , NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or $NHSO_2Me$. In other embodiments, when R_1 is 1-cyano-prop-3-yl and X_1 is CH, V is phenylamino, benzyl, phenyl, NHMe, NH_2 , NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or $NHSO_2Me$. In other embodiments, when R_1 is 1-cyano-prop-3-yl and X_1 is N, V is phenylamino, benzyl, phenyl, NHMe, NH_2 , NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or $NHSO_2Me$. In other embodiments, when R_1 is 3-azetidynyl and X_1 is CH, V is phenylamino, benzyl, phenyl, NHMe, NH_2 , NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or $NHSO_2Me$. In other embodiments, when R_1 is 3-azetidynyl and X_1 is N, V is phenylamino, benzyl, phenyl, NHMe, NH_2 , NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or $NHSO_2Me$.


[00492] In other embodiments, when R_1 is  and X_1 is CH, V is phenylamino, benzyl, phenyl, NHMe, NH_2 , NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or $NHSO_2Me$. In

other embodiments, when R_1 is  and X_1 is N, V is phenylamino, benzyl, phenyl, NHMe, NH_2 , NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or $NHSO_2Me$. In other

embodiments, when R_1 is  and X_1 is CH, V is phenylamino, benzyl, phenyl, NHMe, NH_2 , NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or $NHSO_2Me$. In other embodiments,

when R_1 is  and X_1 is N, V is phenylamino, benzyl, phenyl, NHMe, NH_2 , NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or $NHSO_2Me$. In other embodiments, when R_1

is  and X_1 is CH, V is phenylamino, benzyl, phenyl, NHMe, NH_2 , NEt, NHCOH, NHCOMe,


NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or $NHSO_2Me$. In other embodiments, when R_1 is  and X_1 is N, V is phenylamino, benzyl, phenyl, NHMe, NH_2 , NEt, NHCOH, NHCOMe, NHCOEt,


NHCOiPr, NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,


NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,

NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,


NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,

NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,

NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,

NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,

NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,


NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,


NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,


NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,


NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is N, V is


phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,


NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,


NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,


NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,

NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,


NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,

NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,

NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,


NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,


NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,


NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,


NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,


NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,


NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,


NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,


NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,


NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,


NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,


NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,


NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,


NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,


NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,

NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,

NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,

NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,

NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,

NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,

NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  OH and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,

NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  OH and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,

NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  OH and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,


NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,


NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,

NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,

NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,

NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,


NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,


NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,


NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,


NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,


NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,


NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,


NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,


NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,


NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,


NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,


NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,


NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,


NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,


NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,





NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,





NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,





NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,





NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,





NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,





NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,





NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,





NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,





NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,


NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,


NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,

NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,

NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,

NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,

NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr,


NHCOOMe, CONHMe, or NHSO₂Me. In other embodiments, when R₁ is  and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO₂Me.


[00493] In other embodiments, when R₁ is  OH and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO₂Me.


In other embodiments, when R₁ is  OH and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO₂Me. In other


embodiments, when R₁ is  OH and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO₂Me. In other


embodiments, when R_1 is  and X_1 is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO₂Me. In other


embodiments, when R_1 is  and X_1 is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO₂Me. In other


embodiments, when R_1 is  and X_1 is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO₂Me. In other


embodiments, when R_1 is  and X_1 is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO₂Me. In other


embodiments, when R_1 is  and X_1 is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO₂Me. In other


embodiments, when R_1 is  and X_1 is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO₂Me. In other

embodiments, when R_1 is  and X_1 is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO₂Me. In other

embodiments, when R_1 is  and X_1 is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO₂Me. In other

embodiments, when R_1 is  and X_1 is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO₂Me. In other

embodiments, when R_1 is  and X_1 is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO₂Me. In other

embodiments, when R_1 is  and X_1 is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO₂Me. and X_1 is CH,

V is phenylamino, benzyl, phenyl, NHMe, NH₂, NH₂Et, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO₂Me.

[00494] In other embodiments, when R₁ is  and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NH₂Et, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO₂Me. In other


embodiments, when R₁ is  and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NH₂Et, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO₂Me. In other


embodiments, when R₁ is  and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NH₂Et, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO₂Me. In other

embodiments, when R₁ is  and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NH₂Et, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO₂Me. In other

embodiments, when R₁ is  and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NH₂Et, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO₂Me. In other


embodiments, when R₁ is  and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NH₂Et, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO₂Me. In other


embodiments, when R₁ is  and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NH₂Et, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO₂Me. In other


embodiments, when R₁ is  and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NH₂Et, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO₂Me. In other


embodiments, when R₁ is  and X₁ is CH, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NH₂Et, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO₂Me. In other


embodiments, when R₁ is  and X₁ is N, V is phenylamino, benzyl, phenyl, NHMe, NH₂, NH₂Et, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO₂Me. In other


embodiments, when R_1 is  and X_1 is CH, V is phenylamino, benzyl, phenyl, NHMe, NH_2 , NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or $NHSO_2Me$. In other


embodiments, when R_1 is  and X_1 is N, V is phenylamino, benzyl, phenyl, NHMe, NH_2 , NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or $NHSO_2Me$. In other


embodiments, when R_1 is  and X_1 is CH, V is phenylamino, benzyl, phenyl, NHMe, NH_2 , NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or $NHSO_2Me$. In other


embodiments, when R_1 is  and X_1 is N, V is phenylamino, benzyl, phenyl, NHMe, NH_2 , NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or $NHSO_2Me$. In other


embodiments, when R_1 is  and X_1 is CH, V is phenylamino, benzyl, phenyl, NHMe, NH_2 , NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or $NHSO_2Me$. In other

embodiments, when R_1 is  and X_1 is N, V is phenylamino, benzyl, phenyl, NHMe, NH_2 , NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or $NHSO_2Me$. In other

embodiments, when R_1 is  and X_1 is CH, V is phenylamino, benzyl, phenyl, NHMe, NH_2 , NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or $NHSO_2Me$. In other

embodiments, when R_1 is  and X_1 is N, V is phenylamino, benzyl, phenyl, NHMe, NH_2 , NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or $NHSO_2Me$. In other

embodiments, when R_1 is  and X_1 is CH, V is phenylamino, benzyl, phenyl, NHMe, NH_2 , NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or $NHSO_2Me$. In other


embodiments, when R_1 is  and X_1 is N, V is phenylamino, benzyl, phenyl, NHMe, NH_2 , NEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or $NHSO_2Me$.

[00495] In the noted embodiments, pyridin-2-yl is , N-methylaminocyclohex-4-yl is , N-methylpiperidin-4-yl is , and N-methylaminocyclobut-3-yl is .


[00496] Illustrative compounds of the invention include those of subclass 1a, 1b, 2a, 2b, 3a, 3b, 4a, 4b, 5a, 5b, 6a, 6b, 7a, 7b, 8a, 8b, 9a, 9b, 10a, 10b, 11a, 11b, 12a, 12b, 13a, 13b, 14a, 14b, 15a, 15b, 16a, or 16b, where the substituents R_1 , X_1 , and V are as described below. In some embodiments, when R_1 is H and X_1


[illegible]


morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is *tert*-butyl and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is *tert*-butyl and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is 1-cyano-but-4-yl and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is 1-cyano-but-4-yl and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is 1-cyano-prop-3-yl and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is 1-cyano-prop-3-yl and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is 3-azetidiny and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is 3-azetidiny and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is





and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is  and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-


morpholino. In other embodiments, when R_1 is  and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments,

when R_1 is  and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is



and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is  and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-

morpholino. In other embodiments, when R_1 is  and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments,

when R_1 is  and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is

 and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino,


hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is  and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-

morpholino. In other embodiments, when R_1 is  and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments,

when R_1 is  and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino,

hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is  and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-

morpholino. In other embodiments, when R_1 is  and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments,


when R_1 is  and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino,


hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is  and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-


morpholino. In other embodiments, when R_1 is  and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments,


when R_1 is  and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino,


morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is  and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino,


hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is  and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-


morpholino. In other embodiments, when R_1 is  and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments,

when R_1 is  and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino,


morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is  and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino,


hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is  and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-

morpholino. In other embodiments, when R_1 is  and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments,


when R_1 is  and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino,


hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is  and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-

morpholino. In other embodiments, when R_1 is  and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments,


when R_1 is  and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino,


morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is  and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino,


hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is  and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-


morpholino. In other embodiments, when R_1 is  and X_1 is N, V is cyclopropanecarboxamido,


cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments,


when R_1 is  and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino,

morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is  and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino,

hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is  and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-


morpholino. In other embodiments, when R_1 is  and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments,


when R_1 is  and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino,


morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is  and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino,


hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is  and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-

morpholino. In other embodiments, when R_1 is  and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments,

when R_1 is  and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino,

morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is  and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino,

hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is  and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-

morpholino. In other embodiments, when R_1 is  and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments,

when R_1 is  OH and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino,

hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is  OH and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-

morpholino. In other embodiments, when R_1 is  OH and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments,


when R_1 is  OH and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino,

hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is  CONHMe and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-


morpholino. In other embodiments, when R_1 is  CONHMe and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments,

when R_1 is  NHAc and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino,

morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is  NHAc and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino,




hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is  and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-




morpholino. In other embodiments, when R_1 is  and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments,



when R_1 is  and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino,




morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is  and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino,





hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is  and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-





morpholino. In other embodiments, when R_1 is  and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments,





when R_1 is  and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino,




morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is  and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino,




hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is  and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-





morpholino. In other embodiments, when R_1 is  and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments,





when R_1 is  and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino,





morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is  and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino,





hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is  and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-





morpholino. In other embodiments, when R_1 is  and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments,





when R_1 is  and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino,





morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is  and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino,





hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is  and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-





morpholino. In other embodiments, when R_1 is  and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments,





when R_1 is  and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino,





morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is  and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino,


hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is  and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-


morpholino. In other embodiments, when R_1 is  and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments,


when R_1 is  and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino,


morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is  and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino,


hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is  and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-

morpholino. In other embodiments, when R_1 is  and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments,

when R_1 is  and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino,

morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is  and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino,

hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is  and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-


morpholino. In other embodiments, when R_1 is  and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-morpholino.


[00497] In other embodiments, when R_1 is  OH and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments,


when R_1 is  OH and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is


 OH and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino,


hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is  OH and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-


morpholino. In other embodiments, when R_1 is  OH and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-


morpholino. In other embodiments, when R_1 is  OH and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments,


when R_1 is  OH and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is


 OH and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino,


hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is  OH and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-

morpholino. In other embodiments, when R_1 is  OH and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments,

when R_1 is  NH₂ and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is


 NH₂ and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino,


hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is  and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-

morpholino. In other embodiments, when R_1 is  and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-morpholino. and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-morpholino.

[00498] In other embodiments, when R_1 is  and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments,


when R_1 is  and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino,


hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is  and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-


morpholino. In other embodiments, when R_1 is  and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments,


when R_1 is  and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino,


morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is  and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino,


hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is  and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-


morpholino. In other embodiments, when R_1 is  and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments,


when R_1 is  and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino,


morpholinoethylamino, hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is  and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino,


hydroxyethylamino, or N-morpholino. In other embodiments, when R_1 is  and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-


morpholino. In other embodiments, when R_1 is  and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-


morpholino. In other embodiments, when R_1 is  and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-


morpholino. In other embodiments, when R_1 is  and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-


morpholino. In other embodiments, when R_1 is  and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-

morpholino. In other embodiments, when R_1 is  and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-

morpholino. In other embodiments, when R_1 is  and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-

morpholino. In other embodiments, when R_1 is  and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-

morpholino. In other embodiments, when R_1 is  and X_1 is CH, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-

morpholino. In other embodiments, when R_1 is  and X_1 is N, V is cyclopropanecarboxamido, cyclopropylamino, morpholinoethylamino, hydroxyethylamino, or N-morpholino.
































[00499] In the noted embodiments, cyclopropanecarboxamido is , cyclopropylamino is , 2-morpholinoethylamino is , hydroxyethylamino is , and N-morpholino is .

Table 1. Biological activity of several illustrative mTor inhibitor compounds of the invention.

	Structure	mTOR IC ₅₀ (nM)	PI3K α IC ₅₀ (nM)	PI3K β IC ₅₀ (nM)	PI3K γ IC ₅₀ (nM)	PI3K δ IC ₅₀ (nM)	PC3 EC ₅₀ (nM)
1		++++	+++	++	++++	+++	++++
2		++++	++	+	+++	+++	+++
3		++	+	++	++	++	
4		+++	++	++	+++	+++	++
5		++++	+++	++	++++	+++	++++
6		++++	++	+	++	+++	+++


7		++++	+++	++	++	+++	++
8		++++	+++	+	+++	+++	++++
9		++++	++	+	+++	+++	++++
10		++					+
11		+++					+
12		+++					+
13		++	++		+++	+++	


14		++	++		+++	++	
15		+	+		+	+	
16		+	+		++	+	
17		+	+		+	+	
18		+	+		+	+	
19		++	+	+		+	
20		++	++	+		++	
21		+++	+	+	+	+	

22		++++	++++	++	+++	+++	++
23		++++	++	+	++	++	
24			+	+	+	+	
25			+++	++	++++	+++	
26			++++	+++	++++	+++	
27			++	+	+	+++	

[00500] Table 1 shows the biological activity in mTOR and PI3K kinase assays of several compounds of the invention. The scale utilized in Table 1 is as follows: ++++less than 100nM; +++ less than 1.0 μ M; ++ less than 10 μ M; and + greater than 10 μ M.

[00501] In other embodiments, the present invention provides the following compounds:

















[00502] Any of the compounds shown above may show a biological activity in an mTOR or PI3K inhibition assay of between about 0.5nM and 25 μ M (IC_{50}).








[00503] Additional compounds which are mTor inhibitors of the invention are shown in Table 2.







[00504] Table 2. *In vitro* IC_{50} values for Illustrative mTor Inhibitor Compounds of the Invention.






#	Structure	mTORC IC_{50} (nM)	PI3K α IC_{50} (nM)	PI3K β IC_{50} (nM)	PI3K γ IC_{50} (nM)	PI3K δ IC_{50} (nM)	PC3 prolif- eration (nM)
1		++++	+	+	++	++	+++
2		+	-	-	-	-	-





#	Structure	mTORC IC ₅₀ (nM)	PI3K α IC ₅₀ (nM)	PI3K β IC ₅₀ (nM)	PI3K γ IC ₅₀ (nM)	PI3K δ IC ₅₀ (nM)	PC3 prolif- eration (nM)
3		++	+	-	-	-	-
4		+	+				-
5		+	+				+
6		+	+				+
7		+++	+				+
8		+	+				+






#	Structure	mTORC IC ₅₀ (nM)	PI3K α IC ₅₀ (nM)	PI3K β IC ₅₀ (nM)	PI3K γ IC ₅₀ (nM)	PI3K δ IC ₅₀ (nM)	PC3 prolif- eration (nM)
9		++++	+				+
10		+++++	+	+	+	+	+
11		+++++ +	+	+	++	++	++++
12		+++++	+	+	++	+	++++
13		+	+				+
14		+	+				-
15		+++++ +	+	+	++++	++++	++++






#	Structure	mTORC IC ₅₀ (nM)	PI3K α IC ₅₀ (nM)	PI3K β IC ₅₀ (nM)	PI3K γ IC ₅₀ (nM)	PI3K δ IC ₅₀ (nM)	PC3 prolif- eration (nM)
16		++++++ +	+	+	++	+++	++
17		+	+				+
18		+	*				*
19		+	+				-
20		+	+				-
21		++++	++	+	++	++	+
22		++++++ +	+	+	-	+	++





#	Structure	mTORC IC ₅₀ (nM)	PI3K α IC ₅₀ (nM)	PI3K β IC ₅₀ (nM)	PI3K γ IC ₅₀ (nM)	PI3K δ IC ₅₀ (nM)	PC3 prolif- eration (nM)
23		+	+				-
24		+	+				+
25		++	+				+
26		++++++	+	+	++	+++	++
27		+++++					++
28		++	+	+	-	+	+



#	Structure	mTORC IC ₅₀ (nM)	PI3K α IC ₅₀ (nM)	PI3K β IC ₅₀ (nM)	PI3K γ IC ₅₀ (nM)	PI3K δ IC ₅₀ (nM)	PC3 prolif- eration (nM)
29		+					-
30		+++++	+	+	-	+	+
31		+++++	+	+	-	++	+
32		++	+	-	+	+	+
33		++	+	-	+	+	+





#	Structure	mTORC IC ₅₀ (nM)	PI3K α IC ₅₀ (nM)	PI3K β IC ₅₀ (nM)	PI3K γ IC ₅₀ (nM)	PI3K δ IC ₅₀ (nM)	PC3 prolif- eration (nM)
34		+	+	-	+	+	-
35		+	+	-	+	+	-
36		++++++	+	-	+++	++	+++
37		+	++	-	++	++	-
38		++	+	-	+	+	+






#	Structure	mTORC IC ₅₀ (nM)	PI3K α IC ₅₀ (nM)	PI3K β IC ₅₀ (nM)	PI3K γ IC ₅₀ (nM)	PI3K δ IC ₅₀ (nM)	PC3 prolif- eration (nM)
39		+++++++	+	-	+	+	+
40		+++	+	-	+	+	+
41		+++++++	+	+	++++	+	+
42		+++++++ +	+	+	-	+++	+
43		+	+	+	-	+	-





#	Structure	mTORC IC ₅₀ (nM)	PI3K α IC ₅₀ (nM)	PI3K β IC ₅₀ (nM)	PI3K γ IC ₅₀ (nM)	PI3K δ IC ₅₀ (nM)	PC3 prolif- eration (nM)
44		+++	+	+	-	+	-
45		+					
46							-
47							-
48		++++	+	+	+	+	



#	Structure	mTORC IC ₅₀ (nM)	PI3K α IC ₅₀ (nM)	PI3K β IC ₅₀ (nM)	PI3K γ IC ₅₀ (nM)	PI3K δ IC ₅₀ (nM)	PC3 prolif- eration (nM)
49		++++++	+	+	++	++	
50		++++	+	+	++	++	
51		++++	+	+	++	++	
52		++	+	+	+	++	

#	Structure	mTORC IC ₅₀ (nM)	PI3K α IC ₅₀ (nM)	PI3K β IC ₅₀ (nM)	PI3K γ IC ₅₀ (nM)	PI3K δ IC ₅₀ (nM)	PC3 prolif- eration (nM)
53		+++	+	+	+	-	
54		+++++	+	+	+	-	
55		++	+	+	+	-	
56		+	+	+	+	-	

#	Structure	mTORC IC ₅₀ (nM)	PI3K α IC ₅₀ (nM)	PI3K β IC ₅₀ (nM)	PI3K γ IC ₅₀ (nM)	PI3K δ IC ₅₀ (nM)	PC3 prolif- eration (nM)
57		+++++	+	+	+	-	
58		+	+	+	+	-	
59		+	+	+	+	-	
60		+++	+	+	+++	-	

#	Structure	mTORC IC ₅₀ (nM)	PI3K α IC ₅₀ (nM)	PI3K β IC ₅₀ (nM)	PI3K γ IC ₅₀ (nM)	PI3K δ IC ₅₀ (nM)	PC3 prolif- eration (nM)
61		++++++	+	+	+	+	
62		++++++ +	+	+	+	+++	
63		++++++ +	++	+	+++++	+++++	
64		+++++	+	+	++	++	
65		++++++	++++	+	+++++	+++++	

#	Structure	mTORC IC ₅₀ (nM)	PI3K α IC ₅₀ (nM)	PI3K β IC ₅₀ (nM)	PI3K γ IC ₅₀ (nM)	PI3K δ IC ₅₀ (nM)	PC3 prolif- eration (nM)
66		+	+	+	+	+	
67		+	+	+	+	+	
68		++++++ +	++	+	++++	+++++	
69		++++++ +	+	+	+	++	

#	Structure	mTORC IC ₅₀ (nM)	PI3K α IC ₅₀ (nM)	PI3K β IC ₅₀ (nM)	PI3K γ IC ₅₀ (nM)	PI3K δ IC ₅₀ (nM)	PC3 prolif- eration (nM)
70		+++++++ +	++	+	+++	+++++	
71		+++	+	+	+	+	

[00505] In Table 2 above, a ++++++ indicates an IC₅₀ of 5 nM or less; a ++++++ indicates an IC₅₀ of 10 nM or less; a +++++ indicates an IC₅₀ of 25nM or less; an +++++ indicates an IC₅₀ of 50nm or less, a +++ indicates an IC₅₀ of 100nM or less, a ++ indicates an IC₅₀ of 500nM or less, and a + indicates an IC₅₀ of more than 500nM.

[00506] In some embodiments, the invention provides a treatment regimen involving the use of an mTor inhibitor, which can be a compound as provided herein and a first agent also as provided herein. In some embodiments, the mTor inhibitor is a compound of Formula I, Formula I-A, Formula I-B1, Formula I-C, Formula I-C1a, or a compound of Table 1 or Table 2, and the first agent is an antiangiogenic agent. For example, the mTor inhibitor is a compound of Formula I where M1 is a bicyclic heteroaryl system, including, for instance, benzothiazolyl, quinoliny, quinazoliny, benzoxazolyl, and benzoimidazolyl, and the first agent is an antiangiogenic agent. In other embodiments, the mTor inhibitor is a compound of Formula I where M1 is of formula M1-A, M1-B, M1-C or M1-D, and the first agent is an antiangiogenic agent. In yet other embodiments, the mTor inhibitor is of Formula I-B1 and M1 is of formula M1-F1, and the first agent is an an antiangiogenic agent. In still other embodiments, the mTor inhibitor is of Formula I-C, and the first agent is an antiangiogenic agent. In still other embodiments, the mTor inhibitor is of Formula I-C1a and the first agent is an antiangiogenic agent.

[00507] In some embodiments, the mTor inhibitor is a compound of Formula I, Formula I-A, Formula I-B1, Formula I-C, Formula I-C1a, or a compound of Table 1 or Table 2, and the first agent is sorafenib. For example, the mTor inhibitor is a compound of Formula I where M1 is a bicyclic heteroaryl system, including, for instance, benzothiazolyl, quinoliny¹ quinazoliny, benzoxazolyl, and benzoimidazolyl, and

the first agent is sorafenib. In other embodiments, the mTor inhibitor is a compound of Formula I where M1 is of formula M1-A, M1-B, M1-C or M1-D, and the first agent is sorafenib. In yet other embodiments, the mTor inhibitor is of Formula I-B1 and M1 is of formula M1-F1, and the first agent is sorafenib. In still other embodiments, the mTor inhibitor is of Formula I-C, and the first agent is sorafenib. In still other embodiments, the mTor inhibitor is of Formula I-C1a and the first agent is sorafenib.

[00508] In some embodiments, the mTor inhibitor is a compound of Formula I where M1 is of formula M1-A, M1-B, M1-C or M1-D, and the first agent is sorafenib. In some embodiments, the mTor inhibitor is a compound of Table 1, and the first agent is sorafenib. For example, the mTor inhibitor is compound 1 of Table 1. In other embodiments, the mTor inhibitor is a compound of Table 2, and the first agent is sorafenib.

Disease Targets

[00509] The subject methods are useful for treating any disease conditions for which current treatment regimens result in side effects, toxicity, or patient non-compliance. In some embodiments, the disease condition is a proliferative disorder, such as described herein, including but not limited to cancer. In other embodiments, the disorder is diabetes. In still other embodiments, the disorder is an autoimmune disorder.

[00510] In some embodiments, the disease condition is associated with mTor and/or PI3-kinase. A vast diversity of disease conditions associated with mTOR and/or PI3-kinase have been reported. PI3-kinase α , one of the four isoforms of type I PI3-kinases has been implicated, for example, in a variety of human proliferative disorders, such as cancers. Angiogenesis has been shown to selectively require the α isoform of PI3K in the control of endothelial cell migration. (Graupera et al, Nature 2008;453;662-6). Mutations in the gene coding for PI3K α or mutations which lead to upregulation of PI3K α are believed to occur in many human cancers such as lung, stomach, endometrial, ovarian, bladder, breast, colon, brain and skin cancers. Often, mutations in the gene coding for PI3K α are point mutations clustered within several hotspots in helical and kinase domains, such as E542K, E545K, and H1047R. Many of these mutations have been shown to be oncogenic gain-of-function mutations. Because of the high rate of PI3K α mutations, targeting of this pathway provides valuable therapeutic opportunities. While other PI3K isoforms such as PI3K δ or PI3K γ are expressed primarily in hematopoietic cells, PI3K α , along with PI3K β , is expressed constitutively.

[00511] Disease conditions associated with PI3-kinase and/or mTOR can also be characterized by abnormally high level of activity and/or expression of downstream messengers of mTOR and PI3-kinase. For example, proteins or messengers such as PIP2, PIP3, PDK, Akt, PTEN, PRAS40, GSK-3 β , p21, p27 may be present in abnormal amounts which can be identified by any assays known in the art.

[00512] Deregulation of the mTOR pathway is emerging as a common theme in diverse human diseases and as a consequence drugs that target mTOR have therapeutic value. The diseases associated with deregulation of mTORC1 include, but are not limited to, tuberous sclerosis complex (TSC) and lymphangioleiomyomatosis (LAM), both of which are caused by mutations in TSC1 or TSC2 tumor

suppressors. Patients with TSC develop benign tumors that when present in brain, however, can cause seizures, mental retardation and death. LAM is a serious lung disease. Inhibition of mTORC1 may help patients with Peutz-Jeghers cancer-prone syndrome caused by the LKB 1 mutation. mTORC1 may also have role in the genesis of sporadic cancers. Inactivation of several tumor suppressors, in particular PTEN, p53, VHL and NF1, has been linked to mTORC1 activation. Rapamycin and its analogues (eg CCI-779, RAD001 and AP23573) inhibit TORC1 and have shown moderate anti-cancer activity in phase II clinical trials. However, due to the negative signal from S6K1 to the insulin/PI3K/Akt pathway, it is important to note that inhibitors of mTORC1, like rapalogs, can activate PKB/Akt. If this effect persists with chronic rapamycin treatment, it may provide cancer cells with an increased survival signal that may be clinically undesirable. The PI3K/Akt pathway is activated in many cancers. Activated Akt regulates cell survival, cell proliferation and metabolism by phosphorylating proteins such as BAD, FOXO, NF-KB, p21Cip1, p27Kip1, GSK3 β and others. Akt might also promote cell growth by phosphorylating TSC2. Akt activation may promote cellular transformation and resistance to apoptosis by collectively promoting growth, proliferation and survival, while inhibiting apoptotic pathways.

[00513] Where desired, the subject to be treated is tested prior to treatment using a diagnostic assay to determine the sensitivity of tumor cells to a first agent or an mTOR inhibitor. Any method known in the art that can determine the sensitivity of the tumor cells of a subject to a first agent or an mTOR inhibitor can be employed. In these methods one or more additional anti-cancer agents or treatments can be co-administered according to a treatment regimen of the invention using the first agent and the second agent which is an mTOR inhibitor, as judged to be appropriate by the administering physician given the prediction of the likely responsiveness of the subject to the combination of first agent and mTOR inhibitor, in combination with any additional circumstances pertaining to the individual subject.

[00514] The data presented in the Examples herein below demonstrate that the anti-tumor effects of a regimen of the invention involving a first agent and a second agent which is an mTOR inhibitor (where the mTOR inhibitor is administered according to a treatment regimen) are superior to the anti-tumor effects of either agent by itself or both administered simultaneously or in a reverse order. As such, the subject methods are particularly useful for treating a proliferative disorder, such as a neoplastic condition. Non-limiting examples of such conditions include but are not limited to Acanthoma, Acinic cell carcinoma, Acoustic neuroma, Acral lentiginous melanoma, Acrospiroma, Acute eosinophilic leukemia, Acute lymphoblastic leukemia, Acute megakaryoblastic leukemia, Acute monocytic leukemia, Acute myeloblastic leukemia with maturation, Acute myeloid dendritic cell leukemia, Acute myeloid leukemia, Acute promyelocytic leukemia, Adamantinoma, Adenocarcinoma, Adenoid cystic carcinoma, Adenoma, Adenomatoid odontogenic tumor, Adrenocortical carcinoma, Adult T-cell leukemia, Aggressive NK-cell leukemia, AIDS-Related Cancers, AIDS-related lymphoma, Alveolar soft part sarcoma, Ameloblastic fibroma, Anal cancer, Anaplastic large cell lymphoma, Anaplastic thyroid cancer, Angioimmunoblastic T-cell lymphoma, Angiomyolipoma, Angiosarcoma, Appendix cancer, Astrocytoma, Atypical teratoid rhabdoid tumor, Basal cell carcinoma, Basal-like carcinoma, B-cell leukemia, B-cell lymphoma, Bellini duct carcinoma, Biliary tract cancer, Bladder cancer, Blastoma, Bone Cancer, Bone tumor, Brain Stem

Glioma, Brain Tumor, Breast Cancer, Brenner tumor, Bronchial Tumor, Bronchioloalveolar carcinoma, Brown tumor, Burkitt's lymphoma, Cancer of Unknown Primary Site, Carcinoid Tumor, Carcinoma, Carcinoma in situ, Carcinoma of the penis, Carcinoma of Unknown Primary Site, Carcinosarcoma, Castleman's Disease, Central Nervous System Embryonal Tumor, Cerebellar Astrocytoma, Cerebral Astrocytoma, Cervical Cancer, Cholangiocarcinoma, Chondroma, Chondrosarcoma, Chordoma, Choriocarcinoma, Choroid plexus papilloma, Chronic Lymphocytic Leukemia, Chronic monocytic leukemia, Chronic myelogenous leukemia, Chronic Myeloproliferative Disorder, Chronic neutrophilic leukemia, Clear-cell tumor, Colon Cancer, Colorectal cancer, Craniopharyngioma, Cutaneous T-cell lymphoma, Degos disease, Dermatofibrosarcoma protuberans, Dermoid cyst, Desmoplastic small round cell tumor, Diffuse large B cell lymphoma, Dysembryoplastic neuroepithelial tumor, Embryonal carcinoma, Endodermal sinus tumor, Endometrial cancer, Endometrial Uterine Cancer, Endometrioid tumor, Enteropathy-associated T-cell lymphoma, Ependymblastoma, Ependymoma, Epithelioid sarcoma, Erythroleukemia, Esophageal cancer, Esthesioneuroblastoma, Ewing Family of Tumor, Ewing Family Sarcoma, Ewing's sarcoma, Extracranial Germ Cell Tumor, Extragonadal Germ Cell Tumor, Extrahepatic Bile Duct Cancer, Extramammary Paget's disease, Fallopian tube cancer, Fetus in fetu, Fibroma, Fibrosarcoma, Follicular lymphoma, Follicular thyroid cancer, Gallbladder Cancer, Gallbladder cancer, Ganglioglioma, Ganglioneuroma, Gastric Cancer, Gastric lymphoma, Gastrointestinal cancer, Gastrointestinal Carcinoid Tumor, Gastrointestinal Stromal Tumor, Gastrointestinal stromal tumor, Germ cell tumor, Germinoma, Gestational choriocarcinoma, Gestational Trophoblastic Tumor, Giant cell tumor of bone, Glioblastoma multiforme, Glioma, Gliomatosis cerebri, Glomus tumor, Glucagonoma, Gonadoblastoma, Granulosa cell tumor, Hairy Cell Leukemia, Hairy cell leukemia, Head and Neck Cancer, Head and neck cancer, Heart cancer, Hemangioblastoma, Hemangiopericytoma, Hemangiosarcoma, Hematological malignancy, Hepatocellular carcinoma, Hepatosplenic T-cell lymphoma, Hereditary breast-ovarian cancer syndrome, Hodgkin Lymphoma, Hodgkin's lymphoma, Hypopharyngeal Cancer, Hypothalamic Glioma, Inflammatory breast cancer, Intraocular Melanoma, Islet cell carcinoma, Islet Cell Tumor, Juvenile myelomonocytic leukemia, Sarcoma, Kaposi's sarcoma, Kidney Cancer, Klatskin tumor, Krukenberg tumor, Laryngeal Cancer, Laryngeal cancer, Lentigo maligna melanoma, Leukemia, Leukemia, Lip and Oral Cavity Cancer, Liposarcoma, Lung cancer, Luteoma, Lymphangioma, Lymphangiosarcoma, Lymphoepithelioma, Lymphoid leukemia, Lymphoma, Macroglobulinemia, Malignant Fibrous Histiocytoma, Malignant fibrous histiocytoma, Malignant Fibrous Histiocytoma of Bone, Malignant Glioma, Malignant Mesothelioma, Malignant peripheral nerve sheath tumor, Malignant rhabdoid tumor, Malignant triton tumor, MALT lymphoma, Mantle cell lymphoma, Mast cell leukemia, Mediastinal germ cell tumor, Mediastinal tumor, Medullary thyroid cancer, Medulloblastoma, Medulloblastoma, Medulloepithelioma, Melanoma, Melanoma, Meningioma, Merkel Cell Carcinoma, Mesothelioma, Mesothelioma, Metastatic Squamous Neck Cancer with Occult Primary, Metastatic urothelial carcinoma, Mixed Mullerian tumor, Monocytic leukemia, Mouth Cancer, Mucinous tumor, Multiple Endocrine Neoplasia Syndrome, Multiple Myeloma, Multiple myeloma, Mycosis Fungoides, Mycosis fungoides, Myelodysplastic Disease, Myelodysplastic Syndromes, Myeloid leukemia,

Myeloid sarcoma, Myeloproliferative Disease, Myxoma, Nasal Cavity Cancer, Nasopharyngeal Cancer, Nasopharyngeal carcinoma, Neoplasm, Neurinoma, Neuroblastoma, Neuroblastoma, Neurofibroma, Neuroma, Nodular melanoma, Non-Hodgkin Lymphoma, Non-Hodgkin lymphoma, Nonmelanoma Skin Cancer, Non-Small Cell Lung Cancer, Ocular oncology, Oligoastrocytoma, Oligodendroglioma, Oncocytoma, Optic nerve sheath meningioma, Oral Cancer, Oral cancer, Oropharyngeal Cancer, Osteosarcoma, Osteosarcoma, Ovarian Cancer, Ovarian cancer, Ovarian Epithelial Cancer, Ovarian Germ Cell Tumor, Ovarian Low Malignant Potential Tumor, Paget's disease of the breast, Pancoast tumor, Pancreatic Cancer, Pancreatic cancer, Papillary thyroid cancer, Papillomatosis, Paraganglioma, Paranasal Sinus Cancer, Parathyroid Cancer, Penile Cancer, Perivascular epithelioid cell tumor, Pharyngeal Cancer, Pheochromocytoma, Pineal Parenchymal Tumor of Intermediate Differentiation, Pineoblastoma, Pituicytoma, Pituitary adenoma, Pituitary tumor, Plasma Cell Neoplasm, Pleuropulmonary blastoma, Polyembryoma, Precursor T-lymphoblastic lymphoma, Primary central nervous system lymphoma, Primary effusion lymphoma, Primary Hepatocellular Cancer, Primary Liver Cancer, Primary peritoneal cancer, Primitive neuroectodermal tumor, Prostate cancer, Pseudomyxoma peritonei, Rectal Cancer, Renal cell carcinoma, Respiratory Tract Carcinoma Involving the NUT Gene on Chromosome 15, Retinoblastoma, Rhabdomyoma, Rhabdomyosarcoma, Richter's transformation, Sacrococcygeal teratoma, Salivary Gland Cancer, Sarcoma, Schwannomatosis, Sebaceous gland carcinoma, Secondary neoplasm, Seminoma, Serous tumor, Sertoli-Leydig cell tumor, Sex cord-stromal tumor, Sezary Syndrome, Signet ring cell carcinoma, Skin Cancer, Small blue round cell tumor, Small cell carcinoma, Small Cell Lung Cancer, Small cell lymphoma, Small intestine cancer, Soft tissue sarcoma, Somatostatinoma, Soot wart, Spinal Cord Tumor, Spinal tumor, Splenic marginal zone lymphoma, Squamous cell carcinoma, Stomach cancer, Superficial spreading melanoma, Supratentorial Primitive Neuroectodermal Tumor, Surface epithelial-stromal tumor, Synovial sarcoma, T-cell acute lymphoblastic leukemia, T-cell large granular lymphocyte leukemia, T-cell leukemia, T-cell lymphoma, T-cell prolymphocytic leukemia, Teratoma, Terminal lymphatic cancer, Testicular cancer, Thecoma, Throat Cancer, Thymic Carcinoma, Thymoma, Thyroid cancer, Transitional Cell Cancer of Renal Pelvis and Ureter, Transitional cell carcinoma, Urachal cancer, Urethral cancer, Urogenital neoplasm, Uterine sarcoma, Uveal melanoma, Vaginal Cancer, Verner Morrison syndrome, Verrucous carcinoma, Visual Pathway Glioma, Vulvar Cancer, Waldenstrom's macroglobulinemia, Warthin's tumor, Wilms' tumor, or any combination thereof.

[00515] In some embodiments, a treatment regimen involves administering a first agent in conjunction with administering a second agent which is an mTOR inhibitor for the treatment of renal cell carcinoma (also known as RCC or hypernephroma). Renal cell carcinoma is a kidney cancer that originates in the lining of the proximal convoluted tubule. Any known type of renal cell carcinoma may be treated using the treatment regimens of the invention, including clear renal cell carcinoma, papillary renal cell carcinoma, chromophobe renal cell carcinoma and collecting duct carcinoma. Any stage of the disease may be treated using the methods of the invention, including early stage as well as later stages (e.g. metastatic renal cell carcinoma).

[00516] In other embodiments, the treatment regimen involves administering a first agent in conjunction with administering a second agent which is an mTOR inhibitor for treatment of heart conditions including atherosclerosis, heart hypertrophy, cardiac myocyte dysfunction, elevated blood pressure and vasoconstriction. The invention also relates to a method of treating diseases related to vasculogenesis or angiogenesis in a mammal that comprises administering to said mammal a therapeutically effective amount of a first agent and an mTOR inhibitor of the present invention, or any pharmaceutically acceptable salt, ester, prodrug, solvate, hydrate or derivative thereof.

[00517] In some embodiments, said method is for treating a disease selected from the group consisting of tumor angiogenesis, chronic inflammatory disease such as rheumatoid arthritis, atherosclerosis, inflammatory bowel disease, skin diseases such as psoriasis, eczema, and scleroderma, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma, glioma, melanoma, sarcoma and ovarian, breast, lung, pancreatic, prostate, colon and epidermoid cancer.

[00518] In some embodiments, the invention provides a treatment regimen involving administering a first agent in conjunction with administering a second agent which is an mTOR inhibitor for treating a disease condition associated with PI3-kinase α and/or mTOR, including, but not limited to, conditions related to an undesirable, over-active, harmful or deleterious immune response in a mammal, collectively termed "autoimmune disease." Autoimmune disorders include, but are not limited to, Crohn's disease, ulcerative colitis, psoriasis, psoriatic arthritis, juvenile arthritis and ankylosing spondylitis. Other non-limiting examples of autoimmune disorders include autoimmune diabetes, multiple sclerosis, systemic lupus erythematosus (SLE), rheumatoid spondylitis, gouty arthritis, allergy, autoimmune uveitis, nephrotic syndrome, multisystem autoimmune diseases, autoimmune hearing loss, adult respiratory distress syndrome, shock lung, chronic pulmonary inflammatory disease, pulmonary sarcoidosis, pulmonary fibrosis, silicosis, idiopathic interstitial lung disease, chronic obstructive pulmonary disease, asthma, restenosis, spondyloarthropathies, Reiter's syndrome, autoimmune hepatitis, inflammatory skin disorders, vasculitis of large vessels, medium vessels or small vessels, endometriosis, prostatitis and Sjogren's syndrome. Undesirable immune response can also be associated with or result in, e.g., asthma, emphysema, bronchitis, psoriasis, allergy, anaphylaxis, auto-immune diseases, rheumatoid arthritis, graft versus host disease, transplantation rejection, lung injuries, and lupus erythematosus. The pharmaceutical compositions of the present invention can be used to treat other respiratory diseases including but not limited to diseases affecting the lobes of lung, pleural cavity, bronchial tubes, trachea, upper respiratory tract, or the nerves and muscle for breathing. The methods of the invention can be further used to treat multiorgan failure.

[00519] The invention also provides a treatment regimen involving administering a first agent in conjunction with administering a second agent which is an mTOR inhibitor for treating liver diseases (including diabetes), pancreatitis or kidney disease (including proliferative glomerulonephritis and diabetes-induced renal disease) or pain in a mammal.

[00520] The invention further provides a treatment regimen involving administering a first agent in conjunction with administering a second agent which is an mTOR inhibitor for treating sperm motility.

The invention also provides a treatment regimen involving administering a first agent in conjunction with administering a second agent which is an mTOR inhibitor for treating neurological or neurodegenerative diseases including, but not limited to, Alzheimer's disease, Huntington's disease, CNS trauma, and stroke.

[00521] The invention further provides a treatment regimen involving administering a first agent in conjunction with administering a second agent which is an mTOR inhibitor for the prevention of blastocyte implantation in a mammal.

[00522] The invention also relates to a treatment regimen involving administering a first agent in conjunction with administering a second agent which is an mTOR inhibitor for treating a disease related to vasculogenesis or angiogenesis in a mammal which can manifest as tumor angiogenesis, chronic inflammatory disease such as rheumatoid arthritis, inflammatory bowel disease, atherosclerosis, skin diseases such as psoriasis, eczema, and scleroderma, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma, glioma, melanoma, sarcoma and ovarian, breast, lung, pancreatic, prostate, colon and epidermoid cancer.

[00523] The invention further provides a treatment regimen involving administering a first agent in conjunction with administering a second agent which is an mTOR inhibitor for the treatment of disorders involving platelet aggregation or platelet adhesion, including but not limited to Bernard-Soulier syndrome, Glanzmann's thrombasthenia, Scott's syndrome, von Willebrand disease, Hermansky-Pudlak Syndrome, and Gray platelet syndrome.

[00524] In some embodiments, a treatment regimen is provided involving administering a first agent in conjunction with administering a second agent which is an mTOR inhibitor to treat disease which is skeletal muscle atrophy, skeletal muscle hypertrophy, leukocyte recruitment in cancer tissue, invasion metastasis, melanoma, sarcoma, acute and chronic bacterial and viral infections, sepsis, glomerulo sclerosis, glomerulo, nephritis, or progressive renal fibrosis.

[00525] Certain embodiments contemplate a human subject such as a subject that has been diagnosed as having or being at risk for developing or acquiring a proliferative disorder condition. Certain other embodiments contemplate a non-human subject, for example a non-human primate such as a macaque, chimpanzee, gorilla, vervet, orangutan, baboon or other non-human primate, including such non-human subjects that can be known to the art as preclinical models, including preclinical models for inflammatory disorders. Certain other embodiments contemplate a non-human subject that is a mammal, for example, a mouse, rat, rabbit, pig, sheep, horse, bovine, goat, gerbil, hamster, guinea pig or other mammal. There are also contemplated other embodiments in which the subject or biological source can be a non-mammalian vertebrate, for example, another higher vertebrate, or an avian, amphibian or reptilian species, or another subject or biological source. In certain embodiments of the present invention, a transgenic animal is utilized. A transgenic animal is a non-human animal in which one or more of the cells of the animal includes a nucleic acid that is non-endogenous (i.e., heterologous) and is present as an extrachromosomal element in a portion of its cell or stably integrated into its germ line DNA (i.e., in the genomic sequence of most or all of its cells).

Therapeutic Efficacy

[00526] In some embodiments, therapeutic efficacy is measured based on an effect of treating a proliferative disorder, such as cancer. In general, therapeutic efficacy of the methods and compositions of the invention, with regard to the treatment of a proliferative disorder (e.g. cancer, whether benign or malignant), may be measured by the degree to which the methods and compositions promote inhibition of tumor cell proliferation, the inhibition of tumor vascularization, the eradication of tumor cells, and/or a reduction in the size of at least one tumor such that a human is treated for the proliferative disorder. Several parameters to be considered in the determination of therapeutic efficacy are discussed herein. The proper combination of parameters for a particular situation can be established by the clinician. The progress of the inventive method in treating cancer (e.g., reducing tumor size or eradicating cancerous cells) can be ascertained using any suitable method, such as those methods currently used in the clinic to track tumor size and cancer progress. The primary efficacy parameter used to evaluate the treatment of cancer by the inventive method and compositions preferably is a reduction in the size of a tumor. Tumor size can be figured using any suitable technique, such as measurement of dimensions, or estimation of tumor volume using available computer software, such as FreeFlight software developed at Wake Forest University that enables accurate estimation of tumor volume. Tumor size can be determined by tumor visualization using, for example, CT, ultrasound, SPECT, spiral CT, MRI, photographs, and the like. In embodiments where a tumor is surgically resected after completion of the therapeutic period, the presence of tumor tissue and tumor size can be determined by gross analysis of the tissue to be resected, and/or by pathological analysis of the resected tissue.

[00527] In some embodiments, tumor size is reduced as a result of the inventive method preferably without significant adverse events in the subject. Adverse events are categorized or “graded” by the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI), with Grade 0 representing minimal adverse side effects and Grade 4 representing the most severe adverse events. The NCI toxicity scale (published April 1999) and Common Toxicity Criteria Manual (updated August 1999) is available through the NCI, e.g., through the NCI internet website at www.ctep.info.nih.gov or in the Investigator's Handbook for participants in clinical trials of investigational agents sponsored by the Division of Cancer Treatment and Diagnosis, NCI. Desirably, the inventive method is associated with minimal adverse events, e.g. Grade 0, Grade 1, or Grade 2 adverse events, as graded by the CTEP/NCI. Specific toxicity criteria for weight loss, a common way to measure toxicity of anti-neoplastic agents, are shown in Table 3. For most patients, weight loss is measured as characterized by a decrease in overall body weight. Alternatively, such as in pediatric cases, weight loss is measured as the amount of weight below the expected (baseline) growth curve.

Table 3. National Cancer Institute's Common Toxicity Criteria version 4 grading system for weight loss.

Grade	0	1	2	3
% Weight Loss	<5%	5-10%	10-20%	≥20%

[00528] Specific toxicity criteria for skin toxicity, another common side effect of anti-neoplastic drugs such as sorafenib, are shown in Table 4.

Table 4. Grading system for skin toxicity.

Skin Toxicity Grade	1	2	3
Adverse Effect	Numbness, dysesthesia, paresthesia, tingling, painless swelling, erythema or discomfort of the hands or feet which does not disrupt the patient's normal activities	Painful erythema and swelling of the hands or feet and/or discomfort affecting the patient's normal activities	Moist desquamation, ulceration, blistering or severe pain of the hands or feet, or severe discomfort that causes the patient to be unable to work or perform activities of daily living

[00529] In some embodiments, a treatment regimen of the invention allows the administration of a first agent, such as an antiangiogenic or anti-neoplastic agent, in a higher dose or for a longer period of time than would be possible in an alternative regimen where the antiangiogenic agent is administered alone. In other embodiments, a treatment regimen of the invention allows the administration of a first agent, such as an antiangiogenic or anti-neoplastic agent, at a higher dose or for a longer period of time than an alternative regimen where the antiangiogenic agent is administered simultaneously with the mTor inhibitor. For example, the treatment regimen of the invention allows a patient to receive treatment for a period of time which is longer by 1, 2, 4, 6, 8, 10, 12, 24, 48, 52, 64, or 104 weeks than in an alternative regimen where the antiangiogenic agent is administered simultaneously with the mTor inhibitor. In some embodiments, the treatment regimen of the invention allows a patient to receive treatment at a normal dose of between 300 and 500 mg of an antiangiogenic agent (twice daily), where the patient would not be capable of receiving this dose in an alternative regimen where the antiangiogenic agent is administered simultaneously with the mTor inhibitor. For example, the treatment regimen of the invention allows a patient to receive treatment at a normal dose of between 400 mg of sorafenib (twice daily), where the patient would not be capable of receiving this dose in an alternative regimen where the antiangiogenic agent is administered simultaneously with the mTor inhibitor. In other embodiments, the patient is pregnant, and the treatment of the invention allows the patient to be administered a higher dose of the first agent than would be acceptable in an alternative regimen where the antiangiogenic agent is administered simultaneously with the mTor inhibitor.

[00530] Skin toxicities, including rash and hand-foot skin reactions, are common dose-limiting side effects of antiangiogenic inhibitors. Other adverse side effects during treatment with angiogenic inhibitors

include diarrhea, skin redness, itching or peeling, fatigue, hair thinning or loss, nausea/vomiting, mouth sores, loss of appetite, weakness, tiredness, pruritus, hypertension, hemorrhage, numbness, tingling or pain in hands and feet, other neuropathies, abdominal pain, or weight loss. In some embodiments, a treatment regimen according to the invention helps alleviate one or more side effects compared to an alternative regimen where the antiangiogenic agent is administered alone or an alternative regimen where the antiangiogenic agent is administered simultaneously with the mTor inhibitor.

[00531] In some embodiments, the synergistic effect of a treatment regimen of the invention is measured as a relative decrease in fatigue. Fatigue is characterized by a state of generalized weakness with a pronounced inability to summon sufficient energy to accomplish daily activities. Grade 1 fatigue includes fatigue capable of being relieved by rest. Grade 2 fatigue includes fatigue not capable of being relieved by rest, and with a pronounced effect on instrumental activities of daily living (including preparing meals, shopping for groceries or clothes, using the telephone, managing money, etc). Grade 3 fatigue includes fatigue not capable of being relieved by rest, and with a pronounced effect on self-care activities of daily living (bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not being bedridden). In some embodiments, a synergistic effect of a treatment regimen of the invention includes a relative reduction in the grade of fatigue of the subject.

[00532] In some embodiments, the synergistic effect of a treatment regimen of the invention is measured as a relative decrease in alopecia. Grade 1 alopecia includes hair loss of <50% of normal for that individual that is not obvious from a distance but only on close inspection, and where a different hair style may be required to cover the hair loss but does not require a wig or hair piece to camouflage. Grade 2 alopecia includes hair loss of $\geq 50\%$ normal for that individual that is readily apparent to others, and a wig or hair piece is necessary if the patient desires to completely camouflage the hair loss. Grade 2 alopecia is often associated with psychosocial impact. In some embodiments, a synergistic effect of a treatment regimen of the invention includes a relative reduction in the grade of alopecia of the subject.

[00533] In some embodiments, the synergistic effect of a treatment regimen of the invention is measured as a relative decrease in diarrhea. Grade 1 diarrhea includes an increase of <4 stools per day over baseline and/or a mild increase in ostomy output compared to baseline. Grade 2 diarrhea includes an increase of 4 - 6 stools per day over baseline and/or a moderate increase in ostomy output compared to baseline. Grade 3 diarrhea includes an increase of ≥ 7 stools per day over baseline, incontinence, and/or severe increase in ostomy output compared to baseline. Hospitalization is generally indicated in grade 3 diarrhea. Grade 4 diarrhea includes life-threatening consequences for the patient and requires urgent intervention. Grade 5 diarrhea includes death. In some embodiments, a synergistic effect of a treatment regimen of the invention includes a relative reduction in the grade of diarrhea of the subject.

[00534] In some embodiments, the synergistic effect of a treatment regimen of the invention is measured as a relative decrease in nausea. Grade 1 nausea includes loss of appetite without alteration in eating habits. Grade 2 nausea includes decreased oral intake without significant weight loss, dehydration or malnutrition. Grade 3 nausea includes inadequate oral caloric or fluid intake; tube feeding, TPN, or

hospitalization is generally indicated. In some embodiments, a synergistic effect of a treatment regimen of the invention includes a relative reduction in the grade of nausea of the subject.

[00535] In some embodiments, the synergistic effect of a treatment regimen of the invention is measured as a relative decrease in abdominal pain, which is a disorder characterized by a sensation of marked discomfort in the abdominal region. Grade 1 abdominal pain includes mild pain. Grade 2 abdominal pain includes moderate pain and/or limiting instrumental activities of daily living (including preparing meals, shopping for groceries or clothes, using the telephone, managing money, etc). Grade 3 abdominal pain includes severe pain and/or limiting self care activities of daily living (bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not being bedridden). In some embodiments, a synergistic effect of a treatment regimen of the invention includes a relative reduction in the grade of abdominal pain of the subject.

[00536] In some embodiments, the synergistic effect of a treatment regimen of the invention manifests itself as a decrease in the level of hypoxia in a tissue or cell of the subject. Hypoxia is a condition resulting from an inadequate supply of oxygen to tissues or cells and resulting from functionally impaired microcirculation and diffusion. Hypoxia may be characterized, for example, biochemically by a state of oxygen-limited electron transport within a tissue or cell, or physiologically or clinically as a state of reduced oxygen availability or decreased oxygen partial pressure that affects the function of an organ, tissue or cell. Hypoxia is believed to contribute to tumor propagation, malignant progression, and resistance to therapy. In tumor cells, hypoxia may be characterized by the effects noted above, or alternatively by other clinical, biological or molecular effects. For example, hypoxia may induce or mediate changes of proteins within neoplastic or stroma cells which can be observed or characterized biochemically. Factors contributing to hypoxia are deteriorating diffusion geometry, severe structural abnormalities of tumor microvessels, and disturbed microcirculation, anemia, and formation of methemoglobin or carboxyhemoglobin which reduce the blood's capacity to carry oxygen. Hypoxia is associated with reduced mitochondrial oxygen consumption rate and ATP production, hindering active transport of tumor cells. Effects include collapse of sodium and/or potassium gradients across the cell membrane, membrane depolarization, cellular uptake of chloride ion, cell swelling, increased cytosolic calcium concentration, and decreased cytosolic pH. Hypoxic conditions may further manifest themselves either acutely or chronically. Phenotypically, hypoxia in a tumor may, for example, also manifest itself in a more rapid growth of the tumor as compared to a tumor not showing hypoxic conditions. Further, the tumor may show increased resistance to an antineoplastic agent as compared to a tumor not showing hypoxic conditions. All of the effects noted herein may be alleviated or reduced by the use of a treatment regimen of the invention relative to other treatment regimens. In some embodiments, a treatment regimen is provided comprising administering to a subject a first agent, and a second agent which is an mTor inhibitor, wherein the first and second agent are administered according to a dosing schedule of the invention, and which dosing schedule results in reduced tumor hypoxia relative to a treatment regimen in which the first and second agent are administered simultaneously. Reduced tumor hypoxia may be measured, for example, as evidenced in a biochemical assay which measures cellular or tissue changes

associated with hypoxia. Such assays include, for example, changes in protein expression or prevalence. In some embodiments, reduced hypoxia is measured by pimonidazole staining. In other embodiments, reduced hypoxia is measured by a comet assay. In patients, hypoxia levels may be determined, among other methods, by direct measurement of tissue oxygen partial pressure (pO_2) through polarographic oxygen sensitive probes, measurement of tumor osteopontin levels, measurement of plasma osteopontin levels, measurement of Hif-1 α levels, or measurement of carbonic anhydrase levels.

[00537] In some embodiments, the synergistic effect of a treatment regimen of the invention manifests itself as a decreased incidence of a lab-detectable abnormalities during treatment. Such abnormalities include using antiangiogenic agents include hypophosphatemia, elevated lipase, elevated amylase, lymphopenia, neutropenia, and thrombocytopenia. In some embodiments, a treatment regimen according to the invention helps alleviate one or more abnormalities compared to an alternative regimen where the antiangiogenic agent is administered alone or an alternative regimen where the antiangiogenic agent is administered simultaneously with the mTor inhibitor.

[00538] Cardiac ischemia/infarction is higher in patients using sorafenib compared to those taking placebo. In some embodiments, a treatment regimen according to the invention helps improve blood flow, alleviate ischemia, or reduce the risk of infarction compared to an alternative regimen where the antiangiogenic agent is administered alone or an alternative regimen where the antiangiogenic agent is administered simultaneously with the mTor inhibitor.

[00539] As discussed herein, reduction of tumor size, although preferred, is not required in that the actual size of tumor may not shrink despite the eradication of tumor cells. Eradication of cancerous cells is sufficient to realize a therapeutic effect. Likewise, any reduction in tumor size is sufficient to realize a therapeutic effect.

[00540] Desirably, the growth of a tumor is stabilized (i.e., one or more tumors do not increase more than 1%, 5%, 10%, 15%, or 20% in size, and/or do not metastasize) as a result of the inventive method and compositions. In some embodiments, a tumor is stabilized for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more weeks. In some embodiments, a tumor is stabilized for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more months. In some embodiments, a tumor is stabilized for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more years. Preferably, the inventive method reduces the size of a tumor at least about 5% (e.g., at least about 10%, 15%, 20%, or 25%). More preferably, tumor size is reduced at least about 30% (e.g., at least about 35%, 40%, 45%, 50%, 55%, 60%, or 65%). Even more preferably, tumor size is reduced at least about 70% (e.g., at least about 75%, 80%, 85%, 90%, or 95%). Most preferably, the tumor is completely eliminated, or reduced below a level of detection. In some embodiments, a subject remains tumor free (e.g. in remission) for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more weeks following treatment. In some embodiments, a subject remains tumor free for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more months following treatment. In some embodiments, a subject remains tumor free for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more years after treatment.

[00541] When a tumor is subject to surgical resection following completion of the therapeutic period, the efficacy of the inventive method in reducing tumor size can be determined by measuring the percentage of

resected tissue that is necrotic (i.e., dead). In some embodiments, a treatment is therapeutically effective if the necrosis percentage of the resected tissue is greater than about 20% (e.g., at least about 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%), more preferably about 90% or greater (e.g., about 90%, 95%, or 100%). Most preferably, the necrosis percentage of the resected tissue is 100%, that is, no tumor tissue is present or detectable.

[00542] A number of secondary parameters can be employed to determine the efficacy of the inventive method. Examples of secondary parameters include, but are not limited to, detection of new tumors, detection of tumor antigens or markers (e.g., CEA, PSA, or CA-125), biopsy, surgical downstaging (i.e., conversion of the surgical stage of a tumor from unresectable to resectable), PET scans, survival, disease progression-free survival, time to disease progression, quality of life assessments such as the Clinical Benefit Response Assessment, and the like, all of which can point to the overall progression (or regression) of cancer in a human. Biopsy is particularly useful in detecting the eradication of cancerous cells within a tissue. Radioimmunodetection (RAID) is used to locate and stage tumors using serum levels of markers (antigens) produced by and/or associated with tumors (“tumor markers” or “tumor-associated antigens”), and can be useful as a pre-treatment diagnostic predicate, a post-treatment diagnostic indicator of recurrence, and a post-treatment indicator of therapeutic efficacy. Examples of tumor markers or tumor-associated antigens that can be evaluated as indicators of therapeutic efficacy include, but are not limited to, carcinoembryonic antigen (CEA) prostate-specific antigen (PSA), CA-125, CA19-9, ganglioside molecules (e.g., GM2, GD2, and GD3), MART-1, heat shock proteins (e.g., gp96), sialyl Tn (STn), tyrosinase, MUC-1, HER-2/neu, c-erb-B2, KSA, PSMA, p53, RAS, EGF-R, VEGF, MAGE, and gp100. Other tumor-associated antigens are known in the art. RAID technology in combination with endoscopic detection systems also efficiently distinguishes small tumors from surrounding tissue (see, for example, U.S. Pat. No. 4,932,412).

[00543] Desirably, in accordance with the inventive method, the treatment of cancer in a human patient is evidenced by one or more of the following results: (a) the complete disappearance of a tumor (i.e., a complete response), (b) about a 25% to about a 50% reduction in the size of a tumor for at least four weeks after completion of the therapeutic period as compared to the size of the tumor before treatment, (c) at least about a 50% reduction in the size of a tumor for at least four weeks after completion of the therapeutic period as compared to the size of the tumor before the therapeutic period, and (d) at least a 2% decrease (e.g., about a 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90% decrease) in a specific tumor-associated antigen level at about 4-12 weeks after completion of the therapeutic period as compared to the tumor-associated antigen level before the therapeutic period. While at least a 2% decrease in a tumor-associated antigen level is preferred, any decrease in the tumor-associated antigen level is evidence of treatment of a cancer in a patient by the inventive method. For example, with respect to unresectable, locally advanced pancreatic cancer, treatment can be evidenced by at least a 10% decrease in the CA19-9 tumor-associated antigen level at 4-12 weeks after completion of the therapeutic period as compared to the CA19-9 level before the therapeutic period. Similarly, with respect to locally advanced rectal cancer, treatment can be evidenced by at least a 10% decrease in the CEA tumor-associated antigen level at 4-12

weeks after completion of the therapeutic period as compared to the CEA level before the therapeutic period.

[00544] With respect to quality of life assessments, such as the Clinical Benefit Response Criteria, the therapeutic benefit of the treatment in accordance with the invention can be evidenced in terms of pain intensity, analgesic consumption, and/or the Karnofsky Performance Scale score. The Karnofsky Performance Scale allows patients to be classified according to their functional impairment. The Karnofsky Performance Scale is scored from 0-100. In general, a lower Karnofsky score is predictive of a poor prognosis for survival. Thus, the treatment of cancer in a human patient alternatively, or in addition, is evidenced by (a) at least a 50% decrease (e.g., at least a 60%, 70%, 80%, 90%, or 100% decrease) in pain intensity reported by a patient, such as for any consecutive four week period in the 12 weeks after completion of treatment, as compared to the pain intensity reported by the patient before treatment, (b) at least a 50% decrease (e.g., at least a 60%, 70%, 80%, 90%, or 100% decrease) in analgesic consumption reported by a patient, such as for any consecutive four week period in the 12 weeks after completion of treatment as compared to the analgesic consumption reported by the patient before treatment, and/or (c) at least a 20 point increase (e.g., at least a 30 point, 50 point, 70 point, or 90 point increase) in the Karnofsky Performance Scale score reported by a patient, such as for any consecutive four week period in the 12 weeks after completion of the therapeutic period as compared to the Karnofsky Performance Scale score reported by the patient before the therapeutic period.

[00545] The treatment of a proliferative disorder (e.g. cancer, whether benign or malignant) in a human patient desirably is evidenced by one or more (in any combination) of the foregoing results, although alternative or additional results of the referenced tests and/or other tests can evidence treatment efficacy.

[00546] Detection, monitoring, and rating of various cancers in a human are further described in Cancer Facts and Figures 2001, American Cancer Society, New York, N.Y., and International Patent Application WO 01/24684. Accordingly, a clinician can use standard tests to determine the efficacy of the various embodiments of the inventive method in treating cancer. However, in addition to tumor size and spread, the clinician also may consider quality of life and survival of the subject in evaluating efficacy of treatment.

[00547] In some embodiments, administration of a first agent in conjunction with administration of an mTOR inhibitor according to the method of the invention provides improved therapeutic efficacy over treatment with either agent alone or treatment with both agents delivered simultaneously. Improved efficacy may be measured using any method known in the art, including but not limited to those described herein. In some embodiments, the improved therapeutic efficacy is an improvement of at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 90%, 95%, 100%, 110%, 120%, 150%, 200%, 300%, 400%, 500%, 600%, 700%, 1000%, 10000% or more, using an appropriate measure (e.g. tumor size reduction, duration of tumor size stability, duration of time free from metastatic events, duration of disease-free survival). Improved efficacy may also be expressed as fold improvement, such as at least about 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 20-fold, 30-fold, 40-fold, 50-fold, 60-fold, 70-fold, 80-fold, 90-fold, 100-fold, 1000-fold, 10000-fold, or more, using an appropriate

measure (e.g. tumor size reduction, duration of tumor size stability, duration of time free from metastatic events, duration of disease-free survival).

Pharmaceutical compositions and administration

[00548] A combination treatment may further comprise the administration of one or more additional therapeutic agents, including one or more additional agents described herein as candidate first agents, and one or more additional agents described herein as candidate mTOR inhibitors. Such one or more additional agents can be administered simultaneously or separately with respect to the first agent, the mTOR inhibitor, or both. Administration in combination utilizing one or more additional agents includes, for example, administration of two agents in the same dosage form, simultaneous administration in separate dosage forms, and separate administration. For example, multiple therapeutic agents can be formulated together in the same dosage form and administered simultaneously. The term “combination treatments” also embraces the administration of the therapeutic agents as described herein in further combination with other biologically active compounds or ingredients and non-drug therapies (e.g., surgery or radiation treatment).

[00549] Administration of the compounds of the present invention can be effected by any method that enables delivery of the compounds to the site of action. These methods include oral routes, intraduodenal routes, parenteral injection (including intravenous, intraarterial, subcutaneous, intramuscular, intravascular, intraperitoneal or infusion), topical (e.g., transdermal application), rectal administration, via local delivery by catheter or stent or through inhalation. Compounds can also be administered intraadiposally or intrathecally. An effective amount of an inhibitor of the invention may be administered in either single or multiple doses by any of the accepted modes of administration of agents having similar utilities, including rectal, buccal, intranasal and transdermal routes, by intra-arterial injection, intravenously, intraperitoneally, parenterally, intramuscularly, subcutaneously, orally, topically, as an inhalant, or via an impregnated or coated device such as a stent, for example, or an artery-inserted cylindrical polymer. Sequential administration of a first agent, an mTOR inhibitor, and/or any additional therapeutic agent can be effected by any appropriate route as noted above and including, but not limited to, oral routes, intravenous routes, intramuscular routes, and direct absorption through mucous membrane tissues. The therapeutic agents can be administered by the same route or by different routes. For example, a first therapeutic agent of the combination selected may be administered by intravenous injection while the other therapeutic agents of the combination may be administered orally. Alternatively, for example, all therapeutic agents may be administered orally or all therapeutic agents may be administered by intravenous injection.

[00550] Methods of determining the most effective means and dosage of administration are well known to those of skill in the art and will vary with the composition used for therapy, the purpose of the therapy, the target cell or tissue being treated, and the subject being treated. Single or multiple administrations (e.g. about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, or more doses) can be carried out with the dose level and pattern being selected by the treating physician.

[00551] A first agent may be administered in any suitable amount, and in the order disclosed herein. In some embodiments, a first agent is administered to a subject within a range of about 0.1mg/kg-50mg/kg per day, such as about, less than about, or more than about, 1mg/kg, 2mg/kg, 3mg/kg, 4mg/kg, 5mg/kg, 6mg/kg, 7mg/kg, 8mg/kg, 9mg/kg, 10mg/kg, 11mg/kg, 12mg/kg, 13mg/kg, 14mg/kg, 15mg/kg, 16mg/kg, 17mg/kg, 18mg/kg, 19mg/kg, 20mg/kg, 25mg/kg, 30mg/kg, 35mg/kg, 40mg/kg, 45mg/kg, or 50mg/kg per day. In some embodiments, a first agent is administered to a subject within a range of about 0.1mg/kg-400mg/kg per week, such as about, less than about, or more than about 1mg/kg, 5mg/kg, 10mg/kg, 15mg/kg, 20mg/kg, 25mg/kg, 30mg/kg, 35mg/kg, 40mg/kg, 45mg/kg, 50mg/kg, 100mg/kg, 150mg/kg, 200mg/kg, 250mg/kg, 300mg/kg, 350mg/kg, or 400mg/kg per week. In some embodiments, a first agent is administered to a subject within a range of about 0.1mg/kg-1500mg/kg per month, such as about, less than about, or more than about 50mg/kg, 100mg/kg, 150mg/kg, 200mg/kg, 250mg/kg, 300mg/kg, 350mg/kg, 400mg/kg, 450mg/kg, 500mg/kg, 550mg/kg, 600mg/kg, 650mg/kg, 700mg/kg, 750mg/kg, 800mg/kg, 850mg/kg, 900mg/kg, 950mg/kg, or 1000mg/kg per month. In some embodiments, a first agent is administered to a subject within a range of about 0.1mg/m²-200mg/m² per week, such as about, less than about, or more than about 5mg/m², 10mg/m², 15mg/m², 20mg/m², 25mg/m², 30mg/m², 35mg/m², 40mg/m², 45mg/m², 50mg/m², 55mg/m², 60mg/m², 65mg/m², 70mg/m², 75mg/m², 100mg/m², 125mg/m², 150mg/m², 175mg/m², or 200mg/m² per week. The target dose may be administered in a single dose. Alternatively, the target dose may be administered in about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, or more doses. For example, a dose of about 20mg/kg per week may be delivered weekly at a dose of about 20mg/kg, or may be delivered at a dose of about 6.67mg/kg administered on each of three days over the course of the week, which days may or may not be consecutive. The administration schedule may be repeated according to any prescribed regimen, including any administration schedule described herein. In some embodiments, a first agent is administered to a subject in the range of about 0.1mg/m²-500mg/m², such as about, less than about, or more than about 5mg/m², 10 mg/m², 15mg/m², 20mg/m², 25mg/m², 30mg/m², 35mg/m², 40mg/m², 45mg/m², 50mg/m², 55mg/m², 60mg/m², 65mg/m², 70mg/m², 75mg/m², 100mg/m², 130mg/m², 135mg/m², 155mg/m², 175mg/m², 200mg/m², 225mg/m², 250mg/m², 300mg/m², 350mg/m², 400mg/m², 420mg/m², 450mg/m², or 500mg/m².

[00552] When the first agent is sorafenib, a single dose of sorafenib is between about 50 mg and about 400 or 600 mg twice daily of sorafenib. A dose may be about, at least about, or at most about 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, 625, 650, 675, 700, 725, 750, 775, 800, 825, 850, 875, 900, 925, 950, 975, 1000 mg or mg/kg, or any range derivable therein. It is contemplated that a dosage of mg/kg refers to the mg amount of sorafenib per kg of total body weight of the subject. It is contemplated that when multiple doses are given to a patient, the doses may vary in amount or they may be the same. In some embodiments, the sorafenib dose is 500 mg/m²/day on a body surface area basis.

[00553] The amount of each inhibitor or compound administered will be dependent on the mammal being treated, the severity of the disorder or condition, the rate of administration, the disposition of the compound and the discretion of the prescribing physician. However, an effective dosage of an mTOR inhibitor may be in the range of about 0.001 to about 100 mg per kg body weight per day, preferably about 1 to about 35 mg/kg/day, in single or divided doses. For a 70 kg human, this would amount to about 0.05 to 7 g/day, preferably about 0.05 to about 2.5 g/day. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, e.g., by dividing such larger doses into several small doses for administration throughout the day.

[00554] The subject pharmaceutical compositions can be formulated to provide a therapeutically effective amount of therapeutic agents of the present invention, or pharmaceutically acceptable salts, esters, prodrugs, solvates, hydrates or derivatives thereof. Where desired, the pharmaceutical compositions contain pharmaceutically acceptable salt and/or coordination complex thereof, and one or more pharmaceutically acceptable excipients, carriers, including inert solid diluents and fillers, diluents, including sterile aqueous solution and various organic solvents, permeation enhancers, solubilizers and adjuvants.

[00555] The subject pharmaceutical compositions can be administered as a combination of a first agent and an mTOR inhibitor, or in further combination with one or more other agents, which are also typically administered in the form of pharmaceutical compositions, wherein the composition is formulated such that a substantial portion of the first agent (e.g. at least 70%, 80%, 85%, 90%, 95%, 99%, or more) is released from the composition prior to the release of a significant portion of the mTOR inhibitor (e.g. less than about 50%, 40%, 30%, 20%, 10%, 5%, 4%, 3%, 2%, 1%, or less). For example, a drug-eluting stent may comprise a layer of first agent nearer to an exposed surface than, and coating a second layer comprising an mTOR inhibitor. Alternatively, a composition for oral administration may comprise an mTOR inhibitor formulated for delayed release, such that a first agent is released from the composition to the subject substantially prior to the release of the mTOR inhibitor. Methods and compositions for preparing coated drug eluting stents, and other delayed release formulations are known in the art. Where desired, the subject combinations and other agent(s) may be mixed into a preparation or both components may be formulated into separate preparations to use them in combination separately or at the same time, while still effecting administration of a first agent prior to administration of an mTOR inhibitor.

[00556] In some embodiments, the concentration of one or more of the compounds provided in the pharmaceutical compositions of the present invention is less than 100%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%, 0.01%, 0.009%, 0.008%, 0.007%, 0.006%, 0.005%, 0.004%, 0.003%, 0.002%, 0.001%, 0.0009%, 0.0008%, 0.0007%, 0.0006%, 0.0005%, 0.0004%, 0.0003%, 0.0002%, or 0.0001% w/w, w/v or v/v.

[00557] In some embodiments, the concentration of one or more of the compounds of the present invention is greater than 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19.75%, 19.50%, 19.25% 19%,

18.75%, 18.50%, 18.25% 18%, 17.75%, 17.50%, 17.25% 17%, 16.75%, 16.50%, 16.25% 16%, 15.75%, 15.50%, 15.25% 15%, 14.75%, 14.50%, 14.25% 14%, 13.75%, 13.50%, 13.25% 13%, 12.75%, 12.50%, 12.25% 12%, 11.75%, 11.50%, 11.25% 11%, 10.75%, 10.50%, 10.25% 10%, 9.75%, 9.50%, 9.25% 9%, 8.75%, 8.50%, 8.25% 8%, 7.75%, 7.50%, 7.25% 7%, 6.75%, 6.50%, 6.25% 6%, 5.75%, 5.50%, 5.25% 5%, 4.75%, 4.50%, 4.25% 4%, 3.75%, 3.50%, 3.25% 3%, 2.75%, 2.50%, 2.25% 2%, 1.75%, 1.50%, 1.25% 1%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%, 0.01%, 0.009%, 0.008%, 0.007%, 0.006%, 0.005%, 0.004%, 0.003%, 0.002%, 0.001%, 0.0009%, 0.0008%, 0.0007%, 0.0006%, 0.0005%, 0.0004%, 0.0003%, 0.0002%, or 0.0001% w/w, w/v, or v/v.

[00558] In some embodiments, the concentration of one or more of the compounds of the present invention is in the range from approximately 0.0001% to approximately 50%, approximately 0.001% to approximately 40 %, approximately 0.01% to approximately 30%, approximately 0.02% to approximately 29%, approximately 0.03% to approximately 28%, approximately 0.04% to approximately 27%, approximately 0.05% to approximately 26%, approximately 0.06% to approximately 25%, approximately 0.07% to approximately 24%, approximately 0.08% to approximately 23%, approximately 0.09% to approximately 22%, approximately 0.1% to approximately 21%, approximately 0.2% to approximately 20%, approximately 0.3% to approximately 19%, approximately 0.4% to approximately 18%, approximately 0.5% to approximately 17%, approximately 0.6% to approximately 16%, approximately 0.7% to approximately 15%, approximately 0.8% to approximately 14%, approximately 0.9% to approximately 12%, approximately 1% to approximately 10% w/w, w/v or v/v. v/v.

[00559] In some embodiments, the concentration of one or more of the compounds of the present invention is in the range from approximately 0.001% to approximately 10%, approximately 0.01% to approximately 5%, approximately 0.02% to approximately 4.5%, approximately 0.03% to approximately 4%, approximately 0.04% to approximately 3.5%, approximately 0.05% to approximately 3%, approximately 0.06% to approximately 2.5%, approximately 0.07% to approximately 2%, approximately 0.08% to approximately 1.5%, approximately 0.09% to approximately 1%, approximately 0.1% to approximately 0.9% w/w, w/v or v/v.

[00560] In some embodiments, the amount of one or more of the compounds of the present invention is equal to or less than 10 g, 9.5 g, 9.0 g, 8.5 g, 8.0 g, 7.5 g, 7.0 g, 6.5 g, 6.0 g, 5.5 g, 5.0 g, 4.5 g, 4.0 g, 3.5 g, 3.0 g, 2.5 g, 2.0 g, 1.5 g, 1.0 g, 0.95 g, 0.9 g, 0.85 g, 0.8 g, 0.75 g, 0.7 g, 0.65 g, 0.6 g, 0.55 g, 0.5 g, 0.45 g, 0.4 g, 0.35 g, 0.3 g, 0.25 g, 0.2 g, 0.15 g, 0.1 g, 0.09 g, 0.08 g, 0.07 g, 0.06 g, 0.05 g, 0.04 g, 0.03 g, 0.02 g, 0.01 g, 0.009 g, 0.008 g, 0.007 g, 0.006 g, 0.005 g, 0.004 g, 0.003 g, 0.002 g, 0.001 g, 0.0009 g, 0.0008 g, 0.0007 g, 0.0006 g, 0.0005 g, 0.0004 g, 0.0003 g, 0.0002 g, or 0.0001 g.

[00561] In some embodiments, the amount of one or more of the compounds of the present invention is more than 0.0001 g, 0.0002 g, 0.0003 g, 0.0004 g, 0.0005 g, 0.0006 g, 0.0007 g, 0.0008 g, 0.0009 g, 0.001 g, 0.0015 g, 0.002 g, 0.0025 g, 0.003 g, 0.0035 g, 0.004 g, 0.0045 g, 0.005 g, 0.0055 g, 0.006 g, 0.0065 g, 0.007 g, 0.0075 g, 0.008 g, 0.0085 g, 0.009 g, 0.0095 g, 0.01 g, 0.015 g, 0.02 g, 0.025 g, 0.03 g, 0.035 g, 0.04 g, 0.045 g, 0.05 g, 0.055 g, 0.06 g, 0.065 g, 0.07 g, 0.075 g, 0.08 g, 0.085 g, 0.09 g, 0.095 g, 0.1 g, 0.15 g, 0.2 g, 0.25 g, 0.3 g, 0.35 g, 0.4 g, 0.45 g, 0.5 g, 0.55 g, 0.6 g, 0.65 g, 0.7 g, 0.75 g, 0.8 g, 0.85 g,

0.9 g, 0.95 g, 1 g, 1.5 g, 2 g, 2.5, 3 g, 3.5, 4 g, 4.5 g, 5 g, 5.5 g, 6 g, 6.5g, 7 g, 7.5g, 8 g, 8.5 g, 9 g, 9.5 g, or 10 g.

[00562] In some embodiments, the amount of one or more of the compounds of the present invention is in the range of 0.0001-10 g, 0.0005-9 g, 0.001-8 g, 0.005-7 g, 0.01-6 g, 0.05-5 g, 0.1-4 g, 0.5-4 g, or 1-3 g.

[00563] The treatments according to the invention are effective over a wide dosage range. For example, in the treatment of adult humans, dosages from 0.01 to 1000 mg, from 0.5 to 100 mg, from 1 to 50 mg per day, and from 5 to 40 mg per day are examples of dosages that may be used. An exemplary dosage is 10 to 30 mg per day. The exact dosage will depend upon the agent selected, the route of administration, the form in which the compound is administered, the subject to be treated, the body weight of the subject to be treated, and the preference and experience of the attending physician.

[00564] A pharmaceutical composition of the present invention typically contains an active ingredient (e.g., an inhibitor of the present invention or a pharmaceutically acceptable salt and/or coordination complex thereof, and one or more pharmaceutically acceptable excipients, carriers, including but not limited inert solid diluents and fillers, diluents, sterile aqueous solution and various organic solvents, permeation enhancers, solubilizers and adjuvants.

[00565] Described below are non-limiting exemplary pharmaceutical compositions and methods for preparing the same.

[00566] Pharmaceutical compositions for oral administration In some embodiments, the invention provides a pharmaceutical composition for oral administration containing at least one therapeutic agent (such as a first agent or a second agent), and a pharmaceutical excipient suitable for oral administration.

[00567] In one embodiment, the present invention provides an oral dosage form comprising 100 mg to 1.5g of an agent of the invention. The oral dosage form can be a tablet, formulated in form of liquid, in immediate or sustained release format.

[00568] In some embodiments, the invention also provides a solid pharmaceutical composition for oral administration containing: (i) a first agent such as an antiangiogenic agent; (ii) a second compound which is an mTor inhibitor formulated for release substantially after release of the first agent (e.g. at least 70%, 80%, 85%, 90%, 95%, 99%, or more of the mTOR inhibitor released after release of a substantial portion of the first agent, e.g. at least 70%, 80%, 85%, 90%, 95%, 99%, or more of the first agent); and (iii) a pharmaceutical excipient suitable for oral administration. In some embodiments, the composition further contains: (iv) a third agent or even a fourth agent. In some embodiments, each compound or agent is present in a therapeutically effective amount. In other embodiments, one or more compounds or agents is present in a sub-therapeutic amount, and the compounds or agents act synergistically to provide a therapeutically effective pharmaceutical composition.

[00569] In some embodiments, the pharmaceutical composition may be a liquid pharmaceutical composition suitable for oral consumption. Pharmaceutical compositions of the invention suitable for oral administration can be presented as discrete dosage forms, such as capsules, cachets, or tablets, or liquids or aerosol sprays each containing a predetermined amount of an active ingredient as a powder or in granules, a solution, or a suspension in an aqueous or non-aqueous liquid, an oil-in-water emulsion, or a

water-in-oil liquid emulsion, including liquid dosage forms (e.g., a suspension or slurry), and oral solid dosage forms (e.g., a tablet or bulk powder). As used herein the term "tablet" refers generally to tablets, caplets, capsules, including soft gelatin capsules, and lozenges. Oral dosage forms may be formulated as tablets, pills, dragees, capsules, emulsions, lipophilic and hydrophilic suspensions, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by an individual or a patient to be treated. Such dosage forms can be prepared by any of the methods of pharmacy, but all methods include the step of bringing the active ingredient into association with the carrier, which constitutes one or more necessary ingredients. In one embodiment, the inhibitor of the invention is contained in capsules. Capsules suitable for oral administration include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. Optionally, the inventive composition for oral use can be obtained by mixing a first agent or mTOR inhibitor with a solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). In general, the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired presentation. For example, a tablet can be prepared by compression or molding, optionally with one or more accessory ingredients. Compressed tablets can be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as powder or granules, optionally mixed with an excipient such as, but not limited to, a binder, a lubricant, an inert diluent, and/or a surface active or dispersing agent. Molded tablets can be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.

[00570] This invention further encompasses anhydrous pharmaceutical compositions and dosage forms comprising an active ingredient, since water can facilitate the degradation of some compounds. For example, water may be added (e.g., 5%) in the pharmaceutical arts as a means of simulating long-term storage in order to determine characteristics such as shelf-life or the stability of formulations over time. Anhydrous pharmaceutical compositions and dosage forms of the invention can be prepared using anhydrous or low moisture containing ingredients and low moisture or low humidity conditions. Pharmaceutical compositions and dosage forms of the invention which contain lactose can be made anhydrous if substantial contact with moisture and/or humidity during manufacturing, packaging, and/or storage is expected. An anhydrous pharmaceutical composition may be prepared and stored such that its anhydrous nature is maintained. Accordingly, anhydrous compositions may be packaged using materials known to prevent exposure to water such that they can be included in suitable formulary kits. Examples of

suitable packaging include, but are not limited to, hermetically sealed foils, plastic or the like, unit dose containers, blister packs, and strip packs.

[00571] An active ingredient can be combined in an intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier can take a wide variety of forms depending on the form of preparation desired for administration. In preparing the compositions for an oral dosage form, any of the usual pharmaceutical media can be employed as carriers, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and the like in the case of oral liquid preparations (such as suspensions, solutions, and elixirs) or aerosols; or carriers such as starches, sugars, micro-crystalline cellulose, diluents, granulating agents, lubricants, binders, and disintegrating agents can be used in the case of oral solid preparations, in some embodiments without employing the use of lactose. For example, suitable carriers include powders, capsules, and tablets, with the solid oral preparations. If desired, tablets can be coated by standard aqueous or nonaqueous techniques.

[00572] Binders suitable for use in pharmaceutical compositions and dosage forms include, but are not limited to, corn starch, potato starch, or other starches, gelatin, natural and synthetic gums such as acacia, sodium alginate, alginic acid, other alginates, powdered tragacanth, guar gum, cellulose and its derivatives (e.g., ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethyl cellulose), polyvinyl pyrrolidone, methyl cellulose, pre-gelatinized starch, hydroxypropyl methyl cellulose, microcrystalline cellulose, and mixtures thereof.

[00573] Examples of suitable fillers for use in the pharmaceutical compositions and dosage forms disclosed herein include, but are not limited to, talc, calcium carbonate (e.g., granules or powder), microcrystalline cellulose, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, starch, pre-gelatinized starch, and mixtures thereof.

[00574] Disintegrants may be used in the compositions of the invention to provide tablets that disintegrate when exposed to an aqueous environment. Too much of a disintegrant may produce tablets which may disintegrate in the bottle. Too little may be insufficient for disintegration to occur and may thus alter the rate and extent of release of the active ingredient(s) from the dosage form. Thus, a sufficient amount of disintegrant that is neither too little nor too much to detrimentally alter the release of the active ingredient(s) may be used to form the dosage forms of the compounds disclosed herein. The amount of disintegrant used may vary based upon the type of formulation and mode of administration, and may be readily discernible to those of ordinary skill in the art. About 0.5 to about 15 weight percent of disintegrant, or about 1 to about 5 weight percent of disintegrant, may be used in the pharmaceutical composition. Disintegrants that can be used to form pharmaceutical compositions and dosage forms of the invention include, but are not limited to, agar-agar, alginic acid, calcium carbonate, microcrystalline cellulose, croscarmellose sodium, crospovidone, polacrillin potassium, sodium starch glycolate, potato or tapioca starch, other starches, pre-gelatinized starch, other starches, clays, other alginates, other celluloses, gums or mixtures thereof.

[00575] Lubricants which can be used to form pharmaceutical compositions and dosage forms of the invention include, but are not limited to, calcium stearate, magnesium stearate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc, hydrogenated vegetable oil (e.g., peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil), zinc stearate, ethyl oleate, ethyl laurate, agar, or mixtures thereof. Additional lubricants include, for example, a syloid silica gel, a coagulated aerosol of synthetic silica, or mixtures thereof. A lubricant can optionally be added, in an amount of less than about 1 weight percent of the pharmaceutical composition.

[00576] Lubricants can be also be used in conjunction with tissue barriers which include, but are not limited to, polysaccharides, polyglycans, seprafilm, interceed and hyaluronic acid.

[00577] When aqueous suspensions and/or elixirs are desired for oral administration, the essential active ingredient therein may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if so desired, emulsifying and/or suspending agents, together with such diluents as water, ethanol, propylene glycol, glycerin and various combinations thereof.

[00578] The tablets can be uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate can be employed. Formulations for oral use can also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil.

[00579] Surfactant which can be used to form pharmaceutical compositions and dosage forms of the invention include, but are not limited to, hydrophilic surfactants, lipophilic surfactants, and mixtures thereof. That is, a mixture of hydrophilic surfactants may be employed, a mixture of lipophilic surfactants may be employed, or a mixture of at least one hydrophilic surfactant and at least one lipophilic surfactant may be employed.

[00580] A suitable hydrophilic surfactant may generally have an HLB value of at least 10, while suitable lipophilic surfactants may generally have an HLB value of or less than about 10. An empirical parameter used to characterize the relative hydrophilicity and hydrophobicity of non-ionic amphiphilic compounds is the hydrophilic-lipophilic balance ("HLB" value). Surfactants with lower HLB values are more lipophilic or hydrophobic, and have greater solubility in oils, while surfactants with higher HLB values are more hydrophilic, and have greater solubility in aqueous solutions. Hydrophilic surfactants are generally considered to be those compounds having an HLB value greater than about 10, as well as anionic, cationic, or zwitterionic compounds for which the HLB scale is not generally applicable. Similarly, lipophilic (i.e., hydrophobic) surfactants are compounds having an HLB value equal to or less than about 10. However, HLB value of a surfactant is merely a rough guide generally used to enable formulation of industrial, pharmaceutical and cosmetic emulsions.

[00581] Hydrophilic surfactants may be either ionic or non-ionic. Suitable ionic surfactants include, but are not limited to, alkylammonium salts; fusidic acid salts; fatty acid derivatives of amino acids, oligopeptides, and polypeptides; glyceride derivatives of amino acids, oligopeptides, and polypeptides; lecithins and hydrogenated lecithins; lysolecithins and hydrogenated lysolecithins; phospholipids and derivatives thereof; lysophospholipids and derivatives thereof; carnitine fatty acid ester salts; salts of alkylsulfates; fatty acid salts; sodium docusate; acylactylates; mono- and di-acetylated tartaric acid esters of mono- and di-glycerides; succinylated mono- and di-glycerides; citric acid esters of mono- and di-glycerides; and mixtures thereof.

[00582] Within the aforementioned group, ionic surfactants include, by way of example: lecithins, lysolecithin, phospholipids, lysophospholipids and derivatives thereof; carnitine fatty acid ester salts; salts of alkylsulfates; fatty acid salts; sodium docusate; acylactylates; mono- and di-acetylated tartaric acid esters of mono- and di-glycerides; succinylated mono- and di-glycerides; citric acid esters of mono- and di-glycerides; and mixtures thereof.

[00583] Ionic surfactants may be the ionized forms of lecithin, lysolecithin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidic acid, phosphatidylserine, lysophosphatidylcholine, lysophosphatidylethanolamine, lysophosphatidylglycerol, lysophosphatidic acid, lysophosphatidylserine, PEG-phosphatidylethanolamine, PVP-phosphatidylethanolamine, lactic esters of fatty acids, stearyl-2-lactylate, stearyl lactylate, succinylated monoglycerides, mono/diacetylated tartaric acid esters of mono/diglycerides, citric acid esters of mono/diglycerides, choly sarcosine, caproate, caprylate, caprate, laurate, myristate, palmitate, oleate, ricinoleate, linoleate, linolenate, stearate, lauryl sulfate, teracecyl sulfate, docusate, lauroyl carnitines, palmitoyl carnitines, myristoyl carnitines, and salts and mixtures thereof.

[00584] Hydrophilic non-ionic surfactants may include, but not limited to, alkylglucosides; alkylmaltosides; alkylthioglucosides; lauryl macroglycerides; polyoxyalkylene alkyl ethers such as polyethylene glycol alkyl ethers; polyoxyalkylene alkylphenols such as polyethylene glycol alkyl phenols; polyoxyalkylene alkyl phenol fatty acid esters such as polyethylene glycol fatty acids monoesters and polyethylene glycol fatty acids diesters; polyethylene glycol glycerol fatty acid esters; polyglycerol fatty acid esters; polyoxyalkylene sorbitan fatty acid esters such as polyethylene glycol sorbitan fatty acid esters; hydrophilic transesterification products of a polyol with at least one member of the group consisting of glycerides, vegetable oils, hydrogenated vegetable oils, fatty acids, and sterols; polyoxyethylene sterols, derivatives, and analogues thereof; polyoxyethylated vitamins and derivatives thereof; polyoxyethylene-polyoxypropylene block copolymers; and mixtures thereof; polyethylene glycol sorbitan fatty acid esters and hydrophilic transesterification products of a polyol with at least one member of the group consisting of triglycerides, vegetable oils, and hydrogenated vegetable oils. The polyol may be glycerol, ethylene glycol, polyethylene glycol, sorbitol, propylene glycol, pentaerythritol, or a saccharide.

[00585] Other hydrophilic-non-ionic surfactants include, without limitation, PEG-10 laurate, PEG-12 laurate, PEG-20 laurate, PEG-32 laurate, PEG-32 dilaurate, PEG-12 oleate, PEG-15 oleate, PEG-20

oleate, PEG-20 dioleate, PEG-32 oleate, PEG-200 oleate, PEG-400 oleate, PEG-15 stearate, PEG-32 distearate, PEG-40 stearate, PEG-100 stearate, PEG-20 dilaurate, PEG-25 glyceryl trioleate, PEG-32 dioleate, PEG-20 glyceryl laurate, PEG-30 glyceryl laurate, PEG-20 glyceryl stearate, PEG-20 glyceryl oleate, PEG-30 glyceryl oleate, PEG-30 glyceryl laurate, PEG-40 glyceryl laurate, PEG-40 palm kernel oil, PEG-50 hydrogenated castor oil, PEG-40 castor oil, PEG-35 castor oil, PEG-60 castor oil, PEG-40 hydrogenated castor oil, PEG-60 hydrogenated castor oil, PEG-60 corn oil, PEG-6 caprate/caprylate glycerides, PEG-8 caprate/caprylate glycerides, polyglyceryl-10 laurate, PEG-30 cholesterol, PEG-25 phyto sterol, PEG-30 soya sterol, PEG-20 trioleate, PEG-40 sorbitan oleate, PEG-80 sorbitan laurate, polysorbate 20, polysorbate 80, POE-9 lauryl ether, POE-23 lauryl ether, POE-10 oleyl ether, POE-20 oleyl ether, POE-20 stearyl ether, tocopheryl PEG-100 succinate, PEG-24 cholesterol, polyglyceryl-10oleate, Tween 40, Tween 60, sucrose monostearate, sucrose monolaurate, sucrose monopalmitate, PEG 10-100 nonyl phenol series, PEG 15-100 octyl phenol series, and poloxamers.

[00586] Suitable lipophilic surfactants include, by way of example only: fatty alcohols; glycerol fatty acid esters; acetylated glycerol fatty acid esters; lower alcohol fatty acids esters; propylene glycol fatty acid esters; sorbitan fatty acid esters; polyethylene glycol sorbitan fatty acid esters; sterols and sterol derivatives; polyoxyethylated sterols and sterol derivatives; polyethylene glycol alkyl ethers; sugar esters; sugar ethers; lactic acid derivatives of mono- and di-glycerides; hydrophobic transesterification products of a polyol with at least one member of the group consisting of glycerides, vegetable oils, hydrogenated vegetable oils, fatty acids and sterols; oil-soluble vitamins/vitamin derivatives; and mixtures thereof. Within this group, preferred lipophilic surfactants include glycerol fatty acid esters, propylene glycol fatty acid esters, and mixtures thereof, or are hydrophobic transesterification products of a polyol with at least one member of the group consisting of vegetable oils, hydrogenated vegetable oils, and triglycerides.

[00587] In one embodiment, the composition may include a solubilizer to ensure good solubilization and/or dissolution of the compound of the present invention and to minimize precipitation of the compound of the present invention. This can be especially important for compositions for non-oral use, e.g., compositions for injection. A solubilizer may also be added to increase the solubility of the hydrophilic drug and/or other components, such as surfactants, or to maintain the composition as a stable or homogeneous solution or dispersion.

[00588] Examples of suitable solubilizers include, but are not limited to, the following: alcohols and polyols, such as ethanol, isopropanol, butanol, benzyl alcohol, ethylene glycol, propylene glycol, butanediols and isomers thereof, glycerol, pentaerythritol, sorbitol, mannitol, transcitol, dimethyl isosorbide, polyethylene glycol, polypropylene glycol, polyvinylalcohol, hydroxypropyl methylcellulose and other cellulose derivatives, cyclodextrins and cyclodextrin derivatives; ethers of polyethylene glycols having an average molecular weight of about 200 to about 6000, such as tetrahydrofurfuryl alcohol PEG ether (glycofurol) or methoxy PEG ; amides and other nitrogen-containing compounds such as 2-pyrrolidone, 2-piperidone, .epsilon.-caprolactam, N-alkylpyrrolidone, N-hydroxyalkylpyrrolidone, N-alkylpiperidone, N-alkylcaprolactam, dimethylacetamide and polyvinylpyrrolidone; esters such as ethyl propionate, tributylcitrate, acetyl triethylcitrate, acetyl tributyl citrate, triethylcitrate, ethyl oleate, ethyl

caprylate, ethyl butyrate, triacetin, propylene glycol monoacetate, propylene glycol diacetate, ϵ -caprolactone and isomers thereof, δ -valerolactone and isomers thereof, β -butyrolactone and isomers thereof; and other solubilizers known in the art, such as dimethyl acetamide, dimethyl isosorbide, N-methyl pyrrolidones, mono-octanoin, diethylene glycol monoethyl ether, and water.

[00589] Mixtures of solubilizers may also be used. Examples include, but not limited to, triacetin, triethylcitrate, ethyl oleate, ethyl caprylate, dimethylacetamide, N-methylpyrrolidone, N-hydroxyethylpyrrolidone, polyvinylpyrrolidone, hydroxypropyl methylcellulose, hydroxypropyl cyclodextrins, ethanol, polyethylene glycol 200-100, glycofurol, transcutool, propylene glycol, and dimethyl isosorbide. Particularly preferred solubilizers include sorbitol, glycerol, triacetin, ethyl alcohol, PEG-400, glycofurol and propylene glycol.

[00590] The amount of solubilizer that can be included is not particularly limited. The amount of a given solubilizer may be limited to a bioacceptable amount, which may be readily determined by one of skill in the art. In some circumstances, it may be advantageous to include amounts of solubilizers far in excess of bioacceptable amounts, for example to maximize the concentration of the drug, with excess solubilizer removed prior to providing the composition to a subject using conventional techniques, such as distillation or evaporation. Thus, if present, the solubilizer can be in a weight ratio of 10%, 25%, 50%, 100%, or up to about 200% by weight, based on the combined weight of the drug, and other excipients. If desired, very small amounts of solubilizer may also be used, such as 5%, 2%, 1% or even less. Typically, the solubilizer may be present in an amount of about 1% to about 100%, more typically about 5% to about 25% by weight.

[00591] The composition can further include one or more pharmaceutically acceptable additives and excipients. Such additives and excipients include, without limitation, detackifiers, anti-foaming agents, buffering agents, polymers, antioxidants, preservatives, chelating agents, viscomodulators, tonicifiers, flavorants, colorants, odorants, opacifiers, suspending agents, binders, fillers, plasticizers, lubricants, and mixtures thereof.

[00592] In addition, an acid or a base may be incorporated into the composition to facilitate processing, to enhance stability, or for other reasons. Examples of pharmaceutically acceptable bases include amino acids, amino acid esters, ammonium hydroxide, potassium hydroxide, sodium hydroxide, sodium hydrogen carbonate, aluminum hydroxide, calcium carbonate, magnesium hydroxide, magnesium aluminum silicate, synthetic aluminum silicate, synthetic hydrocalcite, magnesium aluminum hydroxide, diisopropylethylamine, ethanolamine, ethylenediamine, triethanolamine, triethylamine, triisopropanolamine, trimethylamine, tris(hydroxymethyl)aminomethane (TRIS) and the like. Also suitable are bases that are salts of a pharmaceutically acceptable acid, such as acetic acid, acrylic acid, adipic acid, alginic acid, alkanesulfonic acid, amino acids, ascorbic acid, benzoic acid, boric acid, butyric acid, carbonic acid, citric acid, fatty acids, formic acid, fumaric acid, gluconic acid, hydroquinonesulfonic acid, isoascorbic acid, lactic acid, maleic acid, oxalic acid, para-bromophenylsulfonic acid, propionic acid, p-toluenesulfonic acid, salicylic acid, stearic acid, succinic acid, tannic acid, tartaric acid, thioglycolic acid, toluenesulfonic acid, uric acid, and the like. Salts of polyprotic acids, such as sodium phosphate,

disodium hydrogen phosphate, and sodium dihydrogen phosphate can also be used. When the base is a salt, the cation can be any convenient and pharmaceutically acceptable cation, such as ammonium, alkali metals, alkaline earth metals, and the like. Example may include, but not limited to, sodium, potassium, lithium, magnesium, calcium and ammonium.

[00593] Suitable acids are pharmaceutically acceptable organic or inorganic acids. Examples of suitable inorganic acids include hydrochloric acid, hydrobromic acid, hydriodic acid, sulfuric acid, nitric acid, boric acid, phosphoric acid, and the like. Examples of suitable organic acids include acetic acid, acrylic acid, adipic acid, alginic acid, alkanesulfonic acids, amino acids, ascorbic acid, benzoic acid, boric acid, butyric acid, carbonic acid, citric acid, fatty acids, formic acid, fumaric acid, gluconic acid, hydroquinosulfonic acid, isoascorbic acid, lactic acid, maleic acid, methanesulfonic acid, oxalic acid, para-bromophenylsulfonic acid, propionic acid, p-toluenesulfonic acid, salicylic acid, stearic acid, succinic acid, tannic acid, tartaric acid, thioglycolic acid, toluenesulfonic acid, uric acid and the like.

[00594] Pharmaceutical compositions for injection. In some embodiments, the invention provides a pharmaceutical composition for injection containing at least one compound of the present invention and a pharmaceutical excipient suitable for injection. For example, pharmaceutical compositions comprising a first agent are provided as well as pharmaceutical compositions comprising an mTor inhibitor, where the first agent is administered before the mTor inhibitor. The first agent and the mTor inhibitor are formulated separately, and may further include a third therapeutic agent. Components and amounts of agents in the compositions are as described herein. In some embodiments, an injectable composition comprising both the first agent and the mTOR inhibitor is formulated such that the mTOR inhibitor is an initially inactive component that becomes active substantially after the first agent (e.g. at least 70%, 80%, 85%, 90%, 95%, 99% or more of the mTOR inhibitor becomes active after 70%, 80%, 85%, 90%, 95%, 99%, or more of the first agent is in active form). For example, the first agent may be formulated such that it is active immediately upon injection, while the mTOR inhibitor is formulated to become active at a later time.

[00595] The forms in which the novel compositions of the present invention may be incorporated for administration by injection include aqueous or oil suspensions, or emulsions, with sesame oil, corn oil, cottonseed oil, or peanut oil, as well as elixirs, mannitol, dextrose, or a sterile aqueous solution, and similar pharmaceutical vehicles.

[00596] Aqueous solutions in saline are also conventionally used for injection. Ethanol, glycerol, propylene glycol, liquid polyethylene glycol, and the like (and suitable mixtures thereof), cyclodextrin derivatives, and vegetable oils may also be employed. The proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, for the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.

[00597] Sterile injectable solutions are prepared by incorporating the compound of the present invention in the required amount in the appropriate solvent with various other ingredients as enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the

various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, certain desirable methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

[00598] Pharmaceutical compositions for topical (e.g., transdermal) delivery. In some embodiments, the invention provides a pharmaceutical composition for transdermal delivery containing at least one compound of the present invention and a pharmaceutical excipient suitable for transdermal delivery. Provided are pharmaceutical compositions for topical delivery comprising a first agent, and pharmaceutical compositions for topical delivery comprising an mTor inhibitor, where the first agent is administered before or after the mTor inhibitor. The first agent and the mTor inhibitor may be formulated separately, and may further include a third therapeutic agent. In some embodiments, compositions comprising both the first agent and the mTOR inhibitor are formulated such that the mTOR inhibitor is delivered substantially after the first agent (e.g. at least 70%, 80%, 85%, 90%, 95%, 99% or more of the mTOR inhibitor is delivered after 70%, 80%, 85%, 90%, 95%, 99%, or more of the first agent is delivered). For example, a transdermal patch may comprise a layer comprising a first agent (e.g. paclitaxel) that is closer to the skin than, and covering a layer comprising an mTOR inhibitor.

[00599] Compositions of the present invention can be formulated into preparations in solid, semi-solid, or liquid forms suitable for local or topical administration, such as gels, water soluble jellies, creams, lotions, suspensions, foams, powders, slurries, ointments, solutions, oils, pastes, suppositories, sprays, emulsions, saline solutions, dimethylsulfoxide (DMSO)-based solutions. In general, carriers with higher densities are capable of providing an area with a prolonged exposure to the active ingredients. In contrast, a solution formulation may provide more immediate exposure of the active ingredient to the chosen area.

[00600] The pharmaceutical compositions also may comprise suitable solid or gel phase carriers or excipients, which are compounds that allow increased penetration of, or assist in the delivery of, therapeutic molecules across the stratum corneum permeability barrier of the skin. There are many of these penetration-enhancing molecules known to those trained in the art of topical formulation. Examples of such carriers and excipients include, but are not limited to, humectants (e.g., urea), glycols (e.g., propylene glycol), alcohols (e.g., ethanol), fatty acids (e.g., oleic acid), surfactants (e.g., isopropyl myristate and sodium lauryl sulfate), pyrrolidones, glycerol monolaurate, sulfoxides, terpenes (e.g., menthol), amines, amides, alkanes, alkanols, water, calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.

[00601] Another exemplary formulation for use in the methods of the present invention employs transdermal delivery devices ("patches"). Such transdermal patches may be used to provide continuous or discontinuous infusion of an inhibitor of the present invention in controlled amounts, either with or without another agent.

[00602] The construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art. See, e.g., U.S. Pat. Nos. 5,023,252, 4,992,445 and 5,001,139. Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.

[00603] Pharmaceutical compositions for inhalation. Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra. Preferably the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions in preferably pharmaceutically acceptable solvents may be nebulized by use of inert gases. Nebulized solutions may be inhaled directly from the nebulizing device or the nebulizing device may be attached to a face mask tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions may be administered, preferably orally or nasally, from devices that deliver the formulation in an appropriate manner.

[00604] Other pharmaceutical compositions. Pharmaceutical compositions may also be prepared from compositions described herein and one or more pharmaceutically acceptable excipients suitable for sublingual, buccal, rectal, intraosseous, intraocular, intranasal, epidural, or intraspinal administration. Preparations for such pharmaceutical compositions are well-known in the art. See, e.g., See, e.g., Anderson, Philip O.; Knoben, James E.; Troutman, William G, eds., *Handbook of Clinical Drug Data*, Tenth Edition, McGraw-Hill, 2002; Pratt and Taylor, eds., *Principles of Drug Action*, Third Edition, Churchill Livingstone, New York, 1990; Katzung, ed., *Basic and Clinical Pharmacology*, Ninth Edition, McGraw Hill, 20037ybg; Goodman and Gilman, eds., *The Pharmacological Basis of Therapeutics*, Tenth Edition, McGraw Hill, 2001; *Remingtons Pharmaceutical Sciences*, 20th Ed., Lippincott Williams & Wilkins., 2000; Martindale, *The Extra Pharmacopoeia*, Thirty-Second Edition (The Pharmaceutical Press, London, 1999); all of which are incorporated by reference herein in their entirety.

[00605] The compositions of the invention may also be delivered via an impregnated or coated device such as a stent, for example, or an artery-inserted cylindrical polymer. Such a method of administration may, for example, aid in the prevention or amelioration of restenosis following procedures such as balloon angioplasty. An agent may be administered, for example, by local delivery from the struts of a stent, from a stent graft, from grafts, or from the cover or sheath of a stent. In some embodiments, an agent is admixed with a matrix. Such a matrix may be a polymeric matrix, and may serve to bond the compound to the stent. Polymeric matrices suitable for such use, include, for example, lactone-based polyesters or copolyesters such as polylactide, polycaprolactone, polyglycolide, polyorthoesters, polyanhydrides, polyaminoacids, polysaccharides, polyphosphazenes, poly (ether-ester) copolymers (e.g., PEO-PLLA); polydimethylsiloxane, poly(ethylene-vinylacetate), acrylate-based polymers or copolymers (e.g., polyhydroxyethyl methylmethacrylate, polyvinyl pyrrolidinone), fluorinated polymers such as polytetrafluoroethylene and cellulose esters. Suitable matrices may be nondegrading or may degrade with time, releasing the compound or compounds. Agents may be applied to the surface of the stent by various methods such as dip/spin coating, spray coating, dip-coating, and/or brush-coating. The agents may be applied in a solvent and the solvent may be allowed to evaporate, thus forming a layer of compound onto

the stent. Alternatively, the agent may be located in the body of the stent or graft, for example in microchannels or micropores. When implanted, the agent diffuses out of the body of the stent to contact the arterial wall. Such stents may be prepared by dipping a stent manufactured to contain such micropores or microchannels into a solution of the compound of the invention in a suitable solvent, followed by evaporation of the solvent. Excess agent on the surface of the stent may be removed via an additional brief solvent wash. In yet other embodiments, agents of the invention may be covalently linked to a stent or graft. A covalent linker may be used which degrades *in vivo*, leading to the release of the agent of the invention. Any bio-labile linkage may be used for such a purpose, such as ester, amide or anhydride linkages. Agents of the invention may additionally be administered intravascularly from a balloon used during angioplasty. Extravascular administration of the agents via the pericard or via advential application of formulations of the invention may also be performed to decrease restenosis.

[00606] A variety of stent devices which may be used as described are disclosed, for example, in the following references, all of which are hereby incorporated by reference: U.S. Pat. No. 5451233; U.S. Pat. No. 5040548; U.S. Pat. No. 5061273; U.S. Pat. No. 5496346; U.S. Pat. No. 5292331; U.S. Pat. No. 5674278; U.S. Pat. No. 3657744; U.S. Pat. No. 4739762; U.S. Pat. No. 5195984; U.S. Pat. No. 5292331; U.S. Pat. No. 5674278; U.S. Pat. No. 5879382; U.S. Pat. No. 6344053.

[00607] The agents of the invention may be administered in dosages. It is known in the art that due to intersubject variability in compound pharmacokinetics, individualization of dosing regimen is necessary for optimal therapy. Dosing for an inhibitor of the invention may be found by routine experimentation in light of the instant disclosure.

[00608] The subject pharmaceutical composition may, for example, be in a form suitable for oral administration as a tablet, capsule, pill, powder, sustained release formulations, solution, suspension, for parenteral injection as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository. The pharmaceutical composition may be in unit dosage forms suitable for single administration of precise dosages. The pharmaceutical composition will include a conventional pharmaceutical carrier or excipient and an inhibitor according to the invention as an active ingredient. In addition, it may include other medicinal or pharmaceutical agents, carriers, adjuvants, etc.

[00609] Exemplary parenteral administration forms include solutions or suspensions of active compound in sterile aqueous solutions, for example, aqueous propylene glycol or dextrose solutions. Such dosage forms can be suitably buffered, if desired.

[00610] The invention also provides kits. The kits include one or more first agent, one or more mTOR inhibitor, and/or other compounds of the present invention as described herein, in suitable packaging, and written material that can include instructions for use, discussion of clinical studies, listing of side effects, and the like. Such kits may also include information, such as scientific literature references, package insert materials, clinical trial results, and/or summaries of these and the like, which indicate or establish the activities and/or advantages of the composition, and/or which describe dosing, administration, side effects, drug interactions, or other information useful to the health care provider. Such information may

be based on the results of various studies, for example, studies using experimental animals involving *in vivo* models and studies based on human clinical trials. The kit may further contain another agent. In some embodiments, the compound of the present invention and the agent are provided as separate compositions in separate containers within the kit. In some embodiments, the compound of the present invention and the agent are provided as a single composition within a container in the kit. Suitable packaging and additional articles for use (e.g., measuring cup for liquid preparations, foil wrapping to minimize exposure to air, and the like) are known in the art and may be included in the kit. Kits described herein can be provided, marketed and/or promoted to health providers, including physicians, nurses, pharmacists, formulary officials, and the like. Kits may also, in some embodiments, be marketed directly to the consumer.

[00611] In some embodiments, the subject is a human in need of treatment for cancer, or a precancerous condition or lesion, wherein the cancer is preferably renal cell carcinoma, unresectable hepatocellular carcinoma, or thyroid carcinoma. Subjects that can be treated with treatment regimens of the present invention, or pharmaceutically acceptable salt, ester, prodrug, solvate, hydrate or derivatives of the therapeutic agents, according to the methods of this invention include, for example, subjects that have been diagnosed as having psoriasis; restenosis; atherosclerosis; BPH; breast cancer such as a ductal carcinoma in duct tissue in a mammary gland, medullary carcinomas, colloid carcinomas, tubular carcinomas, and inflammatory breast cancer; ovarian cancer, including epithelial ovarian tumors such as adenocarcinoma in the ovary and an adenocarcinoma that has migrated from the ovary into the abdominal cavity; uterine cancer; cervical cancer such as adenocarcinoma in the cervix epithelial including squamous cell carcinoma and adenocarcinomas; prostate cancer, such as a prostate cancer selected from the following: an adenocarcinoma or an adenocarcinoma that has migrated to the bone; pancreatic cancer such as epithelioid carcinoma in the pancreatic duct tissue and an adenocarcinoma in a pancreatic duct; bladder cancer such as a transitional cell carcinoma in urinary bladder, urothelial carcinomas (transitional cell carcinomas), tumors in the urothelial cells that line the bladder, squamous cell carcinomas, adenocarcinomas, and small cell cancers; leukemia such as acute myeloid leukemia (AML), acute lymphocytic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, hairy cell leukemia, myelodysplasia, myeloproliferative disorders, acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), mastocytosis, chronic lymphocytic leukemia (CLL), multiple myeloma (MM), and myelodysplastic syndrome (MDS); bone cancer; lung cancer such as non-small cell lung cancer (NSCLC), which is divided into squamous cell carcinomas, adenocarcinomas, and large cell undifferentiated carcinomas, and small cell lung cancer; skin cancer such as basal cell carcinoma, melanoma, squamous cell carcinoma and actinic keratosis, which is a skin condition that sometimes develops into squamous cell carcinoma; eye retinoblastoma; cutaneous or intraocular (eye) melanoma; primary liver cancer (cancer that begins in the liver); kidney cancer; thyroid cancer such as papillary, follicular, medullary and anaplastic; AIDS-related lymphoma such as diffuse large B-cell lymphoma, B-cell immunoblastic lymphoma and small non-cleaved cell lymphoma; Kaposi's Sarcoma; viral-induced cancers including hepatitis B virus (HBV), hepatitis C virus (HCV), and hepatocellular carcinoma; human lymphotropic

virus-type 1 (HTLV-1) and adult T-cell leukemia/lymphoma; and human papilloma virus (HPV) and cervical cancer; central nervous system cancers (CNS) such as primary brain tumor, which includes gliomas (astrocytoma, anaplastic astrocytoma, or glioblastoma multiforme), Oligodendroglioma, Ependymoma, Meningioma, Lymphoma, Schwannoma, and Medulloblastoma; peripheral nervous system (PNS) cancers such as acoustic neuromas and malignant peripheral nerve sheath tumor (MPNST) including neurofibromas and schwannomas, malignant fibrous cytoma, malignant fibrous histiocytoma, malignant meningioma, malignant mesothelioma, and malignant mixed Müllerian tumor; oral cavity and oropharyngeal cancer such as, hypopharyngeal cancer, laryngeal cancer, nasopharyngeal cancer, and oropharyngeal cancer; stomach cancer such as lymphomas, gastric stromal tumors, and carcinoid tumors; testicular cancer such as germ cell tumors (GCTs), which include seminomas and nonseminomas, and gonadal stromal tumors, which include Leydig cell tumors and Sertoli cell tumors; thymus cancer such as to thymomas, thymic carcinomas, Hodgkin disease, non-Hodgkin lymphomas carcinoids or carcinoid tumors; rectal cancer; and colon cancer.

[00612] The invention also relates to a method of treating diabetes in a mammal that comprises treating said mammal according to a treatment regimen of the invention.

[00613] In addition, the treatment regimens described herein may be used to treat acne.

[00614] In addition, the treatment regimens described herein may be used for the treatment of arteriosclerosis, including atherosclerosis. Arteriosclerosis is a general term describing any hardening of medium or large arteries. Atherosclerosis is a hardening of an artery specifically due to an atheromatous plaque.

[00615] Further the treatment regimens described herein may be used for the treatment of glomerulonephritis. Glomerulonephritis is a primary or secondary autoimmune renal disease characterized by inflammation of the glomeruli. It may be asymptomatic, or present with hematuria and/or proteinuria. There are many recognized types, divided in acute, subacute or chronic glomerulonephritis. Causes are infectious (bacterial, viral or parasitic pathogens), autoimmune or paraneoplastic.

[00616] Additionally, the treatment regimens described herein may be used for the treatment of bursitis, lupus, acute disseminated encephalomyelitis (ADEM), addison's disease, antiphospholipid antibody syndrome (APS), aplastic anemia, autoimmune hepatitis, coeliac disease, crohn's disease, diabetes mellitus (type 1), goodpasture's syndrome, graves' disease, guillain-barré syndrome (GBS), hashimoto's disease, inflammatory bowel disease, lupus erythematosus, myasthenia gravis, opsoclonus myoclonus syndrome (OMS), optic neuritis, ord's thyroiditis,osteoarthritis, uveoretinitis, pemphigus, polyarthritis, primary biliary cirrhosis, reiter's syndrome, takayasu's arteritis, temporal arteritis, warm autoimmune hemolytic anemia, wegener's granulomatosis, alopecia universalis, chagas' disease, chronic fatigue syndrome, dysautonomia, endometriosis, hidradenitis suppurativa, interstitial cystitis, neuromyotonia, sarcoidosis, scleroderma, ulcerative colitis, vitiligo, vulvodynia, appendicitis, arteritis, arthritis, blepharitis, bronchiolitis, bronchitis, cervicitis, cholangitis, cholecystitis, chorioamnionitis, colitis, conjunctivitis, cystitis, dacryoadenitis, dermatomyositis, endocarditis, endometritis, enteritis, enterocolitis,

epicondylitis, epididymitis, fasciitis, fibrositis, gastritis, gastroenteritis, gingivitis, hepatitis, hidradenitis, ileitis, iritis, laryngitis, mastitis, meningitis, myelitis, myocarditis, myositis, nephritis, omphalitis, oophoritis, orchitis, osteitis, otitis, pancreatitis, parotitis, pericarditis, peritonitis, pharyngitis, pleuritis, phlebitis, pneumonitis, proctitis, prostatitis, pyelonephritis, rhinitis, salpingitis, sinusitis, stomatitis, synovitis, tendonitis, tonsillitis, uveitis, vaginitis, vasculitis, or vulvitis.

[00617] The invention also relates to a method of treating a cardiovascular disease in a mammal that comprises treating said mammal according to a treatment regimen of the invention. Examples of cardiovascular conditions include, but are not limited to, atherosclerosis, restenosis, vascular occlusion, carotid obstructive disease, or ischemic conditions.

[00618] In another aspect, the present invention provides methods of disrupting the function of a leukocyte or disrupting a function of an osteoclast.

[00619] In another aspect of the present invention, methods are provided for treating ophthalmic disease. Methods are further provided for administering the treatment regimens of the present invention via eye drop, intraocular injection, intravitreal injection, topically, or through the use of a drug eluting device, microcapsule, implant, or microfluidic device. In some cases, such treatments are administered with a carrier or excipient that increases the intraocular penetrance of the compound such as an oil and water emulsion with colloid particles having an oily core surrounded by an interfacial film.

[00620] In some cases, the colloid particles include at least one cationic agent and at least one non-ionic surfactant such as a poloxamer, tyloxapol, a polysorbate, a polyoxyethylene castor oil derivative, a sorbitan ester, or a polyoxyl stearate. In some cases, the cationic agent is an alkylamine, a tertiary alkyl amine, a quaternary ammonium compound, a cationic lipid, an amino alcohol, a biguanidine salt, a cationic compound or a mixture thereof. In some cases the cationic agent is a biguanidine salt such as chlorhexidine, polyaminopropyl biguanidine, phenformin, alkylbiguanidine, or a mixture thereof. In some cases, the quaternary ammonium compound is a benzalkonium halide, lauralkonium halide, cetrimide, hexadecyltrimethylammonium halide, tetradecyltrimethylammonium halide, dodecyltrimethylammonium halide, cetrimonium halide, benzethonium halide, behenalkonium halide, cetalkonium halide, cetethyldimonium halide, cetylpyridinium halide, benzododecinium halide, chlorallyl methenamine halide, myristylalkonium halide, stearylalkonium halide or a mixture of two or more thereof. In some cases, cationic agent is a benzalkonium chloride, lauralkonium chloride, benzododecinium bromide, benzethonium chloride, hexadecyltrimethylammonium bromide, tetradecyltrimethylammonium bromide, dodecyltrimethylammonium bromide or a mixture of two or more thereof. In some cases, the oil phase is mineral oil and light mineral oil, medium chain triglycerides (MCT), coconut oil; hydrogenated oils comprising hydrogenated cottonseed oil, hydrogenated palm oil, hydrogenate castor oil or hydrogenated soybean oil; polyoxyethylene hydrogenated castor oil derivatives comprising polyoxyl-40 hydrogenated castor oil, polyoxyl-60 hydrogenated castor oil or polyoxyl-100 hydrogenated castor oil.

[00621] In some embodiments, the invention provides methods of inhibiting the kinase activity by contacting a cell, tissue, or organ that expresses a kinase of interest. In some embodiments, the subject

treated is a rodents or other mammal (e.g., human). In some embodiments, the percentage of kinase inhibition by the mTOR inhibitor exceeds 50%, 60%, 70%, 80%, or 90%.

Further combination therapies

[00622] The present invention also provides methods for further combination therapies in which, in addition to a first agent and an mTor inhibitor, one or more third agents known to modulate other pathways, or other components of the same pathway, or even overlapping sets of target enzymes is used or a pharmaceutically acceptable salt, ester, prodrug, solvate, hydrate or derivative thereof. In one aspect, such therapy includes but is not limited to the combination of the composition comprising a first agent and/or an mTor inhibitor, as described herein, with other first agents as described herein, chemotherapeutic agents, therapeutic antibodies, and radiation treatment, to provide, where desired, a synergistic or additive therapeutic effect. Pathways that may be targeted by administering a third agent include, but are not limited to, MAP kinase, Akt, NFkB, WNT, RAS/ RAF/MEK/ERK, JNK/SAPK, p38 MAPK, Src Family Kinases, JAK/STAT and/or PKC signaling pathways. Third agents may target one or more members of one or more signaling pathways. Representative members of the nuclear factor-kappaB (NFkB) pathway include but are not limited to RelA (p65), RelB, c-Rel, p50/p105 (NF- κ B 1), p52/p 100 (NF- κ B2), I κ B, and I κ B kinase. Non-limiting examples of receptor tyrosine kinases that are members of the phosphatidylinositol 3-kinase (PI3K)/AKT pathway that may be targeted by one or more third agents include FLT3 LIGAND, EGFR, IGF-1R, HER2/neu, VEGFR, and PDGFR. Downstream members of the PI3K/AKT pathway that may be targeted by third agents according to the methods of the invention include, but are not limited to, forkhead box O transcription factors, Bad, GSK-3 β , I- κ B, mTOR, MDM-2, and S6 ribosomal subunit.

[00623] Third agents useful in the methods of the invention include any capable of modulating a target molecule, either directly or indirectly. Non-limiting examples of target molecules modulated by third agents include enzymes, enzyme substrates, products of transitions, antibodies, antigens, membrane proteins, nuclear proteins, cytosolic proteins, mitochondrial proteins, lysosomal proteins, scaffold proteins, lipid rafts, phosphoproteins, glycoproteins, membrane receptors, G-protein-coupled receptors, nuclear receptors, protein tyrosine kinases, protein serine/threonine kinases, phosphatases, proteases, hydrolases, lipases, phospholipases, ligases, reductases, oxidases, synthases, transcription factors, ion channels, RNA, DNA, RNase, DNase, phospholipids, sphingolipids, nuclear receptors, ion channel proteins, nucleotide-binding proteins, calcium-binding proteins, chaperones, DNA binding proteins, RNA binding proteins, scaffold proteins, tumor suppressors, cell cycle proteins, and histones.

[00624] Third agents may target one or more signaling molecules including but not limited to the following: HER receptors, PDGF receptors, Kit receptor, FGF receptors, Eph receptors, Trk receptors, IGF receptors, Insulin receptor, Met receptor, Ret, VEGF receptors, TIE1, TIE2, FAK, Jak1, Jak2, Jak3, Tyk2, Src, Lyn, Fyn, Lck, Fgr, Yes, Csk, Ab1, Btk, ZAP70, Syk, IRAKs, cRaf, ARaf, BRAF, Mos, Lim kinase, ILK, Tp1, ALK, TGF β receptors, BMP receptors, MEKKs, ASK, MLKs, DLK, PAKs, Mek 1, Mek 2, MKK3/6, MKK4/7, ASK1, Cot, NIK, Bub, Myt 1, Wee1, Casein kinases, PDK1, SGK1, SGK2,

SGK3, Akt1, Akt2, Akt3, p90Rsk, p70S6 Kinase, Prks, PKCs, PKAs, ROCK 1, ROCK 2, Auroras, CaMKs, MNKs, AMPKs, MELK, MARKs, Chk1, Chk2, LKB-1, MAPKAPKs, Pim1, Pim2, Pim3, IKKs, Cdk, Jnks, Erks, IKKs, GSK3 α , GSK3 β , Cdk, CLKs, PKR, PI3-Kinase class 1, class 2, class 3, mTor, SAPK/JNK1,2,3, p38s, PKR, DNA-PK, ATM, ATR, Receptor protein tyrosine phosphatases (RPTPs), LAR phosphatase, CD45, Non receptor tyrosine phosphatases (NRPPTs), SHPs, MAP kinase phosphatases (MKPs), Dual Specificity phosphatases (DUSPs), CDC25 phosphatases, Low molecular weight tyrosine phosphatase, Eyes absent (EYA) tyrosine phosphatases, Slingshot phosphatases (SSH), serine phosphatases, PP2A, PP2B, PP2C, PP1, PP5, inositol phosphatases, PTEN, SHIPs, myotubularins, phosphoinositide kinases, phospholipases, prostaglandin synthases, 5-lipoxygenase, sphingosine kinases, sphingomyelinases, adaptor/scaffold proteins, Shc, Grb2, BLNK, LAT, B cell adaptor for PI3-kinase (BCAP), SLAP, Dok, KSR, MyD88, Crk, CrkL, GAD, Nck, Grb2 associated binder (GAB), Fas associated death domain (FADD), TRADD, TRAF2, RIP, T-Cell leukemia family, IL-2, IL-4, IL-8, IL-6, interferon β , interferon α , suppressors of cytokine signaling (SOCs), Cbl, SCF ubiquitination ligase complex, APC/C, adhesion molecules, integrins, Immunoglobulin-like adhesion molecules, selectins, cadherins, catenins, focal adhesion kinase, p130CAS, fodrin, actin, paxillin, myosin, myosin binding proteins, tubulin, eg5/KSP, CENPs, β -adrenergic receptors, muscarinic receptors, adenylyl cyclase receptors, small molecular weight GTPases, H- Ras, K- Ras, N- Ras, Ran, Rac, Rho, Cdc42, Arfs, RABs, RHEB, Vav, Tiam, Sos, Dbp, PRK, TSC1,2, Ras-GAP, Arf-GAPs, Rho-GAPs, caspases, Caspase 2, Caspase 3, Caspase 6, Caspase 7, Caspase 8, Caspase 9, Bcl-2, Mcl-1, Bcl-XL, Bcl-w, Bcl-B, A1, Bax, Bak, Bok, Bik, Bad, Bid, Bim, Bmf, Hrk, Noxa, Puma, IAPs, XIAP, Smac, Cdk4, Cdk 6, Cdk 2, Cdk1, Cdk 7, Cyclin D, Cyclin E, Cyclin A, Cyclin B, Rb, p16, p14Arf, p27KIP, p21CIP, molecular chaperones, Hsp90s, Hsp70, Hsp27, metabolic enzymes, Acetyl-CoA Carboxylase, ATP citrate lyase, nitric oxide synthase, caveolins, endosomal sorting complex required for transport (ESCRT) proteins, vesicular protein sorting (Vsp), hydroxylases, prolyl-hydroxylases PHD-1, 2 and 3, asparagine hydroxylase FIH transferases, Pin1 prolyl isomerase, topoisomerases, deacetylases, Histone deacetylases, sirtuins, histone acetylases, CBP/P300 family, MYST family, ATF2, DNA methyl transferases, Histone H3K4 demethylases, H3K27, JHDM2A, UTX, VHL, WT-1, p53, Hdm, ubiquitin proteases, urokinase-type plasminogen activator (uPA) and uPA receptor (uPAR) system, cathepsins, metalloproteinases, esterases, hydrolases, separase, potassium channels, sodium channels, multi-drug resistance proteins, P-Glycoprotein, nucleoside transporters, Ets, Elk, SMADs, Rel-A (p65-NF κ B), CREB, NFAT, ATF-2, AFT, Myc, Fos, Sp1, Egr-1, T-bet, β -catenin, HIFs, FOXOs, E2Fs, SRFs, TCFs, Egr-1, {tilde over (β)}-catenin, FOXO STAT1, STAT 3, STAT 4, STAT 5, STAT 6, p53, WT-1, HMGA, pS6, 4EPB-1, eIF4E-binding protein, RNA polymerase, initiation factors, and elongation factors.

[00625] The compounds of the invention are also useful as co-therapeutic compounds for use in combination with other drug substances such as anti-inflammatory, bronchodilatory or antihistamine drug substances, particularly in the treatment of obstructive or inflammatory airways diseases such as those mentioned hereinbefore, for example as potentiators of therapeutic activity of such drugs or as a means of reducing required dosaging or potential side effects of such drugs. A first agent and/or an inhibitor of the

invention may be mixed with the other drug substance in a fixed pharmaceutical composition or it may be administered separately, before, simultaneously with or after the other drug substance. Accordingly the invention includes a combination of an inhibitor of the invention as described with an anti-inflammatory, bronchodilatory, antihistamine or anti-tussive drug substance, said compound of the invention and said drug substance being in the same or different pharmaceutical composition. Suitable anti-inflammatory drugs include steroids, in particular glucocorticosteroids such as budesonide, beclamethasone dipropionate, fluticasone propionate, ciclesonide or mometasone furoate, or steroids described in WO 02/88167, WO 02/12266, WO 02/100879, WO 02/00679 (especially those of Examples 3, 11, 14, 17, 19, 26, 34, 37, 39, 51, 60, 67, 72, 73, 90, 99 and 101), WO 03/035668, WO 03/048181, WO 03/062259, WO 03/064445, WO 03/072592, non-steroidal glucocorticoid receptor agonists such as those described in WO 00/00531, WO 02/10143, WO 03/082280, WO 03/082787, WO 03/104195, WO 04/005229; LTB₄ antagonists such LY293111, CGS025019C, CP-195543, SC-53228, BIIL 284, ONO 4057, SB 209247 and those described in US 5451700; LTD₄ antagonists such as montelukast and zafirlukast; PDE₄ inhibitors such cilomilast (Ariflo® GlaxoSmithKline), Roflumilast (Byk Gulden), V-11294A (Napp), BAY19-8004 (Bayer), SCH-351591 (Schering-Plough), Arofylline (Almirall Prodesfarma), PD189659 / PD168787 (Parke-Davis), AWD-12-281 (Asta Medica), CDC-801 (Celgene), SeICID(TM) CC-10004 (Celgene), VM554/UM565 (Vernalis), T-440 (Tanabe), KW-4490 (Kyowa Hakko Kogyo), and those disclosed in WO 92/19594, WO 93/19749, WO 93/19750, WO 93/19751, WO 98/18796, WO 99/16766, WO 01/13953, WO 03/104204, WO 03/104205, WO 03/39544, WO 04/000814, WO 04/000839, WO 04/005258, WO 04/018450, WO 04/018451, WO 04/018457, WO 04/018465, WO 04/018431, WO 04/018449, WO 04/018450, WO 04/018451, WO 04/018457, WO 04/018465, WO 04/019944, WO 04/019945, WO 04/045607 and WO 04/037805; A_{2a} agonists such as those disclosed in EP 409595A2, EP 1052264, EP 1241176, WO 94/17090, WO 96/02543, WO 96/02553, WO 98/28319, WO 99/24449, WO 99/24450, WO 99/24451, WO 99/38877, WO 99/41267, WO 99/67263, WO 99/67264, WO 99/67265, WO 99/67266, WO 00/23457, WO 00/77018, WO 00/78774, WO 01/23399, WO 01/27130, WO 01/27131, WO 01/60835, WO 01/94368, WO 02/00676, WO 02/22630, WO 02/96462, WO 03/086408, WO 04/039762, WO 04/039766, WO 04/045618 and WO 04/046083; A_{2b} antagonists such as those described in WO 02/42298; and beta-2 adrenoceptor agonists such as albuterol (salbutamol), metaproterenol, terbutaline, salmeterol fenoterol, procaterol, and especially, formoterol and pharmaceutically acceptable salts thereof, and compounds (in free or salt or solvate form) of formula I of WO 0075114, which document is incorporated herein by reference, preferably compounds of the Examples thereof, as well as compounds (in free or salt or solvate form) of formula I of WO 04/16601, and also compounds of WO 04/033412. Suitable bronchodilatory drugs include anticholinergic or antimuscarinic compounds, in particular ipratropium bromide, oxitropium bromide, tiotropium salts and CHF 4226 (Chiesi), and glycopyrrolate, but also those described in WO 01/04118, WO 02/51841, WO 02/53564, WO 03/00840, WO 03/87094, WO 04/05285, WO 02/00652, WO 03/53966, EP 424021, US 5171744, US 3714357, WO 03/33495 and WO 04/018422.

[00626] Suitable antihistamine drug substances include cetirizine hydrochloride, acetaminophen, clemastine fumarate, promethazine, loratidine, desloratidine, diphenhydramine and fexofenadine hydrochloride, activastine, astemizole, azelastine, ebastine, epinastine, mizolastine and tefenadine as well as those disclosed in WO 03/099807, WO 04/026841 and JP 2004107299.

[00627] Other useful combinations of compounds of the invention with anti-inflammatory drugs are those with antagonists of chemokine receptors, e.g., CCR-1, CCR-2, CCR-3, CCR-4, CCR-5, CCR-6, CCR-7, CCR-8, CCR-9 and CCR10, CXCR1, CXCR2, CXCR3, CXCR4, CXCR5, particularly CCR-5 antagonists such as Schering-Plough antagonists SC-351 125, SCH- 55700 and SCH-D, Takeda antagonists such as TAK-770, and CCR-5 antagonists described in US 6166037 (particularly claims 18 and 19), WO 00/66558 (particularly claim 8), WO 00/66559 (particularly claim 9), WO 04/018425 and WO 04/026873.

[00628] The compounds of the invention may be formulated or administered in conjunction with other agents that act to relieve the symptoms of inflammatory conditions such as encephalomyelitis, asthma, and the other diseases described herein. These agents include non-steroidal anti-inflammatory drugs (NSAIDs), e.g., acetylsalicylic acid; ibuprofen; naproxen; indomethacin; nabumetone; tolmetin; etc. Corticosteroids are used to reduce inflammation and suppress activity of the immune system. The most commonly prescribed drug of this type is Prednisone. Chloroquine (Aralen) or hydroxychloroquine (Plaquenil) may also be very useful in some individuals with lupus. They are most often prescribed for skin and joint symptoms of lupus. Azathioprine (Imuran) and cyclophosphamide (Cytoxan) suppress inflammation and tend to suppress the immune system. Other agents, e.g., methotrexate and cyclosporin are used to control the symptoms of lupus. Anticoagulants are employed to prevent blood from clotting rapidly. They range from aspirin at very low dose which prevents platelets from sticking, to heparin/coumadin.

[00629] In one aspect, this invention also relates to methods and pharmaceutical compositions for inhibiting abnormal cell growth in a mammal which comprises an amount of a first agent and/or an mTOR inhibitor of the present invention, or a pharmaceutically acceptable salt, ester, prodrug, solvate, hydrate or derivative thereof, in combination with an amount of an anti-cancer agent (e.g., a chemotherapeutic agent). Many chemotherapeutics are presently known in the art and can be used in combination with the compounds of the invention.

[00630] This invention further relates to a method for using the compounds or pharmaceutical composition in combination with other tumor treatment approaches, including surgery, ionizing radiation, photodynamic therapy, or implants, e.g., with corticosteroids, hormones, or used as radiosensitizers.

[00631] One such approach may be, for example, radiation therapy in inhibiting abnormal cell growth or treating the proliferative disorder in the mammal. Techniques for administering radiation therapy are known in the art, and these techniques can be used in the combination therapy described herein. The administration of the compound of the invention in this combination therapy can be determined as described herein.

[00632] Radiation therapy can be administered through one of several methods, or a combination of methods, including without limitation external-beam therapy, internal radiation therapy, implant radiation,

stereotactic radiosurgery, systemic radiation therapy, radiotherapy and permanent or temporary interstitial brachytherapy. The term “brachytherapy,” as used herein, refers to radiation therapy delivered by a spatially confined radioactive material inserted into the body at or near a tumor or other proliferative tissue disease site. The term is intended without limitation to include exposure to radioactive isotopes (e.g., At-211, I-131, I-125, Y-90, Re-186, Re-188, Sm-153, Bi-212, P-32, and radioactive isotopes of Lu). Suitable radiation sources for use as a cell conditioner of the present invention include both solids and liquids. By way of non-limiting example, the radiation source can be a radionuclide, such as I-125, I-131, Yb-169, Ir-192 as a solid source, I-125 as a solid source, or other radionuclides that emit photons, beta particles, gamma radiation, or other therapeutic rays. The radioactive material can also be a fluid made from any solution of radionuclide(s), e.g., a solution of I-125 or I-131, or a radioactive fluid can be produced using a slurry of a suitable fluid containing small particles of solid radionuclides, such as Au-198, Y-90. Moreover, the radionuclide(s) can be embodied in a gel or radioactive micro spheres.

[00633] Without being limited by any theory, the compounds of the present invention can render abnormal cells more sensitive to treatment with radiation for purposes of killing and/or inhibiting the growth of such cells. Accordingly, this invention further relates to a method for sensitizing abnormal cells in a mammal to treatment with radiation which comprises administering to the mammal an amount of a first agent followed by administering an amount of an mTOR inhibitor of the present invention, or a pharmaceutically acceptable salt, ester, prodrug, solvate, hydrate or derivative thereof, which combined amounts are effective in sensitizing abnormal cells to treatment with radiation. The amount of the compound, salt, or solvate in this method can be determined according to the means for ascertaining effective amounts of such compounds described herein.

[00634] Photodynamic therapy includes therapy which uses certain chemicals known as photosensitizing compounds to treat or prevent cancers. Examples of photodynamic therapy include treatment with compounds, such as e.g., VISUDYNE and porfimer sodium. Angiostatic steroids include compounds which block or inhibit angiogenesis, such as, e.g., anecortave, triamcinolone, hydrocortisone, 11- α -epihydrocortisol, cortexolone, 17 α -hydroxyprogesterone, corticosterone, desoxycorticosterone, testosterone, estrone and dexamethasone.

[00635] Implants containing corticosteroids include compounds, such as e.g., fluocinolone and dexamethasone. Other chemotherapeutic compounds include, but are not limited to, plant alkaloids, hormonal compounds and antagonists; biological response modifiers, preferably lymphokines or interferons; antisense oligonucleotides or oligonucleotide derivatives; shRNA or siRNA; or miscellaneous compounds or compounds with other or unknown mechanism of action.

[00636] The invention also relates to a method of and to a pharmaceutical composition of treating a cardiovascular disease in a mammal which comprises administering an amount of a first agent, followed by administering an amount of an mTOR inhibitor of the present invention, or a pharmaceutically acceptable salt, ester, prodrug, solvate, hydrate or derivative thereof, or an isotopically-labeled derivative thereof, and, separately or in combination with the first agent and/or the mTOR inhibitor, administering an amount of one or more therapeutic agents useful for the treatment of cardiovascular diseases.

[00637] Exemplary agents for use in cardiovascular disease applications are anti-thrombotic agents, e.g., prostacyclin and salicylates, thrombolytic agents, e.g., streptokinase, urokinase, tissue plasminogen activator (TPA) and anisoylated plasminogen-streptokinase activator complex (APSAC), anti-platelets agents, e.g., acetyl-salicylic acid (ASA) and clopidogrel, vasodilating agents, e.g., nitrates, calcium channel blocking drugs, anti-proliferative agents, e.g., colchicine and alkylating agents, intercalating agents, growth modulating factors such as interleukins, transformation growth factor-beta and congeners of platelet derived growth factor, monoclonal antibodies directed against growth factors, anti-inflammatory agents, both steroidal and non-steroidal, and other agents that can modulate vessel tone, function, arteriosclerosis, and the healing response to vessel or organ injury post intervention. Antibiotics can also be included in combinations or coatings comprised by the invention. Moreover, a coating can be used to effect therapeutic delivery focally within the vessel wall. By incorporation of the active agent in a swellable polymer, the active agent will be released upon swelling of the polymer.

[00638] Medicaments which may be administered in conjunction with the methods described herein include any suitable drugs usefully delivered by inhalation for example, analgesics, e.g., codeine, dihydromorphine, ergotamine, fentanyl or morphine; anginal preparations, e.g., diltiazem; antiallergics, e.g., cromoglycate, ketotifen or nedocromil; anti-infectives, e.g., cephalosporins, penicillins, streptomycin, sulphonamides, tetracyclines or pentamidine; antihistamines, e.g., methapyrilene; anti-inflammatories, e.g., beclomethasone, flunisolide, budesonide, tipredane, triamcinolone acetonide or fluticasone; antitussives, e.g., noscapine; bronchodilators, e.g., ephedrine, adrenaline, fenoterol, formoterol, isoprenaline, metaproterenol, phenylephrine, phenylpropanolamine, pirbuterol, reproterol, rimiterol, salbutamol, salmeterol, terbutalin, isoetharine, tulobuterol, orciprenaline or (-)-4-amino-3,5-dichloro- α -[[[6-[2-(2-pyridinyl)ethoxy]hexyl]-amino]methyl]benzenemethanol; diuretics, e.g., amiloride; anticholinergics e.g., ipratropium, atropine or oxitropium; hormones, e.g., cortisone, hydrocortisone or prednisolone; xanthines e.g., aminophylline, choline theophyllinate, lysine theophyllinate or theophylline; and therapeutic proteins and peptides, e.g., insulin or glucagon. It will be clear to a person skilled in the art that, where appropriate, the medicaments may be used in the form of salts (e.g., as alkali metal or amine salts or as acid addition salts) or as esters (e.g., lower alkyl esters) or as solvates (e.g., hydrates) to optimize the activity and/or stability of the medicament.

[00639] Other exemplary therapeutic agents useful for a combination therapy include but are not limited to agents as described above, radiation therapy, hormone antagonists, hormones and their releasing factors, thyroid and antithyroid drugs, estrogens and progestins, androgens, adrenocorticotrophic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones, insulin, oral hypoglycemic agents, and the pharmacology of the endocrine pancreas, agents affecting calcification and bone turnover: calcium, phosphate, parathyroid hormone, vitamin D, calcitonin, vitamins such as water-soluble vitamins, vitamin B complex, ascorbic acid, fat-soluble vitamins, vitamins A, K, and E, growth factors, cytokines, chemokines, muscarinic receptor agonists and antagonists; anticholinesterase agents; agents acting at the neuromuscular junction and/or

autonomic ganglia; catecholamines, sympathomimetic drugs, and adrenergic receptor agonists or antagonists; and 5-hydroxytryptamine (5-HT, serotonin) receptor agonists and antagonists.

[00640] Therapeutic agents can also include agents for pain and inflammation such as histamine and histamine antagonists, bradykinin and bradykinin antagonists, 5-hydroxytryptamine (serotonin), lipid substances that are generated by biotransformation of the products of the selective hydrolysis of membrane phospholipids, eicosanoids, prostaglandins, thromboxanes, leukotrienes, aspirin, nonsteroidal anti-inflammatory agents, analgesic-antipyretic agents, agents that inhibit the synthesis of prostaglandins and thromboxanes, selective inhibitors of the inducible cyclooxygenase, selective inhibitors of the inducible cyclooxygenase-2, autacoids, paracrine hormones, somatostatin, gastrin, cytokines that mediate interactions involved in humoral and cellular immune responses, lipid-derived autacoids, eicosanoids, β -adrenergic agonists, ipratropium, glucocorticoids, methylxanthines, sodium channel blockers, opioid receptor agonists, calcium channel blockers, membrane stabilizers and leukotriene inhibitors.

[00641] Additional therapeutic agents contemplated herein include diuretics, vasopressin, agents affecting the renal conservation of water, rennin, angiotensin, agents useful in the treatment of myocardial ischemia, anti-hypertensive agents, angiotensin converting enzyme inhibitors, β -adrenergic receptor antagonists, agents for the treatment of hypercholesterolemia, and agents for the treatment of dyslipidemia.

[00642] Other therapeutic agents contemplated include drugs used for control of gastric acidity, agents for the treatment of peptic ulcers, agents for the treatment of gastroesophageal reflux disease, prokinetic agents, antiemetics, agents used in irritable bowel syndrome, agents used for diarrhea, agents used for constipation, agents used for inflammatory bowel disease, agents used for biliary disease, agents used for pancreatic disease. Therapeutic agents used to treat protozoan infections, drugs used to treat Malaria, Amebiasis, Giardiasis, Trichomoniasis, Trypanosomiasis, and/or Leishmaniasis, and/or drugs used in the chemotherapy of helminthiasis. Other therapeutic agents include antimicrobial agents, sulfonamides, trimethoprim-sulfamethoxazole quinolones, and agents for urinary tract infections, penicillins, cephalosporins, and other, β -Lactam antibiotics, an agent comprising an aminoglycoside, protein synthesis inhibitors, drugs used in the chemotherapy of tuberculosis, mycobacterium avium complex disease, and leprosy, antifungal agents, antiviral agents including nonretroviral agents and antiretroviral agents.

[00643] Examples of therapeutic antibodies that can be combined with a subject compound include but are not limited to anti-receptor tyrosine kinase antibodies (cetuximab, panitumumab, trastuzumab), anti CD20 antibodies (rituximab, tositumomab), and other antibodies such as alemtuzumab, bevacizumab, and gemtuzumab.

[00644] Moreover, therapeutic agents used for immunomodulation, such as immunomodulators, immunosuppressive agents, tolerogens, and immunostimulants are contemplated by the methods herein. In addition, therapeutic agents acting on the blood and the blood-forming organs, hematopoietic agents, growth factors, minerals, and vitamins, anticoagulant, thrombolytic, and antiplatelet drugs.

[00645] Further therapeutic agents that can be combined with a subject compound may be found in Goodman and Gilman's "The Pharmacological Basis of Therapeutics" Tenth Edition edited by Hardman,

Limbird and Gilman or the Physician's Desk Reference, both of which are incorporated herein by reference in their entirety.

[00646] The examples and preparations provided below further illustrate and exemplify the compounds of the present invention and methods of preparing such compounds. It is to be understood that the scope of the present invention is not limited in any way by the scope of the following examples and preparations. In the following examples molecules with a single chiral center, unless otherwise noted, exist as a racemic mixture. Those molecules with two or more chiral centers, unless otherwise noted, exist as a racemic mixture of diastereomers. Single enantiomers/diastereomers may be obtained by methods known to those skilled in the art.

EXAMPLES

Example 1. Simultaneous Treatment Regimen Using Compound A and Sorafenib.

[00647] 5×10^6 of 786-0 (Figure 1A) or A498 (Figure 1B) cells were implanted on the flank of nude mice subcutaneously. Once the tumor reached 300-400mm³, mice were randomized into four groups (5 mice each) and treated with vehicle, Compound A (compound 1 in Table 1, administered at 1mg/kg, PO, QD), Sorafenib (40mg/kg, IP, QD), or a combination of both. Tumor volumes were measured with caliper twice a week and calculated with the formula $V = \frac{a^2 \times b}{2}$, where a is the short axis and b is the long axis of the tumor. The data is presented as the mean $\pm$ SD. Body weight was measured using an electronic scale at the same day with tumor volume measurement and presented as percentage change vs those before treatment with the formula $(b-a)/a \times 100$, where a is the body weight on the day treatment started and b is the body weight on the day tumor volume was measured. Mice were sacrificed if the body weight decrease more than 20% according to the protocol. The results show limited tolerability as displayed in Figures 1A and 1B.

Example 2. Treatment Regimen of the Invention using Compound A and Sorafenib.

[00648] 786-0 and A498 cells were implanted as described in Example 1. Once the tumor reached 350-450mm³, mice were randomized into four groups (5 mice each) and treated with vehicle, Compound A (1mg/kg, PO, 3day on/4day off), Sorafenib (40mg/kg, IP, 3day off/4day on), or dosing alternatively (Compound A, 1mg/kg 3days followed by Sorafenib 40mg/kg for 4 days in each cycle). Tumor volumes were measured as described above on day 3 and day 7. The data is presented as the mean $\pm$ SD. Body weight was measured using an electronic scale at the same day with tumor volume measurement and presented as percentage change as in Figures 1A and 1B. The results, shown in Figures 1C and 1D show synergistic anti-tumor efficacy and well tolerated.

Example 3. Immunohistochemistry Analysis of CD34 and HIF-2 α Expression in a Treatment Regimen of the Invention.

[00649] Tumor tissues were excised after vehicle, Compound A, or Sorafenib dosing in cycle 7 and fixed in 10% neutral formalin. 4 μ m sections were cut from paraffin embedded blocks and incubated with either rat anti-mouse CD34 (Figure 2A) or rabbit anti-HIF-2 α (Figure 2B) antibodies at 4C over night. HRP

conjugated secondary antibodies were added to visualize protein expression with DAB (dark brown) and counterstained with hematoxylin. A representative picture in each treatment is shown.

Example 4. Western Blot and Immunohistochemistry Analysis of Signaling, Cell Proliferation and Apoptosis Pathways in Tumors Treated According to a Regimen of the Invention.

[00650] A western blot analysis of mTOR and ERK pathway activity in 786-0 xenograft tumor tissues was conducted. Results are shown in Figure 3A. Tumors (n=2) treated with vehicle, intermittent Compound A (1mg/kg, 3 days on 4 days off), intermittent sorafenib (40mg/kg, 3 days off 4 days on) or alternative Compound A/Sorafenib (1mg/40mg, 3day/4day) were excised 2hrs after the last vehicle, Compound A or Sorafenib dosing at cycle 7 and snap frozen in liquid nitrogen. Tumor lysates were made in lysis buffer with phosphatase inhibitors. Phosphorylation of AKT s473, S6 s235/236, 4EBP-1 s37/46 and ERK s42/44 were identified with specific phospho-antibodies, respectively. An immunohistochemistry analysis of cell proliferation and apoptosis was conducted (results shown in Figures 3B and 3C, respectively). Mice were injected with BrdU 30 min. before sacrifice. Half of tumor tissues were freshly fixed in 10% formalin (as in Figure 3A) and 4µm sections were cut from paraffin embedded blocks. The tissue sections were incubated with either rat anti-BrdU (Figure 3B) or rabbit anti-cleaved caspase 3 (Figure 3C) antibodies at 4°C over night. HRP conjugated secondary antibodies were added to visualize protein expression with DAB (dark brown) and counterstained with hematoxylin. Five representative view fields in each tumor were photographed and the mean percentage ± SD of BrdU or cleaved caspase 3 positive cells over total cells in the field were presented.

Example 5: Expression and Inhibition Assays of mTOR

[00651] Inhibition of mTor can be measured according to any procedures known in the art or methods disclosed below. The compounds described herein and any other mTor inhibitors known in the art can be tested against recombinant mTOR (Invitrogen) in an assay containing 50 mM HEPES, pH 7.5, 1mM EGTA, 10 mM MgCl₂, 2.5 mM, 0.01% Tween, 10 µM ATP (2.5 µCi of µ-32P-ATP), and 3 µg/mL BSA. Rat recombinant PHAS-1/4EBP1 (Calbiochem; 2 mg/mL) is used as a substrate. Reactions are terminated by spotting onto nitrocellulose, which is washed with 1M NaCl/1% phosphoric acid (approximately 6 times, 5-10 minutes each). Sheets are dried and the transferred radioactivity quantitated by phosphorimaging.

[00652] Other kits or systems for assaying mTOR activity are commercially available. For instance, one can use Invitrogen's LanthaScreen™ Kinase assay to test the inhibitors of mTOR disclosed herein. This assay is a time resolved FRET platform that measures the phosphorylation of GFP labeled 4EBP1 by mTOR kinase. The kinase reaction is performed in a white 384 well microtitre plate. The total reaction volume is 20µl per well and the reaction buffer composition is 50mM HEPES pH7.5, 0.01% Polysorbate 20, 1mM EGTA, 10mM MnCl₂, and 2mM DTT. In the first step, each well receives 2µl of test compound in 20% dimethylsulphoxide resulting in a 2% DMSO final concentration. Next, 8µl of mTOR diluted in reaction buffer is added per well for a 60ng/ml final concentration. To start the reaction, 10µl of an ATP/GFP-4EBP1 mixture (diluted in reaction buffer) is added per well for a final concentration of 10µM ATP and 0.5µM GFP-4EBP1. The plate is sealed and incubated for 1 hour at room temperature. The

reaction is stopped by adding 10ul per well of a Tb-anti-pT46 4EBP1 antibody/EDTA mixture (diluted in TR-FRET buffer) for a final concentration of 1.3nM antibody and 6.7mM EDTA. The plate is sealed, incubated for 1 hour at room temperature, and then read on a plate reader set up for LanthaScreen™ TR-FRET. Data is analyzed and IC50s are generated using GraphPad Prism 5.

Example 6: B Cell Activation and Proliferation Assay

[00653] Inhibition of B cell activation and proliferation by administering a first agent followed by an mTOR inhibitor, is determined according to standard procedures known in the art. For example, an *in vitro* cellular proliferation assay is established that measures the metabolic activity of live cells. The assay is performed in a 96 well microtiter plate using Alamar Blue reduction. Balb/c splenic B cells are purified over a Ficoll-Paque™ PLUS gradient followed by magnetic cell separation using a MACS B cell Isolation Kit (Miletenyi). Cells are plated in 90ul at 50,000 cells/well in B Cell Media (RPMI + 10%FBS + Penn/Strep + 50μM bME + 5mM HEPES). A compound disclosed herein is diluted in B Cell Media and added in a 10ul volume. Plates are incubated for 30min at 37C and 5% CO₂ (0.2% DMSO final concentration). This incubation step can be repeated for the addition of a second agent, such as an mTOR inhibitor. A 50ul B cell stimulation cocktail is then added containing either 10ug/ml LPS or 5ug/ml F(ab')₂ Donkey anti-mouse IgM plus 2ng/ml recombinant mouse IL4 in B Cell Media. Plates are incubated for 72 hours at 37°C and 5% CO₂. A volume of 15μL of Alamar Blue reagent is added to each well and plates are incubated for 5 hours at 37C and 5% CO₂. Alamar Blue fluoresce is read at 560Ex/590Em, and IC50 or EC50 values are calculated using GraphPad Prism 5.

Example 7: Tumor Cell Line Proliferation Assay

[00654] Inhibition of tumor cell line proliferation by the subject methods is determined according to standard procedures known in the art. For instance, an *in vitro* cellular proliferation assay can be performed to measure the metabolic activity of live cells. The assay is performed in a 96 well microtiter plate using Alamar Blue reduction. Human tumor cell lines are obtained from ATCC (e.g., MCF7, U-87 MG, MDA-MB-468, PC-3), grown to confluency in T75 flasks, trypsinized with 0.25% trypsin, washed one time with Tumor Cell Media (DMEM + 10%FBS), and plated in 90ul at 5,000 cells/well in Tumor Cell Media. A compound disclosed herein is diluted in Tumor Cell Media and added in a 10ul volume. Plates are incubated for 72 hours at 37C and 5% CO₂. After addition of the first compound, such as during this subsequent 72 hour period (e.g. after 24 hours), a second agent, such as an mTOR inhibitor, can be similarly added to the cells. A volume of 10uL of Alamar Blue reagent is added to each well and plates are incubated for 3 hours at 37C and 5% CO₂. Alamar Blue fluoresce is read at 560Ex/590Em, and IC50 values are calculated using GraphPad Prism 5.

Example 8: Antitumor Activity *in vivo*

[00655] Inhibition of tumor growth by the subject method can be determined by the following murine tumor models.

[00656] Paclitaxel-refractory Tumor Models

[00657] 1. Clinically-derived Ovarian Carcinoma Model.

[00658] This tumor model is established from a tumor biopsy of an ovarian cancer patient. Tumor biopsy is taken from the patient.

[00659] The compounds described herein are administered to nude mice bearing staged tumors, with paclitaxel administered weekly, and an mTOR inhibitor administered 1 day after each paclitaxel administration.

[00660] 2. A2780Tax Human Ovarian Carcinoma Xenograft (Mutated Tubulin).

[00661] A2780Tax is a paclitaxel-resistant human ovarian carcinoma model. It is derived from the sensitive parent A2780 line by co-incubation of cells with paclitaxel and verapamil, an MDR-reversal agent. Its resistance mechanism has been shown to be non-MDR related and is attributed to a mutation in the gene encoding the beta-tubulin protein.

[00662] The compounds described herein are administered to nude mice bearing staged tumors, with paclitaxel administered weekly, and an mTOR inhibitor administered 1 day after each paclitaxel administration.

[00663] 3. HCT116/VM46 Human Colon Carcinoma Xenograft (Multi-Drug Resistant).

[00664] HCT116/VM46 is an MDR-resistant colon carcinoma developed from the sensitive HCT116 parent line. *In vivo*, grown in nude mice, HCT116/VM46 has consistently demonstrated high resistance to paclitaxel.

[00665] The compounds described herein are administered to nude mice bearing staged tumors, with paclitaxel administered weekly, and an mTOR inhibitor administered 1 day after each paclitaxel administration.

[00666] 5. M5076 Murine Sarcoma Model

[00667] M5076 is a mouse fibrosarcoma that is inherently refractory to paclitaxel *in vivo*.

[00668] The compounds described herein are administered to nude mice bearing staged tumors, with paclitaxel administered weekly, and an mTOR inhibitor administered 1 day after each paclitaxel administration.

[00669] Treatment by methods of the invention can be used in combination other therapeutic agents *in vivo* in the multidrug resistant human colon carcinoma xenografts HCT/VM46 or any other model known in the art including those described herein.

[00670] The results are expected to show that treatment with a first agent, e.g. paclitaxel, followed by treatment with an mTOR inhibitor is a potent therapeutic regimen for the treatment of tumor growth *in vivo* under the conditions tested.

Example 9: Akt Kinase Assay

[00671] Inhibition of Akt by the subject method can be determined by the following assay. Cells comprising components of the Akt/mTOR pathway, including but not limited to L6 myoblasts, B-ALL cells, B-cells, T-cells, leukemia cells, bone marrow cells, p190 transduced cells, philadelphia chromosome positive cells (Ph+), and mouse embryonic fibroblasts, are typically grown in cell growth media such as DMEM supplemented with fetal bovine serum and/or antibiotics, and grown to confluency.

[00672] Cells are serum starved overnight and incubated with the first agent followed by an mTor inhibitor for approximately 1 minute to about 1 hour prior to stimulation with insulin (e.g., 100 nM) for about 1 minutes to about 1 hour. Cells are lysed by scraping into ice cold lysis buffer containing detergents such as sodium dodecyl sulfate and protease inhibitors (e.g., PMSF). After contacting cells with lysis buffer, the solution is briefly sonicated, cleared by centrifugation, resolved by SDS-PAGE, transferred to nitrocellulose or PVDF and immunoblotted using antibodies to phospho- Akt S473, phospho- Akt T308, Akt, and β -actin (Cell Signaling Technologies).

Example 10: Kinase Signaling in Blood

[00673] PI3K/ Akt /mTor signaling is measured in blood cells using the phosflow method (Methods Enzymol. 2007;434:131-54). The advantage of this method is that it is by nature a single cell assay so that cellular heterogeneity can be detected rather than population averages. This allows concurrent distinction of signaling states in different populations defined by other markers. Phosflow is also highly quantitative. Unfractionated splenocytes, or peripheral blood mononuclear cells are stimulated with anti-CD3 to initiate T-cell receptor signaling. The cells are then fixed and stained for surface markers and intracellular phosphoproteins.

[00674] Similarly, aliquots of whole blood are incubated for 15 minutes with vehicle (e.g., 0.1%DMSO) or kinase inhibitors at various concentrations, before addition of stimuli to crosslink the T cell receptor (TCR) (anti-CD3 with secondary antibody) or the B cell receptor (BCR) using anti-kappa light chain antibody (Fab'2 fragments). After approximately 5 and 15 minutes, samples are fixed (e.g., with cold 4% paraformaldehyde) and used for phosflow. Surface staining is used to distinguish T and B cells using antibodies directed to cell surface markers that are known to the art. The level of phosphorylation of kinase substrates such as Akt and S6 are then measured by incubating the fixed cells with labeled antibodies specific to the phosphorylated isoforms of these proteins. The population of cells is then analyzed by flow cytometry.

Example 11: Colony Formation Assay

[00675] Murine bone marrow cells freshly transformed with a p190 BCR-Abl retrovirus (herein referred to as p190 transduced cells) are plated in the presence of various drug combinations in M3630 methylcellulose media for about 7 days with recombinant human IL-7 in about 30% serum, and the number of colonies formed is counted by visual examination under a microscope.

[00676] Alternatively, human peripheral blood mononuclear cells are obtained from Philadelphia chromosome positive (Ph+) and negative (Ph-) patients upon initial diagnosis or relapse. Live cells are isolated and enriched for CD19+ CD34+ B cell progenitors. After overnight liquid culture, cells are plated in methocult GF+ H4435, Stem Cell Technologies) supplemented with cytokines (IL-3, IL-6, IL-7, G-CSF, GM-CSF, CF, Flt3 ligand, and erythropoietin) and various concentrations of known chemotherapeutic agents are added to the cultures, followed at a later time point (e.g. 24 hours) by the addition of an mTOR inhibitor. Colonies are counted by microscopy 12-14 days later. This method can be used to test for evidence of additive or synergistic activity. The results are expected to show that the ordered treatment using the first agent and an mTor inhibitor is effective in inhibiting colony formation.

Example 12: *In vivo* Effect of Kinase Inhibitors on Leukemic Cells

[00677] Female recipient mice are lethally irradiated from a γ source in two doses about 4 hr apart, with approximately 5Gy each. About 1hr after the second radiation dose, mice are injected i.v. with about 1×10^6 leukemic cells (e.g., Ph+ human or murine cells, or p190 transduced bone marrow cells). These cells are administered together with a radioprotective dose of about 5×10^6 normal bone marrow cells from 3-5 week old donor mice. Recipients are given antibiotics in the water and monitored daily. Mice who become sick after about 14 days are euthanized and lymphoid organs are harvested for analysis. Treatment with a first agent, such as paclitaxel, is administered weekly, beginning about ten days after leukemic cell injection and continues daily until the mice become sick or a maximum of approximately 35 days post-transplant. Treatment with mTOR inhibitor is provided beginning on one or more of day 10, 11, and 12, and is repeated weekly. For example, some mice receive both the first agent and the mTOR inhibitor on day 10, with further mTOR inhibitor treatments on days 11 and 12, with the cycle repeated beginning on day 17. Some mice receive only the first agent on day 10, and the mTOR inhibitor on day 11, with the cycle repeated weekly. Some mice receive only the first agent or the mTOR inhibitor, according to a schedule matched to mice receiving combination therapy, in order to determine synergistic effect. Inhibitor is given by oral gavage.

[00678] Peripheral blood cells are collected approximately on day 10 (pre-treatment) and upon euthanization (post treatment), contacted with labeled anti-hCD4 antibodies and counted by flow cytometry. By the additional treatment with further chemotherapeutic agents, this method can be also used to demonstrate a synergistic effect of combinations with additional known chemotherapeutic agents. Synergy may be demonstrated by significant reduction of leukemic blood cell counts as compared to treatment with any of the compounds (e.g., paclitaxel, mTOR inhibitor, Gleevec) alone under the conditions tested.

Example 13: Murine Bone Marrow Transplant Assay

[00679] Female recipient mice are lethally irradiated from a γ ray source. About 1hr after the radiation dose, mice are injected with about 1×10^6 leukemic cells from early passage p190 transduced cultures (e.g., as described in *Cancer Genet Cytogenet.* 2005 Aug;161(1):51-6). These cells are administered together with a radioprotective dose of approximately 5×10^6 normal bone marrow cells from 3-5wk old donor mice. Recipients are given antibiotics in the water and monitored daily. Mice who become sick after about 14 days are euthanized and lymphoid organs harvested for flow cytometry and/or magnetic enrichment. Treatment begins on approximately day 10 and continues until mice become sick, or after a maximum of about 35 days post-transplant. Treatment with a first agent, such as paclitaxel, is administered weekly, beginning on approximately day 10. Treatment with mTOR inhibitor is provided beginning on one or more of day 10, 11, 12, and 13, and is repeated weekly. For example, some mice receive both the first agent and the mTOR inhibitor on day 10, with further mTOR inhibitor treatments alone on days 11 and 12, with the cycle repeated beginning on day 17. Some mice receive only the first agent on day 10, and the mTOR inhibitor alone on days 11, 12, and 13, with the cycle repeated weekly. Some mice receive both the first agent and the mTOR inhibitor on day 10, repeated weekly beginning on day 17. Some mice

receive only the first agent on day 10, followed by the mTOR inhibitor alone on day 11, with the cycle repeated weekly beginning day 17. Some mice receive only the first agent or the mTOR inhibitor, according to a schedule matched to mice receiving combination therapy, in order to determine synergistic effect. mTOR inhibitors are given by oral gavage (p.o.). In a pilot experiment a dose of a first agent that is not curative but delays leukemia onset by about one week or less is identified; controls are vehicle-treated or treated with the first agent, previously shown to delay but not cure leukemogenesis in this model (e.g., imatinib at about 70mg/kg twice daily). For the first phase p190 cells that express eGFP are used, and postmortem analysis is limited to enumeration of the percentage of leukemic cells in bone marrow, spleen and lymph node (LN) by flow cytometry. In the second phase, p190 cells that express a tailless form of human CD4 are used and the postmortem analysis includes magnetic sorting of hCD4+ cells from spleen followed by immunoblot analysis of key signaling endpoints: p Akt -T308 and S473; pS6 and p4EBP-1. As controls for immunoblot detection, sorted cells are incubated in the presence or absence of kinase inhibitors of the present disclosure inhibitors before lysis. Optionally, "phosflow" is used to detect p Akt - S473 and pS6-S235/236 in hCD4-gated cells without prior sorting. These signaling studies are particularly useful if, for example, drug-treated mice have not developed clinical leukemia at the 35 day time point. Kaplan-Meier plots of survival are generated and statistical analysis done according to methods known in the art. Results from p190 cells are analyzed separated as well as cumulatively.

[00680] Samples of peripheral blood (100-200µl) are obtained weekly from all mice, starting on day 10 immediately prior to commencing treatment. Plasma is used for measuring drug concentrations, and cells are analyzed for leukemia markers (eGFP or hCD4) and signaling biomarkers as described herein.

[00681] This general assay known in the art may be used to establish that the subject method is effective in inhibiting the proliferation of leukemic cells.

Example 14: The administration of the first agent of the present invention followed by an mTor inhibitor for inhibition of tumor growth

[00682] The following cell and animal models can be used to establish that the subject method is effective in inhibiting tumor cell growth.

Cell Lines

[00683] Cell lines of interest (A549, U87, ZR-75-1 and 786-O) are obtained from American Type Culture Collection (ATCC, Manassas, VA). Cells are proliferated and preserved cryogenically at early passage (e.g., passage 3). One aliquot is used for further proliferation to get enough cells for one TGI study (at about passage 9).

Animals

[00684] Female athymic nude mice are supplied by Harlan. Mice are received at 4 to 6 weeks of age. All mice are acclimated for about one day to two weeks prior to handling. The mice are housed in microisolator cages and maintained under specific pathogen-free conditions. The mice are fed with irradiated mouse chow and freely available autoclaved water is provided.

Tumor Xenograft Model

[00685] Mice are inoculated subcutaneously in the right flank with 0.01 to 0.5 ml of tumor cells (approximately 1.0×10^5 to 1.0×10^8 cells/mouse). Five to 10 days following inoculation, tumors are measured using calipers and tumor weight is calculated, for example using the animal study management software, such as Study Director V.1.6.70 (Study Log). Mice with tumor sizes of about 120 mg are pair-matched into desired groups using Study Director (Day 1). Body weights are recorded when the mice are pair-matched. Tumor volume and bodyweight measurements are taken one to four times weekly and gross observations are made at least once daily. On Day 1, compounds of the present invention and reference compounds as well as vehicle control are administered by oral gavage or iv as indicated, such as according to a schedule as described in Example 9. At the last day of the experiment, mice are sacrificed and their tumors are collected 1-4 hours after the final dose. The tumors are excised and cut into two sections. One third of the tumor is fixed in formalin and embedded in paraffin blocks and the remaining two thirds of tumor is snap frozen and stored at -80°C .

Data and Statistical Analysis

[00686] Mean tumor growth inhibition (TGI) is calculated utilizing the following formula:

$$\text{TGI} = \left[1 - \frac{(\bar{X}_{\text{Treated (Final)}} - \bar{X}_{\text{Treated (Day1)}})}{(\bar{X}_{\text{Control (Final)}} - \bar{X}_{\text{Control (Day1)}})} \right] \times 100\%$$

[00687] Tumors that regress from the Day 1 starting size are removed from the calculations. Individual tumor shrinkage (TS) is calculated using the formula below for tumors that show regression relative to Day 1 tumor weight. The mean tumor shrinkage of each group is calculated and reported.

$$\text{TS} = \left[1 - \frac{(\text{Tumor Weight}_{\text{(Final)}})}{(\text{Tumor Weight}_{\text{(Day1)}})} \right] \times 100\%$$

[00688] The model can be employed to show whether the compounds of the present invention can inhibit tumor cell growth such as renal carcinoma cell growth, breast cancer cell growth, lung cancer cell growth, or glioblastoma cell growth under the conditions tested.

Example 15: Inhibition of PI3K pathway and proliferation of tumor cells with PI3K α mutation

[00689] Cells comprising one or more mutations in PI3K α , including but not limited to breast cancer cells (e.g., MDA-MB-361, T47D, SKOV-3), and cells comprising one or more mutations in PTEN including but not limited to prostate cancer cells (e.g., PC3), are typically grown in cell growth media such as DMEM supplemented with fetal bovine serum and/or antibiotics, and grown to confluency. Cells are then treated with various concentrations of test compound for about 2 hours and subsequently lysed in cell lysis buffer. Lysates are subjected to SDS-PAGE followed by Western blot analysis to detect downstream signaling markers, including but not limited to pAKT(S473), pAKT(T308), pS6, and p4E-BP1. Degree of proliferation (and proliferation inhibition) can also be measured for cells at various doses of compound of the present invention such as Compound B (compound 1 of Table 1). β -Actin can be used as a housekeeping protein to ascertain proper loading.

Example 16: *In vitro* inhibition of angiogenesis

[00690] The following assay can be used to establish that the subject method is effective in inhibiting angiogenesis. Angiogenic capacity can be measured in vitro using an endothelial cell line, such as human umbilical vein endothelial cells (HUVEC). The assay is conducted according to the kit instructions, in the presence or absence of compound. Briefly, a gel matrix is applied to a cell culture surface, cells are added to the matrix-covered surface along with growth factors, with some samples also receiving an inhibitor compound, cells are incubated at 37°C and 5% CO₂ long enough for control samples (no compound added) to form tube structures (such as overnight), cells are stained using a cell-permeable dye (e.g., calcein), and cells are visualized to identify the degree of tube formation. Any decrease in tube formation relative to un-inhibited control cells is indicative of angiogenic inhibition. Based on doses tested and the corresponding degree of tube formation inhibition, IC₅₀ values for tube formation are calculated. IC₅₀ values for cell viability can be measured using any number of methods known in the art, such as staining methods that distinguish live from dead cells (e.g., Image-iT DEAD Green viability stain commercially available from Invitrogen).

Example 17: Effect of a treatment regimen of the invention on hypoxia in tumor cells.

[00691] Mice bearing A498 xenografts were treated as shown below in Table 5 for 6 weeks or cycles (each cycle consisting of 7 days). During cycle 6, mice were sacrificed 2 hours after dosing. Pimonidazole hydrochloride, which binds to proteins in hypoxia conditions, was injected intraperitoneally 60 minutes before the tumor was harvested. Tumors were collected either at 2hr of vehicle (Groups A, C, and D), Compound A (Groups B, C, and E) or sorafenib (Group D) dosing. Tumor tissues were formalin fixed and paraffin embedded. Tissue sections were stained with anti-pimonidazole antibody and visualized with DAB (dark brown). Results are shown in Figures 4A-E. Vehicle treated tumor (control) displays areas of hypoxia (Figure 4A). Compound A treatment, whether continuously or subjected to intermittent dosing, significantly reduced hypoxia in the tumor (Figures 4B, 4C and 4E). In the intermittent Compound A treatment regimen, the tumor became pimonidazole positive on the off phase, correlating with a fast growth rate in the TGI study (Figure 4C, top and bottom). Sorafenib treatment caused necrosis and cells surrounding the necrosis area appear pimonidazole positive (Figure 4D, top). On the sorafenib off phase, pimonidazole staining intensity was reduced (Figure 4D, bottom). Alternating Compound A / Sorafenib dosing regimen significantly reduced the level of hypoxia (Figure 4E, top and bottom).

Table 5. Compound A, Sorafenib Alternating Dosing on Tumor Growth

Group	Treatment	Dose (mg/kg)	Schedule	Route
A	Vehicle		QD	PO
B	Compound A	1	QD	PO
C	Compound A	1	3QW	PO
D	Sorafenib	40	4QW	IP
E	Compound A/Sorafenib	1/40	3QW/4QW	PO/IP

[00692] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.

CLAIMS

WHAT IS CLAIMED IS:

1. A method of treating a disorder in a subject according to a regimen comprising:

administering to the subject a first agent, and a second agent which is an mTor inhibitor, wherein the first and second agent are administered according to a dosing schedule such that the first agent and the second agent are not administered within 12 hours of each other;

and wherein administering the first and second agent in accordance with the dosing schedule results in a synergistic effect as evidenced by either a) a reduced toxicity level of the first or second agent, as compared to an alternative regimen in which the first and second agent are administered simultaneously or b) enhanced efficacy of the first or second agent, as compared to an alternative regimen in which the first and second agent are administered simultaneously; and

wherein the toxicity level is measured by a change in bodyweight of the subject, a decrease in skin toxicity grade of the subject, a decrease in fatigue of the subject, a decrease in rashes or desquamation of the subject, a decrease in hand-foot skin reactions of the subject, a decrease in alopecia of the subject, a decrease in diarrhea of the subject, a decrease in anorexia of the subject, a decrease in nausea of the subject or a decrease in abdominal pain of the subject;

and wherein the enhanced efficacy is measured by an improved clinical outcome.

2. The method of claim 1, wherein the toxicity level is measured by a decrease in the bodyweight of the subject.

3. The method of claim 2, wherein during the treatment regimen the subject is capable of maintaining bodyweight at a level of $\pm 20\%$ of the starting weight.

4. The method of claim 1, wherein the toxicity level is measured by a decrease in the skin toxicity grade of the subject.

5. The method of claim 1, wherein the first agent is administered for two, three, four, five, six, seven or eight consecutive days.

6. The method of claim 1, wherein the second agent is administered for two, three, four, five, six, seven or eight consecutive days.


7. A method of treating a neoplastic condition in a subject according to a regimen comprising:

administering to the subject a first agent, and a second agent which is an mTor inhibitor, wherein the first and second agent are administered according to a dosing schedule comprising at least one cycle that

provides for one, two, three, four, five, six, seven or eight consecutive day(s) of administration of the first agent, followed by at least one day of administration of the second agent, wherein the regimen yields a synergistic effect in treating said neoplastic condition.

8. The method of claim 1 or 7, wherein the regimen comprises at least one cycle providing for two, three, four or five consecutive days of administration of the first agent, followed by two, three, four or five consecutive days of administration of the second agent.
9. The method of claim 1 or 7, wherein the regimen comprises at least two cycles providing for administration of the first agent for at least one day and administration of the second agent for at least one day.
10. The method of claim 1 or 7, wherein the regimen comprises at least one cycle which begins by administration of the first agent and is followed by administration of the second agent.
11. The method of claim 1 or 7, wherein the regimen comprises at least one cycle which begins by administration of the second agent and is followed by administration of the first agent.
12. The method of claim 1, wherein the disorder is a proliferative disorder.
13. The method of claim 12, wherein the proliferative disorder is a neoplastic condition.
14. The method of claim 7 or 13, wherein the neoplastic condition is selected from the group consisting of NSCLC, head and neck squamous cell carcinoma, pancreatic cancer, breast cancer, ovarian cancer, sarcoma, renal cell carcinoma, prostate cancer, neuroendocrine cancer, and endometrial cancer.
15. The method of claim 14, wherein the neoplastic condition is renal cell carcinoma.
16. The method of claim 1, wherein the first agent is an anti-diabetic agent.
17. The method of claim 16, wherein the disorder is diabetes.
18. The method of claim 1, wherein the first agent is an anti-inflammatory agent.
19. The method of claim 18, wherein the disorder is inflammation.
20. The method of claim 1 or 7, where the first agent is an anti-neoplastic agent.
21. The method of claim 20, wherein the anti-neoplastic agent is a receptor tyrosine kinase inhibitor.
22. The method of claim 20, wherein the anti-neoplastic agent is an antiproliferative antibody.
23. The method of claim 21, wherein the anti-neoplastic agent is axitinib, cediranib, pazopanib, regorafenib, semaxanib, sorafenib, sunitinib, toceranib, or vandetanib.

24. The method of claim 1 or 7, wherein the second agent is rapamycin or a rapamycin derivative or analogue.
25. The method of claim 1 or 7, wherein the second agent is an mTorC1/mTorC2 inhibitor.
26. The method of claim 1 or 7, wherein the second agent inhibits both mTORC1 and mTORC2 with an IC₅₀ value of about 100 nM or less as ascertained in an *in vitro* kinase assay.
27. The method of claim 1 or 7, wherein the second agent inhibits both mTORC1 and mTORC2 with an IC₅₀ value of about 10 nM or less as ascertained in an *in vitro* kinase assay.
28. The method of claim 1 or 7, wherein said first or second agent are administered parenterally, orally, intraperitoneally, intravenously, intraarterially, transdermally, intramuscularly, liposomally, via local delivery by catheter or stent, subcutaneously, intraadiposally, or intrathecally.
29. The method of claim 1 or 7, wherein both first and second agents are administered orally.
30. The method of claim 1 or 7, wherein said second agent is a compound of Formula I:



Formula I

or a pharmaceutically acceptable salt thereof, wherein:

X₁ is N or C-E¹, X₂ is N or C, X₃ is N or C, X₄ is C-R⁹ or N, X₅ is N or C-E¹, X₆ is C or N, and X₇ is C or N; and wherein no more than two nitrogen ring atoms are adjacent;

R₁ is H, -L-C₁₋₁₀alkyl, -L-C₃₋₈cycloalkyl, -L-C₁₋₁₀alkyl-C₃₋₈cycloalkyl, -L-aryl, -L-heteroaryl, -L-C₁₋₁₀alkylaryl, -L-C₁₋₁₀alkylhetaryl, -L-C₁₋₁₀alkylheterocylyl, -L-C₂₋₁₀alkenyl, -L-C₂₋₁₀alkynyl, -L-C₂₋₁₀alkenyl-C₃₋₈cycloalkyl, -L-C₂₋₁₀alkynyl-C₃₋₈cycloalkyl, -L-heteroalkyl, -L-heteroalkylaryl, -L-heteroalkylheteroaryl, -L-heteroalkyl-heterocylyl, -L-heteroalkyl-C₃₋₈cycloalkyl, -L-aralkyl, -L-heteroaralkyl, or -L-heterocyclyl, each of which is unsubstituted or is substituted by one or more independent R³;

L is absent, -(C=O)-, -C(=O)O-, -C(=O)N(R³¹)-, -S-, -S(O)-, -S(O)₂-, -S(O)₂N(R³¹)-, or -N(R³¹)-;

E¹ and E² are independently -(W¹)_j-R⁴;

M₁ is a 5, 6, 7, 8, 9, or 10 membered ring system, wherein the ring system is monocyclic or bicyclic, substituted with R₅ and additionally optionally substituted with one or more -(W²)_k-R²;

each k is 0 or 1;

j in E¹ or j in E², is independently 0 or 1;

W^1 is $-O-$, $-NR^7-$, $-S(O)_{0-2}-$, $-C(O)-$, $-C(O)N(R^7)-$, $-N(R^7)C(O)-$, $-N(R^7)S(O)-$, $-N(R^7)S(O)_2-$, $-C(O)O-$, $-CH(R^7)N(C(O)OR^8)-$, $-CH(R^7)N(C(O)R^8)-$, $-CH(R^7)N(SO_2R^8)-$, $-CH(R^7)N(R^8)-$, $-CH(R^7)C(O)N(R^8)-$, $-CH(R^7)N(R^8)C(O)-$, $-CH(R^7)N(R^8)S(O)-$, or $-CH(R^7)N(R^8)S(O)_2-$;

W^2 is $-O-$, $-NR^7-$, $-S(O)_{0-2}-$, $-C(O)-$, $-C(O)N(R^7)-$, $-N(R^7)C(O)-$, $-N(R^7)C(O)N(R^8)-$, $-N(R^7)S(O)-$, $-N(R^7)S(O)_2-$, $-C(O)O-$, $-CH(R^7)N(C(O)OR^8)-$, $-CH(R^7)N(C(O)R^8)-$, $-CH(R^7)N(SO_2R^8)-$, $-CH(R^7)N(R^8)-$, $-CH(R^7)C(O)N(R^8)-$, $-CH(R^7)N(R^8)C(O)-$, $-CH(R^7)N(R^8)S(O)-$, or $-CH(R^7)N(R^8)S(O)_2-$;

R^2 is hydrogen, halogen, $-OH$, $-R^{31}$, $-CF_3$, $-OCF_3$, $-OR^{31}$, $-NR^{31}R^{32}$, $-NR^{34}R^{35}$, $-C(O)R^{31}$, $-CO_2R^{31}$, $-C(=O)NR^{31}R^{32}$, $-C(=O)NR^{34}R^{35}$, $-NO_2$, $-CN$, $-S(O)_{0-2}R^{31}$, $-SO_2NR^{31}R^{32}$, $-SO_2NR^{34}R^{35}$, $-NR^{31}C(=O)R^{32}$, $-NR^{31}C(=O)OR^{32}$, $-NR^{31}C(=O)NR^{32}R^{33}$, $-NR^{31}S(O)_{0-2}R^{32}$, $-C(=S)OR^{31}$, $-C(=O)SR^{31}$, $-NR^{31}C(=NR^{32})NR^{33}R^{32}$, $-NR^{31}C(=NR^{32})OR^{33}$, $-NR^{31}C(=NR^{32})SR^{33}$, $-OC(=O)OR^{33}$, $-OC(=O)NR^{31}R^{32}$, $-OC(=O)SR^{31}$, $-SC(=O)OR^{31}$, $-P(O)OR^{31}OR^{32}$, $-SC(=O)NR^{31}R^{32}$, aryl (e.g. bicyclic aryl, unsubstituted aryl, or substituted monocyclic aryl), hetaryl, C_{1-10} alkyl, C_{3-8} cycloalkyl, C_{1-10} alkyl- C_{3-8} cycloalkyl, C_{3-8} cycloalkyl- C_{1-10} alkyl, C_{3-8} cycloalkyl- C_{2-10} alkenyl, C_{3-8} cycloalkyl- C_{2-10} alkynyl, C_{1-10} alkyl- C_{2-10} alkenyl, C_{1-10} alkyl- C_{2-10} alkynyl, C_{1-10} alkylaryl (e.g. C_{2-10} alkyl-monocyclic aryl, C_{1-10} alkyl-substituted monocyclic aryl, or C_{1-10} alkylbicycloaryl), C_{1-10} alkylhetaryl, C_{1-10} alkylheterocyclyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{2-10} alkenyl- C_{1-10} alkyl, C_{2-10} alkynyl- C_{1-10} alkyl, C_{2-10} alkenylaryl, C_{2-10} alkenylhetaryl, C_{2-10} alkenylheteroalkyl, C_{2-10} alkenylheterocyclyl, C_{2-10} alkenyl- C_{3-8} cycloalkyl, C_{2-10} alkynylaryl, C_{2-10} alkynylhetaryl, C_{2-10} alkynylheteroalkyl, C_{2-10} alkynylheterocyclyl, C_{2-10} alkynyl- C_{3-8} cycloalkenyl, C_{1-10} alkoxy C_{1-10} alkyl, C_{1-10} alkoxy- C_{2-10} alkenyl, C_{1-10} alkoxy- C_{2-10} alkynyl, heterocyclyl, heteroalkyl, heterocyclyl- C_{1-10} alkyl, heterocyclyl- C_{2-10} alkenyl, heterocyclyl- C_{2-10} alkynyl, aryl- C_{1-10} alkyl (e.g. monocyclic aryl- C_{2-10} alkyl, substituted monocyclic aryl- C_{1-10} alkyl, or bicycloaryl- C_{1-10} alkyl), aryl- C_{2-10} alkenyl, aryl- C_{2-10} alkynyl, aryl-heterocyclyl, hetaryl- C_{1-10} alkyl, hetaryl- C_{2-10} alkenyl, hetaryl- C_{2-10} alkynyl, hetaryl- C_{3-8} cycloalkyl, hetaryl-heteroalkyl, or hetaryl-heterocyclyl, wherein each of said bicyclic aryl or heteroaryl moiety is unsubstituted, or wherein each of bicyclic aryl, heteroaryl moiety or monocyclic aryl moiety is substituted with one or more independent alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl,

heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, halo, $-OH$, $-R^{31}$, $-CF_3$, $-OCF_3$, $-OR^{31}$, $-NR^{31}R^{32}$, $-NR^{34}R^{35}$, $-C(O)R^{31}$, $-CO_2R^{31}$, $-C(=O)NR^{31}R^{32}$, $-C(=O)NR^{34}R^{35}$, $-NO_2$, $-CN$, $-S(O)_{0-2}R^{31}$, $-SO_2NR^{31}R^{32}$, $-SO_2NR^{34}R^{35}$, $-NR^{31}C(=O)R^{32}$, $-NR^{31}C(=O)OR^{32}$, $-NR^{31}C(=O)NR^{32}R^{33}$, $-NR^{31}S(O)_{0-2}R^{32}$, $-C(=S)OR^{31}$, $-C(=O)SR^{31}$, $-NR^{31}C(=NR^{32})NR^{33}R^{32}$, $-NR^{31}C(=NR^{32})OR^{33}$, $-NR^{31}C(=NR^{32})SR^{33}$, $-OC(=O)OR^{33}$, $-OC(=O)NR^{31}R^{32}$, $-OC(=O)SR^{31}$, $-SC(=O)OR^{31}$, $-P(O)OR^{31}OR^{32}$, or $-SC(=O)NR^{31}R^{32}$, and wherein each of said alkyl, cycloalkyl, heterocyclyl, or heteroalkyl moiety is unsubstituted or is substituted with one or more alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, halo, $-OH$, $-R^{31}$, $-CF_3$, $-OCF_3$, $-OR^{31}$, $-O$ -aryl, $-NR^{31}R^{32}$, $-NR^{34}R^{35}$, $-C(O)R^{31}$, $-CO_2R^{31}$, $-C(=O)NR^{34}R^{35}$, or $-C(=O)NR^{31}R^{32}$;

R^3 and R^4 are independently hydrogen, halogen, $-OH$, $-R^{31}$, $-CF_3$, $-OCF_3$, $-OR^{31}$, $-NR^{31}R^{32}$, $-NR^{34}R^{35}$, $-C(O)R^{31}$, $-CO_2R^{31}$, $-C(=O)NR^{31}R^{32}$, $-C(=O)NR^{34}R^{35}$, $-NO_2$, $-CN$, $-S(O)_{0-2}R^{31}$, $-SO_2NR^{31}R^{32}$, $-SO_2NR^{34}R^{35}$, $-NR^{31}C(=O)R^{32}$, $-NR^{31}C(=O)OR^{32}$, $-NR^{31}C(=O)NR^{32}R^{33}$, $-NR^{31}S(O)_{0-2}R^{32}$, $-C(=S)OR^{31}$, $-$

$C(=O)SR^{31}$, $-NR^{31}C(=NR^{32})NR^{33}R^{32}$, $-NR^{31}C(=NR^{32})OR^{33}$, $-NR^{31}C(=NR^{32})SR^{33}$, $-OC(=O)OR^{33}$, $-OC(=O)NR^{31}R^{32}$, $-OC(=O)SR^{31}$, $-SC(=O)OR^{31}$, $-P(O)OR^{31}OR^{32}$, $-SC(=O)NR^{31}R^{32}$, aryl, hetaryl, C_{1-10} alkyl, C_{1-10} alkenyl, C_{3-8} cycloalkyl, C_{1-10} alkyl- C_{3-8} cycloalkyl, C_{3-8} cycloalkyl- C_{1-10} alkyl, C_{3-8} cycloalkyl- C_{2-10} alkenyl, C_{3-8} cycloalkyl- C_{2-10} alkynyl, C_{1-10} alkyl- C_{2-10} alkenyl, C_{1-10} alkyl- C_{2-10} alkynyl, C_{1-10} alkylaryl, C_{1-10} alkylhetaryl, C_{1-10} alkylheterocyclyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{2-10} alkenyl- C_{1-10} alkyl, C_{2-10} alkynyl- C_{1-10} alkyl, C_{2-10} alkenylaryl, C_{2-10} alkenylhetaryl, C_{2-10} alkenylheteroalkyl, C_{2-10} alkenylheterocyclyl, C_{2-10} alkenyl- C_{3-8} cycloalkyl, C_{2-10} alkynyl- C_{3-8} cycloalkyl, C_{2-10} alkynylaryl, C_{2-10} alkynylhetaryl, C_{2-10} alkynylheteroalkyl, C_{2-10} alkynylheterocyclyl, C_{2-10} alkynyl- C_{3-8} cycloalkyl, C_{1-10} alkoxy C_{1-10} alkyl, C_{1-10} alkoxy- C_{2-10} alkenyl, C_{1-10} alkoxy- C_{2-10} alkynyl, heterocyclyl, heterocyclyl- C_{1-10} alkyl, heterocyclyl- C_{2-10} alkenyl, heterocyclyl- C_{2-10} alkynyl, aryl- C_{1-10} alkyl, aryl- C_{2-10} alkenyl, aryl- C_{2-10} alkynyl, aryl-heterocyclyl, hetaryl- C_{1-10} alkyl, hetaryl- C_{2-10} alkenyl, hetaryl- C_{2-10} alkynyl, hetaryl- C_{3-8} cycloalkyl, heteroalkyl, hetaryl-heteroalkyl, or hetaryl-heterocyclyl, wherein each of said aryl or heteroaryl moiety is unsubstituted or is substituted with one or more independent halo, $-OH$, $-R^{31}$, $-CF_3$, $-OCF_3$, $-OR^{31}$, $-NR^{31}R^{32}$, $-NR^{34}R^{35}$, $-C(O)R^{31}$, $-CO_2R^{31}$, $-C(=O)NR^{31}R^{32}$, $-C(=O)NR^{34}R^{35}$, $-NO_2$, $-CN$, $-S(O)_{0-2}R^{31}$, $-SO_2NR^{31}R^{32}$, $-SO_2NR^{34}R^{35}$, $-NR^{31}C(=O)R^{32}$, $-NR^{31}C(=O)OR^{32}$, $-NR^{31}C(=O)NR^{32}R^{33}$, $-NR^{31}S(O)_{0-2}R^{32}$, $-C(=S)OR^{31}$, $-C(=O)SR^{31}$, $-NR^{31}C(=NR^{32})NR^{33}R^{32}$, $-NR^{31}C(=NR^{32})OR^{33}$, $-NR^{31}C(=NR^{32})SR^{33}$, $-OC(=O)OR^{33}$, $-OC(=O)NR^{31}R^{32}$, $-OC(=O)SR^{31}$, $-SC(=O)OR^{31}$, $-P(O)OR^{31}OR^{32}$, or $-SC(=O)NR^{31}R^{32}$, and wherein each of said alkyl, cycloalkyl, heterocyclyl, or heteroalkyl moiety is unsubstituted or is substituted with one or more halo, $-OH$, $-R^{31}$, $-CF_3$, $-OCF_3$, $-OR^{31}$, $-O$ -aryl, $-NR^{31}R^{32}$, $-NR^{34}R^{35}$, $-C(O)R^{31}$, $-CO_2R^{31}$, $-C(=O)NR^{34}R^{35}$, or $-C(=O)NR^{31}R^{32}$;

R^5 is hydrogen, halogen, $-OH$, $-R^{31}$, $-CF_3$, $-OCF_3$, $-OR^{31}$, $-NR^{31}R^{32}$, $-NR^{34}R^{35}$, $-C(O)R^{31}$, $-CO_2R^{31}$, $-C(=O)NR^{31}R^{32}$, $-C(=O)NR^{34}R^{35}$, $-NO_2$, $-CN$, $-S(O)_{0-2}R^{31}$, $-SO_2NR^{31}R^{32}$, $-SO_2NR^{34}R^{35}$, $-NR^{31}C(=O)R^{32}$, $-NR^{31}C(=O)OR^{32}$, $-NR^{31}C(=O)NR^{32}R^{33}$, $-NR^{31}S(O)_{0-2}R^{32}$, $-C(=S)OR^{31}$, $-C(=O)SR^{31}$, $-NR^{31}C(=NR^{32})NR^{33}R^{32}$, $-NR^{31}C(=NR^{32})OR^{33}$, $-NR^{31}C(=NR^{32})SR^{33}$, $-OC(=O)OR^{33}$, $-OC(=O)NR^{31}R^{32}$, $-OC(=O)SR^{31}$, $-SC(=O)OR^{31}$, $-P(O)OR^{31}OR^{32}$, or $-SC(=O)NR^{31}R^{32}$;

each of R^{31} , R^{32} , and R^{33} is independently H or C_{1-10} alkyl, wherein the C_{1-10} alkyl is unsubstituted or is substituted with one or more aryl, heteroalkyl, heterocyclyl, or hetaryl group, wherein each of said aryl, heteroalkyl, heterocyclyl, or hetaryl group is unsubstituted or is substituted with one or more halo, $-OH$, $-C_{1-10}$ alkyl, $-CF_3$, $-O$ -aryl, $-OCF_3$, $-OC_{1-10}$ alkyl, $-NH_2$, $-N(C_{1-10}alkyl)(C_{1-10}alkyl)$, $-NH(C_{1-10}alkyl)$, $-NH(aryl)$, $-NR^{34}R^{35}$, $-C(O)(C_{1-10}alkyl)$, $-C(O)(C_{1-10}alkyl-aryl)$, $-C(O)(aryl)$, $-CO_2-C_{1-10}alkyl$, $-CO_2-C_{1-10}alkylaryl$, $-CO_2-aryl$, $-C(=O)N(C_{1-10}alkyl)(C_{1-10}alkyl)$, $-C(=O)NH(C_{1-10}alkyl)$, $-C(=O)NR^{34}R^{35}$, $-C(=O)NH_2$, $-OCF_3$, $-O(C_{1-10}alkyl)$, $-O$ -aryl, $-N(aryl)(C_{1-10}alkyl)$, $-NO_2$, $-CN$, $-S(O)_{0-2}C_{1-10}alkyl$, $-S(O)_{0-2}C_{1-10}alkylaryl$, $-S(O)_{0-2}aryl$, $-SO_2N(aryl)$, $-SO_2N(C_{1-10}alkyl)(C_{1-10}alkyl)$, $-SO_2NH(C_{1-10}alkyl)$ or $-SO_2NR^{34}R^{35}$;

R^{34} and R^{35} in $-NR^{34}R^{35}$, $-C(=O)NR^{34}R^{35}$, or $-SO_2NR^{34}R^{35}$, are taken together with the nitrogen atom to which they are attached to form a 3-10 membered saturated or unsaturated ring; wherein said ring is independently unsubstituted or is substituted by one or more $-NR^{31}R^{32}$, hydroxyl, halogen, oxo, aryl,

hetaryl, C₁₋₆alkyl, or O-aryl, and wherein said 3-10 membered saturated or unsaturated ring independently contains 0, 1, or 2 more heteroatoms in addition to the nitrogen atom;


each of R⁷ and R⁸ is independently hydrogen, C₁₋₁₀alkyl, C₂₋₁₀alkenyl, aryl, heteroaryl, heterocyclyl or C₃₋₁₀cycloalkyl, each of which except for hydrogen is unsubstituted or is substituted by one or more independent R⁶;

R⁶ is halo, -OR³¹, -SH, -NH₂, -NR³⁴R³⁵, -NR³¹R³², -CO₂R³¹, -CO₂aryl, -C(=O)NR³¹R³², C(=O)NR³⁴R³⁵, -NO₂, -CN, -S(O)₀₋₂ C₁₋₁₀alkyl, -S(O)₀₋₂aryl, -SO₂NR³⁴R³⁵, -SO₂NR³¹R³², C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl; aryl-C₁₋₁₀alkyl, aryl-C₂₋₁₀alkenyl, aryl-C₂₋₁₀alkynyl, hetaryl-C₁₋₁₀alkyl, hetaryl-C₂₋₁₀alkenyl, hetaryl-C₂₋₁₀alkynyl, wherein each of said alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heterocyclyl, or hetaryl group is unsubstituted or is substituted with one or more independent halo, cyano, nitro, -OC₁₋₁₀alkyl, C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, haloC₁₋₁₀alkyl, haloC₂₋₁₀alkenyl, haloC₂₋₁₀alkynyl, -COOH, -C(=O)NR³¹R³², -C(=O)NR³⁴R³⁵, -SO₂NR³⁴R³⁵, -SO₂NR³¹R³², -NR³¹R³², or -NR³⁴R³⁵; and

R⁹ is H, halo, -OR³¹, -SH, -NH₂, -NR³⁴R³⁵, -NR³¹R³², -CO₂R³¹, -CO₂aryl, -C(=O)NR³¹R³², C(=O)NR³⁴R³⁵, -NO₂, -CN, -S(O)₀₋₂ C₁₋₁₀alkyl, -S(O)₀₋₂aryl, -SO₂NR³⁴R³⁵, -SO₂NR³¹R³², C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl; aryl-C₁₋₁₀alkyl, aryl-C₂₋₁₀alkenyl, aryl-C₂₋₁₀alkynyl, hetaryl-C₁₋₁₀alkyl, hetaryl-C₂₋₁₀alkenyl, hetaryl-C₂₋₁₀alkynyl, wherein each of said alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heterocyclyl, or hetaryl group is unsubstituted or is substituted with one or more independent halo, cyano, nitro, -OC₁₋₁₀alkyl, C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, haloC₁₋₁₀alkyl, haloC₂₋₁₀alkenyl, haloC₂₋₁₀alkynyl, -COOH, -C(=O)NR³¹R³², -C(=O)NR³⁴R³⁵, -SO₂NR³⁴R³⁵, -SO₂NR³¹R³², -NR³¹R³², or -NR³⁴R³⁵.

31. A method of treating a disorder in a subject according to a regimen comprising:

administering to the subject a first agent which is an antiangiogenic agent and a second agent which is a compound of Formula:



or a pharmaceutically acceptable salt thereof, wherein:

X₁ is N or C-E¹ and X₂ is N; or X₁ is NH or CH-E¹ and X₂ is C;
R₁ is hydrogen, -L-C₁₋₁₀alkyl, -L-C₃₋₈cycloalkyl, -L-C₁₋₁₀alkyl-C₃₋₈cycloalkyl, -L-aryl, -L-heteroaryl, -L-C₁₋₁₀alkylaryl, -L-C₁₋₁₀alkylheteroaryl, -L-C₁₋₁₀alkylheterocyclyl, -L-C₂₋₁₀alkenyl, -L-C₂₋₁₀alkynyl, -L-C₂₋₁₀alkenyl-C₃₋₈cycloalkyl, -L-C₂₋₁₀alkynyl-C₃₋₈cycloalkyl, -L-heteroalkyl, -L-heteroalkylaryl, -L-

heteroalkylheteroaryl, -L-heteroalkyl-heterocyclyl, -L-heteroalkyl-C₃₋₈cycloalkyl, -L-aryl, -L-heteroaryl, or -L-heterocyclyl, each of which is unsubstituted or substituted by one or more independent R³ substituents;

L is absent, C=O, -C(=O)O-, -C(=O)N(R³¹)-, -S-, -S(O)-, -S(O)₂-, -S(O)₂N(R³¹)-, or -N(R³¹)-;

k is 0 or 1;

E¹ and E² are independently -(W¹)_j-R⁴;

j in E¹ or j in E², is independently 0 or 1;

W¹ is -O-, -NR⁷-, -S(O)_{0.2}-, -C(O)-, -C(O)N(R⁷)-, -N(R⁷)C(O)-, -N(R⁷)S(O)-, -N(R⁷)S(O)₂-, -C(O)O-, -CH(R⁷)N(C(O)OR⁸)-, -CH(R⁷)N(C(O)R⁸)-, -CH(R⁷)N(SO₂R⁸)-, -CH(R⁷)N(R⁸)-, -CH(R⁷)C(O)N(R⁸)-, -CH(R⁷)N(R⁸)C(O)-, -CH(R⁷)N(R⁸)S(O)-, or -CH(R⁷)N(R⁸)S(O)₂-;

W² is -O-, -NR⁷-, -S(O)_{0.2}-, -C(O)-, -C(O)N(R⁷)-, -N(R⁷)C(O)-, -N(R⁷)C(O)N(R⁸)-, -N(R⁷)S(O)-, -N(R⁷)S(O)₂-, -C(O)O-, -CH(R⁷)N(C(O)OR⁸)-, -CH(R⁷)N(C(O)R⁸)-, -CH(R⁷)N(SO₂R⁸)-, -CH(R⁷)N(R⁸)-, -CH(R⁷)C(O)N(R⁸)-, -CH(R⁷)N(R⁸)C(O)-, -CH(R⁷)N(R⁸)S(O)-, or -CH(R⁷)N(R⁸)S(O)₂-;

R³ and R⁴ are independently hydrogen, halogen, -OH, -R³¹, -CF₃, -OCF₃, -OR³¹, -NR³¹R³², -NR³⁴R³⁵, -C(O)R³¹, -CO₂R³¹, -C(=O)NR³¹R³², -C(=O)NR³⁴R³⁵, -NO₂, -CN, -S(O)_{0.2}R³¹, -SO₂NR³¹R³², -SO₂NR³⁴R³⁵, -NR³¹C(=O)R³², -NR³¹C(=O)OR³², -NR³¹C(=O)NR³²R³³, -NR³¹S(O)_{0.2}R³², -C(=S)OR³¹, -C(=O)SR³¹, -NR³¹C(=NR³²)NR³³R³², -NR³¹C(=NR³²)OR³³, -NR³¹C(=NR³²)SR³³, -OC(=O)OR³³, -OC(=O)NR³¹R³², -OC(=O)SR³¹, -SC(=O)OR³¹, -P(O)OR³¹OR³², -SC(=O)NR³¹R³², aryl, heteroaryl, C₁₋₁₀alkyl, C₃₋₈cycloalkyl, C₁₋₁₀alkyl-C₃₋₈cycloalkyl, C₃₋₈cycloalkyl-C₁₋₁₀alkyl, C₃₋₈cycloalkyl-C₂₋₁₀alkenyl, C₃₋₈cycloalkyl-C₂₋₁₀alkynyl, C₁₋₁₀alkyl-C₂₋₁₀alkenyl, C₁₋₁₀alkyl-C₂₋₁₀alkynyl, C₁₋₁₀alkylaryl, C₁₋₁₀alkylheteroaryl, C₁₋₁₀alkylheterocyclyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₂₋₁₀alkenyl-C₁₋₁₀alkyl, C₂₋₁₀alkynyl-C₁₋₁₀alkyl, C₂₋₁₀alkenylaryl, C₂₋₁₀alkenylheteroaryl, C₂₋₁₀alkenylheteroalkyl, C₂₋₁₀alkenylheterocyclyl, C₂₋₁₀alkenyl-C₃₋₈cycloalkyl, C₂₋₁₀alkynyl-C₃₋₈cycloalkyl, C₂₋₁₀alkynylaryl, C₂₋₁₀alkynylheteroaryl, C₂₋₁₀alkynylheteroalkyl, C₂₋₁₀alkynylheterocyclyl, C₂₋₁₀alkoxy C₁₋₁₀alkyl, C₁₋₁₀alkoxy-C₂₋₁₀alkenyl, C₁₋₁₀alkoxy-C₂₋₁₀alkynyl, heterocyclyl, heterocyclyl-C₁₋₁₀alkyl, heterocyclyl-C₂₋₁₀alkenyl, heterocyclyl-C₂₋₁₀alkynyl, aryl-C₁₋₁₀alkyl, aryl-C₂₋₁₀alkenyl, aryl-C₂₋₁₀alkynyl, aryl-heterocyclyl, heteroaryl-C₁₋₁₀alkyl, heteroaryl-C₂₋₁₀alkenyl, heteroaryl-C₂₋₁₀alkynyl, heteroaryl-C₃₋₈cycloalkyl, heteroalkyl, heteroaryl-heteroalkyl, or heteroaryl-heterocyclyl, wherein each of said aryl or heteroaryl moiety is unsubstituted or is substituted with one or more independent halo, -OH, -R³¹, -CF₃, -OCF₃, -OR³¹, -NR³¹R³², -NR³⁴R³⁵, -C(O)R³¹, -CO₂R³¹, -C(=O)NR³¹R³², -C(=O)NR³⁴R³⁵, -NO₂, -CN, -S(O)_{0.2}R³¹, -SO₂NR³¹R³², -SO₂NR³⁴R³⁵, -NR³¹C(=O)R³², -NR³¹C(=O)OR³², -NR³¹C(=O)NR³²R³³, -NR³¹S(O)_{0.2}R³², -C(=S)OR³¹, -C(=O)SR³¹, -NR³¹C(=NR³²)NR³³R³², -NR³¹C(=NR³²)OR³³, -NR³¹C(=NR³²)SR³³, -OC(=O)OR³³, -OC(=O)NR³¹R³², -OC(=O)SR³¹, -SC(=O)OR³¹, -P(O)OR³¹OR³², or -SC(=O)NR³¹R³², and wherein each of said alkyl, cycloalkyl, heterocyclyl, or heteroalkyl moiety is unsubstituted or substituted with one or more halo, -OH, -R³¹, -CF₃, -OCF₃, -OR³¹, -O-aryl, -NR³¹R³², -NR³⁴R³⁵, -C(O)R³¹, -CO₂R³¹, -C(=O)NR³⁴R³⁵, or -C(=O)NR³¹R³²;

R^2 is hydrogen, halogen, $-OH$, $-R^{31}$, $-CF_3$, $-OCF_3$, $-OR^{31}$, $-NR^{31}R^{32}$, $-NR^{34}R^{35}$, $-C(O)R^{31}$, $-CO_2R^{31}$, $-C(=O)NR^{31}R^{32}$, $-C(=O)NR^{34}R^{35}$, $-NO_2$, $-CN$, $-S(O)_{0-2}R^{31}$, $-SO_2NR^{31}R^{32}$, $-SO_2NR^{34}R^{35}$, $-NR^{31}C(=O)R^{32}$, $-NR^{31}C(=O)OR^{32}$, $-NR^{31}C(=O)NR^{32}R^{33}$, $-NR^{31}S(O)_{0-2}R^{32}$, $-C(=S)OR^{31}$, $-C(=O)SR^{31}$, $-NR^{31}C(=NR^{32})NR^{33}R^{32}$, $-NR^{31}C(=NR^{32})OR^{33}$, $-NR^{31}C(=NR^{32})SR^{33}$, $-OC(=O)OR^{33}$, $-OC(=O)NR^{31}R^{32}$, $-OC(=O)SR^{31}$, $-SC(=O)OR^{31}$, $-P(O)OR^{31}OR^{32}$, $-SC(=O)NR^{31}R^{32}$, bicyclic aryl, substituted monocyclic aryl, heteroaryl, C_{1-10} alkyl, C_{3-8} cycloalkyl, C_{1-10} alkyl- C_{3-8} cycloalkyl, C_{3-8} cycloalkyl- C_{1-10} alkyl, C_{3-8} cycloalkyl- C_{2-10} alkenyl, C_{3-8} cycloalkyl- C_{2-10} alkynyl, C_{2-10} alkyl-monocyclic aryl, monocyclic aryl- C_{2-10} alkyl, C_{1-10} alkylbicycloaryl, bicycloaryl- C_{1-10} alkyl, substituted C_{1-10} alkylaryl, substituted aryl- C_{1-10} alkyl, C_{1-10} alkylheteroaryl, C_{1-10} alkylheterocyclyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{2-10} alkenylaryl, C_{2-10} alkenylheteroaryl, C_{2-10} alkenylheteroalkyl, C_{2-10} alkenylheterocyclyl, C_{2-10} alkynylaryl, C_{2-10} alkynylheteroaryl, C_{2-10} alkynylheteroalkyl, C_{2-10} alkynylheterocyclyl, C_{2-10} alkenyl- C_{3-8} cycloalkyl, C_{2-10} alkynyl- C_{3-8} cycloalkyl, C_{1-10} alkoxy C_{1-10} alkyl, C_{1-10} alkoxy C_{2-10} alkenyl, C_{1-10} alkoxy C_{2-10} alkynyl, heterocyclyl, heterocyclyl C_{1-10} alkyl, heterocyclyl C_{2-10} alkenyl, heterocyclyl- C_{2-10} alkynyl, aryl- C_{2-10} alkenyl, aryl- C_{2-10} alkynyl, aryl-heterocyclyl, heteroaryl- C_{1-10} alkyl, heteroaryl- C_{2-10} alkenyl, heteroaryl- C_{2-10} alkynyl, heteroaryl- C_{3-8} cycloalkyl, heteroaryl-heteroalkyl, or heteroaryl-heterocyclyl, wherein each of said bicyclic aryl, monocyclic aryl, or heteroaryl moiety is unsubstituted or is substituted with one or more independent halo, $-OH$, $-R^{31}$, $-CF_3$, $-OCF_3$, $-OR^{31}$, $-NR^{31}R^{32}$, $-NR^{34}R^{35}$, $-C(O)R^{31}$, $-CO_2R^{31}$, $-C(=O)NR^{31}R^{32}$, $-C(=O)NR^{34}R^{35}$, $-NO_2$, $-CN$, $-S(O)_{0-2}R^{31}$, $-SO_2NR^{31}R^{32}$, $-SO_2NR^{34}R^{35}$, $-NR^{31}C(=O)R^{32}$, $-NR^{31}C(=O)OR^{32}$, $-NR^{31}C(=O)NR^{32}R^{33}$, $-NR^{31}S(O)_{0-2}R^{32}$, $-C(=S)OR^{31}$, $-C(=O)SR^{31}$, $-NR^{31}C(=NR^{32})NR^{33}R^{32}$, $-NR^{31}C(=NR^{32})OR^{33}$, $-NR^{31}C(=NR^{32})SR^{33}$, $-OC(=O)OR^{33}$, $-OC(=O)NR^{31}R^{32}$, $-OC(=O)SR^{31}$, $-SC(=O)OR^{31}$, $-P(O)OR^{31}OR^{32}$, or $-SC(=O)NR^{31}R^{32}$, and wherein each of said alkyl, cycloalkyl, heterocyclyl, or heteroalkyl moiety is unsubstituted or is substituted with one or more halo, $-OH$, $-R^{31}$, $-CF_3$, $-OCF_3$, $-OR^{31}$, $-O$ -aryl, $-NR^{31}R^{32}$, $-NR^{34}R^{35}$, $-C(O)R^{31}$, $-CO_2R^{31}$, $-C(=O)NR^{34}R^{35}$, or $-C(=O)NR^{31}R^{32}$;

each of R^{31} , R^{32} , and R^{33} is independently H or C_{1-10} alkyl, wherein the C_{1-10} alkyl is unsubstituted or is substituted with one or more aryl, heteroalkyl, heterocyclyl, or heteroaryl substituent, wherein each of said aryl, heteroalkyl, heterocyclyl, or heteroaryl substituent is unsubstituted or is substituted with one or more halo, $-OH$, $-C_{1-10}$ alkyl, $-CF_3$, $-O$ -aryl, $-OCF_3$, $-OC_{1-10}$ alkyl, $-NH_2$, $-N(C_{1-10}alkyl)(C_{1-10}alkyl)$, $-NH(C_{1-10}alkyl)$, $-NH(aryl)$, $-NR^{34}R^{35}$, $-C(O)(C_{1-10}alkyl)$, $-C(O)(C_{1-10}alkyl-aryl)$, $-C(O)(aryl)$, $-CO_2-C_{1-10}alkyl$, $-CO_2-C_{1-10}alkylaryl$, $-CO_2-aryl$, $-C(=O)N(C_{1-10}alkyl)(C_{1-10}alkyl)$, $-C(=O)NH(C_{1-10}alkyl)$, $-C(=O)NR^{34}R^{35}$, $-C(=O)NH_2$, $-OCF_3$, $-O(C_{1-10}alkyl)$, $-O$ -aryl, $-N(aryl)(C_{1-10}alkyl)$, $-NO_2$, $-CN$, $-S(O)_{0-2}C_{1-10}alkyl$, $-S(O)_{0-2}C_{1-10}alkylaryl$, $-S(O)_{0-2}aryl$, $-SO_2N(aryl)$, $-SO_2N(C_{1-10}alkyl)(C_{1-10}alkyl)$, $-SO_2NH(C_{1-10}alkyl)$ or $-SO_2NR^{34}R^{35}$;

R^{34} and R^{35} in $-NR^{34}R^{35}$, $-C(=O)NR^{34}R^{35}$, or $-SO_2NR^{34}R^{35}$, are taken together with the nitrogen atom to which they are attached to form a 3-10 membered saturated or unsaturated ring; wherein said ring is independently unsubstituted or is substituted by one or more $-NR^{31}R^{32}$, hydroxyl, halogen, oxo, aryl, heteroaryl, C_{1-6} alkyl, or O -aryl, and wherein said 3-10 membered saturated or unsaturated ring independently contains 0, 1, or 2 more heteroatoms in addition to the nitrogen atom;


each of R^7 and R^8 is independently hydrogen, C_{1-10} alkyl, C_{2-10} alkenyl, aryl, heteroaryl, heterocyclyl or C_{3-10} cycloalkyl, each of which except for hydrogen is unsubstituted or is substituted by one or more independent R^6 substituents; and

R^6 is halo, $-OR^{31}$, $-SH$, NH_2 , $-NR^{34}R^{35}$, $-NR^{31}R^{32}$, $-CO_2R^{31}$, $-CO_2$ aryl, $-C(=O)NR^{31}R^{32}$, $C(=O)NR^{34}R^{35}$, $-NO_2$, $-CN$, $-S(O)_{0-2}C_{1-10}$ alkyl, $-S(O)_{0-2}$ aryl, $-SO_2NR^{34}R^{35}$, $-SO_2NR^{31}R^{32}$, C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, aryl- C_{1-10} alkyl, aryl- C_{2-10} alkenyl, aryl- C_{2-10} alkynyl, heteroaryl- C_{1-10} alkyl, heteroaryl- C_{2-10} alkenyl, or heteroaryl- C_{2-10} alkynyl, each of which is unsubstituted or is substituted with one or more independent halo, cyano, nitro, $-OC_{1-10}$ alkyl, C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, halo- C_{1-10} alkyl, halo- C_{2-10} alkenyl, halo- C_{2-10} alkynyl, $-COOH$, $-C(=O)NR^{31}R^{32}$, $-C(=O)NR^{34}R^{35}$, $-SO_2NR^{34}R^{35}$, $-SO_2NR^{31}R^{32}$, $-NR^{31}R^{32}$, or $-NR^{34}R^{35}$;

wherein the first and second agent are administered according to a dosing schedule such that the first agent and the second agent are administered in an alternating manner;

and wherein administering the first and second agent in accordance with the dosing schedule results in a synergistic effect as evidenced by a reduced toxicity level or enhanced efficacy of the first and second agent, as compared to an alternative regimen in which the first and second agent are administered simultaneously.

32. The method of claim 31, wherein the second agent has the Formula:



wherein:

X_1 is N or $C-E^1$ and X_2 is N;

R_1 is $-L-C_{1-10}$ alkyl, $-L-C_{3-8}$ cycloalkyl, $-L-C_{1-10}$ alkylheterocyclyl, or $-L$ -heterocyclyl, each of which is unsubstituted or substituted by one or more independent R^3 substituents; and

R^3 is hydrogen, $-OH$, $-OR^{31}$, $-NR^{31}R^{32}$, $-C(O)R^{31}$, $-C(=O)NR^{31}R^{32}$, $-C(=O)NR^{34}R^{35}$, aryl, heteroaryl, C_{1-10} alkyl, C_{3-8} cycloalkyl, or heterocyclyl, wherein each of said aryl or heteroaryl moiety is unsubstituted or is substituted with one or more independent alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl,

heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, halo, $-OH$, $-R^{31}$, $-CF_3$, $-OCF_3$, $-OR^{31}$, $-NR^{31}R^{32}$, $-NR^{34}R^{35}$, $-C(O)R^{31}$, $-CO_2R^{31}$, $-C(=O)NR^{31}R^{32}$, $-C(=O)NR^{34}R^{35}$, $-NO_2$, $-CN$, $-S(O)_{0-2}R^{31}$, $-SO_2NR^{31}R^{32}$, $-SO_2NR^{34}R^{35}$, $-NR^{31}C(=O)R^{32}$, $-NR^{31}C(=O)OR^{32}$, $-NR^{31}C(=O)NR^{32}R^{33}$, $-NR^{31}S(O)_{0-2}R^{32}$, $-C(=S)OR^{31}$, $-C(=O)SR^{31}$, $-NR^{31}C(=NR^{32})NR^{33}R^{32}$, $-NR^{31}C(=NR^{32})OR^{33}$, $-NR^{31}C(=NR^{32})SR^{33}$, $-OC(=O)OR^{33}$, $-OC(=O)NR^{31}R^{32}$, $-OC(=O)SR^{31}$, $-SC(=O)OR^{31}$, $-P(O)OR^{31}OR^{32}$, or $-SC(=O)NR^{31}R^{32}$,

and wherein each of said alkyl, cycloalkyl, or heterocyclyl moiety is unsubstituted or is substituted with one or more alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, halo, $-\text{OH}$, $-\text{R}^{31}$, $-\text{CF}_3$, $-\text{OCF}_3$, $-\text{OR}^{31}$, $-\text{O-aryl}$, $-\text{NR}^{31}\text{R}^{32}$, $-\text{NR}^{34}\text{R}^{35}$, $-\text{C(O)R}^{31}$, $-\text{CO}_2\text{R}^{31}$, $-\text{C(=O)NR}^{34}\text{R}^{35}$, or $-\text{C(=O)NR}^{31}\text{R}^{32}$.

33. The method of claim 31, wherein X_1 and X_2 are N.

34. The method of claim 32, wherein R_1 is isopropyl.

35. The method of claim 31, wherein the first agent is sorafenib.

36. The method of claim 31, wherein a cycle of said dosing schedule comprises administering the first agent consecutively for at least two days, followed by administering the second agent for at least two days.

37. The method of claim 36, wherein the cycle comprises administering the first agent for four days, followed by administering the second agent for three days.




Figure 1.




Figure 1 (cont.)





Figure 2.






Figure 4.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 12/64239

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - C07D 487/00 (2012.01)

USPC - 544/262

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC - C07D487/00

USPC - 544/262

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
IPC - 544/262; 514/262.1

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

PatBase, Google Patents, Google Scholar (mtor, inhibitor, pyrazolo, pyrimidine, body weight, bodyweight, synergistic, compared, simultaneous, sequential, neoplastic, proliferative, skin, toxic, fatigue, rash, anorexia, diarrhea nausea, abdominal pain, rash, desquamat, schedule, protocol, regiment, days, hours, hrs, dosing, consecutive, cycle)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y	US 2010/0184760 A1 (REN, et al.) 22 July 2010 (22.07.2010) entire document, especially para[0392], [0398], [0400],[0403], [0429], [0431], [0889], [0940], [0945]-[0946], [0956]-[0958], [0962]-[0963], [0976], [0989]-[0990], [1000], [1003]-[1004], [1056], [1087]; pg 153, col 1	7, 8-11/7, 14-15/7, 20-30/7 ----- 1-6, 8-11/1, 12-13, 14-15/13, 16-19, 20-30/1, 31-37
Y	EP 1880723 A1 (NORVATIS) 23 January 2008 (23.01.2008) entire document, especially para[0005], [0017], [0021]	1-6, 8-11/1, 12-13, 14-15/13, 16-19, 20-30/1, 31-37
Y	WO 2011/062930 A1 (GILMER, et al.) 26 May 2011 (26.05.2011) entire document, especially pg 1, ln 51-; pg 2, ln 35-pg 3, ln 7; pg 6, ln 11-15	1-6, 8-11/1, 12-13, 14-15/13, 16-19, 20-30/1, 31-37

☐ Further documents are listed in the continuation of Box C.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

22 December 2012 (22.12.2012)

Date of mailing of the international search report

28 JAN 2013

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents

P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-3201

Authorized officer:

Lee W. Young

PCT Helpdesk: 571-272-4300

PCT OSP: 571-272-7774

摘要

本發明提供了採用包括多種藥劑的治療方案來治療病症的方法和藥物組合物。一方面，提供了一種治療方法，其通過根據所述的給藥時間表給藥導致毒性降低和/或協同效應。